<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:ynews="http://news.yahoo.com/rss/">
    <channel>
        <title>Nova Reader - Subject</title>
        <link>https://www.novareader.co</link>
        <description>Default RSS Feed</description>
        <language>en-us</language>
        <copyright>Newgen KnowledgeWorks</copyright>
        <item>
            <title><![CDATA[Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766072554827-bec7d404-beb3-4581-a733-b37225670632/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009064</link>
            <description><![CDATA[<p class="para" id="N65539">Vaccines of outstanding efficiency, safety, and public acceptance are needed to halt the current SARS-CoV-2 pandemic. Concerns include potential side effects caused by the antigen itself and safety of viral DNA and RNA delivery vectors. The large SARS-CoV-2 spike (S) protein is the main target of current COVID-19 vaccine candidates but can induce non-neutralizing antibodies, which might cause vaccination-induced complications or enhancement of COVID-19 disease. Besides, encoding of a functional S in replication-competent virus vector vaccines may result in the emergence of viruses with altered or expanded tropism. Here, we have developed a safe single round rhabdovirus replicon vaccine platform for enhanced presentation of the S receptor-binding domain (RBD). Structure-guided design was employed to build a chimeric minispike comprising the globular RBD linked to a transmembrane stem-anchor sequence derived from rabies virus (RABV) glycoprotein (G). Vesicular stomatitis virus (VSV) and RABV replicons encoding the minispike not only allowed expression of the antigen at the cell surface but also incorporation into the envelope of secreted non-infectious particles, thus combining classic vector-driven antigen expression and particulate virus-like particle (VLP) presentation. A single dose of a prototype replicon vaccine complemented with VSV G, VSVΔG-minispike-eGFP (G), stimulated high titers of SARS-CoV-2 neutralizing antibodies in mice, equivalent to those found in COVID-19 patients, and protected transgenic K18-hACE2 mice from COVID-19-like disease. Homologous boost immunization further enhanced virus neutralizing activity. The results demonstrate that non-spreading rhabdovirus RNA replicons expressing minispike proteins represent effective and safe alternatives to vaccination approaches using replication-competent viruses and/or the entire S antigen.</p><p class="para" id="N65542">Two critical problems are associated with replicating paramyxo- and rhabdovirus vaccines expressing SARS-CoV-2 spike (S) protein such as VSVΔG(S). One is eliciting of potentially disease-enhancing non-neutralizing antibodies, the other the S-mediated spread in humans. In view of the multi-organ tropism of SARS-CoV-2 in humans, their pathogenic outcome is not predictable. Here, we address and resolve both issues. We describe an innovative VSV vaccine, which is safe both in terms of virus propagation and immune response, as it is a non-spreading single round replicon vector, and the immunogen is limited to the spike’s receptor binding domain (RBD), which emerged as the antigen eliciting the desired virus-neutralizing antibodies in humans. An excellent protective immune response in animals is achieved by the design of a chimeric RBD-minispike, which allows a combined “2-in-1” approach, meaning that the optimized antigen is simultaneously presented on cells and on noninfectious virus-like particles (VLPs). With such enhanced RBD antigen presentation it is thus not necessary to use replication-competent virus or entire S antigen.</p>]]></description>
            <pubDate><![CDATA[2021-04-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Plasmacytoid dendritic cells have divergent effects on HIV infection of initial target cells and induce a pro-retention phenotype]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766071990292-13a0feb9-050c-44c8-ba6d-3f8f2c760186/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009522</link>
            <description><![CDATA[<p class="para" id="N65539">Although HIV infection inhibits interferon responses in its target cells <i>in vitro</i>, interferon signatures can be detected <i>in vivo</i> soon after sexual transmission, mainly attributed to plasmacytoid dendritic cells (pDCs). In this study, we examined the physiological contributions of pDCs to early HIV acquisition using coculture models of pDCs with myeloid DCs, macrophages and the resting central, transitional and effector memory CD4 T cell subsets. pDCs impacted infection in a cell-specific manner. In myeloid cells, HIV infection was decreased via antiviral effects, cell maturation and downregulation of CCR5 expression. In contrast, in resting memory CD4 T cells, pDCs induced a subset-specific increase in intracellular HIV p24 protein expression without any activation or increase in CCR5 expression, as measured by flow cytometry. This increase was due to reactivation rather than enhanced viral spread, as blocking HIV entry via CCR5 did not alter the increased intracellular p24 expression. Furthermore, the load and proportion of cells expressing HIV DNA were restricted in the presence of pDCs while reverse transcriptase and p24 ELISA assays showed no increase in particle associated reverse transcriptase or extracellular p24 production. In addition, pDCs also markedly induced the expression of CD69 on infected CD4 T cells and other markers of CD4 T cell tissue retention. These phenotypic changes showed marked parallels with resident memory CD4 T cells isolated from anogenital tissue using enzymatic digestion. Production of IFNα by pDCs was the main driving factor for all these results. Thus, pDCs may reduce HIV spread during initial mucosal acquisition by inhibiting replication in myeloid cells while reactivating latent virus in resting memory CD4 T cells and retaining them for immune clearance.</p><p class="para" id="N65542">IFNs constitute one of the first and most important innate immune controls to restrict initial viral replication and spread. As HIV has evolved mechanisms to block IFN-I induction in its target cells, but not in infiltrating pDCs, understanding how pDCs influence HIV infection of target cells upon initial transmission is critical to prevent or control initial infection. Therefore, we modelled the early events occurring immediately as HIV enters the human genital mucosa. We showed that IFNα secreting pDC compensated for HIV inhibition of IFN-I production in its target cells in two different ways: i) reduced infection in DCs and macrophages which would limit viral spread to resident or newly infiltrating memory CD4 T cells; ii) reactivation of latent HIV in all subsets of resting memory CD4 T cell subsets, accompanied by limited viral spread, upregulation of MHC-I and induction of a tissue retention phenotype. The increased HIV protein, MHC-I expression and retention may enhance exposure to CD8 T cell surveillance. This model suggests that IFNα reactivation of latent HIV combined with adoptive immunotherapy using CD8 T cells or those expressing chimeric antigen receptors (CAR) could provide a novel ‘kick and kill’ approach to eradicate HIV reservoirs.</p>]]></description>
            <pubDate><![CDATA[2021-04-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Human parvovirus B19 interacts with globoside under acidic conditions as an essential step in endocytic trafficking]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766071126751-10ebd9aa-b393-4b68-ba27-edd5ce2bc42d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009434</link>
            <description><![CDATA[<p class="para" id="N65539">The glycosphingolipid (GSL) globoside (Gb4) is essential for parvovirus B19 (B19V) infection. Historically considered the cellular receptor of B19V, the role of Gb4 and its interaction with B19V are controversial. In this study, we applied artificial viral particles, genetically modified cells, and specific competitors to address the interplay between the virus and the GSL. Our findings demonstrate that Gb4 is not involved in the binding or internalization process of the virus into permissive erythroid cells, a function that corresponds to the VP1u cognate receptor. However, Gb4 is essential at a post-internalization step before the delivery of the single-stranded viral DNA into the nucleus. In susceptible erythroid Gb4 knockout cells, incoming viruses were arrested in the endosomal compartment, showing no cytoplasmic spreading of capsids as observed in Gb4-expressing cells. Hemagglutination and binding assays revealed that pH acts as a switch to modulate the affinity between the virus and the GSL. Capsids interact with Gb4 exclusively under acidic conditions and dissociate at neutral pH. Inducing a specific Gb4-mediated attachment to permissive erythroid cells by acidification of the extracellular environment led to a non-infectious uptake of the virus, indicating that low pH-mediated binding to the GSL initiates active membrane processes resulting in vesicle formation. In summary, this study provides mechanistic insight into the interaction of B19V with Gb4. The strict pH-dependent binding to the ubiquitously expressed GSL prevents the redirection of the virus to nonpermissive tissues while promoting the interaction in acidic intracellular compartments as an essential step in infectious endocytic trafficking.</p><p class="para" id="N65542">The neutral glycosphingolipid globoside (Gb4) has been historically considered the cellular receptor of B19V, however, its wide expression profile does not correlate well with the restricted tropism of the virus. Here, we show that Gb4 is essential for the infection at a step following virus uptake and before the delivery of the viral ssDNA into the nucleus. B19V interacts with Gb4 exclusively under acidic conditions, prohibiting the interaction on the plasma membrane and promoting it inside the acidic endosomal compartments, which are engaged by the virus and the GSL after internalization. In the absence of Gb4, incoming viruses are retained in the endocytic compartment and the infection is aborted. This study reveals the mechanism of the interaction between the virus and the glycosphingolipid and redefines the role of Gb4 as an essential intracellular partner required for infectious entry.</p>]]></description>
            <pubDate><![CDATA[2021-04-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Hepatitis B virus infection and its determinants among HIV positive pregnant women: Multicenter unmatched case-control study]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766071063153-730fcfe0-ed68-4749-bf6c-b6261ef92a38/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0251084</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Hepatitis B virus (HBV) kills millions of people globally; it is worse in pregnant women. HBV and Human Immune Virus (HIV) co-infection is associated with increased liver diseases such as cirrhosis and hepatocellular carcinoma. This study aimed at identifying the determinants of HBV infection among HIV-positive pregnant women.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A multicentre unmatched case-control study was conducted among 109 cases (HBV/HIV co-infected) and 327 controls (HIV positive) pregnant women in seven hospitals of the Eastern Amhara region. Interview and chart review data collection techniques were employed by trained personnel. A binary logistic regression model was used to identify independent predictors of hepatitis B virus infection. Variables with a p-value of &lt;0.05 and 95% confidence interval for odds ratio not containing 1 considered independent predictors of HBV infection.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">The findings of this study revealed that history of STI [AOR, 1.97, 95%CI, 1.09–3.56], hospital admission [AOR, 3.08, 95%CI, 1.69–5.61], traditional delivery care [AOR, 3.31, 95%CI, 1.72–6.37], family history of HBV [AOR, 3.33, 95%CI, 1.72–6.37], presence of opportunistic infections [AOR, 0.23, 95%CI, 0.12–0.58], viral load [AOR, 7.58, 95%CI, 3.18–8.01], CD4 count [AOR, 2.15, 95% CI, 1.01–4.59], anaemia [AOR, 3.07, 95% CI, 1.71–5.51] and unsafe sex [AOR, 1.98, 95%CI, 1.09–3.61] had a statistically significant association with HBV infection.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65561">Several exposure variables had statistically significant association with HBV infection. High Viral Load appeared to be the largest predictor of HBV infection in HIV patients. Therefore, targeted interventions such as behavioral change intervention for unsafe sex and STI should be in place, and screening tests and treatment at the early stage of conception for both partners is necessary.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-30T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Evaluation of COVID-19 vaccination strategies with a delayed second dose]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766071043736-70cb937d-ebc7-4e0b-bf80-459a91298ae1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pbio.3001211</link>
            <description><![CDATA[<p class="para" id="N65539">Two of the Coronavirus Disease 2019 (COVID-19) vaccines currently approved in the United States require 2 doses, administered 3 to 4 weeks apart. Constraints in vaccine supply and distribution capacity, together with a deadly wave of COVID-19 from November 2020 to January 2021 and the emergence of highly contagious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, sparked a policy debate on whether to vaccinate more individuals with the first dose of available vaccines and delay the second dose or to continue with the recommended 2-dose series as tested in clinical trials. We developed an agent-based model of COVID-19 transmission to compare the impact of these 2 vaccination strategies, while varying the temporal waning of vaccine efficacy following the first dose and the level of preexisting immunity in the population. Our results show that for Moderna vaccines, a delay of at least 9 weeks could maximize vaccination program effectiveness and avert at least an additional 17.3 (95% credible interval [CrI]: 7.8–29.7) infections, 0.69 (95% CrI: 0.52–0.97) hospitalizations, and 0.34 (95% CrI: 0.25–0.44) deaths per 10,000 population compared to the recommended 4-week interval between the 2 doses. Pfizer-BioNTech vaccines also averted an additional 0.60 (95% CrI: 0.37–0.89) hospitalizations and 0.32 (95% CrI: 0.23–0.45) deaths per 10,000 population in a 9-week delayed second dose (DSD) strategy compared to the 3-week recommended schedule between doses. However, there was no clear advantage of delaying the second dose with Pfizer-BioNTech vaccines in reducing infections, unless the efficacy of the first dose did not wane over time. Our findings underscore the importance of quantifying the characteristics and durability of vaccine-induced protection after the first dose in order to determine the optimal time interval between the 2 doses.</p><p class="para" id="N65540">There are two widely used COVID-19 vaccination strategies; administering the two doses three to four weeks apart or delaying the administration of the second dose. A modelling study calibrated to COVID-19 spread and vaccination in the US shows that delaying the second dose can maximize the benefits of vaccination programs under certain conditions.</p>]]></description>
            <pubDate><![CDATA[2021-04-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The dinucleotide composition of the Zika virus genome is shaped by conflicting evolutionary pressures in mammalian hosts and mosquito vectors]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766070927595-dc9e2ed7-90c7-4ff8-a38c-8664ca7a87c1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pbio.3001201</link>
            <description><![CDATA[<p class="para" id="N65539">Most vertebrate RNA viruses show pervasive suppression of CpG and UpA dinucleotides, closely resembling the dinucleotide composition of host cell transcriptomes. In contrast, CpG suppression is absent in both invertebrate mRNA and RNA viruses that exclusively infect arthropods. Arthropod-borne (arbo) viruses are transmitted between vertebrate hosts by invertebrate vectors and thus encounter potentially conflicting evolutionary pressures in the different cytoplasmic environments. Using a newly developed Zika virus (ZIKV) model, we have investigated how demands for CpG suppression in vertebrate cells can be reconciled with potentially quite different compositional requirements in invertebrates and how this affects ZIKV replication and transmission. Mutant viruses with synonymously elevated CpG or UpA dinucleotide frequencies showed attenuated replication in vertebrate cell lines, which was rescued by knockout of the zinc-finger antiviral protein (ZAP). Conversely, in mosquito cells, ZIKV mutants with elevated CpG dinucleotide frequencies showed substantially enhanced replication compared to wild type. Host-driven effects on virus replication attenuation and enhancement were even more apparent in mouse and mosquito models. Infections with CpG- or UpA-high ZIKV mutants in mice did not cause typical ZIKV-induced tissue damage and completely protected mice during subsequent challenge with wild-type virus, which demonstrates their potential as live-attenuated vaccines. In contrast, the CpG-high mutants displayed enhanced replication in <i>Aedes aegypti</i> mosquitoes and a larger proportion of mosquitoes carried infectious virus in their saliva. These findings show that mosquito cells are also capable of discriminating RNA based on dinucleotide composition. However, the evolutionary pressure on the CpG dinucleotides of viral genomes in arthropod vectors directly opposes the pressure present in vertebrate host cells, which provides evidence that an adaptive compromise is required for arbovirus transmission. This suggests that the genome composition of arbo flaviviruses is crucial to maintain the balance between high-level replication in the vertebrate host and persistent replication in the mosquito vector.</p><p class="para" id="N65540">The genome of the flavivirus Zika virus is stuck in a tug-of-war between two directly opposing evolutionary pressures that are present in the cells of mammalian host organisms and mosquito vectors; this results in an adaptive compromise, as manifested in the virus’s genome dinucleotide composition.</p>]]></description>
            <pubDate><![CDATA[2021-04-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Balancing the influenza neuraminidase and hemagglutinin responses by exchanging the vaccine virus backbone]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766070693428-25acd0b4-2cd1-44d5-b105-41d0f1ccb42f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009171</link>
            <description><![CDATA[<p class="para" id="N65539">Virions are a common antigen source for many viral vaccines. One limitation to using virions is that the antigen abundance is determined by the content of each protein in the virus. This caveat especially applies to viral-based influenza vaccines where the low abundance of the neuraminidase (NA) surface antigen remains a bottleneck for improving the NA antibody response. Our systematic analysis using recent H1N1 vaccine antigens demonstrates that the NA to hemagglutinin (HA) ratio in virions can be improved by exchanging the viral backbone internal genes, especially the segment encoding the polymerase PB1 subunit. The purified inactivated virions with higher NA content show a more spherical morphology, a shift in the balance between the HA receptor binding and NA receptor release functions, and induce a better NA inhibitory antibody response in mice. These results indicate that influenza viruses support a range of ratios for a given NA and HA pair which can be used to produce viral-based influenza vaccines with higher NA content that can elicit more balanced neutralizing antibody responses to NA and HA.</p><p class="para" id="N65542">Influenza vaccines are produced on a large scale to meet the annual U.S. and global demand. To efficiently produce the required number of influenza vaccine doses, virions are commonly used as the antigen source due to their high viral protein content. A draw-back to using virions is that the final antigen composition of the vaccine is determined by the inherent properties of the vaccine virus. While this approach for influenza vaccines is beneficial for the more abundant HA antigen, it likely limits the protective response generated by the less abundant NA antigen. Our results demonstrate that the NA and HA content in vaccine viruses can be optimized by changing the internal genes of the vaccine virus, thereby preserving the surface antigens. The increase in the virion NA content that was achieved elicited higher NA antibody titres and generated more balanced neutralizing antibody responses to HA and NA. Since HA and NA neutralizing antibodies are both protective, this approach could help to improve the suboptimal efficacy of current influenza vaccines and to generate vaccines that provide broader coverage against circulating strains.</p>]]></description>
            <pubDate><![CDATA[2021-04-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Potential for online crowdsourced biological recording data to complement surveillance for arthropod vectors]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766070421793-297de292-c72f-4085-a569-e7d9d673cc78/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250382</link>
            <description><![CDATA[<p class="para" id="N65539">Voluntary contributions by citizen scientists can gather large datasets covering wide geographical areas, and are increasingly utilized by researchers for multiple applications, including arthropod vector surveillance. Online platforms such as iNaturalist accumulate crowdsourced biological observations from around the world and these data could also be useful for monitoring vectors. The aim of this study was to explore the availability of observations of important vector taxa on the iNaturalist platform and examine the utility of these data to complement existing vector surveillance activities. Of ten vector taxa investigated, records were most numerous for mosquitoes (Culicidae; 23,018 records, 222 species) and ticks (Ixodida; 16,214 records, 87 species), with most data from 2019–2020. Case studies were performed to assess whether images associated with records were of sufficient quality to identify species and compare iNaturalist observations of vector species to the known situation at the state, national and regional level based on existing published data. Firstly, tick data collected at the national (United Kingdom) or state (Minnesota, USA) level were sufficient to determine seasonal occurrence and distribution patterns of important tick species, and were able to corroborate and complement known trends in tick distribution. Importantly, tick species with expanding distributions (<i>Haemaphysalis punctata</i> in the UK, and <i>Amblyomma americanum</i> in Minnesota) were also detected. Secondly, using iNaturalist data to monitor expanding tick species in Europe (<i>Hyalomma</i> spp.) and the USA (<i>Haemaphysalis longicornis</i>), and invasive <i>Aedes</i> mosquitoes in Europe, showed potential for tracking these species within their known range as well as identifying possible areas of expansion. Despite known limitations associated with crowdsourced data, this study shows that iNaturalist can be a valuable source of information on vector distribution and seasonality that could be used to supplement existing vector surveillance data, especially at a time when many surveillance programs may have been interrupted by COVID-19 restrictions.</p>]]></description>
            <pubDate><![CDATA[2021-04-30T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[DNA damage and oxidative stress in human cells infected by <i>Trypanosoma cruzi</i>]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766070203721-d7825737-6b91-4411-b80e-92c617ed87a6/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009502</link>
            <description><![CDATA[<p class="para" id="N65539"><i>Trypanosoma cruzi</i> is the etiologic agent of Chagas’ disease. Infected cells with <i>T</i>. <i>cruzi</i> activate several responses that promote unbalance of reactive oxygen species (ROS) that may cause DNA damage that activate cellular responses including DNA repair processes. In this work, HeLa cells and AC16 human cardiomyocyte cell line were infected with <i>T</i>. <i>cruzi</i> to investigate host cell responses at genome level during parasites intracellular life cycle. In fact, alkaline sensitive sites and oxidized DNA bases were detected in the host cell genetic material particularly in early stages of infection. These DNA lesions were accompanied by phosphorylation of the histone H2Ax, inducing γH2Ax, a marker of genotoxic stress. Moreover, Poly [ADP-ribose] polymerase-1 (PARP1) and 8-oxoguanine glycosylase (OGG1) are recruited to host cell nuclei, indicating activation of the DNA repair process. In infected cells, chromatin-associated proteins are carbonylated, as a possible consequence of oxidative stress and the nuclear factor erythroid 2–related factor 2 (NRF2) is induced early after infection, suggesting that the host cell antioxidant defenses are activated. However, at late stages of infection, NRF2 is downregulated. Interestingly, host cells treated with glutathione precursor, N-acetyl cysteine, NRF2 activator (Sulforaphane), and also Benznidonazol (BNZ) reduce parasite burst significantly, and DNA damage. These data indicate that the balance of oxidative stress and DNA damage induction in host cells may play a role during the process of infection itself, and interference in these processes may hamper <i>T</i>. <i>cruzi</i> infection, revealing potential target pathways for the therapy support.</p><p class="para" id="N65542">Chagas’ disease is a neglected disease that afflicts over eight million individuals worldwide. Oxidative stress is an important cell response when infected by <i>Trypanosoma cruzi</i>, etiologic agent of Chagas disease, although its role in host cell DNA/RNA metabolism has not been fully described. In this study, we investigated how <i>T</i>. <i>cruzi</i> infection and oxidative stress affect DNA molecule and the host cell metabolism. Data show that <i>T</i>. <i>cruzi</i> infection promote oxidative stress, which induce protein oxidation and DNA damage in human cells. Interestingly, control of the oxidative stress reduces the parasite capacity of infection. Until now, drug treatment with Nifurtimox or Benznidazole (BNZ) is only effective in the acute phase of the disease. This work revealed that pre administered BNZ to the host cells was also efficient in reducing oxidative stress and DNA damage, caused by parasite infection. Therefore, BNZ could be preparing cellular metabolism to respond to <i>T</i>. <i>cruzi</i> infection also by controlling the oxidative stress that may be necessary for the parasite propagation.</p>]]></description>
            <pubDate><![CDATA[2021-04-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A call for diversity, equity, and inclusion: Highlights from the Consortium of Universities for Global Health 2021 conference]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766069517826-1cc852e3-7391-4b48-b21f-33b594e52609/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pmed.1003607</link>
            <description><![CDATA[<p class="para" id="N65540">Beryne Odeny reports from the CUGH 2021 virtual conference.</p>]]></description>
            <pubDate><![CDATA[2021-04-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766069419888-b55bf874-6b28-47c1-81a7-df34e9e14bd9/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244771</link>
            <description><![CDATA[<p class="para" id="N65539">Although current antiretroviral therapies (ART) are successful in controlling HIV-1 infection, a stable viral reservoir reactivates when ART is discontinued. Consequently, there is a major research effort to develop approaches to disrupt the latent viral reservoir and enhance the immune system’s ability to clear HIV-1. A number of small molecules, termed latency reversal agents (LRAs), have been identified which can reactivate latent HIV-1 in cell lines and patients’ cells <i>ex vivo</i>. However, clinical trials have suggested that combinations of LRAs will be required to efficiently reactivate HIV-1 <i>in vivo</i>, especially LRAs that act synergistically by functioning through distinct pathways. To identify novel LRAs, we used an image-based assay to screen a natural compound library for the ability to induce a low level of aggregation of resting primary CD4<sup>+</sup> T cells from healthy donors. We identified celastrol as a novel LRA. Celastrol functions synergistically with other classes of LRA to reactivate latent HIV-1 in a Jurkat cell line, suggesting a novel mechanism in its LRA activity. Additionally, celastrol does not appear to activate resting CD4<sup>+</sup> T cells at levels at which it can reactivate latent HIV-1. Celastrol appears to represent a novel class of LRAs and it therefore can serve as a lead compound for LRA development.</p>]]></description>
            <pubDate><![CDATA[2021-04-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Development of multiplex real-time RT-PCR assay for the detection of SARS-CoV-2]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766069246672-c62b8dd9-3a07-4fa0-8b21-71402a6f884a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250942</link>
            <description><![CDATA[<p class="para" id="N65539">The outbreak of the new human coronavirus SARS-CoV-2 (also known as 2019-nCoV) continues to increase globally. The real-time reverse transcription polymerase chain reaction (rRT-PCR) is the most used technique in virus detection. However, possible false-negative and false-positive results produce misleading consequences, making it necessary to improve existing methods. Here, we developed a multiplex rRT-PCR diagnostic method, which targets two viral genes (<i>RdRP</i> and <i>E</i>) and one human gene (<i>RP</i>) simultaneously. The reaction was tested by using <i>pseudoviral</i> RNA and human target mRNA sequences as a template. Also, the protocol was validated by using 14 clinical SARS-CoV-2 positive samples. The results are in good agreement with the CDC authorized Cepheid`s Xpert<sup>®</sup> Xpress SARS-CoV-2 diagnostic system (100%). Unlike single gene targeting strategies, the current method provides the amplification of two viral regions in the same PCR reaction. Therefore, an accurate SARS-CoV-2 diagnostic assay was provided, which allows testing of 91 samples in 96-well plates in per run. Thanks to this strategy, fast, reliable, and easy-to-use rRT-PCR method is obtained to diagnose SARS-CoV-2.</p>]]></description>
            <pubDate><![CDATA[2021-04-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Structures of Foot-and-mouth Disease Virus with neutralizing antibodies derived from recovered natural host reveal a mechanism for cross-serotype neutralization]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766069075897-87e59486-da77-4341-a4dd-6a822aab31f0/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009507</link>
            <description><![CDATA[<p class="para" id="N65539">The development of a universal vaccine against foot-and-mouth disease virus (FMDV) is hindered by cross-serotype antigenic diversity and by a lack of knowledge regarding neutralization of the virus in natural hosts. In this study, we isolated serotype O-specific neutralizing antibodies (NAbs) (F145 and B77) from recovered natural bovine hosts by using the single B cell antibody isolation technique. We also identified a serotype O/A cross-reacting NAb (R50) and determined virus-NAb complex structures by cryo-electron microscopy at near-atomic resolution. F145 and B77 were shown to engage the capsid of FMDV-O near the icosahedral threefold axis, binding to the BC/HI-loop of VP2. In contrast, R50 engages the capsids of both FMDV-O and FMDV-A between the 2- and 5-fold axes and binds to the BC/EF/GH-loop of VP1 and to the GH-loop of VP3 from two adjacent protomers, revealing a previously unknown antigenic site. The cross-serotype neutralizing epitope recognized by R50 is highly conserved among serotype O/A. These findings help to elucidate FMDV neutralization by natural hosts and provide epitope information for the development of a universal vaccine for cross-serotype protection against FMDV.</p><p class="para" id="N65542">FMDV is the causative agent of foot-and-mouth disease, one of the most contagious and economically devastating diseases of cloven-hoofed animals. The antigenic diversities of the currently known epitopes throughout FMDV serotypes and the lack of understanding of FMDV neutralization in natural hosts limit the development of a vaccine that is able to provide cross-serotype protection. In this work, we isolated FMDV serotype O-specific neutralizing antibodies (NAbs) (F145 and B77) and a serotype O/A cross-reacting NAb (R50) from recovered natural bovine hosts and determined virus-NAb complex structures by cryo-electron microscopy at near-atomic resolution. Structures of virus-NAb complex reveal F145 and B77 engage the capsid of FMDV-O near the icosahedral threefold axis. In contrast, R50 engages the capsids of both FMDV-O and FMDV-A between the 2- and 5-fold axes, revealing a previously unknown antigenic site. This is the first time to present structure details of FMDV neutralization by natural hosts. And this work also provides epitope information for the development of a universal vaccine for cross-serotype protection against FMDV.</p>]]></description>
            <pubDate><![CDATA[2021-04-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Immunization by exposure to live virus (SIV<sub>mne</sub>/HIV-2<sub>287</sub>) during antiretroviral drug prophylaxis may reduce risk of subsequent viral challenge]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766068467668-99e50736-8b8d-43c3-9412-5a351f765c43/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0240495</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Rationale/Study design</h3><p class="para" id="N65543">A major challenge in the development of HIV vaccines is finding immunogens that elicit protection against a broad range of viral strains. Immunity to a narrow range of viral strains may protect infants of HIV-infected women or partners discordant for HIV. We hypothesized that immunization to the relevant viral variants could be achieved by exposure to infectious virus during prophylaxis with antiretroviral drugs. To explore this approach in an animal model, macaques were exposed to live virus (SIV<sub>mne</sub> or HIV-2<sub>287</sub>) during prophylaxis with parenteral tenofovir and humoral and cellular immune responses were quantified. Subsequently, experimental animals were challenged with homologous virus to evaluate protection from infection, and if infection occurred, the course of disease was compared to control animals. Experimental animals uninfected with SIV<sub>mne</sub> were challenged with heterologous HIV-2<sub>287</sub> to assess resistance to retroviral infection.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methodology/Principal findings</h3><p class="para" id="N65561">Juvenile female <i>Macaca nemestrina</i> (N = 8) were given ten weekly intravaginal exposures with either moderately (SIV<sub>mne</sub>) or highly (HIV-2<sub>287</sub>) pathogenic virus during tenofovir prophylaxis. Tenofovir protected all 8 experimental animals from infection, while all untreated control animals became infected. Specific non-neutralizing antibodies were elicited in blood and vaginal secretions of experimental animals, but no ELISPOT responses were detected. Six weeks following the cessation of tenofovir, intravaginal challenge with homologous virus infected 2/4 (50%) of the SIV<sub>mne</sub>-immunized animals and 4/4 (100%) of the HIV-2<sub>287</sub>-immunized animals. The two SIV<sub>mne</sub>-infected and 3 (75%) HIV-2<sub>287</sub>-infected had attenuated disease, suggesting partial protection.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusions/Significance</h3><p class="para" id="N65588">Repeated exposure to SIV<sub>mne</sub> or HIV-2<sub>287</sub>, during antiretroviral prophylaxis that blocked infection, induced binding antibodies in the blood and mucosa, but not neutralizing antibodies or specific cellular immune responses. Studies to determine whether antibodies are similarly induced in breastfeeding infants and sexual partners discordant for HIV infection and receiving pre-exposure antiretroviral prophylaxis are warranted, including whether these antibodies appear to confer partial or complete protection from infection.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Two courses of deconstructed coronavirus please]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766068120156-4ccfb9ad-410d-4a71-898e-6f92833544e8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009547</link>
            <description><![CDATA[]]></description>
            <pubDate><![CDATA[2021-04-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Human plasmacytoid dendritic cells at the crossroad of type I interferon-regulated B cell differentiation and antiviral response to tick-borne encephalitis virus]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766067688584-c426bfd8-82e8-4e71-aebb-7df9334a139f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009505</link>
            <description><![CDATA[<p class="para" id="N65539">The Tick-borne encephalitis virus (TBEV) causes different disease symptoms varying from asymptomatic infection to severe encephalitis and meningitis suggesting a crucial role of the human host immune system in determining the fate of the infection. There is a need to understand the mechanisms underpinning TBEV-host interactions leading to protective immunity. To this aim, we studied the response of human peripheral blood mononuclear cells (PBMC) to the whole formaldehyde inactivated TBEV (I-TBEV), the drug substance of Encepur, one of the five commercially available vaccine. Immunophenotyping, transcriptome and cytokine profiling of PBMC revealed that I-TBEV generates differentiation of a sub-population of plasmacytoid dendritic cells (pDC) that is specialized in type I interferon (IFN) production. In contrast, likely due to the presence of aluminum hydroxide, Encepur vaccine was a poor pDC stimulus. We demonstrated I-TBEV-induced type I IFN together with Interleukin 6 and BAFF to be critical for B cell differentiation to plasmablasts as measured by immunophenotyping and immunoglobulin production. Robust type I IFN secretion was induced by pDC with the concerted action of both viral E glycoprotein and RNA mirroring previous data on dual stimulation of pDC by both <i>S</i>. <i>aureus</i> and influenza virus protein and nucleic acid that leads to a type I IFN-mediated sustained immune response. E glycoprotein neutralization or high temperature denaturation and inhibition of Toll-like receptor 7 signalling confirmed the importance of preserving the functional integrity of these key viral molecules during the inactivation procedure and manufacturing process to produce a vaccine able to stimulate strong immune responses.</p><p class="para" id="N65542">Though vaccination is generally considered effective in reducing tick-borne encephalitis (TBE) incidence, several studies have shown that the antibody response to TBEV vaccination declines with age resulting in more frequent TBE cases among 50+ year-old vaccinees. These observations together with the lack of a specific antiviral drug impose to pinpoint novel host- and pathogen-directed therapies and to improve the control of vaccine efficacy. Thus, we interrogated <i>in vitro</i> human PBMC, whose response to TBEV may provide a picture closer to what occurs <i>in vivo</i> in humans after vaccination or natural infection compared to animal models. The role of E glycoprotein and viral RNA in promoting antiviral and B cell-mediated responses was investigated. Thus, these key viral molecules should be considered, in future, for novel subunit vaccine formulations than the current whole inactivated TBEV-based vaccines, which require laborious manipulation in biosafety level-3 laboratory and animal testing for manufacturing and batch release.</p>]]></description>
            <pubDate><![CDATA[2021-04-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Willingness to vaccinate against COVID-19 among Bangladeshi adults: Understanding the strategies to optimize vaccination coverage]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766067184899-4e91a6b9-85cf-47d4-9f96-799e68f63543/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250495</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Although the approved COVID-19 vaccine has been shown to be safe and effective, mass vaccination in Bangladeshi people remains a challenge. As a vaccination effort, the study provided an empirical evidence on willingness to vaccinate by sociodemographic, clinical and regional differences in Bangladeshi adults.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">This cross-sectional analysis from a household survey of 3646 adults aged 18 years or older was conducted in 8 districts of Bangladesh, from December 12, 2020, to January 7, 2021. Multinomial regression examined the impact of socio-demographic, clinical and healthcare-releated factors on hesitancy and reluctance of vaccination for COVID-19.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Of the 3646 respondents (2212 men [60.7%]; mean [sd] age, 37.4 [13.9] years), 74.6% reported their willingness to vaccinate against COVID-19 when a safe and effective vaccine is available without a fee, while 8.5% were reluctant to vaccinate. With a minimum fee, 46.5% of the respondents showed intent to vaccinate. Among the respondents, 16.8% reported adequate adherence to health safety regulations, and 35.5% reported high confidence in the country’s healthcare system. The COVID-19 vaccine refusal was significantly high in elderly, rural, semi-urban, and slum communities, farmers, day-laborers, homemakers, low-educated group, and those who had low confidence in the country’s healthcare system. Also, the prevalence of vaccine hesitancy was high in the elderly population, low-educated group, day-laborers, people with chronic diseases, and people with low confidence in the country’s healthcare system.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">A high prevalence of vaccine refusal and hesitancy was observed in rural people and slum dwellers in Bangladesh. The rural community and slum dwellers had a low literacy level, low adherence to health safety regulations and low confidence in healthcare system. The ongoing app-based registration for vaccination increased hesitancy and reluctancy in low-educated group. For rural, semi-urban, and slum people, outreach centers for vaccination can be established to ensure the vaccine’s nearby availability and limit associated travel costs. In rural areas, community health workers, valued community-leaders, and non-governmental organizations can be utilized to motivate and educate people for vaccination against COVID-19. Further, emphasis should be given to the elderly and diseased people with tailored health messages and assurance from healthcare professionals. The media may play a responsible role with the vaccine education program and eliminate the social stigma about the vaccination. Finally, vaccination should be continued without a fee and thus Bangladesh’s COVID vaccination program can become a model for other low and middle-income countries.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-27T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The antiviral sirtuin 3 bridges protein acetylation to mitochondrial integrity and metabolism during human cytomegalovirus infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766067146884-2fb88784-380b-48c5-9fa0-630b35e1adcf/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009506</link>
            <description><![CDATA[<p class="para" id="N65539">Regulation of mitochondrial structure and function is a central component of infection with viruses, including human cytomegalovirus (HCMV), as a virus means to modulate cellular metabolism and immune responses. Here, we link the activity of the mitochondrial deacetylase SIRT3 and global mitochondrial acetylation status to host antiviral responses via regulation of both mitochondrial structural integrity and metabolism during HCMV infection. We establish that SIRT3 deacetylase activity is necessary for suppressing virus production, and that SIRT3 maintains mitochondrial pH and membrane potential during infection. By defining the temporal dynamics of SIRT3-substrate interactions during infection, and overlaying acetylome and proteome information, we find altered SIRT3 associations with the mitochondrial fusion factor OPA1 and acetyl-CoA acyltransferase 2 (ACAA2), concomitant with changes in their acetylation levels. Using mutagenesis, microscopy, and virology assays, we determine OPA1 regulates mitochondrial morphology of infected cells and inhibits HCMV production. OPA1 acetylation status modulates these functions, and we establish K834 as a site regulated by SIRT3. Control of SIRT3 protein levels or enzymatic activity is sufficient for regulating mitochondrial filamentous structure. Lastly, we establish a virus restriction function for ACAA2, an enzyme involved in fatty acid beta-oxidation. Altogether, we highlight SIRT3 activity as a regulatory hub for mitochondrial acetylation and morphology during HCMV infection and point to global acetylation as a reflection of mitochondrial health.</p><p class="para" id="N65542">Given their functions in cellular metabolism and immune responses, mitochondria are targeted and disrupted by numerous prevalent viral pathogens, including human cytomegalovirus (HCMV). To characterize mechanisms underlying mitochondrial regulation during HCMV infection in human fibroblasts, this study integrates enzyme-substrate interaction studies, mass spectrometry quantification of protein abundance and acetylation, mutagenesis, microscopy, and virology assays. These analyses establish a link between the mitochondrial acetylation status and mitochondrial structure and metabolism during HCMV infection. We demonstrate that the mitochondrial deacetylase SIRT3 acts in host defense by modulating proteins that regulate mitochondrial structure and fatty acid oxidation. SIRT3 helps to maintain mitochondrial integrity through several mechanisms, including regulation of mitochondrial pH, membrane potential, and the balance between mitochondrial fission and fusion. As excess mitochondrial acetylation is detrimental to mitochondrial metabolism, the virus-induced alterations in SIRT3 functions and mitochondrial acetylation may be linked to known HCMV pathologies, such as the metabolic syndrome and cardiac hypertrophy.</p>]]></description>
            <pubDate><![CDATA[2021-04-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766067124082-22f39920-e9bb-411b-b854-2526c3d79cbf/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250780</link>
            <description><![CDATA[<p class="para" id="N65539">The spike protein receptor-binding domain (RBD) of SARS-CoV-2 is the molecular target for many vaccines and antibody-based prophylactics aimed at bringing COVID-19 under control. Such a narrow molecular focus raises the specter of viral immune evasion as a potential failure mode for these biomedical interventions. With the emergence of new strains of SARS-CoV-2 with altered transmissibility and immune evasion potential, a critical question is this: how easily can the virus escape neutralizing antibodies (nAbs) targeting the spike RBD? To answer this question, we combined an analysis of the RBD structure-function with an evolutionary modeling framework. Our structure-function analysis revealed that epitopes for RBD-targeting nAbs overlap one another substantially and can be evaded by escape mutants with ACE2 affinities comparable to the wild type, that are observed in sequence surveillance data and infect cells <i>in vitro</i>. This suggests that the fitness cost of nAb-evading mutations is low. We then used evolutionary modeling to predict the frequency of immune escape before and after the widespread presence of nAbs due to vaccines, passive immunization or natural immunity. Our modeling suggests that SARS-CoV-2 mutants with one or two mildly deleterious mutations are expected to exist in high numbers due to neutral genetic variation, and consequently resistance to vaccines or other prophylactics that rely on one or two antibodies for protection can develop quickly -and repeatedly- under positive selection. Predicted resistance timelines are comparable to those of the decay kinetics of nAbs raised against vaccinal or natural antigens, raising a second potential mechanism for loss of immunity in the population. Strategies for viral elimination should therefore be diversified across molecular targets and therapeutic modalities.</p>]]></description>
            <pubDate><![CDATA[2021-04-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Deciphering the introduction and transmission of SARS-CoV-2 in the Colombian Amazon Basin]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766066860440-efb80543-25b7-44ef-9d4a-21b1e668c079/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0009327</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">The SARS-CoV-2 pandemic has forced health authorities across the world to take important decisions to curtail its spread. Genomic epidemiology has emerged as a valuable tool to understand introductions and spread of the virus in a specific geographic location.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methodology/Principal findings</h3><p class="para" id="N65549">Here, we report the sequences of 59 SARS-CoV-2 samples from inhabitants of the Colombian Amazonas department. The viral genomes were distributed in two robust clusters within the distinct GISAID clades GH and G. Spatial-temporal analyses revealed two independent introductions of SARS-CoV-2 in the region, one around April 1, 2020 associated with a local transmission, and one around April 2, 2020 associated with other South American genomes (Uruguay and Brazil). We also identified ten lineages circulating in the Amazonas department including the P.1 variant of concern (VOC).</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusions/Significance</h3><p class="para" id="N65555">This study represents the first genomic epidemiology investigation of SARS-CoV-2 in one of the territories with the highest report of indigenous communities of the country. Such findings are essential to decipher viral transmission, inform on global spread and to direct implementation of infection prevention and control measures for these vulnerable populations, especially, due to the recent circulation of one of the variants of concern (P.1) associated with major transmissibility and possible reinfections.</p></div><p class="para" id="N65542">SARS-CoV-2 has dramatically impacted Amerindian native communities across South America, particularly in the Amazonian basin. In order to unveil the introduction and initial spread of this pandemic virus into this region, we conducted a genomic epidemiology study where we sequenced 59 genomes from cases in the Amazonas department of Colombia. Our results showed two independent introductions of the virus into the department, one of these associated with asymptomatic cases. This represents the first genomic epidemiology study focused on the Colombian Amazonas department where a great amount of native Amerindian indigenous communities inhabits. Our results provide insights of the transmission dynamic in this region and reported relevant information to pursue strategies to mitigate the spread of the virus in the Amazon population which currently are facing new risks due to the circulating new variant of concern P.1.</p>]]></description>
            <pubDate><![CDATA[2021-04-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[<i>Orientia tsutsugamushi</i> modulates cellular levels of NF-κB inhibitor p105]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766066666046-ceb1015c-1312-402e-b1d7-a7779b9c580b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0009339</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Scrub typhus is a neglected tropical disease that threatens more than one billion people. If antibiotic therapy is delayed, often due to mis- or late diagnosis, the case fatality rate can increase considerably. Scrub typhus is caused by the obligate intracellular bacterium, <i>Orientia tsutsugamushi</i>, which invades phagocytes and endothelial cells <i>in vivo</i> and diverse tissue culture cell types <i>in vitro</i>. The ability of <i>O</i>. <i>tsutsugamushi</i> to replicate in the cytoplasm indicates that it has evolved to counter eukaryotic host cell immune defense mechanisms. The transcription factor, NF-κB, is a tightly regulated initiator of proinflammatory and antimicrobial responses. Typically, the inhibitory proteins p105 and IκBα sequester the NF-κB p50:p65 heterodimer in the cytoplasm. Canonical activation of NF-κB via TNFα involves IKKβ-mediated serine phosphorylation of IκBα and p105, which leads to their degradation and enables NF-κB nuclear translocation. A portion of p105 is also processed into p50. <i>O</i>. <i>tsutsugamushi</i> impairs NF-κB translocation into the nucleus, but how it does so is incompletely defined.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Principal findings</h3><p class="para" id="N65570">Western blot, densitometry, and quantitative RT-PCR analyses of <i>O</i>. <i>tsutsugamushi</i> infected host cells were used to determine if the pathogen’s ability to inhibit NF-κB is linked to modulation of p105. Results demonstrate that p105 levels are elevated several-fold in <i>O</i>. <i>tsutsugamushi</i> infected HeLa and RF/6A cells with only a nominal increase in p50. The <i>O</i>. <i>tsutsugamushi</i>-stimulated increase in p105 is bacterial dose- and protein synthesis-dependent, but does not occur at the level of host cell transcription. While TNFα-induced phosphorylation of p105 serine 932 proceeds unhindered in infected cells, p105 levels remain elevated and NF-κB p65 is retained in the cytoplasm.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusions</h3><p class="para" id="N65594"><i>O</i>. <i>tsutsugamushi</i> specifically stabilizes p105 to inhibit the canonical NF-κB pathway, which advances understanding of how it counters host immunity to establish infection.</p></div><p class="para" id="N65542">Scrub typhus is a neglected disease that can be fatal and occurs predominantly in the Asia-Pacific, one of the most densely populated regions of the world. Notably, cases continue to emerge outside this area. The etiologic agent is <i>Orientia tsutsugamushi</i>, a bacterial pathogen that infects certain leukocytes and cells that line blood vessels in animals and humans. The success of <i>O</i>. <i>tsutsugamushi</i> to colonize these cells is at least partially attributable to its ability to counter host immunity. In this study, we demonstrate that <i>O</i>. <i>tsutsugamushi</i> stabilizes p105, a mammalian inhibitor of the transcription factor, NF-κB, which is otherwise key for activating proinflammatory and antimicrobial gene expression. <i>O</i>. <i>tsutsugamushi</i> is the first example of a bacterium that inhibits NF-κB by promoting elevated levels of p105 and impairing its degradation. Our findings provide fundamental information that helps explain how this important pathogen has evolved to stealthily establish infection in host cells.</p>]]></description>
            <pubDate><![CDATA[2021-04-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Comprehensive at-arrival transcriptomic analysis of post-weaned beef cattle uncovers type I interferon and antiviral mechanisms associated with bovine respiratory disease mortality]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766066300220-27e3d38b-020f-449c-a81b-8c37880c476f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250758</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Despite decades of extensive research, bovine respiratory disease (BRD) remains the most devastating disease in beef cattle production. Establishing a clinical diagnosis often relies upon visual detection of non-specific signs, leading to low diagnostic accuracy. Thus, post-weaned beef cattle are often metaphylactically administered antimicrobials at facility arrival, which poses concerns regarding antimicrobial stewardship and resistance. Additionally, there is a lack of high-quality research that addresses the gene-by-environment interactions that underlie why some cattle that develop BRD die while others survive. Therefore, it is necessary to decipher the underlying host genomic factors associated with BRD mortality versus survival to help determine BRD risk and severity. Using transcriptomic analysis of at-arrival whole blood samples from cattle that died of BRD, as compared to those that developed signs of BRD but lived (n = 3 DEAD, n = 3 ALIVE), we identified differentially expressed genes (DEGs) and associated pathways in cattle that died of BRD. Additionally, we evaluated unmapped reads, which are often overlooked within transcriptomic experiments.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Results</h3><p class="para" id="N65549">69 DEGs (FDR&lt;0.10) were identified between ALIVE and DEAD cohorts. Several DEGs possess immunological and proinflammatory function and associations with TLR4 and IL6. Biological processes, pathways, and disease phenotype associations related to type-I interferon production and antiviral defense were enriched in DEAD cattle at arrival. Unmapped reads aligned primarily to various ungulate assemblies, but failed to align to viral assemblies.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65555">This study further revealed increased proinflammatory immunological mechanisms in cattle that develop BRD. DEGs upregulated in DEAD cattle were predominantly involved in innate immune pathways typically associated with antiviral defense, although no viral genes were identified within unmapped reads. Our findings provide genomic targets for further analysis in cattle at highest risk of BRD, suggesting that mechanisms related to type I interferons and antiviral defense may be indicative of viral respiratory disease at arrival and contribute to eventual BRD mortality.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-26T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Effect of community antiretroviral therapy on treatment outcomes among stable antiretroviral therapy patients in Nigeria: A quasi experimental study]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766066230643-00800763-dfe7-4a2c-b329-c142df2085a5/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250345</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Objectives</h3><p class="para" id="N65543">This study evaluates the effect of Community Anti-retroviral Groups on Immunologic, Virologic and clinical outcomes of stable Antiretroviral Therapy patients in Nigeria.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Method</h3><p class="para" id="N65549">A cohort of 251 eligible adults (≥18 years) on first-line ART for at least 6 months with CD4 counts &gt;200 cells/mm3 and viral load &lt;1000 c/ml were devolved from 10 healthcare facilities to 51 community antiretroviral therapy groups. Baseline immunologic, virologic and clinical parameters were collected and community antiretroviral therapy group patients were followed up for a year after which Human Immunodeficiency Virus treatment outcomes at the baseline and a year after follow-up were compared using paired sample t-test. All the analyses were performed in STATA version 14.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Result</h3><p class="para" id="N65555">Out of the 251 stable antiretroviral therapy adults enrolled, 186 (75.3%) were female, 52 (22.7%) had attained post-secondary education and the mean age of participants was 38 years (SD: 9.5). Also, 66 (27.9%) were employed while 125 (52.7%) were self-employed and 46(19.41%) unemployed. 246 (98.0%) of the participants were retained in care. While there was no statistically significant change in the CD4 counts (456cells/mm3 vs 481cells/mm3 P-0.489) and Log<sub>10</sub> viral load (3.54c/ml vs 3.69c/ml P-0.359) after one year of devolvement into the community, we observed a significant increase in body weight (60.8 vs 65, P-0.01).</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65564">This study demonstrates that community antiretroviral therapy has a potential of maintaining optimum treatment outcomes while improving adherence and retention, and reducing the burden of HIV treatment on the health facility. This study provides baseline information for further research and vital information for HIV program implementers planning to decentralize the management of stable antiretroviral therapy clients.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-26T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The unfolded protein response plays dual roles in rice stripe virus infection through fine-tuning the movement protein accumulation]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766065952984-50dd73c2-3c87-4039-91c2-ff63dc7eace8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009370</link>
            <description><![CDATA[<p class="para" id="N65539">The movement of plant viruses is a complex process that requires support by the virus-encoded movement protein and multiple host factors. The unfolded protein response (UPR) plays important roles in plant virus infection, while how UPR regulates viral infection remains to be elucidated. Here, we show that rice stripe virus (RSV) elicits the UPR in <i>Nicotiana benthamiana</i>. The RSV-induced UPR activates the host autophagy pathway by which the RSV-encoded movement protein, NSvc4, is targeted for autophagic degradation. As a counteract, we revealed that NSvc4 hijacks UPR-activated type-I J-domain proteins, NbMIP1s, to protect itself from autophagic degradation. Unexpectedly, we found NbMIP1 stabilizes NSvc4 in a non-canonical HSP70-independent manner. Silencing <i>NbMIP1</i> family genes in <i>N</i>. <i>benthamiana</i>, delays RSV infection, while over-expressing <i>NbMIP1</i>.<i>4b</i> promotes viral cell-to-cell movement. Moreover, <i>OsDjA5</i>, the homologue of <i>NbMIP1</i> family in rice, behaves in a similar manner toward facilitating RSV infection. This study exemplifies an arms race between RSV and the host plant, and reveals the dual roles of the UPR in RSV infection though fine-tuning the accumulation of viral movement protein.</p><p class="para" id="N65542">The unfolded protein response (UPR) is a cellular response aiming to eliminate abnormal proteins in and restoring ER homeostasis. The infection of many plant viruses can induce the UPR of plant cells, and previous studies show that in most cases, the UPR benefits plant viral infections. However, how the UPR regulates plant viral infections is still poorly understood. Here, we find that a plant virus, rice stripe virus (RSV), can induce host UPR, and the UPR plays dual roles in RSV infection. On the one hand, the RSV-induced UPR activates the host autophagy pathway by which the virus-encoded movement protein, NSvc4, is degraded. On the other hand, the RSV-induced UPR also upregulates the expression of a type-I J-domain protein family in plant, which is hijacked by NSvc4 to protect itself from autophagic degradation. We present an example for an arms race between RSV and the host plant, and illustrate a new model of the UPR regulating viral infection in plants by fine-tuning the accumulation of virus-encoded MP.</p>]]></description>
            <pubDate><![CDATA[2021-03-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766065836971-78c1126f-1fbd-43fe-9fba-35db44a3ec3c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009509</link>
            <description><![CDATA[]]></description>
            <pubDate><![CDATA[2021-04-26T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[What gaps remain in the HIV cascade of care? Results of a population-based survey in Nsanje District, Malawi]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766064812217-d91d29f5-0dae-4710-b4fb-079945f31af7/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0248410</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction</h3><p class="para" id="N65543">The Malawi Ministry of Health (MoH) has been in collaboration with Médecins sans Frontières (MSF) to increase access to quality HIV care through decentralization of antiretroviral therapy (ART) diagnosis and treatment from hospital to clinics in Nsanje District since 2011. A population-based household survey was implemented to provide information on HIV prevalence and cascade of care to inform and prioritize community-based HIV interventions in the district.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A cross-sectional survey was conducted between September 2016 and January 2017. Using two-stage cluster sampling, eligible adult individuals aged ≥15 years living in the selected households were asked to participate. Participants were interviewed and tested for HIV at home. Those tested HIV-positive had their HIV-RNA viral load (VL) measured, regardless of their ART status. All participants tested HIV-positive at the time of the survey were advised to report their HIV test result to the health facility of their choice that MSF was supported in the district. HIV-RNA VL results were made available in this health facility.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Among 5,315 eligible individuals, 91.1% were included in the survey and accepted an HIV test. The overall prevalence was 12.1% (95% Confidence Interval (CI): 11.2–13.0) and was higher in women than in men: 14.0% versus 9.5%, P&lt;0.001. Overall HIV-positive status awareness was 80.0% (95%CI: 76.4–83.1) and was associated with sex (P&lt;0.05). Linkage to care was 78.0% (95%CI: 74.3–81.2) and participants in care 76.2% (95%CI: 72.4–79.5). ART coverage among participants aware of their HIV-positive status was 95.3% (95%CI: 92.9–96.9) and was not associated with sex (P = 0.55). Viral load suppression among participants on ART was 89.9% (95%CI: 86.6–92.4) and was not statistically different by sex (p = 0.40).</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65561">Despite encouraging results in HIV testing coverage, cascade of care, and UNAIDS targets in Nsanje District, some gap remains in the first 90, specifically among men and young adults. Enhanced community engagement and new strategies of testing, such as index testing, could be implemented to identify those who are still undiagnosed, particularly men and young adults.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Health information technology interventions and engagement in HIV care and achievement of viral suppression in publicly funded settings in the US: A cost-effectiveness analysis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766064798865-aee8712c-245d-48cd-a2ec-e29197ae152a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pmed.1003389</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">The US National HIV/AIDS Strategy (NHAS) emphasizes the use of technology to facilitate coordination of comprehensive care for people with HIV. We examined cost-effectiveness from the health system perspective of 6 health information technology (HIT) interventions implemented during 2008 to 2012 in a Ryan White HIV/AIDS Program (RWHAP) Special Projects of National Significance (SPNS) Program demonstration project.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods/findings</h3><p class="para" id="N65549">HIT interventions were implemented at 6 sites: Bronx, New York; Durham, North Carolina; Long Beach, California; New Orleans, Louisiana; New York, New York (2 sites); and Paterson, New Jersey. These interventions included: (1) use of HIV surveillance data to identify out-of-care individuals; (2) extension of access to electronic health records (EHRs) to support service providers; (3) use of electronic laboratory ordering and prescribing; and (4) development of a patient portal. We employed standard microcosting techniques to estimate costs (in 2018 US dollars) associated with intervention implementation. Data from a sample of electronic patient records from each demonstration site were analyzed to compare prescription of antiretroviral therapy (ART), CD4 cell counts, and suppression of viral load, before and after implementation of interventions. Markov models were used to estimate additional healthcare costs and quality-adjusted life-years saved as a result of each intervention. Overall, demonstration site interventions cost $3,913,313 (range = $287,682 to $998,201) among 3,110 individuals (range = 258 to 1,181) over 3 years. Changes in the proportion of patients prescribed ART ranged from a decrease from 87.0% to 72.7% at Site 4 to an increase from 74.6% to 94.2% at Site 6; changes in the proportion of patients with 0 to 200 CD4 cells/mm<sup>3</sup> ranged from a decrease from 20.2% to 11.0% in Site 6 to an increase from 16.7% to 30.2% in Site 2; and changes in the proportion of patients with undetectable viral load ranged from a decrease from 84.6% to 46.0% in Site 1 to an increase from 67.0% to 69.9% in Site 5. Four of the 6 interventions—including use of HIV surveillance data to identify out-of-care individuals, use of electronic laboratory ordering and prescribing, and development of a patient portal—were not only cost-effective but also cost saving ($6.87 to $14.91 saved per dollar invested). In contrast, the 2 interventions that extended access to EHRs to support service providers were not effective and, therefore, not cost-effective. Most interventions remained either cost-saving or not cost-effective under all sensitivity analysis scenarios. The intervention that used HIV surveillance data to identify out-of-care individuals was no longer cost-saving when the effect of HIV on an individual’s health status was reduced and when the natural progression of HIV was increased. The results of this study are limited in that we did not have contemporaneous controls for each intervention; thus, we are only able to assess sites against themselves at baseline and not against standard of care during the same time period.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusions</h3><p class="para" id="N65558">These results provide additional support for the use of HIT as a tool to enhance rapid and effective treatment of HIV to achieve sustained viral suppression. HIT has the potential to increase utilization of services, improve health outcomes, and reduce subsequent transmission of HIV.</p></div><p class="para" id="N65540">Starley Shade and co-workers assess cost-effectiveness of information technology interventions in HIV care programs in the United States.</p><div class="section" id="sec004"><h3 class="BHead" id="nov000-1">Why was this study done?</h3><p class="para" id="N65549">The Health Resources and Services Administration’s Special Projects of National Significance Program (HRSA/SPNS) funded a 4-year initiative (2007 to 2011) in 6 demonstration sites to enhance and evaluate existing health information electronic network systems for people living with HIV (PLHIV) in underserved communities.</p><p class="para" id="N65552">Each of the 6 demonstration sites implemented one or more health information technology (HIT) interventions to facilitate comprehensive care and enhance engagement in HIV medical services. These interventions included: (1) use of HIV surveillance data to identify out-of-care individuals; (2) extension of access to electronic health records to support service providers; (3) use of electronic laboratory ordering and prescribing; and (4) development of a patient portal.</p><p class="para" id="N65555">This study estimates the total costs, cost-effectiveness, and potential cost-savings of these 6 interventions.</p></div><div class="section" id="sec005"><h3 class="BHead" id="nov000-2">What did researchers do and find?</h3><p class="para" id="N65564">We used information on the cost of each intervention and the health status of PLHIV in each setting before and after implementation of each intervention to estimate: (1) changes in the cost of care and other services for PLHIV in each setting; and (2) changes in expected health status (measured as quality-adjusted life-years or QALYs) among PLHIV in each setting. We then used this information to estimate additional healthcare costs and QALYs gained for each intervention.</p><p class="para" id="N65567">Four of the interventions were associated with lower healthcare costs and better health outcomes (QALYs gained) for PLHIV in each setting. These interventions saved between $6.87 and $14.91 per dollar invested.</p><p class="para" id="N65570">Two interventions that provided access to medical record information to support service providers were not associated with improved health outcomes for PLHIV in these settings. These interventions were not effective or cost-effective.</p></div><div class="section" id="sec006"><h3 class="BHead" id="nov000-3">What do these findings mean?</h3><p class="para" id="N65579">These results show that HIT interventions that facilitate changes in patient or provider behavior have the potential to improve the health status of PLHIV and reduce healthcare costs. HIT interventions that only provided additional information to support service providers were less successful.</p><p class="para" id="N65582">This study did not include a contemporaneous comparison group. Therefore, we do not know the degree to which improvements in the health status of PLHIV in these settings were due to changes in the quality of care for PLHIV over the life of the interventions.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[An assessment of potential biomarkers of environment enteropathy and its association with age and microbial infections among children in Bangladesh]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766064400417-f323a918-767b-4369-b749-7b7016cdf7c6/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250446</link>
            <description><![CDATA[<p class="para" id="N65539">Interventional studies targeting environment enteropathy (EE) are impeded by the lack of appropriate, validated, non-invasive biomarkers of EE. Thus, we aimed to validate the association of potential biomarkers for EE with enteric infections and nutritional status in a longitudinal birth cohort study. We measured endotoxin core antibody (EndoCab) and soluble CD14 (sCD14) in serum, and myeloperoxidase (MPO) in feces using commercially available enzyme-linked immunosorbent assay (ELISA) kits. We found that levels of serum EndoCab and sCD14 increase with the cumulative incidence of enteric infections. We observed a significant correlation between the fecal MPO level in the children at 24 months of age with the total number of bacterial and viral infections, the total number of parasitic infections, and the total number of diarrheal episodes and diarrheal duration. We observed that the levels of serum EndoCab, sCD14, and fecal MPO at 3 months of age were significantly associated with whether children were malnourished at 18 months of age or not. Biomarkers such as fecal MPO, serum EndoCab and sCD14 in children at an early age may be useful as a measure of cumulative burden of preceding enteric infections, which are predictive of subsequent malnutrition status and may be useful non-invasive biomarkers for EE.</p>]]></description>
            <pubDate><![CDATA[2021-04-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[COVID-19 infection with asymptomatic or mild disease severity in young patients: Clinical course and association between prevalence of pneumonia and viral load]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766064222595-0de7ae23-2e15-4d65-b778-0d3647a69b29/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250358</link>
            <description><![CDATA[<p class="para" id="N65539">Few studies have focused on clinical courses or viral loads in young asymptomatic or mild patients with COVID-19 infection. We sought to better understand the clinical course and association between viral load and prevalence of pneumonia in young COVID-19 patients with asymptomatic or mild disease severity. In this retrospective study, 106 COVID-19 young patients with asymptomatic or mild disease severity were analyzed for clinical characteristics, clinical course, prevalence of radiologically proven pneumonia and viral load. The cut-off value of viral load for presence of pneumonia was also investigated. The mean age was 28.0±9.3 years. Eleven patients (10.4%) experienced viral remission within one week of diagnosis, but one (0.9%) transferred to the hospital due to aggravation of pneumonia. Patients with pneumonia had significantly higher viral load than those without, and the cut-off value of the Ct value for presence of pneumonia were 31.38. The patients with pneumonia had significantly slower recovery times than those without. Diarrhea was significantly more common in patients with pneumonia than patients without pneumonia. In conclusion, most young asymptomatic and mildly symptomatic patients showed stable clinical course. There were significant differences in viral load and recovery times between patients with and without pneumonia.</p>]]></description>
            <pubDate><![CDATA[2021-04-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Iron enhances the binding rates and translational efficiency of iron responsive elements (IREs) mRNA with initiation factor eIF4F]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766064017199-7c7b7bc2-d1b0-4164-937c-c0ad69f4e3c0/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250374</link>
            <description><![CDATA[<p class="para" id="N65539">Interaction of iron responsive elements (IRE) mRNA with the translational machinery is an early step critical in the initiation of protein synthesis. To investigate the binding specificity of IRE mRNA for eIF4F, kinetic rates for the eIF4F·IRE RNA interactions were determined and correlated with the translational efficiency. The observed rate of eIF4F·FRT IRE RNA interactions was 2-fold greater as compared to eIF4F·ACO2 IRE RNA binding. Addition of iron enhanced the association rates and lowered the dissociation rates for the eIF4F binding to both IRE RNAs, with having higher preferential binding to the FRT IRE RNA. The binding rates of both eIF4F·IRE RNA complexes correlated with the enhancement of protein synthesis <i>in vitro</i>. Presence of iron and eIF4F in the depleted WGE significantly enhanced translation for both IRE RNAs. This suggests that iron promotes translation by enhancing the binding rates of the eIF4F∙IRE RNA complex. eIF4F·IRE RNA binding is temperature-dependent; raising the temperature from 5 to 25°C, enhanced the binding rates of eIF4F·FRT IRE (4-fold) and eIF4F·ACO2 IRE (5-fold). Presence of Fe<sup>2+</sup> caused reduction in the activation energy for the binding of FRT IRE and ACO2 IRE to eIF4F, suggesting a more stable platform for initiating protein synthesis. In the presence of iron, lowered energy barrier has leads to the faster association rate and slower rate of dissociation for the protein-RNA complex, thus favoring efficient protein synthesis. Our results correlate well with the observed translational efficiency of IRE RNA, thereby suggesting that the presence of iron leads to a rapid, favorable, and stable complex formation that directs regulatory system to respond efficiently to cellular iron levels.</p>]]></description>
            <pubDate><![CDATA[2021-04-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Low efficacy of recombinant SV40 in Ugt1a1<sup>-/-</sup> mice with severe inherited hyperbilirubinemia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766063458448-23bcc845-311d-4d2d-b8a8-3ef26ee17fd0/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250605</link>
            <description><![CDATA[<p class="para" id="N65539">In contrast to AAV, Simian Virus 40 (rSV40) not inducing neutralizing antibodies (NAbs) allowing re-treatment seems a promising vector for neonatal treatment of inherited liver disorders. Several studies have reported efficacy of rSV40 in animal models for inherited liver diseases. In all studies the ubiquitous endogenous early promoter controlled transgene expression establishing expression in all transduced tissues. Restricting this expression to the target tissues reduces the risk of immune response to the therapeutic gene. In this study a liver specific rSV40 vector was generated by inserting a hepatocyte specific promoter. This increased the specificity of the expression of hUGT1A1 <i>in vitro</i>. However, <i>in vivo</i> the efficacy of rSV40 appeared too low to demonstrate tissue specificity while increasing the vector dose was not possible because of toxicity. In contrast to earlier studies, neutralizing antibodies were induced. Overall, the lack of a platform to produce high titered and pure rSV40 particles and the induction of NAbs, renders it a poor candidate for <i>in vivo</i> gene therapy.</p>]]></description>
            <pubDate><![CDATA[2021-04-23T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766062115454-cc8b02c3-2c27-4fe0-84d0-9656d605e042/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250263</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">The prevalence of HCV infection is high and it is a major cause of liver-related morbidity and mortality in hemodialysis and renal transplant patients. Diagnosis of hepatitis C virus (HCV) infection requires both HCV antibody screening and confirmatory nucleic acid testing (NAT). Hepatitis C virus core antigen (HCVcAg) is a reliable direct viral marker to identify active HCV infection.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Aim</h3><p class="para" id="N65549">To assess the clinical utility of HCV core antigen to identify active HCV infection in hemodialysis and renal transplant patients.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Methods</h3><p class="para" id="N65555">A representative total of 231 plasma samples with a predominance of low viral load were included for HCVcAg testing and its performance characteristics were compared with the gold standard HCV RNA.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Results</h3><p class="para" id="N65561">Comparison of HCVcAg with HCV RNA showed an excellent specificity of 99% (95% CI: 94.7 to 100%) and sensitivity of 80.62% (95% CI: 73.59 to 87.7%). Likewise, the PPV and NPV of HCVcAg were 99.1% (95% CI: 93.7% to 99.9%) and 80.2% (95% CI: 74% to 85.2%) respectively. The correlation between HCVcAg and HCV RNA was found to be good (R<sup>2</sup> = 0.86, p&lt;0.0001). Among common Indian HCV genotypes (1, 3 &amp; 4), good correlation was observed between HCV RNA and HCVcAg (R<sup>2</sup> = 0.81, p &lt;0.0001).</p></div><div class="section" id="sec005"><h3 class="BHead" id="nov000-5">Conclusions</h3><p class="para" id="N65573">It is the first Indian study to show that HCVcAg is a reliable, cost-effective direct marker to identify active HCV infection in hemodialysis and renal transplant patients. Implementation of HCVcAg testing could improve the accessibility to efficacious and affordable disease management in hemodialysis and renal transplant patients. In HCVcAg negative cases, sequential testing with anti-HCV antibody followed by HCV RNA could be a reliable and cost-effective approach.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766061730147-ba3c27cf-80c5-4710-a824-fd06d624133c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009500</link>
            <description><![CDATA[<p class="para" id="N65539">The high transmissibility of SARS-CoV-2 is related to abundant replication in the upper airways, which is not observed for the other highly pathogenic coronaviruses SARS-CoV and MERS-CoV. We here reveal features of the coronavirus spike (S) protein, which optimize the virus towards the human respiratory tract. First, the S proteins exhibit an intrinsic temperature preference, corresponding with the temperature of the upper or lower airways. Pseudoviruses bearing the SARS-CoV-2 spike (SARS-2-S) were more infectious when produced at 33°C instead of 37°C, a property shared with the S protein of HCoV-229E, a common cold coronavirus. In contrast, the S proteins of SARS-CoV and MERS-CoV favored 37°C, in accordance with virus preference for the lower airways. Next, SARS-2-S-driven entry was efficiently activated by not only TMPRSS2, but also the TMPRSS13 protease, thus broadening the cell tropism of SARS-CoV-2. Both proteases proved relevant in the context of authentic virus replication. TMPRSS13 appeared an effective spike activator for the virulent coronaviruses but not the low pathogenic HCoV-229E virus. Activation of SARS-2-S by these surface proteases requires processing of the S1/S2 cleavage loop, in which both the furin recognition motif and extended loop length proved critical. Conversely, entry of loop deletion mutants is significantly increased in cathepsin-rich cells. Finally, we demonstrate that the D614G mutation increases SARS-CoV-2 stability, particularly at 37°C, and, enhances its use of the cathepsin L pathway. This indicates a link between S protein stability and usage of this alternative route for virus entry. Since these spike properties may promote virus spread, they potentially explain why the spike-G614 variant has replaced the early D614 variant to become globally predominant. Collectively, our findings reveal adaptive mechanisms whereby the coronavirus spike protein is adjusted to match the temperature and protease conditions of the airways, to enhance virus transmission and pathology.</p><p class="para" id="N65542">The devastating COVID-19 pandemic is caused by SARS-CoV-2, a novel virus that despite recent zoonotic introduction is already very well adapted to its human host. Its rapid spread is related to abundant replication in the upper airways, which is not observed for other highly pathogenic human coronaviruses. To understand the role of the viral spike protein in this airway adaptation, we constructed pseudoviruses of SARS-CoV-2 and other coronaviruses that cause severe pneumonia or, on the contrary, a mild common cold. The key findings were verified with authentic virus. We reveal features of the spike proteins, which optimize the coronavirus towards specific parts of the respiratory tract. Namely, we show that the spike proteins exhibit intrinsic temperature preference to precisely match the upper (~33°C) or lower (37°C) airways. We recognized which proteases of human airways activate the spike for virus entry, in particular one protease that may mediate coronavirus virulence. Finally, a link was perceived between spike stability and entry via endosomal proteases. We propose that these mechanisms of spike fine-tuning may have contributed to a global shift in SARS-CoV-2 epidemiology, from the early spike-D614 to the currently predominating G614 variant.</p>]]></description>
            <pubDate><![CDATA[2021-04-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Finding, treating and retaining persons with HIV in a high HIV prevalence and high treatment coverage country: Results from the Botswana Combination Prevention Project]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766061632048-5aff31d4-f95f-428e-834c-ffaf8952df5e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250211</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction</h3><p class="para" id="N65543">The scale-up of Universal Test and Treat has resulted in reductions in HIV morbidity, mortality and incidence. However, healthcare system and personal challenges have impacted the levels of treatment coverage achieved. We implemented interventions to improve linkage to care, retention, viral load (VL) coverage and service delivery, and describe the HIV care cascade over the course of the Botswana Combination Prevention Project (BCPP) study.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">BCPP was designed to evaluate the impact of prevention interventions on HIV incidence in 30 communities in Botswana. We followed a longitudinal cohort of newly identified and known HIV-positive persons not on antiretroviral therapy (ART) identified through community-based testing activities through BCPP and referred with appointments to local HIV clinics in 15 intervention communities. Those who did not keep the first or follow-up appointments were tracked and traced through phone and home contacts. Improvements to service delivery models in the intervention clinics were also implemented.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">A total of 3,657 newly identified or HIV-positive persons not on ART were identified and referred to their local HIV clinic; 90% (3,282/3,657) linked to care and of those, 93% (3,066/3,282) initiated treatment. Near the end of the study, 221 persons remained &gt;90 days late for appointments or missing. Tracing efforts identified 54/3,066 (2%) persons who initiated treatment but died, and 106/3,066 (3%) persons were located and returned to treatment. At study end, 61/3,066 (2%) persons remained missing and were never reached. Overall, 2,951 (98%) persons living with HIV (PLHIV) who initiated treatment were still alive, retained in care and still receiving ART out of the 3,001 persons alive at the end of the study. Of those on ART, 2,854 (97%) had current VL results and 2,784 (98%) of those were virally suppressed at study end.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65561">This study achieved high rates of linkage, treatment initiation, retention and VL coverage and suppression in a cohort of newly identified and known PLHIV not on ART. Tracking and tracing interventions effectively identified those persons who needed more resource intensive follow-up. The interventions implemented to improve service delivery and data quality may have also contributed to high linkage and retention rates.</p><p class="para" id="N65563"><b>Clinical trial number</b>: NCT01965470.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766060419735-c92d827f-ee33-40bc-9d02-336e68dc112e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009469</link>
            <description><![CDATA[<p class="para" id="N65539">Respiratory syncytial virus (RSV) infects the upper and lower respiratory tracts and can cause lower respiratory tract infections in children and elders. RSV has traditionally been isolated, grown, studied and quantified in immortalized cell lines, most frequently HEp-2 cells. However, in vivo RSV infection is modeled more accurately in primary well differentiated human bronchial epithelial (HBE) cultures where RSV targets the ciliated cells and where the putative RSV receptor differs from the receptor on HEp-2 cells. The RSV attachment (G) glycoprotein in virions produced by HEp-2 cells is a highly glycosylated 95 kDa protein with a 32 kDa peptide core. However, virions produced in HBE cultures, RSV (HBE), contain an even larger, 170 kDa, G protein (LgG). Here we show that LgG is found in virions from both subgroups A and B lab-adapted and clinical isolates. Unexpectedly, RSV (HBE) virions were approximately 100-fold more infectious for HBE cultures than for HEp-2 cells. Surprisingly, the cause of this differential infectivity, was reduced infectivity of RSV (HBE) on HEp-2 cells rather than enhanced infectivity on HBE cultures. The lower infectivity of RSV(HBE) for HEp-2 cells is caused by the reduced ability of LgG to interact with heparan sulfate proteoglycans (HSPG), the RSV receptor on HEp-2 cells. The discovery of different infectivity corresponding with the larger form of the RSV attachment protein when produced by HBE cultures highlights the importance of studying a virus produced by its native host cell and the potential impact on quantifying virus infectivity on cell lines where the virus entry mechanisms differ from their natural target cell.</p><p class="para" id="N65542">RSV causes severe bronchiolitis in young children, is the leading cause of hospitalization of infants and a major cause of infant mortality in limited-resourced countries. In elders, it rivals influenza virus as a cause of death during the winter months. Many vaccines and antivirals are in development, but none has yet been approved. RSV targets ciliated cells in the upper and lower respiratory tracts. The use of primary HBE cultures previously enabled us to identify the target cell for RSV and a putative receptor on these cells, as well as to better understand the response to RSV infection, all in the cells it infects in vivo. Here, we found that RSV produced in these primary cultures contains a 170 kDa version of its attachment (G) glycoprotein that has lost most of its ability to infect the standard immortalized cell line used to culture RSV, HEp-2 cells, confirming that the receptor used on the two types of cells are different. These findings also demonstrate that significant structural differences with functional consequences can result from the type of cells used to produce the virus.</p>]]></description>
            <pubDate><![CDATA[2021-04-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766054081655-2fd605fb-dc6e-473d-9046-9597b5fce8df/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009478</link>
            <description><![CDATA[<p class="para" id="N65539">Despite considerable reduction of mother-to-child transmission (MTCT) of HIV through use of maternal and infant antiretroviral therapy (ART), over 150,000 infants continue to become infected with HIV annually, falling far short of the World Health Organization goal of reaching &lt;20,000 annual pediatric HIV cases worldwide by 2020. Prior to the widespread use of ART in the setting of pregnancy, over half of infants born to HIV-infected mothers were protected against HIV acquisition. Yet, the role of maternal immune factors in this protection against vertical transmission is still unclear, hampering the development of synergistic strategies to further reduce MTCT. It has been established that infant transmitted/founder (T/F) viruses are often resistant to maternal plasma, yet it is unknown if the neutralization resistance profile of circulating viruses predicts the maternal risk of transmission to her infant. In this study, we amplified HIV-1 envelope genes (<i>env</i>) by single genome amplification and produced representative Env variants from plasma of 19 non-transmitting mothers from the U.S. Women Infant Transmission Study (WITS), enrolled in the pre-ART era. Maternal HIV Env variants from non-transmitting mothers had similar sensitivity to autologous plasma as observed for non-transmitting variants from transmitting mothers. In contrast, infant variants were on average 30% less sensitive to paired plasma neutralization compared to non-transmitted maternal variants from both transmitting and non-transmitting mothers (p = 0.015). Importantly, a signature sequence analysis revealed that motifs enriched in <i>env</i> sequences from transmitting mothers were associated with broadly neutralizing antibody (bnAb) resistance. Altogether, our findings suggest that circulating maternal virus resistance to bnAb-mediated neutralization, but not autologous plasma neutralization, near the time of delivery, predicts increased MTCT risk. These results caution that enhancement of maternal plasma neutralization through passive or active vaccination during pregnancy may potentially drive the evolution of variants fit for vertical transmission.</p><p class="para" id="N65542">Despite widespread, effective use of ART among HIV infected pregnant women, new pediatric HIV infections increase by about 150,000 every year. Thus, alternative strategies will be required to reduce MTCT and eliminate pediatric HIV infections. Interestingly, in the absence of ART, less than half of HIV-infected pregnant women will transmit HIV, suggesting natural immune protection of infants from virus acquisition. To understand the impact of maternal plasma autologous virus neutralization responses on MTCT, we compared the plasma and bnAb neutralization sensitivity of the circulating viral population present at the time of delivery in untreated, HIV-infected transmitting and non-transmitting mothers. While there was no significant difference in the ability of transmitting and non-transmitting women to neutralize their own circulating virus strains, specific genetic motifs enriched in variants from transmitting mothers were associated with resistance to bnAbs, suggesting that acquired bnAb resistance is a common feature of vertically-transmitted variants. This work suggests that enhancement of plasma neutralization responses in HIV-infected mothers through passive or active vaccination could further drive selection of variants that could be vertically transmitted, and cautions the use of passive bnAbs for HIV-1 prophylaxis or therapy during pregnancy.</p>]]></description>
            <pubDate><![CDATA[2021-04-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Temporal dynamics of SARS-CoV-2 mutation accumulation within and across infected hosts]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766053486505-4ef756a7-e9d5-4d97-8466-58cf5fedba84/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009499</link>
            <description><![CDATA[<p class="para" id="N65539">Analysis of SARS-CoV-2 genetic diversity within infected hosts can provide insight into the generation and spread of new viral variants and may enable high resolution inference of transmission chains. However, little is known about temporal aspects of SARS-CoV-2 intrahost diversity and the extent to which shared diversity reflects convergent evolution as opposed to transmission linkage. Here we use high depth of coverage sequencing to identify within-host genetic variants in 325 specimens from hospitalized COVID-19 patients and infected employees at a single medical center. We validated our variant calling by sequencing defined RNA mixtures and identified viral load as a critical factor in variant identification. By leveraging clinical metadata, we found that intrahost diversity is low and does not vary by time from symptom onset. This suggests that variants will only rarely rise to appreciable frequency prior to transmission. Although there was generally little shared variation across the sequenced cohort, we identified intrahost variants shared across individuals who were unlikely to be related by transmission. These variants did not precede a rise in frequency in global consensus genomes, suggesting that intrahost variants may have limited utility for predicting future lineages. These results provide important context for sequence-based inference in SARS-CoV-2 evolution and epidemiology.</p><p class="para" id="N65542">Understanding the evolution and transmission of SARS-CoV-2 is important for designing public health interventions to prevent outbreaks. Viral genome sequencing has been widely used to reconstruct patterns of SARS-CoV-2 transmission through communities and to monitor the spread of new strains. However, because SARS-CoV-2 can transmit multiple times before a new mutation fixes, consensus sequences often cannot determine “who infected whom.” Identifying individuals who share the same viral genetic variants at low frequencies within each infection may help resolve this problem, but to do this we need to accurately identify within-host genetic variants and understand how they evolve and spread. We investigated within-host diversity of SARS-CoV-2 with samples collected in southeastern Michigan in March–May 2020. We show that there are relatively few genetic variants present in any given infection, and variants do not tend to accumulate in people over time. We also found that people who are not part of the same epidemic cluster can share the same within-host variants, due to chance or various evolutionary forces.</p>]]></description>
            <pubDate><![CDATA[2021-04-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766047111771-32cd5230-5d34-43cb-b6ca-f8f630cb361a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0009308</link>
            <description><![CDATA[<p class="para" id="N65539">Mayaro virus (MAYV) is an alphavirus endemic to South and Central America associated with sporadic outbreaks in humans. MAYV infection causes severe joint and muscle pain that can persist for weeks to months. Currently, there are no approved vaccines or therapeutics to prevent MAYV infection or treat the debilitating musculoskeletal inflammatory disease. In the current study, a prophylactic MAYV vaccine expressing the complete viral structural polyprotein was developed based on a non-replicating human adenovirus V (AdV) platform. Vaccination with AdV-MAYV elicited potent neutralizing antibodies that protected WT mice against MAYV challenge by preventing viremia, reducing viral dissemination to tissues and mitigating viral disease. The vaccine also prevented viral-mediated demise in IFN⍺R1<sup>-/-</sup> mice. Passive transfer of immune serum from vaccinated animals similarly prevented infection and disease in WT mice as well as virus-induced demise of IFN⍺R1<sup>-/-</sup> mice, indicating that antiviral antibodies are protective. Immunization with AdV-MAYV also generated cross-neutralizing antibodies against two related arthritogenic alphaviruses–chikungunya and Una viruses. These cross-neutralizing antibodies were protective against lethal infection in IFN⍺R1<sup>-/-</sup> mice following challenge with these heterotypic alphaviruses. These results indicate AdV-MAYV elicits protective immune responses with substantial cross-reactivity and protective efficacy against other arthritogenic alphaviruses. Our findings also highlight the potential for development of a multi-virus targeting vaccine against alphaviruses with endemic and epidemic potential in the Americas.</p><p class="para" id="N65542">Mayaro virus is an understudied alphavirus that is currently circulating in tropical environments in South and Central America without an approved vaccine. Recent outbreaks have suggested a broadening range and higher likelihood of urban outbreaks, increasing the public health risk. Mayaro virus is closely related to other arthritogenic alphaviruses with overlapping circulation such as chikungunya and Una viruses, both of which also lack clinically approved vaccines. Identification of a safe, easily manufactured, and effective strategy to vaccinate at risk populations is important to control outbreak potential. Here we report on a vaccination approach using a non-replicating adenovirus viral vector that encodes Mayaro virus structural proteins that assemble into non-infectious virus-like particles upon expression following vaccination. These particles stimulate strong immune responses against Mayaro virus. Upon testing against other alphaviruses, it was determined that the vaccine elicits cross-reactive neutralizing antibodies against chikungunya and Una viruses, significantly diminishes disease severity, and protects immunocompromised, highly susceptible mice from death following viral challenge. Our study provides new approaches to protect against these co-circulating viruses using a single vaccine. This approach is highly amenable to other virus targets for vaccine development and its ability to provide protection against chikungunya virus has global ramifications.</p>]]></description>
            <pubDate><![CDATA[2021-04-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Vaccination coverage estimation in Mexico in children under five years old: Trends and associated factors]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766046886783-4af5cf84-43a1-415a-9e4e-8b7d5f1a027a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0250172</link>
            <description><![CDATA[<p class="para" id="N65539">We aimed to estimate vaccination coverage and factors associated in completing schemes in children under 5 years old between 2000 and 2018. A secondary analysis was carried out on five national health surveys between 2000 and 2018 in Mexico. The sample was 53,898 children under 5 years old, where 30% of missing vaccination information was imputed using chained equations. During this period two basic vaccination schemes (CBS) were identified. For each doses and vaccines of both schemes and completed CBS, the coverage was estimated using weighted logistic regression models. Additionally, the factors associated with incomplete schemes were reported. Between 2000 and 2018, the caretakers who did not show the vaccination card went from 13.8% to 45.6%. During this period, the estimated vaccination coverages did not exceed 95%, except for BCG and marginally the first doses of vaccines against pneumococcus, acellular pentavalent, and Sabin. In the same period, the CBS estimated coverage decreased steadily and was under 90%, except for children aged 6–11 months (92.6%; 91.5–93.7) in 2000. Not having health insurance stands out as an associated factor with incomplete vaccination schemes. In conclusion, the imputation allowed to recuperate information and obtain better data of vaccination coverage. The estimated vaccination coverage and CBS do not reach sufficient levels to guarantee herd immunity, hence innovative strategies to improve vaccination must be established in Mexico.</p>]]></description>
            <pubDate><![CDATA[2021-04-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Comparison of tracheal and choanal cleft swabs and poultry dust samples for detection of Newcastle disease virus and infectious bronchitis virus genome in vaccinated meat chicken flocks]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766045523487-dcd9b773-e11e-408b-9e22-169c063f8343/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247729</link>
            <description><![CDATA[<p class="para" id="N65539">This study assessed different methods (tracheal and choanal cleft swabs from individual birds, and poultry dust as a population level measure) to evaluate the shedding kinetics of infectious bronchitis virus (IBV) and Newcastle disease virus (NDV) genome in meat chicken flocks after spray vaccination at hatchery. Dust samples and tracheal and choanal cleft swabs were collected from four meat chicken flocks at 10, 14, 21 and 31 days post vaccination (dpv) and tested for IBV and NDV genome copies (GC) by reverse transcriptase (RT)-PCR. IBV and NDV GC were detected in all sample types throughout the study period. Detection rates for choanal cleft and tracheal swabs were comparable, with moderate and fair agreement between sample types for IBV (McNemar’s = 0.27, kappa = 0.44) and NDV (McNemar’s = 0.09; kappa = 0.31) GC respectively. There was no significant association for IBV GC in swabs and dust samples (R<sup>2</sup> = 0.15, P = 0.13) but NDV detection rates and viral load in swabs were strongly associated with NDV GC in dust samples (R<sup>2</sup> = 0.86 and R<sup>2</sup> = 0.90, P&lt;0.001). There was no difference in IBV and NDV GC in dust samples collected from different locations within a poultry house. In conclusion, dust samples collected from any location within poultry house show promise for monitoring IBV and NDV GC in meat chickens at a population level and choanal cleft swabs can be used for detection of IBV and NDV GC instead of tracheal swabs in individual birds.</p>]]></description>
            <pubDate><![CDATA[2021-04-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Characteristics and expression profiles of circRNAs during abdominal adipose tissue development in Chinese Gushi chickens]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766036522994-2a6abb2f-910d-4422-9c2f-a80469657ac6/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249288</link>
            <description><![CDATA[<p class="para" id="N65539">Circular RNAs (circRNAs) play important roles in adipogenesis. However, studies on circRNA expression profiles associated with the development of abdominal adipose tissue are lacking in chickens. In this study, 12 cDNA libraries were constructed from the abdominal adipose tissue of Chinese domestic Gushi chickens at 6, 14, 22, and 30 weeks. A total of 1,766 circRNAs were identified by Illumina HiSeq 2500 sequencing. These circRNAs were primarily distributed on chr1 through chr10 and sex chromosomes, and 84.95% of the circRNAs were from gene exons. Bioinformatic analysis showed that each circRNA has 35 miRNA binding sites on average, and 62.71% have internal ribosome entry site (IRES) elements. Meanwhile, these circRNAs were primarily concentrated in TPM &lt; 0.1 and TPM &gt; 60, and their numbers accounted for 18.90% and 80.51%, respectively, exhibiting specific expression patterns in chicken abdominal adipose tissue. In addition, 275 differentially expressed (DE) circRNAs were identified by comparison analysis. Functional enrichment analysis showed that the parental genes of DE circRNAs were primarily involved in biological processes and pathways related to lipid metabolism, such as regulation of fat cell differentiation, fatty acid homeostasis, and triglyceride homeostasis, as well as fatty acid biosynthesis, fatty acid metabolism, and glycerolipid metabolism. Furthermore, ceRNA regulatory networks related to abdominal adipose development were constructed. The results of this study indicated that circRNAs can regulate lipid metabolism, adipocyte proliferation and differentiation, and cell junctions during abdominal adipose tissue development in chickens through complex ceRNA networks between circRNAs, miRNAs, genes, and pathways. The results of this study may help to expand the number of known circRNAs in abdominal adipose tissue and provide a valuable resource for further research on the function of circRNAs in chicken abdominal adipose tissue.</p>]]></description>
            <pubDate><![CDATA[2021-04-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Recent HIV infection among pregnant women in the 2017 antenatal sentinel cross–sectional survey, South Africa: Assay–based incidence measurement]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766035879674-3daefd37-0f0a-4a26-9a5a-85e45c9a4a37/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249953</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction</h3><p class="para" id="N65543">New HIV infection during pre-conception and pregnancy is a significant contributor of mother–to–child transmission of HIV in South Africa. This study estimated HIV incidence (defined as new infection within the last one year from the time of the survey which included both new infections occurred during pregnancy or just before pregnancy) among pregnant women and described the characteristics of recently infected pregnant women at national level.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">Between 1 October and 15 November 2017, we conducted a national cross–sectional survey among pregnant women aged 15–49 years old attending antenatal care at 1,595 public facilities. Blood specimens were collected from pregnant women and tested for HIV in a centralised laboratory. Plasma viral load and Limiting Antigen Avidity Enzyme Immunosorbent Assay (LAg) tests were further performed on HIV positive specimens to differentiate between recent and long–term infections. Recent infection was defined as infection that occurred within one year from the date of collection of blood specimen for the survey. Data on age, age of partner, and marital status were collected through interviews. Women whose specimens were classified as recent by LAg assay and with viral loads &gt;1,000 copies/mL were considered as recently infected. The calculated proportion of HIV positive women with recent infection was adjusted for assay–specific parameters to estimate annual incidence. Survey multinomial logistic regression was used to examine factors associated with being recently infected using HIV negative women as a reference group. Age–disparate relationship was defined as having a partner 5 or more years older.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Of 10,049 HIV positive participants with LAg and viral load data, 1.4% (136) were identified as recently infected. The annual HIV incidence was 1.5% (95% confidence interval (CI): 1.2–1.7). In multivariable analyses, being single (adjusted odds ratio, aOR: 3.4, 95% CI: 1.8–6.2) or cohabiting (aOR: 3.8, 95% CI: 1.8–7.7), compared to being married as well as being in an age–disparate relationship among young women (aOR: 3.1, 95% CI: 2.0–4.7; reference group: young women (15–24years) whose partners were not 5 years or more older) were associated with higher odds of recent infection.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65561">Compared to previous studies among pregnant women, the incidence estimated in this study was substantially lower. However, the UNAIDS target to reduce incidence by 75% by 2020 (which is equivalent to reducing incidence to &lt;1%) has not been met. The implementation of HIV prevention and treatment interventions should be intensified, targeting young women engaged in age–disparate relationship and unmarried women to fast track progress towards the UNAIDS target.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-14T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The synthetic opioid fentanyl enhances viral replication <i>in vitro</i>]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766034612322-4ab1b1f0-8b38-4d86-899d-ae2958224e5d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249581</link>
            <description><![CDATA[<p class="para" id="N65539">The US is in the midst of a major drug epidemic fueled in large part by the widespread recreational use of synthetic opioids such as fentanyl. Persons with opioid use disorder are at significant risk for transmission of injection-associated infections such as hepatitis B virus (HBV) and hepatitis C virus (HCV). Commonly abused substances may antagonize immune responses and promote viral replication. However, the impact of synthetic opioids on virus replication has not been well explored. Thus, we evaluated the impact of fentanyl and carfentanil using <i>in vitro</i> systems that replicate infectious viruses. Fentanyl was used in cell lines replicating HBV or HCV at concentrations of 1 ng, 100 ng, and 10 ug. Viral protein synthesis was quantified by ELISA, while apoptosis and cell death were measured by M30 or MTT assays, respectively. HCV replicative fitness was evaluated in a luciferase-based system. RNAseq was performed to evaluate cellular gene regulation in the presence of fentanyl. Low dose fentanyl had no impact on HCV replication in Huh7.5JFH1 hepatocytes; however, higher doses significantly enhanced HCV replication. Similarly, a dose-dependent increase in HCV replicative fitness was observed in the presence of fentanyl. In the HepG2.2.15 hepatocyte cell line, fentanyl caused a dose-dependent increase in HBV replication, although only a higher doses than for HCV. Addition of fentanyl resulted in significant apoptosis in both hepatocyte cell lines. Cell death was minimal at low drug concentrations. RNAseq identified a number of hepatocyte genes that were differentially regulated by fentanyl, including those related to apoptosis, the antiviral / interferon response, chemokine signaling, and NFκB signaling. Collectively, these data suggest that synthetic opioids promote viral replication but may have distinct effects depending on the drug dose and the viral target. As higher viral loads are associated with pathogenesis and virus transmission, additional research is essential to an enhanced understanding of opioid-virus pathogenesis and for the development of new and optimized treatment strategies.</p>]]></description>
            <pubDate><![CDATA[2021-04-14T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Non-invasive adapted N-95 mask sampling captures variation in viral particles expelled by COVID-19 patients: Implications in understanding SARS-CoV2 transmission]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766031039264-3b1c506d-ba79-4042-aac1-547cdab918ff/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249525</link>
            <description><![CDATA[<p class="para" id="N65539">Infectious respiratory particles expelled by SARS-CoV-2 positive patients are attributed to be the key driver of COVID-19 transmission. Understanding how and by whom the virus is transmitted can help implement better disease control strategies. Here we have described the use of a noninvasive mask sampling method to detect and quantify SARS-CoV-2 RNA in respiratory particles expelled by COVID-19 patients and discussed its relationship to transmission risk. Respiratory particles of 31 symptomatic SARS-CoV-2 positive patients and 31 asymptomatic healthy volunteers were captured on N-95 masks layered with a gelatin membrane in a 30-minute process that involved talking/reading, coughing, and tidal breathing. SARS-CoV-2 viral RNA was detected and quantified using rRT-PCR in the mask and in concomitantly collected nasopharyngeal swab (NPS) samples. The data were analyzed with respect to patient demographics and clinical presentation. Thirteen of 31(41.9%) patients showed SARS-COV-2 positivity in both the mask and NPS samples, while 16 patients were mask negative but NPS positive. Two patients were both mask and NPS negative. All healthy volunteers except one were mask and NPS negative. The mask positive patients had significantly lower NPS Ct value (26) compared to mask negative patients (30.5) and were more likely to be rapid antigen test positive. The mask positive patients could be further grouped into low emitters (expelling &lt;100 viral copies) and high emitters (expelling &gt;1000 viral copies). The study presents evidence for variation in emission of SARS-CoV-2 virus particles by COVID-19 patients reflecting differences in infectivity and transmission risk among individuals. The results conform to reported secondary infection rates and transmission and also suggest that mask sampling could be explored as an effective tool to assess individual transmission risks, at different time points and during different activities.</p>]]></description>
            <pubDate><![CDATA[2021-04-12T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The transcriptional landscape of Venezuelan equine encephalitis virus (TC-83) infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766030827531-53698ee3-577f-472b-8c46-8c3c5c25fa98/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0009306</link>
            <description><![CDATA[<p class="para" id="N65539">Venezuelan Equine Encephalitis Virus (VEEV) is a major biothreat agent that naturally causes outbreaks in humans and horses particularly in tropical areas of the western hemisphere, for which no antiviral therapy is currently available. The host response to VEEV and the cellular factors this alphavirus hijacks to support its effective replication or evade cellular immune responses are largely uncharacterized. We have previously demonstrated tremendous cell-to-cell heterogeneity in viral RNA (vRNA) and cellular transcript levels during flaviviral infection using a novel virus-inclusive single-cell RNA-Seq approach. Here, we used this unbiased, genome-wide approach to simultaneously profile the host transcriptome and vRNA in thousands of single cells during infection of human astrocytes with the live-attenuated vaccine strain of VEEV (TC-83). Host transcription was profoundly suppressed, yet “superproducer cells” with extremely high vRNA abundance emerged during the first viral life cycle and demonstrated an altered transcriptome relative to both uninfected cells and cells with high vRNA abundance harvested at later time points. Additionally, cells with increased structural-to-nonstructural transcript ratio exhibited upregulation of intracellular membrane trafficking genes at later time points. Loss- and gain-of-function experiments confirmed pro- and antiviral activities in both vaccine and virulent VEEV infections among the products of transcripts that positively or negatively correlated with vRNA abundance, respectively. Lastly, comparison with single cell transcriptomic data from other viruses highlighted common and unique pathways perturbed by infection across evolutionary scales. This study provides a high-resolution characterization of the VEEV (TC-83)-host interplay, identifies candidate targets for antivirals, and establishes a comparative single-cell approach to study the evolution of virus-host interactions.</p><p class="para" id="N65542">Little is known about the host response to Venezuelan Equine Encephalitis Virus (VEEV) and the cellular factors this alphavirus hijacks to support effective replication or evade cellular immune responses. Monitoring dynamics of host and viral RNA (vRNA) during viral infection at a single-cell level can provide insight into the virus-host interplay at a high resolution. Here, a single-cell RNA sequencing technology that detects host and viral RNA was used to investigate the interactions between TC-83, the vaccine strain of VEEV, and the human host during the course of infection of U-87 MG cells (human astrocytoma). Virus abundance and host transcriptome were heterogeneous across cells from the same culture. Subsets of differentially expressed genes, positively or negatively correlating with vRNA abundance, were identified and subsequently <i>in vitro</i> validated as candidate proviral and antiviral factors, respectively, in TC-83 and/or virulent VEEV infections. In the first replication cycle, “superproducer” cells exhibited rapid increase in vRNA abundance and unique gene expression patterns. At later time points, cells with increased structural-to-nonstructural transcript ratio demonstrated upregulation of intracellular membrane trafficking genes. Lastly, comparing the VEEV dataset with published datasets on other RNA viruses revealed unique and overlapping responses across viral clades. Overall, this study improves the understanding of VEEV-host interactions, reveals candidate targets for antiviral approaches, and establishes a comparative single-cell approach to study the evolution of virus-host interactions.</p>]]></description>
            <pubDate><![CDATA[2021-03-31T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Mapping of sequences in the 5’ region and 3’ UTR of tomato ringspot virus RNA2 that facilitate cap-independent translation of reporter transcripts <i>in vitro</i>]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766023978594-3921ff00-2f79-4c76-9fde-fe7132ef38e4/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249928</link>
            <description><![CDATA[<p class="para" id="N65539">Tomato ringspot virus (ToRSV, genus <i>Nepovirus</i>, family <i>Secoviridae</i>, order <i>Picornavirales</i>) is a bipartite positive-strand RNA virus, with each RNA encoding one large polyprotein. ToRSV RNAs are linked to a 5’-viral genome-linked protein (VPg) and have a 3’ polyA tail, suggesting a non-canonical cap-independent translation initiation mechanism. The 3’ untranslated regions (UTRs) of RNA1 and RNA2 are unusually long (~1.5 kb) and share several large stretches of sequence identities. Several putative in-frame start codons are present in the 5’ regions of the viral RNAs, which are also highly conserved between the two RNAs. Using reporter transcripts containing the 5’ region and 3’ UTR of the RNA2 of ToRSV Rasp1 isolate (ToRSV-Rasp1) and <i>in vitro</i> wheat germ extract translation assays, we provide evidence that translation initiates exclusively at the first AUG, in spite of a poor codon context. We also show that both the 5’ region and 3’ UTR of RNA2 are required for efficient cap-independent translation of these transcripts. We identify translation-enhancing elements in the 5’ proximal coding region of the RNA2 polyprotein and in the RNA2 3’ UTR. Cap-dependent translation of control reporter transcripts was inhibited when RNAs consisting of the RNA2 3’ UTR were supplied <i>in trans</i>. Taken together, our results suggest the presence of a CITE in the ToRSV-Rasp1 RNA2 3’ UTR that recruits one or several translation factors and facilitates efficient cap-independent translation together with the 5’ region of the RNA. Non-overlapping deletion mutagenesis delineated the putative CITE to a 200 nts segment (nts 773–972) of the 1547 nt long 3’ UTR. We conclude that the general mechanism of ToRSV RNA2 translation initiation is similar to that previously reported for the RNAs of blackcurrant reversion virus, another nepovirus. However, the position, sequence and predicted structures of the translation-enhancing elements differed between the two viruses.</p>]]></description>
            <pubDate><![CDATA[2021-04-09T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Aggressive organ penetration and high vector transmissibility of epidemic dengue virus-2 Cosmopolitan genotype in a transmission mouse model]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766023861048-3939183e-d175-4495-8c8d-55dde2570d10/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009480</link>
            <description><![CDATA[<p class="para" id="N65539">Dengue virus (DENV) causes dengue fever and severe hemorrhagic fever in humans and is primarily transmitted by <i>Aedes aegypti</i> and <i>A</i>. <i>albopictus</i> mosquitoes. The incidence of DENV infection has been gradually increasing in recent years due to global urbanization and international travel. Understanding the virulence determinants in host and vector transmissibility of emerging epidemic DENV will be critical to combat potential outbreaks. The DENV serotype 2 (DENV-2), which caused a widespread outbreak in Taiwan in 2015 (TW2015), is of the Cosmopolitan genotype and is phylogenetically related to the virus strain linked to another large outbreak in Indonesia in 2015. We found that the TW2015 virus was highly virulent in type I and type II interferon-deficient mice, with robust replication in spleen, lung, and intestine. The TW2015 virus also had high transmissibility to <i>Aedes</i> mosquitoes and could be effectively spread in a continuous mosquitoes-mouse-mosquitoes-mouse transmission cycle. By making 16681-based mutants carrying different segments of the TW2015 virus, we identified the structural pre-membrane (prM) and envelope (E) genes as key virulence determinants in the host, with involvement in the high transmissibility of the TW2015 virus in mosquitoes. The transmission mouse model will make a useful platform for evaluation of DENV with high epidemic potential and development of new strategies against dengue outbreaks.</p><p class="para" id="N65542">Dengue fever and dengue hemorrhagic fever in humans are caused by <i>Aedes</i> mosquito-mediated dengue virus infection. Large dengue outbreaks occurred in recent years and many tropical and subtropical countries became hyperendemic with all four dengue virus serotypes. We characterized the endemic dengue virus TW2015, which caused large outbreaks in Taiwan and Indonesia in 2015. Compared to other dengue viruses, the TW2015 virus was highly virulent in mice, with robust replication in spleen, lung, and intestine. The TW2015 virus had high transmissibility between mice and mosquitoes. The TW2015 structural genes that function in attachment of the virus particle to the cell surface during infection may be responsible for the high virulence of the virus in mice and its high transmissibility in mosquitoes. Our study revealed the key components of the dengue virus that contribute to its high likelihood of causing dengue outbreaks. These results will aid in the development of new approaches to prevent future dengue epidemics.</p>]]></description>
            <pubDate><![CDATA[2021-03-30T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Disparate temperature-dependent virus–host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766023249281-13815fb8-de22-4ac9-b13f-d536b9ef1f50/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pbio.3001158</link>
            <description><![CDATA[<p class="para" id="N65539">Since its emergence in December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally and become a major public health burden. Despite its close phylogenetic relationship to SARS-CoV, SARS-CoV-2 exhibits increased human-to-human transmission dynamics, likely due to efficient early replication in the upper respiratory epithelium of infected individuals. Since different temperatures encountered in the human upper and lower respiratory tract (33°C and 37°C, respectively) have been shown to affect the replication kinetics of several respiratory viruses, as well as host innate immune response dynamics, we investigated the impact of temperature on SARS-CoV-2 and SARS-CoV infection using the primary human airway epithelial cell culture model. SARS-CoV-2, in contrast to SARS-CoV, replicated to higher titers when infections were performed at 33°C rather than 37°C. Although both viruses were highly sensitive to type I and type III interferon pretreatment, a detailed time-resolved transcriptome analysis revealed temperature-dependent interferon and pro-inflammatory responses induced by SARS-CoV-2 that were inversely proportional to its replication efficiency at 33°C or 37°C. These data provide crucial insight on pivotal virus–host interaction dynamics and are in line with characteristic clinical features of SARS-CoV-2 and SARS-CoV, as well as their respective transmission efficiencies.</p><p class="para" id="N65540">The temperature in the lower respiratory tract is higher than in the upper respiratory tract. This study compares the viral replication kinetics and host cell response during SARS-CoV-2 and SARS-CoV infection, finding that the temperature of the human respiratory epithelium influences the viral replication and virus-host dynamics of SARS-CoV-2, but not of SARS-CoV.</p>]]></description>
            <pubDate><![CDATA[2021-03-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[On realized serial and generation intervals given control measures: The COVID-19 pandemic case]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766022181259-44f5e441-1a99-4952-8614-68b4eab3c76c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pcbi.1008892</link>
            <description><![CDATA[<p class="para" id="N65539">The SARS-CoV-2 pathogen is currently spreading worldwide and its propensity for presymptomatic and asymptomatic transmission makes it difficult to control. The control measures adopted in several countries aim at isolating individuals once diagnosed, limiting their social interactions and consequently their transmission probability. These interventions, which have a strong impact on the disease dynamics, can affect the inference of the epidemiological quantities. We first present a theoretical explanation of the effect caused by non-pharmaceutical intervention measures on the mean serial and generation intervals. Then, in a simulation study, we vary the assumed efficacy of control measures and quantify the effect on the mean and variance of realized generation and serial intervals. The simulation results show that the realized serial and generation intervals both depend on control measures and their values contract according to the efficacy of the intervention strategies. Interestingly, the mean serial interval differs from the mean generation interval. The deviation between these two values depends on two factors. First, the number of undiagnosed infectious individuals. Second, the relationship between infectiousness, symptom onset and timing of isolation. Similarly, the standard deviations of realized serial and generation intervals do not coincide, with the former shorter than the latter on average. The findings of this study are directly relevant to estimates performed for the current COVID-19 pandemic. In particular, the effective reproduction number is often inferred using both daily incidence data and the generation interval. Failing to account for either contraction or mis-specification by using the serial interval could lead to biased estimates of the effective reproduction number. Consequently, this might affect the choices made by decision makers when deciding which control measures to apply based on the value of the quantity thereof.</p><p class="para" id="N65542">The generation and serial intervals are epidemiological quantities used to describe and predict an ongoing epidemic outbreak. These quantities are related to the contact pattern of individuals, since infection events can take place if infectious and susceptible individuals have a contact. Therefore, intervention measures that reduce the interactions between members of the population are expected to affect both the realized generation and serial intervals. For the current COVID-19 pandemic unprecedented interventions have been adopted worldwide, e.g. strict lockdown, isolation and quarantine, which influence the realized value of generation and serial intervals. The extent of the effect thereof depends on the efficacy of the control measure in place, on the relationship between symptom onset and infectiousness and on the proportion of infectious individuals that can be detected. To get more insight on this, we present an investigation that highlights the effect of quarantine and isolation on realized generation and serial intervals. In particular, we show that not only their variances but also their mean values can differ, suggesting that the use of the mean serial interval as a proxy for the mean generation time can lead to biased estimates of epidemiological quantities.</p>]]></description>
            <pubDate><![CDATA[2021-03-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Functional regulation of the structure-specific endonuclease FEN1 by the human cytomegalovirus protein IE1 suggests a role for the re-initiation of stalled viral replication forks]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766022050427-8b10bb27-9255-4331-99e7-9f762da13818/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009460</link>
            <description><![CDATA[<p class="para" id="N65539">Flap endonuclease 1 (FEN1) is a member of the family of structure-specific endonucleases implicated in regulation of DNA damage response and DNA replication. So far, knowledge on the role of FEN1 during viral infections is limited. Previous publications indicated that poxviruses encode a conserved protein that acts in a manner similar to FEN1 to stimulate homologous recombination, double-strand break (DSB) repair and full-size genome formation. Only recently, cellular FEN1 has been identified as a key component for hepatitis B virus cccDNA formation. Here, we report on a novel functional interaction between Flap endonuclease 1 (FEN1) and the human cytomegalovirus (HCMV) immediate early protein 1 (IE1). Our results provide evidence that IE1 manipulates FEN1 in an unprecedented manner: we observed that direct IE1 binding does not only enhance FEN1 protein stability but also phosphorylation at serine 187. This correlates with nucleolar exclusion of FEN1 stimulating its DSB-generating gap endonuclease activity. Depletion of FEN1 and inhibition of its enzymatic activity during HCMV infection significantly reduced nascent viral DNA synthesis demonstrating a supportive role for efficient HCMV DNA replication. Furthermore, our results indicate that FEN1 is required for the formation of DSBs during HCMV infection suggesting that IE1 acts as viral activator of FEN1 in order to re-initiate stalled replication forks. In summary, we propose a novel mechanism of viral FEN1 activation to overcome replication fork barriers at difficult-to-replicate sites in viral genomes.</p><p class="para" id="N65542">Human cytomegalovirus (HCMV) infection is usually asymptomatic in healthy individuals. However, newborns and immunocompromised patients are suffering from life-threatening diseases upon infection. After decades of research, vaccines are still not available and the use of antiviral therapeutics is limited. During the last years, drugs targeting the cellular DNA damage response (DDR) are increasingly applied in cancer therapy. Interestingly, HCMV utilizes the cellular DDR for its replication thereby implicating DDR components as promising targets for antiviral intervention. In this study, we found that the DDR enzyme flap endonuclease 1 (FEN1) is activated by the HCMV protein IE1 in a unique manner that depends on a direct protein-protein interaction. Moreover, we could demonstrate that FEN1, which is tremendously stabilized by IE1, supports efficient viral DNA replication. We propose a novel mechanism whereby a viral protein manipulates the cellular enzyme FEN1 to facilitate the multiplication of viral DNA genomes. Small molecule inhibitors of FEN1 might thus serve as a new antiviral therapy option.</p>]]></description>
            <pubDate><![CDATA[2021-03-26T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Evaluation of anhydrous processing and storage methods of the temperate bacteriophage ɸV10 for integration into foodborne pathogen detection methodologies]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766021894236-7a9a683c-4e70-42d9-9b00-456246f61092/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249473</link>
            <description><![CDATA[<p class="para" id="N65539">Due to the nascency of bacteriophage-based pathogen detection technologies, several practical hurdles stand in the way between providing promising proof-of-concept data and development of robust detection platforms. One such hurdle, and the focus of this work, is the development of methods for transitioning laboratory stocks of bacteriophage into functional, consistent, and shelf-stable delivery methods in commercial detection kits. Research described here was undertaken to evaluate two methods for their ability to store the bacteriophage ɸV10 at ambient temperature without aqueous storage solutions while limiting loss of viability. ɸV10 is a temperate bacteriophage which solely infects the zero-tolerance food adulterant <i>Escherichia coli</i> O157:H7 and has been genetically modified to generate a detectable phenotype in host cells. In order to integrate this reporter bacteriophage into food-borne pathogen detection methodologies, two methods of processing phage suspensions for long-term, ambient storage were evaluated: printing solutions onto pieces of dissolvable paper and lyophilizing suspensions with sucrose. Applying phage to dissolvable paper yielded key attributes to consider when addressing phage viability, however, optimized methodology still resulted in an approximate five-log reduction in titer of viable phage. Lyophilization of ɸV10 with various concentrations of the cryoprotectant molecule, sucrose, yielded losses of approximately 0.3-log after 120 days of storage at 23°C. Liquid storage buffer samples with and without sucrose saw a reduction of viable phage of at least 3.9-log in the same period. Additionally, the ability for ɸV10 to form lysogens in an <i>E</i>. <i>coli</i> O157:H7 host was not negatively affected by lyophilization. Drying ɸV10 at ambient temperature drastically reduces the viability of the phage. However, lyophilizing ɸV10 in the presence of sucrose is an effective method for dehydration and storage of the phage in ambient environmental conditions for an extended time lending to commercial application and integration into foodborne pathogen detection methodologies.</p>]]></description>
            <pubDate><![CDATA[2021-04-06T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766021528183-232f6949-821d-4776-bf0a-e021a1206948/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009383</link>
            <description><![CDATA[<p class="para" id="N65539">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.</p><p class="para" id="N65542">We have developed an inactivated rabies virus vectored vaccine platform that has been used to develop a vaccine against SARS-CoV-2 (CORAVAX). CORAVAX induced high levels of neutralizing antibodies against SARS-CoV-2. Here we show that vaccinated hamsters, the best animal model for COVID-19, were protected against viral replication, indicating that this vaccine can stop transmission. CORAVAX also prevented lung disease. Rabies virus vaccines have been used in more than 100 million people worldwide, are safe and used in children and pregnant women. Therefore, it is anticipated that CORAVAX will generate robust immune responses against SARS-CoV-2 in humans that may also mimic the long-term protection seen in rabies vaccines.</p>]]></description>
            <pubDate><![CDATA[2021-03-25T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A human coronavirus evolves antigenically to escape antibody immunity]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009986160-fc2bd236-34ee-4a03-9cd5-10320fe7e1e9/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009453</link>
            <description><![CDATA[<p class="para" id="N65539">There is intense interest in antibody immunity to coronaviruses. However, it is unknown if coronaviruses evolve to escape such immunity, and if so, how rapidly. Here we address this question by characterizing the historical evolution of human coronavirus 229E. We identify human sera from the 1980s and 1990s that have neutralizing titers against contemporaneous 229E that are comparable to the anti-SARS-CoV-2 titers induced by SARS-CoV-2 infection or vaccination. We test these sera against 229E strains isolated after sera collection, and find that neutralizing titers are lower against these “future” viruses. In some cases, sera that neutralize contemporaneous 229E viral strains with titers &gt;1:100 do not detectably neutralize strains isolated 8–17 years later. The decreased neutralization of “future” viruses is due to antigenic evolution of the viral spike, especially in the receptor-binding domain. If these results extrapolate to other coronaviruses, then it may be advisable to periodically update SARS-CoV-2 vaccines.</p><p class="para" id="N65542">Hopes for controlling SARS-CoV-2 rely on vaccination or infection to confer immunity that protects against subsequent infection. However, the “common-cold” seasonal coronaviruses re-infect people every few years. It has been unclear if these re-infections occur because immunity wanes rapidly, or because the virus evolves to escape immunity elicited by prior infection. Here we investigate the second hypothesis in the context of the common-cold coronavirus 229E. We test how well antibodies in old human sera neutralize both contemporaneous old 229E viruses, and more recent viruses that evolved after the sera was collected. We find that as 229E evolves, its spike protein accumulates mutations that escape neutralization by older human sera. The rate at which viral evolution degrades immunity varies among individuals, but in some cases less than a decade of evolution is sufficient to completely eliminate neutralization by human sera that is potent against contemporaneous viruses. Many of the viral mutations occur in the same regions of the spike (the RBD and NTD) that are changing in emerging variants of SARS-CoV-2. Therefore, our results suggest that coronavirus vaccines may need to be periodically updated to keep pace with viral evolution.</p>]]></description>
            <pubDate><![CDATA[2021-04-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009832394-9287a323-185e-4f75-9ff7-4864834d7956/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0009300</link>
            <description><![CDATA[<p class="para" id="N65539">Ebola virus has been responsible for two major epidemics over the last several years and there has been a strong effort to find potential treatments that can improve the disease outcome. Antiviral favipiravir was thus tested on non-human primates infected with Ebola virus. Half of the treated animals survived the Ebola virus challenge, whereas the infection was fully lethal for the untreated ones. Moreover, the treated animals that did not survive died later than the controls. We evaluated the hematological, virological, biochemical, and immunological parameters of the animals and performed proteomic analysis at various timepoints of the disease. The viral load strongly correlated with dysregulation of the biological functions involved in pathogenesis, notably the inflammatory response, hemostatic functions, and response to stress. Thus, the management of viral replication in Ebola virus disease is of crucial importance in preventing the immunopathogenic disorders and septic-like shock syndrome generally observed in Ebola virus-infected patients.</p><p class="para" id="N65542">Ebola virus was responsible for several epidemics in the recent years and is now considered as a major public health concern in Central and West African countries. We and others demonstrated that pathogenic events observed during Ebola virus disease are linked to a deleterious immune response. However, the mechanisms implicated are not fully understood. Here, we studied immune responses depending on the viral loads observed in infected cynomolgus monkeys. An antiviral treatment allowed the reduction of viral load in some animals and we observed that these animals did not experience deleterious immune response and the loss of hemostasis. The release of pathogen-associated molecular patterns may thus be limited by the inhibition of viral replication, avoiding the overstimulation of the immune system and consequently the pathogenic events observed in Ebola virus disease.</p>]]></description>
            <pubDate><![CDATA[2021-03-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009134156-0896baed-9206-49fc-a018-c5b9b6b5aedb/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009431</link>
            <description><![CDATA[<p class="para" id="N65539">Tracking evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within infected individuals will help elucidate coronavirus disease 2019 (COVID-19) pathogenesis and inform use of antiviral interventions. In this study, we developed an approach for sequencing the region encoding the SARS-CoV-2 virion surface proteins from large numbers of individual virus RNA genomes per sample. We applied this approach to the WA-1 reference clinical isolate of SARS-CoV-2 passaged <i>in vitro</i> and to upper respiratory samples from 7 study participants with COVID-19. SARS-CoV-2 genomes from cell culture were diverse, including 18 haplotypes with non-synonymous mutations clustered in the spike NH<sub>2</sub>-terminal domain (NTD) and furin cleavage site regions. By contrast, cross-sectional analysis of samples from participants with COVID-19 showed fewer virus variants, without structural clustering of mutations. However, longitudinal analysis in one individual revealed 4 virus haplotypes bearing 3 independent mutations in a spike NTD epitope targeted by autologous antibodies. These mutations arose coincident with a 6.2-fold rise in serum binding to spike and a transient increase in virus burden. We conclude that SARS-CoV-2 exhibits a capacity for rapid genetic adaptation that becomes detectable <i>in vivo</i> with the onset of humoral immunity, with the potential to contribute to delayed virologic clearance in the acute setting.</p><p class="para" id="N65542">Mutant sequences of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) arising during any individual case of coronavirus disease 2019 (COVID-19) could theoretically enable the virus to evade immune responses or antiviral therapies that target the predominant infecting virus sequence. However, commonly used sequencing technologies are not optimally designed to detect variant virus sequences within each sample. To address this issue, we developed novel technology for sequencing large numbers of individual SARS-CoV-2 genomic RNA molecules across the region encoding the virus surface proteins. This technology revealed extensive genetic diversity in cultured viruses from a clinical isolate of SARS-CoV-2, but lower diversity in samples from 7 individuals with COVID-19. Importantly, concurrent analysis of paired serum samples in selected individuals revealed relatively low levels of antibody binding to the SARS-CoV-2 spike protein at the time of initial sequencing. With increased serum binding to spike protein, we detected multiple SARS-CoV-2 variants bearing independent mutations in a single epitope, as well as a transient increase in virus burden. These findings suggest that SARS-CoV-2 replication creates sufficient virus genetic diversity to allow immune-mediated selection of variants within the time frame of acute COVID-19. Large-scale studies of SARS-CoV-2 variation and specific immune responses will help define the contributions of intra-individual SARS-CoV-2 evolution to COVID-19 clinical outcomes and antiviral drug susceptibility.</p>]]></description>
            <pubDate><![CDATA[2021-04-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Rotavirus disease burden pre-vaccine introduction in young children in Rural Southern Mozambique, an area of high HIV prevalence]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766009054849-55979ae2-67ed-4909-b947-0eb1fb401d87/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249714</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Rotavirus vaccines have been adopted in African countries since 2009, including Mozambique (2015). Disease burden data are needed to evaluate the impact of rotavirus vaccine. We report the burden of rotavirus-associated diarrhea in Mozambique from the Global Enteric Multicenter Study (GEMS) before vaccine introduction.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A case-control study (GEMS), was conducted in Manhiça district, recruiting children aged 0–59 months with moderate-to-severe diarrhea (MSD) and less-severe-diarrhea (LSD) between December 2007 and November 2012; including 1–3 matched (age, sex and neighborhood) healthy community controls. Clinical and epidemiological data and stool samples (for laboratory investigation) were collected. Association of rotavirus with MSD or LSD was determined by conditional logistic regression and adjusted attributable fractions (AF) calculated, and risk factors for rotavirus diarrhea assessed.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Overall 91<b><i>5</i></b> cases and 1,97<b><i>7</i></b> controls for MSD, and 431 cases and 43<b><i>0</i></b> controls for LSD were enrolled. Rotavirus positivity was 44% (217/495) for cases and 15% (160/1046) of controls, with AF = 34.9% (95% CI: 32.85–37.06) and adjusted Odds Ratio (aOR) of 6.4 p&lt; 0.0001 in infants with MSD compared to 30% (46/155) in cases and 14% (22/154) in controls yielding AF = 18.7%, (95% CI: 12.02–25.39) and aOR = 2.8, p = 0.0011 in infants with LSD. The proportion of children with rotavirus was 32% (21/66) among HIV-positive children and 23% (128/566) among HIV-negative ones for MSD. Presence of animals in the compound (OR = 1.9; p = 0.0151) and giving stored water to the child (OR = 2.0, p = 0.0483) were risk factors for MSD; while animals in the compound (OR = 2.37, p = 0.007); not having routine access to water on a daily basis (OR = 1.53, p = 0.015) and washing hands before cooking (OR = 1.76, p = 0.0197) were risk factors for LSD.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65573">The implementation of vaccination against rotavirus may likely result in a significant reduction of rotavirus-associated diarrhea, suggesting the need for monitoring of vaccine impact.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Evaluation of rapid SARS-CoV-2 antigen tests, AFIAS COVID-19 Ag and ichroma COVID-19 Ag, with serial nasopharyngeal specimens from COVID-19 patients]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766008873125-6bb34fbd-d512-4d1e-a394-5c2eed77c00c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249972</link>
            <description><![CDATA[<p class="para" id="N65539">We evaluated the diagnostic accuracy of two newly developed, point-of-care, rapid antigen tests (RATs) for detecting SARS-CoV-2, the AFIAS COVID-19 Ag and the ichroma<sup>TM</sup> COVID-19 Ag, and investigated antigen kinetics. A total of 200 serially collected nasopharyngeal (NP) specimens from 38 COVID-19 patients and 122 specimens from negative controls were analyzed. Diagnostic sensitivity and specificity were assessed in comparison to molecular test results and subdivided according to targeted genes (<i>E</i>, <i>RdRP</i>, and <b><i>N</i></b>) and days post-symptom onset (PSO). For the kinetics evaluation, cut-off-indices from serial NP specimens were used according to the number of days PSO. Both RATs showed sensitivity of 91.3‒100% for specimens with cycle threshold (Ct) &lt; 25. The specificity of AFIAS was 98.7‒98.9% and that of ichroma<sup>TM</sup> was 100.0%. The kappa values of AFIAS and ichroma<sup>TM</sup> for the molecular testing of specimens with Ct &lt; 25 (<i>RdRP</i>) were 0.97 and 1.00, respectively. The sensitivity of AFIAS and ichroma<sup>TM</sup> for all genes was lower for specimens collected at 8‒14 PSO than for those collected before 7-days PSO. The kinetics profiles showed that antigen levels gradually decreased from ≤ 7-days PSO to &gt; 22-days PSO. Both RATs showed excellent specificity and acceptable sensitivity for NP specimens with higher viral loads and for specimens collected within 7-days PSO. Hence, they have the potential to become useful tools for the early detection of SARS-CoV-2. However, because of concerns about false negativity, RATs should be used in conjunction with molecular tests.</p>]]></description>
            <pubDate><![CDATA[2021-04-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Evaluation of the Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection in children: Implications for screening in a school setting]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766006836944-b4fa1d81-768a-4164-869e-218fc156a2b8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249710</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Rapid antigen tests hold much promise for use in the school environment. However, the performance of these tests in non-clinical settings and among one of the main target populations in schools—asymptomatic children—is unclear. To address this gap, we examined the positive and negative concordance between the BinaxNOW<sup>™</sup> rapid SARS-CoV-2 antigen assay and an RT-PCR test among children at a community-based Covid-19 testing site.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65552">We conducted rapid antigen (BinaxNOW<sup>™</sup>) and oral fluid RT-PCR (Curative Labs) tests on children presenting at a walk-up testing site in Los Angeles County from November 25, 2020 to December 9, 2020. Positive concordance was determined as the fraction of RT-PCR positive participants that were also antigen positive. Negative concordance was determined as the fraction of RT-PCR negative participants that were also antigen negative. Multivariate logistic regression models were used to examine the association between positive or negative concordance and participant age, race-ethnicity, sex at birth, symptoms and Ct values.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65561">226 children tested positive on RT-PCR; 127 children or 56.2% (95% CI: 49.5% to 62.8%) of these also tested positive on the rapid antigen test. Positive concordance was higher among symptomatic children (64.4%; 95% CI: 53.4% to 74.4%) compared to asymptomatic children (51.1%; 95% CI: 42.5% to 59.7%). Positive concordance was negatively associated with Ct values and was 93.8% (95% CI: 69.8% to 99.8%) for children with Ct values less than or equal to 25. 548 children tested negative on RT-PCR; 539 or 98.4% (95% CI: 96.9% to 99.2%) of these also tested negative on the rapid antigen test. Negative concordance was higher among asymptomatic children.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65567">Rapid antigen testing can successfully identify most COVID infections in children with viral load levels likely to be infectious. Serial rapid testing may help compensate for limited sensitivity in early infection.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[SARS-CoV-2 variants reveal features critical for replication in primary human cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766006575582-b10c5cf4-c96d-4d8a-a700-093b2a0b32ae/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pbio.3001006</link>
            <description><![CDATA[<p class="para" id="N65539">Since entering the human population, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2; the causative agent of Coronavirus Disease 2019 [COVID-19]) has spread worldwide, causing &gt;100 million infections and &gt;2 million deaths. While large-scale sequencing efforts have identified numerous genetic variants in SARS-CoV-2 during its circulation, it remains largely unclear whether many of these changes impact adaptation, replication, or transmission of the virus. Here, we characterized 14 different low-passage replication-competent human SARS-CoV-2 isolates representing all major European clades observed during the first pandemic wave in early 2020. By integrating viral sequencing data from patient material, virus stocks, and passaging experiments, together with kinetic virus replication data from nonhuman Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 features that associate with distinct phenotypes. Notably, naturally occurring variants in Orf3a (Q57H) and nsp2 (T85I) were associated with poor replication in Vero-CCL81 cells but not in BEpCs, while SARS-CoV-2 isolates expressing the Spike D614G variant generally exhibited enhanced replication abilities in BEpCs. Strikingly, low-passage Vero-derived stock preparation of 3 SARS-CoV-2 isolates selected for substitutions at positions 5/6 of E and were highly attenuated in BEpCs, revealing a key cell-specific function to this region. Rare isolate-specific deletions were also observed in the Spike furin cleavage site during Vero-CCL81 passage, but these were rapidly selected against in BEpCs, underscoring the importance of this site for SARS-CoV-2 replication in primary human cells. Overall, our study uncovers sequence features in SARS-CoV-2 variants that determine cell-specific replication and highlights the need to monitor SARS-CoV-2 stocks carefully when phenotyping newly emerging variants or potential variants of concern.</p><p class="para" id="N65540">SARS-CoV-2 variants have appeared throughout the emergence of the current COVID-19 pandemic. In this study, characterization of a panel of infectious SARS-CoV-2 isolates in primary human respiratory cells allows the identification of important sequence features that contribute to virus replication.</p>]]></description>
            <pubDate><![CDATA[2021-03-24T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Probability of consolidation constrains novel serotype emergence in dengue fever virus]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766005954106-ade0fd84-7db3-4053-a6e2-4a3cb13c1fbb/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0248765</link>
            <description><![CDATA[<p class="para" id="N65539">Since their first sequencing 40 years ago, Dengue virus (DENV) genotypes have shown extreme coherence regarding the serotype class they encode. Considering that DENV is a ribonucleic acid (RNA) virus with a high mutation rate, this behavior is intriguing. Here, we explore the effect of various parameters on likelihood of new serotype emergence. In order to determine the time scales of such an event, we used a Timed Markov Transmission Model to explore the influences of sylvatic versus peri-urban transmission, viral mutation rate, and vertical transmission on the probabilities of novel serotype emergence. We found that around 1 000 years are required for a new serotype to emerge, consistent with phylogenetic analysis of extant dengue serotypes. Furthermore, we show that likelihood of establishing chains of mosquito-human-mosquito infection, known as consolidation, is the primary factor which constrains novel serotype emergence. Our work illustrates the restrictions on and provides a mechanistic explanation for the low probability of novel dengue virus serotype emergence and the low number of observed DENV serotypes.</p>]]></description>
            <pubDate><![CDATA[2021-04-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Comparative analysis of various clinical specimens in detection of SARS-CoV-2 using rRT-PCR in new and follow up cases of COVID-19 infection: Quest for the best choice]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766005776749-7d9f57c3-d3fb-4fe4-a597-46607842f4a4/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249408</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">An appropriate specimen is of paramount importance in Real Time reverse transcription-polymerase chain reaction (rRT-PCR) based diagnosis of novel coronavirus (nCoV) disease (COVID-19). Thus, it’s pertinent to evaluate various diversified clinical specimens’ diagnostic utility in both diagnosis and follow-up of COVID-19.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A total of 924 initial specimens from 130 COVID-19 symptomatic cases before initiation of treatment and 665 follow up specimens from 15 randomly selected cases comprising of equal number of nasopharyngeal swab (NPS), oropharyngeal swab (OPS), combined NPS and OPS (Combined swab), sputum, plasma, serum and urine were evaluated by rRT-PCR.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Demographic analysis showed males (86) twice more affected by COVID-19 than females (44) (p = 0.00001). Combined swabs showed a positivity rate of 100% followed by NPS (91.5%), OPS (72.3%), sputum (63%), while nCoV was found undetected in urine, plasma and serum specimens. The lowest cycle threshold (Ct) values of targeted genes <i>E</i>, <i>ORF1b</i> and <i>RdRP</i> are 10.56, 10.14 and 12.26 respectively and their lowest average Ct values were found in combined swab which indicates high viral load in combined swab among all other specimen types. Analysis of 665 follow-up multi-varied specimens also showed combined swab as the last specimen among all specimen types to become negative, after an average 6.6 (range 4–10) days post-treatment, having lowest (15.48) and average (29.96) Ct values of <i>ORF1b</i> respectively indicating posterior nasopharyngeal tract as primary nCoV afflicted site with high viral load.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65573">The combined swab may be recommended as a more appropriate specimen for both diagnosis and monitoring of COVID-19 treatment by rRT-PCR for assessing virus clearance to help physicians in taking evidence-based decision before discharging patients. Implementing combined swabs globally will definitely help in management and control of the pandemic, as it is the need of the hour.</p></div>]]></description>
            <pubDate><![CDATA[2021-04-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Prospective evaluation of accuracy of HIV viral load monitoring using the Aptima HIV Quant Dx assay with fingerstick and venous dried blood spots prepared under field conditions in Kenya]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766004393165-28637d46-0ef1-4492-a3fd-2c135506941d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0249376</link>
            <description><![CDATA[<p class="para" id="N65539">Quantification of HIV-1 RNA is essential for clinical management of HIV patients. The limited throughput and significant hands-on time required by most HIV Viral load (VL) tests makes it challenging for laboratories with high test volume, to turn around patient results quickly. The Hologic Aptima HIV-1 Quant Dx Assay (Aptima), has the potential to alleviate this burden as it is high throughput and fully automated. This assay is validated for both plasma and dried blood spots (DBS), which are commonly used in resource limited settings. The objective of this study was to compare the performance of Aptima to Abbott RealTime HIV-1 Assay (Abbott RT), which was used as reference. This was a cross-sectional prospective study where HIV VL in finger stick (FS) DBS, venous blood (VB) DBS and plasma, collected from 258 consenting adults visiting 5 medical facilities in Kenya, Africa were tested in Aptima. The results were compared to plasma VL in Abbott RT at the medical decision point (MDP) of 1000 copies/mL and across Aptima assay range. The total agreement at MDP between plasma HIV VL in Abbott RT and plasma, FS and VB DBS tested in Aptima were 97.7%, 92.2% and 95.3% respectively with kappa statistic of 0.95, 0.84 and 0.90. The positive and negative agreement for all 3 sample types were &gt;92%. Regression analysis between VL in Abbott RT plasma and various sample types tested in Aptima had a Pearson’s correlation coefficient ≥0.91 with systematic bias of &lt; 0.20 log copies/mL on Bland-Altman analysis. The high level of agreement in Aptima HIV VL results for all 3 sample types with Abbott RT plasma VL along with the high throughput, complete automation, and ease of use of the Panther platform makes Aptima a good option for HIV VL monitoring for busy laboratories with high volume of testing.</p>]]></description>
            <pubDate><![CDATA[2021-04-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Citizenship, Migration and Mobility in a Pandemic (CMMP): A global dataset of COVID-19 restrictions on human movement]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765999089755-36c34a57-6082-4926-a80f-eadf430ad10b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0248066</link>
            <description><![CDATA[<p class="para" id="N65539">This research note introduces a new global dataset, the Citizenship, Migration and Mobility in a Pandemic (CMMP). The dataset features systematic information on border closures and domestic lockdowns in response to the COVID-19 outbreak in 211 countries and territories worldwide from 1 March to 1 June 2020. It documents the evolution of the types and scope of international travel bans and exceptions to them, as well as internal measures including limitations of non-essential movement and curfews in 27 countries. CMMP can be used to study causes and effects of policy restrictions to migration and mobility during the COVID-19 pandemic. The dataset is available through Cadmus and will be regularly updated until the last pandemic-related restriction has been lifted or become long-term.</p>]]></description>
            <pubDate><![CDATA[2021-03-09T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Inhibition of anti-viral stress granule formation by coronavirus endoribonuclease nsp15 ensures efficient virus replication]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765999072739-094fee37-717e-48e6-a497-0dab29a0cbdd/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1008690</link>
            <description><![CDATA[<p class="para" id="N65539">Cytoplasmic stress granules (SGs) are generally triggered by stress-induced translation arrest for storing mRNAs. Recently, it has been shown that SGs exert anti-viral functions due to their involvement in protein synthesis shut off and recruitment of innate immune signaling intermediates. The largest RNA viruses, coronaviruses, impose great threat to public safety and animal health; however, the significance of SGs in coronavirus infection is largely unknown. Infectious Bronchitis Virus (IBV) is the first identified coronavirus in 1930s and has been prevalent in poultry farm for many years. In this study, we provided evidence that IBV overcomes the host antiviral response by inhibiting SGs formation via the virus-encoded endoribonuclease nsp15. By immunofluorescence analysis, we observed that IBV infection not only did not trigger SGs formation in approximately 80% of the infected cells, but also impaired the formation of SGs triggered by heat shock, sodium arsenite, or NaCl stimuli. We further demonstrated that the intrinsic endoribonuclease activity of nsp15 was responsible for the interference of SGs formation. In fact, nsp15-defective recombinant IBV (rIBV-nsp15-H238A) greatly induced the formation of SGs, along with accumulation of dsRNA and activation of PKR, whereas wild type IBV failed to do so. Consequently, infection with rIBV-nsp15-H238A strongly triggered transcription of IFN-β which in turn greatly affected rIBV-nsp15-H238A replication. Further analysis showed that SGs function as an antiviral hub, as demonstrated by the attenuated IRF3-IFN response and increased production of IBV in SG-defective cells. Additional evidence includes the aggregation of pattern recognition receptors (PRRs) and signaling intermediates to the IBV-induced SGs. Collectively, our data demonstrate that the endoribonuclease nsp15 of IBV interferes with the formation of antiviral hub SGs by regulating the accumulation of viral dsRNA and by antagonizing the activation of PKR, eventually ensuring productive virus replication. We further demonstrated that nsp15s from PEDV, TGEV, SARS-CoV, and SARS-CoV-2 harbor the conserved function to interfere with the formation of chemically-induced SGs. Thus, we speculate that coronaviruses employ similar nsp15-mediated mechanisms to antagonize the host anti-viral SGs formation to ensure efficient virus replication.</p><p class="para" id="N65542">Coronavirus encodes the conserved endoribonuclease nsp15, which has been reported to antagonize IFN responses by mediating evasion of recognition by dsRNA sensors. SGs are part of the host cell anti-viral response; not surprisingly, viruses in turn produce an array of antagonists to counteract such host response. Here, we show that IBV prevents the formation of SGs via nsp15, by reducing the accumulation of viral dsRNA, thereby evading the activation of PKR, phosphorylation of eIF2α, and formation of SGs. Depletion of SG scaffold proteins G3BP1/2 decreases IRF3-IFN response and increases the production of IBV. When overexpressed alone, nsp15s from different coronaviruses (IBV, PEDV, TGEV, SARS-CoV, and SARS-CoV-2) interferes with chemically- and physically-induced SGs, probably by targeting essential SGs assembly factors. In this way, coronaviruses antagonize the formation of SGs by nsp15, via reducing the viral dsRNA accumulation and sequestering/depleting critical component of SGs. To our knowledge, this is the first report describing the role of coronavirus nsp15 in the suppression of integral stress response, in crosstalk with anti-innate immune response.</p>]]></description>
            <pubDate><![CDATA[2021-02-26T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Phase separation and DAXX redistribution contribute to LANA nuclear body and KSHV genome dynamics during latency and reactivation]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765998735291-17c186ae-2c1f-45c0-9a85-470dda2c7d94/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009231</link>
            <description><![CDATA[<p class="para" id="N65539">Liquid-liquid phase separation (LLPS) can drive formation of diverse and essential macromolecular structures, including those specified by viruses. Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) genomes associate with the viral encoded Latency-Associated Nuclear Antigen (LANA) to form stable nuclear bodies (NBs) during latent infection. Here, we show that LANA-NB formation and KSHV genome conformation involves LLPS. Using LLPS disrupting solvents, we show that LANA-NBs are partially disrupted, while DAXX and PML foci are highly resistant. LLPS disruption altered the LANA-dependent KSHV chromosome conformation but did not stimulate lytic reactivation. We found that LANA-NBs undergo major morphological transformation during KSHV lytic reactivation to form LANA-associated replication compartments encompassing KSHV DNA. DAXX colocalizes with the LANA-NBs during latency but is evicted from the LANA-associated lytic replication compartments. These findings indicate the LANA-NBs are dynamic super-molecular nuclear structures that partly depend on LLPS and undergo morphological transitions corresponding to the different modes of viral replication.</p><p class="para" id="N65542">During latent infection, gamma-herpesvirus genomes are maintained as extrachromosomal circular DNA, referred to as episomes, by dedicated viral-encoded episome maintenance proteins. KSHV-encoded LANA maintains viral episomes through binding as an oligomeric protein to repetitive DNA elements in the viral terminal repeats (TRs). Viral episomes can be visualized as LANA-associated nuclear bodies (LANA-NBs). Here, we show that LANA-NBs utilize mechanisms of self-assembly through liquid-liquid phase separation (LLPS) to build dynamic structures that change during cell cycle and viral life cycle. We find that DAXX is a component of the latent phase LANA-NBs, but is evicted during the transition to lytic replication where LANA remains associated with KSHV DNA to form a ring-like replication compartment.</p>]]></description>
            <pubDate><![CDATA[2021-01-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Survival, CD4 T lymphocyte count recovery and immune reconstitution pattern during the first-line combination antiretroviral therapy in patients with HIV-1 infection in Mongolia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765996142213-973fd69e-1ebc-490d-ad0a-4b40581cf42d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247929</link>
            <description><![CDATA[<p class="para" id="N65539">Mongolia has a low incidence of human immunodeficiency virus (HIV) infection, with 281 cases reported at the end of 2019 and an estimated incidence rate of &lt;0.01 cases per 1000 population.</p><p class="para" id="N65541">However, no study has analyzed the association between antiretroviral therapy (ART) outcomes and pretreatment characteristics of patients with HIV/acquired immunodeficiency syndrome (AIDS) in Mongolia. This retrospective study aimed to determine the survival, CD4 T cell recovery, and immune reconstitution pattern during ART in HIV patients and to determine baseline patient characteristics associated with ART outcomes. Based on three different World Health Organization (WHO) guidelines, we analyzed the 3-year observation data of 166 patients with HIV/AIDS who received treatment between 2010 and 2017. An increase of &gt;50 cells/μL indicated CD4 T cell count recovery, and a cell count of ≥500 cells/μL in patients with a baseline cell count of &lt;500 cells/μL indicated immune reconstitution. In this study, the 3- and 1-year mortality rates were 5.4% (survival rate: 94.6%) and 3.6%, respectively. A total of 83% of deaths that occurred in the observation time occurred within the first 3 months. The CD4 T cell count recovery rates at 3, 12, and 36 months were 62.7%, 80.7%, and 89.2%, respectively. The CD4 T cell count increased to &gt;500 cells/μL in 95 of 145 (65.5%) patients with a baseline cell count of &lt;500 cells/μL after 36 months of ART. The baseline CD4 T cell count was found to be a sensitive indicator for immune reconstitution. An advanced pretreatment clinical stage of HIV infection (as classified by the WHO classification), a low CD4 T cell count in the peripheral blood, and a high viral load before the initiation of the first-line ART accurately predicted survival, CD4 T cell count recovery, and immune reconstitution in Mongolian patients with HIV/AIDS.</p>]]></description>
            <pubDate><![CDATA[2021-03-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The cost-effectiveness of scaling-up rapid point-of-care testing for early infant diagnosis of HIV in southern Zambia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765995631749-066f507e-0403-412c-87bb-47ec189666e0/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0248217</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction</h3><p class="para" id="N65543">Early infant diagnosis (EID) and treatment can prevent much of the HIV-related morbidity and mortality experienced by children but is challenging to implement in sub-Saharan Africa. Point-of-care (PoC) testing would decentralize testing and increase access to rapid diagnosis. The objective of this study was to determine the cost-effectiveness of PoC testing in Southern Province, Zambia.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A decision tree model was developed to compare health outcomes and costs between the standard of care (SoC) and PoC testing using GeneXpert and m-PIMA platforms. The primary health outcome was antiretroviral treatment (ART) initiation within 60 days of sample collection. Additional outcomes included ART initiation by 12 months of age and death prior to ART initiation. Costs included both capital and recurrent costs. Health outcomes and costs were combined to create incremental cost effectiveness ratios (ICERs).</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">The proportion of children initiating ART within 60 days increased from 27.8% with SoC to 79.8–82.8% with PoC testing depending on the algorithm and platform. The proportion of children initiating ART by 12 months of age increased from 50.9% with SoC to 84.0–86.5% with PoC testing. The proportion of HIV-infected children dying prior to ART initiation decreased from 18.1% with SoC to 3.8–4.6% with PoC testing. Total program costs were similar for the SoC and GeneXpert but higher for m-PIMA. ICERs for PoC testing were favorable, ranging from $23–1,609 for ART initiation within 60 days, $37–2,491 for ART initiation by 12 months of age, and $90–6,188 for deaths prior to ART initiation. Factors impacting the costs of PoC testing, including the lifespan of the testing instruments and integrated utilization of PoC platforms, had the biggest impact on the ICERs. Integrating utilization across programs decreased costs for the EID program, such that PoC testing was cost-saving in some situations.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">PoC testing has the potential to improve linkage to care and ART initiation for HIV-infected infants and should be considered for implementation within EID programs to achieve equity in access to HIV services and reduce HIV-related pediatric morbidity and mortality.</p></div>]]></description>
            <pubDate><![CDATA[2021-03-09T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Genomic characterization and evolution of SARS-CoV-2 of a Canadian population]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765994177679-421121e9-d528-48b0-acda-4b19203bf90e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247799</link>
            <description><![CDATA[<p class="para" id="N65539">COVID-19 has greatly affected public health and world economy. In this study, we analyzed 129 full-length genomes of SARS-CoV-2 viruses of a Canadian population during early phase of the pandemic. Phylogenetic analysis revealed three major paths of transmission of SARS-CoV-2 viruses into Canada. Twenty-one substitutions that have frequencies greater than 3% of viral population were identified. Analysis of these substitutions indicated that P1427I (ORF1b), Y1464C (ORF1b), and Q57H (ORF3a) might affect functions of the corresponding SARS-CoV-2 encoded proteins. Additionally, we found the evidence of positive selection on the ORF3a and codon 614 of Spike protein, suggesting the viral components responsible for host entry and activation of inflammation response were targeted by host immune responses. The study showed genomic variation and evolution of SARS-CoV-2 in a Canadian population. These information may help develop preventive strategies and be used for further study of SARS-CoV-2 pathogenesis and therapeutics development.</p>]]></description>
            <pubDate><![CDATA[2021-03-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765993187262-d63154bd-4826-4575-ba13-9ab2834e1ff4/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247640</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Neutralizing-antibody (nAb) is the major focus of most ongoing COVID-19 vaccine trials. However, nAb response against SARS-CoV-2, when present, decays rapidly. Given the myriad roles of antibodies in immune responses, it is possible that antibodies could also mediate protection against SARS-CoV-2 via effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), which we sought to explore here.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">Plasma of 3 uninfected controls and 20 subjects exposed to, or recovering from, SARS-CoV-2 infection were collected from U.S. and sub-Saharan Africa. Immunofluorescence assay was used to detect the presence of SARS-CoV-2 specific IgG antibodies in the plasma samples. SARS-CoV-2 specific neutralizing capability of these plasmas was assessed with SARS-CoV-2 spike pseudotyped virus. ADCC activity was assessed with a calcein release assay.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">SARS-CoV-2 specific IgG antibodies were detected in all COVID-19 subjects studied. All but three COVID-19 subjects contained nAb at high potency (&gt;80% neutralization). Plasma from 19/20 of COVID-19 subjects also demonstrated strong ADCC activity against SARS-CoV-2 spike glycoprotein, including two individuals without nAb against SARS-CoV-2.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">Both neutralizing and non-neutralizing COVID-19 plasmas can mediate ADCC. Our findings argue that evaluation of potential vaccines against SARS-CoV-2 should include investigation of the magnitude and durability of ADCC, in addition to nAb.</p></div>]]></description>
            <pubDate><![CDATA[2021-03-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Antibody affinity versus dengue morphology influences neutralization]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765992985759-f879bece-96d8-40e6-9078-dd0aa744f8c9/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009331</link>
            <description><![CDATA[<p class="para" id="N65539">Different strains within a dengue serotype (DENV1-4) can have smooth, or “bumpy” surface morphologies with different antigenic characteristics at average body temperature (37°C). We determined the neutralizing properties of a serotype cross-reactive human monoclonal antibody (HMAb) 1C19 for strains with differing morphologies within the DENV1 and DENV2 serotypes. We mapped the 1C19 epitope to E protein domain II by hydrogen deuterium exchange mass spectrometry, cryoEM and molecular dynamics simulations, revealing that this epitope is likely partially hidden on the virus surface. We showed the antibody has high affinity for binding to recombinant DENV1 E proteins compared to those of DENV2, consistent with its strong neutralizing activities for all DENV1 strains tested regardless of their morphologies. This finding suggests that the antibody could out-compete E-to-E interaction for binding to its epitope. In contrast, for DENV2, HMAb 1C19 can only neutralize when the epitope becomes exposed on the bumpy-surfaced particle. Although HMAb 1C19 is not a suitable therapeutic candidate, this study with HMAb 1C19 shows the importance of choosing a high-affinity antibody that could neutralize diverse dengue virus morphologies for therapeutic purposes.</p><p class="para" id="N65542">Dengue virus consists of four serotypes (DENV1-4) and there are different strains within a serotype. DENV can have smooth or bumpy surface morphologies at physiological body temperature of 37°C, depending on the strain. We have determined the cryoEM structures of a cross-reactive neutralizing human monoclonal antibody (HMAb) 1C19 in complex with strains of DENV1 and DENV2 that form either smooth or bumpy surface morphologies. We have mapped the epitope of HMAb 1C19 to E protein domain II and the epitope is likely partially hidden on the virus surface. We showed that the antibody has high affinity for binding to recombinant DENV1 E protein than to DENV2 E protein. This explains the strong neutralization activity for all DENV1 strains tested regardless of their morphologies at physiological temperature, whereas it can only neutralize DENV2 strain that exposes the epitope on the bumpy surface particles. These results suggest that high-affinity therapeutic antibodies could neutralize diverse dengue virus morphologies.</p>]]></description>
            <pubDate><![CDATA[2021-02-23T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The effects of MDR/RR-TB treatment on HIV disease: A systematic review of literature]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765992940337-c9d0e06e-ccaa-4e1a-a8b5-a3f7f1928c3f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0248174</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) and human immunodeficiency virus (HIV) co-infection are a deadly combination. While evidence on the effects of HIV co-infection on MDR/RR-TB treatment outcomes is well-documented, little published evidence describes the effects of MDR/RR-TB treatment on HIV disease.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">We conducted a review of literature published prior to June 2020. We searched Pubmed, CINAHL, and EMBASE using variations of the terms “multidrug-resistant tuberculosis,” “HIV,” and either “CD4” or “viral load.” Two reviewers independently completed title and abstract screening, full-text screening, article evaluation, and data extraction. We also included five published articles evaluated as evidence by the World Health Organization (WHO) in preparation for the 2019 MDR/RR-TB treatment guideline update.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">A total of 459 references were returned, with 362 remaining after duplicate removal. Following article screening, six manuscripts were included. Articles reported CD4 count and/or viral load results for MDR/RR-TB and HIV co-infected patients during and/or after MDR/RR-TB treatment. The additional five references identified from the WHO guideline revision did not report HIV disease indicators after MDR/RR-TB initiation.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">There is a paucity of evidence on HIV disease indicators following MDR/RR-TB treatment. Researchers should report longitudinal HIV disease indicators in co-infected patients in publications.</p></div>]]></description>
            <pubDate><![CDATA[2021-03-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Group testing as a strategy for COVID-19 epidemiological monitoring and community surveillance]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765984254212-8b6d60b0-e097-4b2c-a541-b1581c39a3bd/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pcbi.1008726</link>
            <description><![CDATA[<p class="para" id="N65539">We propose an analysis and applications of sample pooling to the epidemiologic monitoring of COVID-19. We first introduce a model of the RT-qPCR process used to test for the presence of virus in a sample and construct a statistical model for the viral load in a typical infected individual inspired by large-scale clinical datasets. We present an application of group testing for the prevention of epidemic outbreak in closed connected communities. We then propose a method for the measure of the prevalence in a population taking into account the increased number of false negatives associated with the group testing method.</p><p class="para" id="N65542">Sample pooling consists in combining samples from multiple individuals into a single pool that is then tested using a unique test-kit. A positive test means that at least one individual within the pool is infected. Sample pooling could provide the means for rapid and massive testing for the presence of SARS-CoV2 among asymptomatic individuals. Here, we do not address any diagnostic problems—e.g. how to use a minimal number of tests to obtain an individual diagnostic—but rather focus on population-scale application of pooling. We first quantify the reduction of test sensitivity due to sample dilution and quantify the efficiency of large pools in (i) obtaining precise estimates of the proportion of infected individuals in the general population at reduced costs and (ii) implementing regular large-scale screenings beneficial in the early detection of epidemic outbreaks within communities (e.g. nursing homes or university campuses).</p>]]></description>
            <pubDate><![CDATA[2021-03-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Recognizing species as a new focus of virus research]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765983482975-cdda17f0-8fa2-41c5-991a-e58992528bd0/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009318</link>
            <description><![CDATA[<p class="para" id="N65539">Species taxa are the units of taxonomy most suited to measure virus diversity, and they account for more than 70% of all virus taxa. Yet, as evidenced by the content of GenBank entries and illustrated by the recent literature on SARS-CoV-2, they are the most neglected taxa of virus research. To correct this disparity, we propose to make species taxa a first choice for communicating virus taxonomy in publications concerning viruses. We see it as a key step toward promoting research on diverse viruses, including pathogens, at this fundamental level of biology.</p>]]></description>
            <pubDate><![CDATA[2021-03-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Estimated impact of the pneumococcal conjugate vaccine on pneumonia mortality in South Africa, 1999 through 2016: An ecological modelling study]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765981667311-5cb560a0-21f6-4cda-b5cd-e68d7adbb57d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pmed.1003537</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Data on the national-level impact of pneumococcal conjugate vaccine (PCV) introduction on mortality are lacking from Africa. PCV was introduced in South Africa in 2009. We estimated the impact of PCV introduction on all-cause pneumonia mortality in South Africa, while controlling for changes in mortality due to other interventions.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods and findings</h3><p class="para" id="N65549">We used national death registration data in South Africa from 1999 to 2016 to assess the impact of PCV introduction on all-cause pneumonia mortality in all ages, with the exclusion of infants aged &lt;1 month. We created a composite (synthetic) control using Bayesian variable selection of nondiarrheal, nonpneumonia, and nonpneumococcal deaths to estimate the number of expected all-cause pneumonia deaths in the absence of PCV introduction post 2009. We compared all-cause pneumonia deaths from the death registry to the expected deaths in 2012 to 2016. We also estimated the number of prevented deaths during 2009 to 2016. Of the 9,324,638 deaths reported in South Africa from 1999 to 2016, 12·6% were pneumonia-related.</p><p class="para" id="N65551">Compared to number of deaths expected, we estimated a 33% (95% credible interval (CrI) 26% to 43%), 23% (95%CrI 17% to 29%), 25% (95%CrI 19% to 32%), and 23% (95%CrI 11% to 32%) reduction in pneumonia mortality in children aged 1 to 11 months, 1 to 4 years, 5 to 7 years, and 8 to 18 years in 2012 to 2016, respectively. In total, an estimated 18,422 (95%CrI 12,388 to 26,978) pneumonia-related deaths were prevented from 2009 to 2016 in children aged &lt;19 years. No declines were estimated observed among adults following PCV introduction. This study was mainly limited by coding errors in original data that could have led to a lower impact estimate, and unmeasured factors could also have confounded estimates.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusions</h3><p class="para" id="N65557">This study found that the introduction of PCV was associated with substantial reduction in all-cause pneumonia deaths in children aged 1 month to &lt;19 years. The model predicted an effect of PCV in age groups who were eligible for vaccination (1 months to 4 years), and an indirect effect in those too old (8 to 18 years) to be vaccinated. These findings support sustaining pneumococcal vaccination to reduce pneumonia-related mortality in children.</p></div><p class="para" id="N65540">Jackie Kleynhans and colleagues investigate whether introduction of the pneumococcal conjugate vaccine may have reduced all-cause pneumonia mortality in South Africa.</p><div class="section" id="sec004"><h3 class="BHead" id="nov000-1">Why was this study done?</h3><p class="para" id="N65549">The bacterium, <i>Streptococcus pneumoniae</i>, causes a third of childhood pneumonia deaths in sub-Saharan Africa.</p><p class="para" id="N65555">The pneumococcal conjugate vaccine (PCV) has been used in South Africa since 2009 and has been found to be effective in reducing vaccine-serotype invasive pneumococcal disease.</p><p class="para" id="N65558">The effect of PCV on pneumonia mortality has not been assessed in South Africa, or on national scale in Africa.</p><p class="para" id="N65561">We wanted to estimate the impact of this vaccine on all-cause pneumonia mortality in South Africa.</p></div><div class="section" id="sec005"><h3 class="BHead" id="nov000-2">What did the researches do and find?</h3><p class="para" id="N65570">We performed an ecological modelling study using national death registration data in South Africa from 1999 to 2016 to assess the impact of PCV introduction on all-cause pneumonia mortality.</p><p class="para" id="N65573">Due to multiple other changes in South Africa at the time, pneumonia mortality was already decreasing before PCV was introduced. Therefore, we needed to control for these changes while measuring the impact of PCV on pneumonia mortality.</p><p class="para" id="N65576">We did this by creating a synthetic control from multiple other causes of deaths and compared the number of pneumonia deaths after PCV introduction to this synthetic control.</p><p class="para" id="N65579">We estimated that pneumonia mortality reduced between 23% and 33% in children younger than 19 years, with an estimated 18,000 deaths prevented between 2009 and 2016.</p></div><div class="section" id="sec006"><h3 class="BHead" id="nov000-3">What do these findings mean?</h3><p class="para" id="N65588">PCV has contributed in reducing childhood pneumonia mortality in South Africa.</p><p class="para" id="N65591">Vaccination of children with PCV should continue globally and should be expanded to all African countries.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Transmission mode of watermelon silver mottle virus by <i>Thrips palmi</i>]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765981584259-85cc20b6-0ee6-410e-8347-675132d4da3c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247500</link>
            <description><![CDATA[<p class="para" id="N65539">Thrips and thrips-transmitted tospoviruses cause significant losses in crop yields worldwide. The melon thrips (<i>Thrips palmi</i>) is not only a pest of cucurbit crops, but also a vector that transmits tospoviruses, such as the watermelon silver mottle virus (WSMoV). Vector transmission of tospoviruses has been well studied in the tomato spotted wilt virus (TSWV)–<i>Frankliniella occidentalis</i> model system; however, until now the transmission mode of WSMoV by <i>T</i>. <i>palmi</i> has not been sufficiently examined. The results of the transmission assays suggest that <i>T</i>. <i>palmi</i> transmits WSMoV in a persistent manner, and that the virus is mainly transmitted by adults, having been ingested at the first-instar larval stage. Complementary RNAs corresponding to the <i>NSm</i> and <i>NSs</i> genes of WSMoV were detected in viruliferous thrips by reverse transcription-polymerase chain reaction; NSs protein was also detected in viruliferous thrips by western blotting, verifying the replication of WSMoV in <i>T</i>. <i>palmi</i>. Furthermore, we demonstrated that in thrips infected with WSMoV at the first-instar larval stage, the virus eventually infected various tissues of the adult thrips, including the primary salivary glands. Taken together, these results suggest that <i>T</i>. <i>palmi</i> transmits WSMoV in a persistent-propagative mode. The results of this study make a significant contribution to the understanding of the transmission biology of tospoviruses in general.</p>]]></description>
            <pubDate><![CDATA[2021-03-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Magnitude and associated factors of peripheral cytopenia among HIV-infected children attending at University of Gondar Specialized Referral Hospital, Northwest Ethiopia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765981570076-b11e00cc-4d88-4ba8-b785-46066d1d8d2b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247878</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Isolated or multi lineage cytopenia are the most common clinicopathological features and independently associated with increased risk of disease progression and death among human immunodeficiency virus infected children. In the study area, there is scarcity of data about the magnitude of various cytopenia.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Objectives</h3><p class="para" id="N65549">Aimed to determine the magnitude and associated factors of peripheral cytopenia among HIV infected children at the University of Gondar Specialized Referral Hospital ART clinic, Northwest Ethiopia.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Methods</h3><p class="para" id="N65555">Institutional based cross-sectional study was conducted on 255 HIV infected children from January- April 2020. None probable convenient sampling technique was used to select the study participant. Socio demographic data were collected by pre tested structured questionnaire via face-to-face interview and their medical data were obtained from their follow-up medical records. Moreover, blood specimens were collected and examined for complete blood count, viral load and blood film, whereas stool specimens were collected and examined for intestinal parasites. Bi-variable and multi-variable logistic regression models were fitted to identify associated factors of cytopenia. P-Value &lt;0.05 was considered as statistically significant.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Result</h3><p class="para" id="N65561">The overall magnitude of peripheral cytopenia was 38.9%. Anemia, leukopenia, lymphopenia, thrombocytopenia and bi-cytopenia were 21.2%, 12.2%, 11%, 1.6% and 3.9% respectively. Being in the age group of 2–10 years (AOR = 5.38, 95%CI 2.33–12.46), AZT based regimen (AOR = 5.44, 95%CI: 2.24–13.21), no eating green vegetables (AOR = 2.49, 95% CI: 1.26–4.92) and having plasma viral load &gt;1000 copies /ml (AOR = 5.38, 95%CI: 2.22–13.03) showed significant association with anemia.</p></div><div class="section" id="sec005"><h3 class="BHead" id="nov000-5">Conclusion</h3><p class="para" id="N65567">Anemia was the predominant peripheral cytopenia among HIV infected children in this study. It was strongly associated with AZT based drug type, age below 10 years and high viral load. Critical stress should be given for early investigation and management of cytopenia in addition to the use of alternative drug which leads to higher viral suppression and lower risk of toxicity issue.</p></div>]]></description>
            <pubDate><![CDATA[2021-03-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Serum <i>β</i><sub>2</sub>-microglobulin levels in Coronavirus disease 2019 (Covid-19): Another prognosticator of disease severity?]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765978526499-d9e098f9-53bc-47e0-9609-57bd513a83f7/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247758</link>
            <description><![CDATA[<p class="para" id="N65539"><i>β</i><sub>2</sub>-microglobulin (<i>β</i><sub>2</sub>-m), a 11.8 kDa protein, pairs non-covalently with the α3 domain of the major histocompatibility class (MHC) I <i>α</i>-chain and is essential for the conformation of the MHC class I protein complex. Shed <i>β</i><sub>2</sub>-m is measurable in circulation, and various disorders are accompanied by increases in <i>β</i><sub>2</sub>-m levels, including several viral infections. Therefore, we explored whether <i>β</i><sub>2</sub>-m levels could also be elevated in Coronavirus disease 2019 (Covid-19) and whether they predict disease severity. Serum <i>β</i><sub>2</sub>-m levels were measured in a cohort of 34 patients infected with SARS-CoV-2 on admission to a tertiary care hospital in Riyadh, Saudi Arabia, as well as in an approximately age-sex matched group of 34 uninfected controls. Mean <i>β</i><sub>2</sub>-m level was 3.25±1.68 mg/l (reference range 0.8–2.2 mg/l) in patients (mean age 48.2±21.6) and 1.98±0.61 mg/l in controls (mean age 48.2±21.6). 17 patients (mean age 36.9± 18.0) with mean <i>β</i><sub>2</sub>-m levels of 2.27±0.64 mg/l had mild disease by WHO severity categorization, 12 patients (mean age 53.3±18.1) with mean <i>β</i><sub>2</sub>-m levels of 3.57±1.39 mg/l had moderate disease, and five patients (of whom 2 died; mean age 74.4±13.8) with mean <i>β</i><sub>2</sub>-m levels of 5.85±1.85 mg/l had severe disease (<i>P</i> &lt; = 0.001, by ANOVA test for linear trend). In multivariate ordinal regression <i>β</i><sub>2</sub>-m levels were the only significant predictor of disease severity. Our findings suggest that higher <i>β</i><sub>2</sub>-m levels could be an early indicator of severity of disease and predict outcome of Covid-19. As the main limitations of the study are a single-center study, sample size and ethnicity, these results need confirmation in larger cohorts outside the Arabian Peninsula in order to delineate the value of <i>β</i><sub>2</sub>-m measurements. The role of <i>β</i><sub>2</sub>-m in the etiology and pathogenesis of severe Covid-19 remains to be elucidated.</p>]]></description>
            <pubDate><![CDATA[2021-03-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Marek’s disease virus U<sub>S</sub>3 protein kinase phosphorylates chicken HDAC 1 and 2 and regulates viral replication and pathogenesis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765977651369-a6c3b738-cb9d-4333-9ed2-0d0dba95dea6/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009307</link>
            <description><![CDATA[<p class="para" id="N65539">Marek’s disease virus (MDV) is a potent oncogenic alphaherpesvirus that elicits a rapid onset of malignant T-cell lymphomas in chickens. Three MDV types, including GaHV-2 (MDV-1), GaHV-3 (MDV-2) and MeHV-1 (HVT), have been identified and all encode a U<sub>S</sub>3 protein kinase. MDV-1 U<sub>S</sub>3 is important for efficient virus growth <i>in vitro</i>. To study the role of U<sub>S</sub>3 in MDV replication and pathogenicity, we generated an MDV-1 U<sub>S</sub>3-null virus and chimeric viruses by replacing MDV-1 U<sub>S</sub>3 with MDV-2 or HVT U<sub>S</sub>3. Using MD as a natural virus-host model, we showed that both MDV-2 and HVT U<sub>S</sub>3 partially rescued the growth deficiency of MDV-1 U<sub>S</sub>3-null virus. In addition, deletion of MDV-1 U<sub>S</sub>3 attenuated the virus resulting in higher survival rate and lower MDV specific tumor incidence, which could be partially compensated by MDV-2 and HVT U<sub>S</sub>3. We also identified chicken histone deacetylase 1 (chHDAC1) as a common U<sub>S</sub>3 substrate for all three MDV types while only U<sub>S</sub>3 of MDV-1 and MDV-2 phosphorylate chHDAC2. We further determined that U<sub>S</sub>3 of MDV-1 and HVT phosphorylate chHDAC1 at serine 406 (S406), while MDV-2 U<sub>S</sub>3 phosphorylates S406, S410, and S415. In addition, MDV-1 U<sub>S</sub>3 phosphorylates chHDAC2 at S407, while MDV-2 U<sub>S</sub>3 targets S407 and S411. Furthermore, biochemical studies show that MDV U<sub>S</sub>3 mediated phosphorylation of chHDAC1 and 2 affect their stability, transcriptional regulation activity, and interaction network. Using a class I HDAC specific inhibitor, we showed that MDV U<sub>S</sub>3 mediated phosphorylation of chHDAC1 and 2 is involved in regulation of virus replication. Overall, we identified novel substrates for MDV U<sub>S</sub>3 and characterized the role of MDV U<sub>S</sub>3 in MDV pathogenesis.</p><p class="para" id="N65542">Marek’s disease virus (MDV) is a highly contagious and oncogenic avian alphaherpesvirus that causes T-cell lymphomas in chickens. Alphaherpesviruses encoded U<sub>S</sub>3 is a multifunctional protein kinase involved in viral replication, apoptosis resistance, and cell-to-cell spread. In this study, we evaluated the importance of MDV U<sub>S</sub>3 in regulating MDV replication and pathogenesis in chickens. Our results provide first evidence that MDV U<sub>S</sub>3 protein kinase is involved in the replication and pathogenicity of MDV in its natural host. We also identified chicken histone deacetylase 1 and 2 (chHDAC1 and 2) as novel substrates of U<sub>S</sub>3 for MDV and characterized the potential impacts of MDV U<sub>S</sub>3 induced phosphorylation in their protein stability, transcriptional regulation and protein interactions; to our knowledge, this is the first comparative study of the functions of U<sub>S</sub>3 from all three MDV types. This is an important finding towards a better understanding of the functions of alphaherpesviruses encoded U<sub>S</sub>3 protein kinase.</p>]]></description>
            <pubDate><![CDATA[2021-02-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765969279453-51269167-d53b-4826-99ca-8766874a7b94/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pcbi.1008699</link>
            <description><![CDATA[<p class="para" id="N65539">Hepatitis B virus (HBV) infection contributes to hepatocellular carcinoma (HCC) initiation and is associated with worse outcomes. Many prior studies of HBV-related HCC have not accounted for potential heterogeneity among HBV-related tumors by assessing whether HBV activity is present in tumor tissue. Here, we measured tumor HBV RNA, a proxy for viral activity, and investigated the association between HBV RNA status and several clinicogenomic characteristics. We obtained clinical, mutation, RNA-Seq and survival data for 439 HCC tumors from The Cancer Genome Atlas and International Cancer Genome Consortium. Tumors were classified as HBV RNA positive if they harbored &gt;1 HBV RNA read per million human reads. We investigated the association between HBV RNA status and nonsynonymous somatic mutations, gene set expression, homologous recombination deficiency (HRD) score and mutation-specific survival. HBV RNA positive status was associated with higher nonsynonymous mutation rates of multiple genes, including <i>TP53</i> and <i>CDKN2A</i>, while HBV RNA negative status was associated with higher nonsynonymous <i>BAP1</i> mutation rate. HBV RNA positive status was also associated with increased transcription of genes involved in multiple DNA damage repair pathways, genes upregulated by <i>MYC</i> and mTORC1, and genes overexpressed in several HCC subclasses associated with a proliferative phenotype. Further, HBV RNA positive status was associated with increased three-biomarker HRD score (22.2 for HBV RNA+ vs. 16.0 for HBV RNA-). Finally, HBV RNA status was associated with multiple mutation-specific survival differences, including decreased survival for HBV RNA positive patients with nonsynonymous <i>KEAP1</i> mutations compared to those without (hazard ratio 4.26). HCC tumors harboring genomic evidence of HBV activity therefore constitute a distinct HCC subset characterized by specific differences in nonsynonymous mutations, gene set expression, three-biomarker HRD score and mutation-specific survival.</p><p class="para" id="N65542">Hepatocellular carcinoma, the most common type of liver cancer, is the second leading cause of cancer death worldwide and is most commonly caused by hepatitis B virus infection. Currently, scientists have an incomplete understanding of the genomic basis of hepatocellular carcinoma associated with hepatitis B virus infection, because prior studies have been limited by imprecision in assessing hepatitis B virus infection status and heterogeneity in hepatitis B virus activity levels in liver tumors. This has limited scientists’ ability to devise new diagnostic and therapeutic options for hepatocellular carcinoma. In this study, we used computational genomics to directly measure hepatitis B virus RNA levels in a large dataset of hepatocellular carcinoma tumors, and found that tumors with measurable hepatitis B virus RNA levels are associated with a specific set of clinical and genomic characteristics. These characteristics have not previously been reported and harbor implications for future clinical and genomics research in hepatocellular carcinoma, as well as computational genomics efforts in other cancer types.</p>]]></description>
            <pubDate><![CDATA[2021-02-09T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Extraction-free protocol combining proteinase K and heat inactivation for detection of SARS-CoV-2 by RT-qPCR]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765968570666-ef70971a-5cb5-43bc-8bce-0a9bdbe641bc/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247792</link>
            <description><![CDATA[<p class="para" id="N65539">Real-time reverse transcription PCR (RT-qPCR) is the gold-standard technique for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection in nasopharyngeal swabs specimens. The analysis by RT-qPCR usually requires a previous extraction step to obtain the purified viral RNA. Unfortunately, RNA extraction constitutes a bottleneck for early detection in many countries since it is expensive, time-consuming and depends on the availability of commercial kits. Here, we describe an extraction-free protocol for SARS-CoV-2 detection by RT-qPCR from nasopharyngeal swab clinical samples in saline solution. The method includes a treatment with proteinase K followed by heat inactivation (PK+HID method). We demonstrate that PK+HID improves the RT-qPCR performance in comparison to the heat-inactivation procedure. Moreover, we show that this extraction-free protocol can be combined with a variety of multiplexing RT-qPCR kits. The method combined with a multiplexing detection kit targeting N and ORF1ab viral genes showed a sensitivity of 0.99 and a specificity of 0.99 from the analysis of 106 positive and 106 negative clinical samples. In conclusion, PK+HID is a robust, fast and inexpensive procedure for extraction-free RT-qPCR determinations of SARS-CoV-2. The National Administration of Drugs, Foods and Medical Devices of Argentina has recently authorized the use of this method.</p>]]></description>
            <pubDate><![CDATA[2021-02-26T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Association of SARS-CoV-2 viral load at admission with in-hospital acute kidney injury: A retrospective cohort study]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765948881231-e9b2233b-18be-4cf2-b38c-af692315a237/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247366</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated Coronavirus Disease 2019 (COVID-19) is a public health emergency. Acute kidney injury (AKI) is a common complication in hospitalized patients with COVID-19 although mechanisms underlying AKI are yet unclear. There may be a direct effect of SARS-CoV-2 virus on the kidney; however, there is currently no data linking SARS-CoV-2 viral load (VL) to AKI. We explored the association of SARS-CoV-2 VL at admission to AKI in a large diverse cohort of hospitalized patients with COVID-19.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods and findings</h3><p class="para" id="N65549">We included patients hospitalized between March 13<sup>th</sup> and May 19<sup>th</sup>, 2020 with SARS-CoV-2 in a large academic healthcare system in New York City (N = 1,049) with available VL at admission quantified by real-time RT-PCR. We extracted clinical and outcome data from our institutional electronic health records (EHRs). AKI was defined by KDIGO guidelines. We fit a Fine-Gray competing risks model (with death as a competing risk) using demographics, comorbidities, admission severity scores, and log<sub>10</sub> transformed VL as covariates and generated adjusted hazard ratios (aHR) and 95% Confidence Intervals (CIs). VL was associated with an increased risk of AKI (aHR = 1.04, 95% CI: 1.01–1.08, p = 0.02) with a 4% increased hazard for each log<sub>10</sub> VL change. Patients with a viral load in the top 50<sup>th</sup> percentile had an increased adjusted hazard of 1.27 (95% CI: 1.02–1.58, p = 0.03) for AKI as compared to those in the bottom 50<sup>th</sup> percentile.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusions</h3><p class="para" id="N65573">VL is weakly but significantly associated with in-hospital AKI after adjusting for confounders. This may indicate the role of VL in COVID-19 associated AKI. This data may inform future studies to discover the mechanistic basis of COVID-19 associated AKI.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-24T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765939160780-086ed58b-a0bf-420c-abf1-15714df3d71a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247128</link>
            <description><![CDATA[<p class="para" id="N65539">Human coronaviruses (HCoVs) cause mild to severe respiratory infection. Most of the common cold illnesses are caused by one of four HCoVs, namely HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43. Several studies have applied global transcriptomic methods to understand host responses to HCoV infection, with most studies focusing on the pandemic severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome CoV (MERS-CoV) and the newly emerging SARS-CoV-2. In this study, Next Generation Sequencing was used to gain new insights into cellular transcriptomic changes elicited by alphacoronavirus HCoV-229E. HCoV-229E-infected MRC-5 cells showed marked downregulation of superpathway of cholesterol biosynthesis and eIF2 signaling pathways. Moreover, upregulation of cyclins, cell cycle control of chromosomal replication, and the role of BRCA1 in DNA damage response, alongside downregulation of the cell cycle G1/S checkpoint, suggest that HCoV-229E may favors S phase for viral infection. Intriguingly, a significant portion of key factors of cell innate immunity, interferon-stimulated genes (ISGs) and other transcripts of early antiviral response genes were downregulated early in HCoV-229E infection. On the other hand, early upregulation of the antiviral response factor Apolipoprotein B mRNA editing enzyme catalytic subunit 3<i>B (APOBEC3B)</i> was observed. APOBEC3B cytidine deaminase signature (C-to-T) was previously observed in genomic analysis of SARS-CoV-2 but not HCoV-229E. Higher levels of C-to-T mutations were found in countries with high mortality rates caused by SARS-CoV-2. APOBEC activity could be a marker for new emerging CoVs. This study will enhance our understanding of commonly circulating HCoVs and hopefully provide critical information about still-emerging coronaviruses.</p>]]></description>
            <pubDate><![CDATA[2021-02-25T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Convergent antibody evolution and clonotype expansion following influenza virus vaccination]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765938892584-8ee0c885-3132-4da1-8331-a74426125ce0/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247253</link>
            <description><![CDATA[<p class="para" id="N65539">Recent advances in high-throughput single cell sequencing have opened up new avenues into the investigation of B cell receptor (BCR) repertoires. In this study, PBMCs were collected from 17 human participants vaccinated with the split-inactivated influenza virus vaccine during the 2016–2017 influenza season. A combination of Immune Repertoire Capture (IRC<sup>TM</sup>) technology and IgG sequencing was performed on ~7,800 plasmablast (PB) cells and preferential IgG heavy-light chain pairings were investigated. In some participants, a single expanded clonotype accounted for ~22% of their PB BCR repertoire. Approximately 60% (10/17) of participants experienced convergent evolution, possessing public PBs that were elicited independently in multiple participants. Binding profiles of one private and three public PBs confirmed they were all subtype-specific, cross-reactive hemagglutinin (HA) head-directed antibodies. Collectively, this high-resolution antibody repertoire analysis demonstrated the impact evolution can have on BCRs in response to influenza virus vaccination, which can guide future universal influenza prophylactic approaches.</p>]]></description>
            <pubDate><![CDATA[2021-02-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Right ventricular load and contractility in HIV-associated pulmonary hypertension]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765935490291-358122f3-3509-45c8-abfa-f16f7a282faa/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0243274</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">People living with human immunodeficiency virus (PLWH) are at risk of developing pulmonary hypertension (PH) and right ventricular (RV) dysfunction, but understanding of the relationship of RV function to afterload (RV-PA coupling) is limited. We evaluated the clinical and hemodynamic characteristics of human immunodeficiency virus (HIV)-associated PH.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">We performed a retrospective review of patients with a diagnosis of HIV undergoing right heart catheterization (RHC) from 2000–2016 in a tertiary care center. Inclusion criteria were diagnosis of HIV, age ≥ 18 years and availability of RHC data. PH was classified as either pulmonary arterial hypertension (PAH; mean pulmonary arterial pressure [mPAP] ≥ 25mmHg with pulmonary artery wedge pressure [PAWP] ≤ 15mmHg) or pulmonary venous hypertension (PVH; mPAP ≥ 25mmHg with PAWP &gt; 15). We collected demographics, CD4 cell count, HIV viral load, RHC and echocardiographic data. The single beat method was used to calculate RV-PA coupling from RHC.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Sixty-two PLWH with a clinical likelihood for PH underwent RHC. Thirty-two (52%) met PH criteria (15 with PAH, 17 with PVH). Average time from diagnosis of HIV to diagnosis of PH was 11 years. Eleven of 15 individuals with PAH were on antiretroviral therapy (ART) while all 17 patients with PVH were on ART. Compared to PLWH without PH, those with PH had an increased likelihood of having a detectable HIV viral load and lower CD4 cell counts. PLWH with PAH or PVH had increased RV afterload with normal RV contractility, and preserved RV-PA coupling.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">PLWH with PH (PAH or PVH) were more likely to have a detectable HIV viral load and lower CD4 count at the time of RHC. PLWH with PAH or PVH had increased RV afterload, normal RV contractility, with preserved RV-PA coupling suggestive of an early onset, mild, and compensated form of PH. These results should be confirmed in larger studies.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-23T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Viral RNA-binding ability conferred by SUMOylation at PB1 K612 of influenza A virus is essential for viral pathogenesis and transmission]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765934859601-1bf4366b-de74-4d3c-8bbc-e1ba477d3fc5/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009336</link>
            <description><![CDATA[<p class="para" id="N65539">Posttranslational modifications, such as SUMOylation, play specific roles in the life cycle of invading pathogens. However, the effect of SUMOylation on the adaptation, pathogenesis, and transmission of influenza A virus (IAV) remains largely unknown. Here, we found that a conserved lysine residue at position 612 (K612) of the polymerase basic protein 1 (PB1) of IAV is a bona fide SUMOylation site. SUMOylation of PB1 at K612 had no effect on the stability or cellular localization of PB1, but was critical for viral ribonucleoprotein (vRNP) complex activity and virus replication in vitro. When tested in vivo, we found that the virulence of SUMOylation-defective PB1/K612R mutant IAVs was highly attenuated in mice. Moreover, the airborne transmission of a 2009 pandemic H1N1 PB1/K612R mutant virus was impaired in ferrets, resulting in reversion to wild-type PB1 K612. Mechanistically, SUMOylation at K612 was essential for PB1 to act as the enzymatic core of the viral polymerase by preserving its ability to bind viral RNA. Our study reveals an essential role for PB1 K612 SUMOylation in the pathogenesis and transmission of IAVs, which can be targeted for the design of anti-influenza therapies.</p><p class="para" id="N65542">IAV has evolved to exploit the host posttranslational modifications system for its own benefit. The transcription and replication of IAV genome occur in the nucleus of infected cells, which is catalyzed by the RNA-dependent RNA polymerase (RdRp). PB1 is the catalytic subunit and the assembly core of the RdRp. The ability to efficiently bind viral RNA by PB1 is a prerequisite for the RdRp to fulfil its function. In this study, we demonstrated that PB1 protein from different subtypes of IAV is a target of SUMOylation in both transfected and infected cells, and identified K612 of PB1 as the key SUMOylation site. The vRNP complex activity, replication in vitro, pathogenicity in mice and airborne transmission among ferrets were dramatically attenuated when the SUMOylation-defective PB1/K612R mutation was introduced. Notably, we found that SUMOylation at K612 is essential for PB1 to acquire the ability to efficiently bind viral RNA, thus allowing for the RdRp to transcribe and replicate the viral genome. Our findings therefore thoroughly explore the contribution of PB1 SUMOylation on influenza infection and establish SUMOylation site PB1 K612 as a potential target for anti-influenza drug development.</p>]]></description>
            <pubDate><![CDATA[2021-02-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Competitive exclusion during co-infection as a strategy to prevent the spread of a virus: A computational perspective]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765934695726-e2cb4c20-f659-4bd9-b288-e5413ff69664/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247200</link>
            <description><![CDATA[<p class="para" id="N65539">Inspired by the competition exclusion principle, this work aims at providing a computational framework to explore the theoretical feasibility of viral co-infection as a possible strategy to reduce the spread of a fatal strain in a population. We propose a stochastic-based model—called Co-Wish—to understand how competition between two viruses over a shared niche can affect the spread of each virus in infected tissue. To demonstrate the co-infection of two viruses, we first simulate the characteristics of two virus growth processes separately. Then, we examine their interactions until one can dominate the other. We use Co-Wish to explore how the model varies as the parameters of each virus growth process change when two viruses infect the host simultaneously. We will also investigate the effect of the delayed initiation of each infection. Moreover, Co-Wish not only examines the co-infection at the cell level but also includes the innate immune response during viral infection. The results highlight that the waiting times in the five stages of the viral infection of a cell in the model—namely attachment, penetration, eclipse, replication, and release—play an essential role in the competition between the two viruses. While it could prove challenging to fully understand the therapeutic potentials of viral co-infection, we discuss that our theoretical framework hints at an intriguing research direction in applying co-infection dynamics in controlling any viral outbreak’s speed.</p>]]></description>
            <pubDate><![CDATA[2021-02-24T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765934680471-dbf8c825-2c87-4d6b-aeda-3a2bb3258369/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247606</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Since COVID-19 pandemic is a global crisis, tests with high sensitivity and specificity are crucial for the identification and management of COVID-19 patients. There is an urgent need for low-cost rapid antigen COVID-19 test with a good diagnostic performance. Although various antigen rapid detection tests are widely available, strong evidence of their usefulness in clinical practice are still limited. Therefore, our aim was to evaluate clinical performance of STANDARD Q COVID-19 Ag Test (SD Biosensor, Gyeonggi-do, South Korea).</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">The performance of the STANDARD Q COVID-19 Ag Test for the detection of SARS-CoV-2 antigen was evaluated in comparison to RT-qPCR results in 120 symptomatic patients (median age 49, IQR 36–70) who presented to health care facility in Novi Sad, Vojvodina, Serbia.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Twenty five out of 120 samples have been tested positive using STANDARD Q COVID-19 Ag Test, and all of them were also positive on RT-qPCR. Overall, the STANDARD Q COVID-19 Ag Test showed sensitivity of 58.1% (95% CI 42.1–73.0) but it was higher in the early days of disease, when the highest viral loads were detected. During the first five days after the symptom onset, the sensitivity ranged from 66.7% to 100% and the pooled accuracy and Kappa values were high (0.92 and 0.852).</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65561">A strong agreement between performance of STANDARD Q COVID-19 Ag Test and RT-qPCR was observed during the first five days of illness, suggesting that this rapid antigenic test can be very useful for COVID-19 diagnosis in the early phase of disease.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[SARS-CoV-2 viral shedding characteristics and potential evidence for the priority for faecal specimen testing in diagnosis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765934300934-7406e59f-a84a-4f61-9471-5a2ef122a727/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247367</link>
            <description><![CDATA[<p class="para" id="N65539">This study aimed to identify the specimen type that has high positivity and its proper sampling time for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing to promote diagnostic efficiency. All SARS-CoV-2-infected patients with a laboratory-confirmed diagnosis in Zhoushan City were followed up for viral shedding in respiratory tract specimens and faecal samples. Positivity was analysed both qualitatively and quantitatively by proper statistical approaches with strong testing power. Viral shedding in respiratory tract and faecal specimens was prolonged to 45 and 40 days after the last exposure, respectively. The overall positive rate in respiratory tract specimens was low and relatively unstable, being higher in the early-to-mid stage than in the mid-to-late stage of the disease course. Compared with respiratory tract specimens, faecal samples had a higher viral load, higher overall positive rate, and more stable positivity in different disease courses and varied symptomatic status. Faecal specimens have the potential ability to surpass respiratory tract specimens in virus detection. Testing of faecal specimens in diagnosis, especially for identifying asymptomatic carriers, is recommended. Simultaneously, testing respiratory tract specimens at the early-to-mid stage is better than testing at the mid-to-late stage of the disease course. A relatively small sample size was noted, and statistical approaches were used to address it. Information was missing for both specimen types at different stages of the disease course due to censored data. Our research extends the observed viral shedding in both specimen types and highlights the importance of faecal specimen testing in SARS-CoV-2 diagnosis. Healthcare workers, patients, and the general public may all benefit from our study findings. Disposal of sewage from hospitals and residential areas should be performed cautiously because the virus sheds in faeces and can last for a long time.</p>]]></description>
            <pubDate><![CDATA[2021-02-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765924936582-c2834cea-5f21-466e-890a-435c8abfa6bf/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245048</link>
            <description><![CDATA[<p class="para" id="N65539">Gautret and colleagues reported the results of a non-randomised case series which examined the effects of hydroxychloroquine and azithromycin on viral load in the upper respiratory tract of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients. The authors reported that hydroxychloroquine (HCQ) had significant virus reducing effects, and that dual treatment of both HCQ and azithromycin further enhanced virus reduction. In light of criticisms regarding how patients were excluded from analyses, we reanalysed the original data to interrogate the main claims of the paper. We applied Bayesian statistics to assess the robustness of the original paper’s claims by testing four variants of the data: 1) The original data; 2) Data including patients who deteriorated; 3) Data including patients who deteriorated with exclusion of untested patients in the comparison group; 4) Data that includes patients who deteriorated with the assumption that untested patients were negative. To ask if HCQ monotherapy was effective, we performed an A/B test for a model which assumes a positive effect, compared to a model of no effect. We found that the statistical evidence was highly sensitive to these data variants. Statistical evidence for the positive effect model ranged from strong for the original data (BF<sub>+0</sub> ~11), to moderate when including patients who deteriorated (BF<sub>+0</sub> ~4.35), to anecdotal when excluding untested patients (BF<sub>+0</sub> ~2), and to anecdotal negative evidence if untested patients were assumed positive (BF<sub>+0</sub> ~0.6). The fact that the patient inclusions and exclusions are not well justified nor adequately reported raises substantial uncertainty about the interpretation of the evidence obtained from the original paper.</p>]]></description>
            <pubDate><![CDATA[2021-02-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765923940952-0157e3d5-ed10-4fa3-8e71-6c876ffe1d17/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247396</link>
            <description><![CDATA[<p class="para" id="N65539">Among various delivery systems for vaccine and drug delivery, cell-penetrating peptides (CPPs) have been known as a potent delivery system because of their capability to penetrate cell membranes and deliver some types of cargoes into cells. Several CPPs were found in the proteome of viruses such as Tat originated from human immunodeficiency virus-1 (HIV-1), and VP22 derived from herpes simplex virus-1 (HSV-1). In the current study, a wide-range of CPPs was identified in the proteome of SARS-CoV-2, a new member of coronaviruses family, using <i>in silico</i> analyses. These CPPs may play a main role for high penetration of virus into cells and infection of host. At first, we submitted the proteome of SARS-CoV-2 to CellPPD web server that resulted in a huge number of CPPs with ten residues in length. Afterward, we submitted the predicted CPPs to C2Pred web server for evaluation of the probability of each peptide. Then, the uptake efficiency of each peptide was investigated using CPPred-RF and MLCPP web servers. Next, the physicochemical properties of the predicted CPPs including net charge, theoretical isoelectric point (pI), amphipathicity, molecular weight, and water solubility were calculated using protparam and pepcalc tools. In addition, the probability of membrane binding potential and cellular localization of each CPP were estimated by Boman index using APD3 web server, D factor, and TMHMM web server. On the other hand, the immunogenicity, toxicity, allergenicity, hemolytic potency, and half-life of CPPs were predicted using various web servers. Finally, the tertiary structure and the helical wheel projection of some CPPs were predicted by PEP-FOLD3 and Heliquest web servers, respectively. These CPPs were divided into: a) CPP containing tumor homing motif (RGD) and/or tumor penetrating motif (RXXR); b) CPP with the highest Boman index; c) CPP with high half-life (~100 hour) in mammalian cells, and d) CPP with +5.00 net charge. Based on the results, we found a large number of novel CPPs with various features. Some of these CPPs possess tumor-specific motifs which can be evaluated in cancer therapy. Furthermore, the novel and potent CPPs derived from SARS-CoV-2 may be used alone or conjugated to some sequences such as nuclear localization sequence (NLS) for vaccine and drug delivery.</p>]]></description>
            <pubDate><![CDATA[2021-02-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765922445483-722c49da-5616-4d8d-b895-9990c5726e4c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009257</link>
            <description><![CDATA[<p class="para" id="N65539">Stabilized HIV-1 envelope (Env) trimers elicit tier 2 autologous neutralizing antibody (nAb) responses in immunized animals. We previously demonstrated that BG505 SOSIP.664.T332N gp140 (BG505 SOSIP) immunization of rhesus macaques (RM) provided robust protection against autologous intra-vaginal simian-human immunodeficiency virus (SHIV) challenge that was predicted by high serum nAb titers. Here, we show that nAb in these protected RM targeted a glycan hole proximal to residue 465 in gp120 in all cases. nAb also targeted another glycan hole at residues 241/289 and an epitope in V1 at varying frequencies. Non-neutralizing antibodies directed at N611-shielded epitopes in gp41 were also present but were more prevalent in RM with low nAb titers. Longitudinal analysis demonstrated that nAb broadened in some RM during sequential immunization but remained focused in others, the latter being associated with increases in nAb titer. Thirty-eight monoclonal antibodies (mAbs) isolated from a protected RM with an exceptionally high serum neutralization titer bound to the trimer in ELISA, and four of the mAbs potently neutralized the BG505 Env pseudovirus (PV) and SHIV. The four neutralizing mAbs were clonally related and targeted the 465 glycan hole to varying degrees, mimicking the serum. The data demonstrate that the C3/465 glycan hole cluster was the dominant neutralization target in high titer protected RM, despite other co-circulating neutralizing and non-neutralizing specificities. The isolation of a neutralizing mAb family argues that clonotype expansion occurred during BG505 SOSIP immunization, leading to high titer, protective nAb and setting a desirable benchmark for HIV vaccines.</p><p class="para" id="N65542">Despite much effort, an effective vaccine against HIV/AIDS has not been developed. There are many obstacles that continue to undermine this effort, which is focused largely on inducing neutralizing antibodies that can protect against infection. We conducted a pre-clinical vaccine study in nonhuman primates that utilized a trimeric HIV-1 envelope vaccine to induce neutralizing antibodies. We found that all animals that developed very high levels of neutralizing antibodies were protected against infection. When we mapped the neutralizing antibody responses using viral mutants, we found that they mainly targeted one exposed region of the HIV-1 envelope protein that is unique to the strain we used in the vaccine. By isolating individual antibodies from a protected animal with a very high level of neutralizing antibodies, we found that an expanded antibody family was responsible for the neutralization. Our findings demonstrate that neutralizing antibodies targeting mainly one exposed region on the envelope trimer vaccine were associated with protection, and that this could be achieved by a single antibody family that develops and expands during immunization.</p>]]></description>
            <pubDate><![CDATA[2021-02-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Hepatitis B virus infection and associated risk factors among medical students in eastern Ethiopia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765922436914-ff8d0f26-f6a9-400e-af09-b11cb1a0fa5b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247267</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Hepatitis B virus (HBV) is a highly contagious pathogen that has become a severe public health problem and a major cause of morbidity and mortality, particularly in developing countries. Medical students are at high occupational risk during their training. However, no facility-based studies were found among medical students in eastern Ethiopia. Thus, this study aimed to investigate the seroprevalence of Hepatitis B Virus and associated factors among medical students in eastern Ethiopia.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A facility-based cross-sectional study was conducted among 407 randomly selected medical students from March to June 2018. A pretested and structured questionnaire was used to collect data on socio-demographic characteristics and other risk factors. A 5ml blood was collected, and the serum was analyzed for Hepatitis B surface antigen (HBsAg) using the Instant Hepatitis B surface antigen kit. Data were entered using Epidata version 3.1 and analyzed using SPSS statistical packages version 22. Outcome and explanatory variables were described using descriptive summary measures. Binary and multivariable logistic regression was conducted at 95% CI and an association at P-value &lt; 0.05 was declared statistically significant.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">The seroprevalence of hepatitis B virus surface antigen was 11.5% (95%CI = 8.6, 14.7). Poor knowledge of universal precaution guideline (AOR = 2.58; 95% CI = [1.35–4.93]), history of needle stick injury (AOR = 2.11; 95% CI = [1.07–4.18]) and never been vaccinated for HBV (AOR = 2.34; 95% CI = [1.17–4.69]) were found statistically significantly associated with HBsAg positivity after multivariate analysis.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">Hepatitis B virus infection rate is high among health care trainees in eastern Ethiopia. Improvement at health care practice centers safety through training on universal precaution guidelines, and scaling up HBV vaccination is mandatory.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765906336997-8455ed07-fa12-4d32-978e-0744f4ff2e3f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246994</link>
            <description><![CDATA[<p class="para" id="N65539">Therapeutic drug monitoring (TDM) is used in certain clinically selected cases and in research settings to optimize the response to antiretroviral therapy. Plasma of blood is commonly used for TDM, but blood sampling is invasive and at risk for transmission of infectious agents. On the other hand, saliva sampling is noninvasive, safe, cheap, and easily performed compared to blood. Dolutegravir (DTG) is now widely prescribed as a key component of antiretroviral therapy for HIV infection. In this study, we examined the relationship between DTG concentrations in plasma and saliva of treated patients to explore the possibility of using saliva as an alternative body fluid of TDM. A total of 17 pairs of blood and saliva samples were obtained from 15 consented HIV-1-infected subjects treated with DTG containing regimens for more than one month. Both blood and saliva samples were collected within 1 h of each other. Drug concentrations were determined by liquid chromatography-tandem mass spectrometry using DTG-d5 as an internal standard. The LLOQ was 0.5 ng/mL. The calibration curves were prepared with pooled plasma or saliva containing DTG in a range of 0.5–100 ng/mL with precision of &lt;14.4% and accuracy within ±14.7%. The DTG concentrations in the plasma and saliva were significantly correlated (Pearson’s correlation coefficient <i>r</i> = 0.76, <i>p</i> &lt; 0.001). The median ratio of the drug concentration in saliva to those in plasma was 0.0056, which is close to the rate of non-protein-bound DTG in plasma (0.70%), suggesting that only free DTG in plasma is transported to the salivary glands and secreted into saliva. The present study demonstrates that DTG concentration in saliva reflects the pharmacologically active drug concentration in plasma and may provide an easily accessible alternative for monitoring effective antiretroviral treatment.</p>]]></description>
            <pubDate><![CDATA[2021-02-18T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765906013711-8b15fda6-0add-4aaa-9ddd-528b798b6764/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009225</link>
            <description><![CDATA[<p class="para" id="N65539">Since the initial report of the novel Coronavirus Disease 2019 (COVID-19) emanating from Wuhan, China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally. While the effects of SARS-CoV-2 infection are not completely understood, there appears to be a wide spectrum of disease ranging from mild symptoms to severe respiratory distress, hospitalization, and mortality. There are no Food and Drug Administration (FDA)-approved treatments for COVID-19 aside from remdesivir; early efforts to identify efficacious therapeutics for COVID-19 have mainly focused on drug repurposing screens to identify compounds with antiviral activity against SARS-CoV-2 in cellular infection systems. These screens have yielded intriguing hits, but the use of nonhuman immortalized cell lines derived from non-pulmonary or gastrointestinal origins poses any number of questions in predicting the physiological and pathological relevance of these potential interventions. While our knowledge of this novel virus continues to evolve, our current understanding of the key molecular and cellular interactions involved in SARS-CoV-2 infection is discussed in order to provide a framework for developing the most appropriate in vitro toolbox to support current and future drug discovery efforts.</p>]]></description>
            <pubDate><![CDATA[2021-02-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Nonsense-mediated decay controls the reactivation of the oncogenic herpesviruses EBV and KSHV]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765900795210-ab2e9b4a-181c-4bcf-8022-257708bf0f64/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pbio.3001097</link>
            <description><![CDATA[<p class="para" id="N65539">The oncogenic human herpesviruses Epstein–Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) are the causative agents of multiple malignancies. A hallmark of herpesviruses is their biphasic life cycle consisting of latent and lytic infection. In this study, we identified that cellular nonsense-mediated decay (NMD), an evolutionarily conserved RNA degradation pathway, critically regulates the latent-to-lytic switch of EBV and KSHV infection. The NMD machinery suppresses EBV and KSHV Rta transactivator expression and promotes maintenance of viral latency by targeting the viral polycistronic transactivator transcripts for degradation through the recognition of features in their 3′ UTRs. Treatment with a small-molecule NMD inhibitor potently induced reactivation in a variety of EBV- and KSHV-infected cell types. In conclusion, our results identify NMD as an important host process that controls oncogenic herpesvirus reactivation, which may be targeted for the therapeutic induction of lytic reactivation and the eradication of tumor cells.</p>]]></description>
            <pubDate><![CDATA[2021-02-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765900582619-4f73e93b-5e37-41d0-bfa7-a1de8642b9eb/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1008859</link>
            <description><![CDATA[<p class="para" id="N65539">Severe fever with thrombocytopenia syndrome (SFTS) caused by a species Dabie bandavirus (formerly SFTS virus [SFTSV]) is an emerging hemorrhagic infectious disease with a high case-fatality rate. One of the best strategies for preventing SFTS is to develop a vaccine, which is expected to induce both humoral and cellular immunity. We applied a highly attenuated but still immunogenic vaccinia virus strain LC16m8 (m8) as a recombinant vaccine for SFTS. Recombinant m8s expressing SFTSV nucleoprotein (m8-N), envelope glycoprotein precursor (m8-GPC), and both N and GPC (m8-N+GPC) in the infected cells were generated. Both m8-GPC- and m8-N+GPC-infected cells were confirmed to produce SFTSV-like-particles (VLP) <i>in vitro</i>, and the N was incorporated in the VLP produced by the infection of cells with m8-N+GPC. Specific antibodies to SFTSV were induced in mice inoculated with each of the recombinant m8s, and the mice were fully protected from lethal challenge with SFTSV at both 10<sup>3</sup> TCID<sub>50</sub> and 10<sup>5</sup> TCID<sub>50</sub>. In mice that had been immunized with vaccinia virus strain Lister in advance of m8-based SFTSV vaccine inoculation, protective immunity against the SFTSV challenge was also conferred. The pathological analysis revealed that mice immunized with m8-GPC or m8-N+GPC did not show any histopathological changes without any viral antigen-positive cells, whereas the control mice showed focal necrosis with inflammatory infiltration with SFTSV antigen-positive cells in tissues after SFTSV challenge. The passive serum transfer experiments revealed that sera collected from mice inoculated with m8-GPC or m8-N+GPC but not with m8-N conferred protective immunity against lethal SFTSV challenge in naïve mice. On the other hand, the depletion of CD8-positive cells <i>in vivo</i> did not abrogate the protective immunity conferred by m8-based SFTSV vaccines. Based on these results, the recombinant m8-GPC and m8-N+GPC were considered promising vaccine candidates for SFTS.</p><p class="para" id="N65542">Severe fever with thrombocytopenia syndrome (SFTS) is an emerging viral hemorrhagic fever with a high case-fatality rate (approximately 5% to &gt;40%). Indigenous SFTS has been reported in China, Japan, South Korea, and Vietnam. Thus, the development of an effective vaccine for SFTS is urgently needed. Vaccinia virus (VAC) was previously used as a vaccine for smallpox. Unfortunately, after these strains, the so-called second generation of VAC used during the eradication campaign was associated with severe adverse events, and the third generation of VAC strains such as LC16m8 (m8) and modified vaccinia Ankara (MVA) was established. m8 is confirmed to be highly attenuated while still maintaining immunogenicity. m8 is licensed for use in healthy people in Japan. At the present time, approximately 100,000 people have undergone vaccination with m8 without experiencing any severe postvaccine complications. At present, third-generation VAC strains are attractive for a recombinant vaccine vector, especially for viral hemorrhagic infectious diseases, such as Ebola virus disease, Lassa fever, Crimean-Congo hemorrhagic fever, and SFTS. We investigated the practicality of an m8-based recombinant vaccine for SFTS as well as other promising recombinant VAC-based vaccines for viral hemorrhagic infectious diseases.</p>]]></description>
            <pubDate><![CDATA[2021-02-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Non-permissive human conventional CD1c<sup>+</sup> dendritic cells enable <i>trans</i>-infection of human primary renal tubular epithelial cells and protect BK polyomavirus from neutralization]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765900480831-7db44d71-4991-47da-96ff-e0307bc349c1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009042</link>
            <description><![CDATA[<p class="para" id="N65539">The BK polyomavirus (BKPyV) is a ubiquitous human virus that persists in the renourinary epithelium. Immunosuppression can lead to BKPyV reactivation in the first year post-transplantation in kidney transplant recipients (KTRs) and hematopoietic stem cell transplant recipients. In KTRs, persistent DNAemia has been correlated to the occurrence of polyomavirus-associated nephropathy (PVAN) that can lead to graft loss if not properly controlled. Based on recent observations that conventional dendritic cells (cDCs) specifically infiltrate PVAN lesions, we hypothesized that those cells could play a role in BKPyV infection. We first demonstrated that monocyte-derived dendritic cells (MDDCs), an <i>in vitro</i> model for mDCs, captured BKPyV particles through an unconventional GRAF-1 endocytic pathway. Neither BKPyV particles nor BKPyV-infected cells were shown to activate MDDCs. Endocytosed virions were efficiently transmitted to permissive cells and protected from the antibody-mediated neutralization. Finally, we demonstrated that freshly isolated CD1c<sup>+</sup> mDCs from the blood and kidney parenchyma behaved similarly to MDDCs thus extending our results to cells of clinical relevance. This study sheds light on a potential unprecedented CD1c<sup>+</sup> mDC involvement in the BKPyV infection as a promoter of viral spreading.</p><p class="para" id="N65542">Dr Sylvia Gardner first discovered the BK polyomavirus (BKPyV) in the urine of a kidney-transplant recipient in 1970. In the 1990’s, the widespread use of potent immunosuppressive drugs such as tacrolimus, sirolimus or mycophenolate mofetil led to the emergence of BKPyV nephropathy. Recently, various studies reported a specific influx of myeloid dendritic cells (mDCs) in the renal tissue of kidney-transplant patients who were diagnosed with a BKPyV nephropathy. MDCs are immune cells both residing in tissues and migrating to other organs or compartments like the blood when changes in their environment occur. Their main functions are the detection of danger signals such as pathogens or tumors and the processing of antigens to prime naïve specific effectors of the adaptive immune response. Although anti-BKPyV cellular immune responses have been investigated in post-transplant recipients as well as healthy individuals, supporting an active role of mDCs little is known about how mDCs and BKPyV interact with each other. Our study provides the basis to understand the role played by mDCs in virus capture through an unprecedented endocytic mechanism and possibly in viral protection from neutralization by specific antibodies. Moreover, we showed that mDCs are unable to sense BKPyV particles or BKPyV-infected dying cells as a danger signal, supporting the view that other DC subsets might act as the true antigen presenting cells that promote the adaptive immune response against BKPyV infection.</p>]]></description>
            <pubDate><![CDATA[2021-02-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765900413440-45caad5a-97d8-40aa-b7e1-c3b5bad6d018/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009312</link>
            <description><![CDATA[<p class="para" id="N65539">Many small molecules have been identified as entry inhibitors of filoviruses. However, a lack of understanding of the mechanism of action for these molecules limits further their development as anti-filoviral agents. Here we provide evidence that toremifene and other small molecule entry inhibitors have at least three distinctive mechanisms of action and lay the groundwork for future development of anti-filoviral agents. The three mechanisms identified here include: (1) direct binding to the internal fusion loop region of Ebola virus glycoprotein (GP); (2) the HR2 domain is likely the main binding site for Marburg virus GP inhibitors and a secondary binding site for some EBOV GP inhibitors; (3) lysosome trapping of GP inhibitors increases drug exposure in the lysosome and further improves the viral inhibition. Importantly, small molecules targeting different domains on GP are synergistic in inhibiting EBOV entry suggesting these two mechanisms of action are distinct. Our findings provide important mechanistic insights into filovirus entry and rational drug design for future antiviral development.</p><p class="para" id="N65542">Filoviruses are among the deadliest pathogens known to mankind with case-fatality rates ranging from 25–90%. New outbreaks in central Africa and the identification of novel filoviruses in other regions highlight the urgent need to develop novel therapeutics. Although many novel anti-filovirus compounds have been reported as entry inhibitors, to date, none have made to market. This high rate of failure is in part due to a lack of knowledge of the mechanisms of action. In this report, we provide a molecular basis for the multiple mechanisms of action by which small molecule inhibitors of Ebola virus and Marburg virus block virus entry, which provides new mechanistic insight to guide design for next-generation viral entry inhibitors.</p>]]></description>
            <pubDate><![CDATA[2021-02-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The expression in plants of an engineered VP2 protein of Infectious Bursal Disease Virus induces formation of structurally heterogeneous particles that protect from a very virulent viral strain]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765900380326-05fb4829-b38b-408f-8ec1-0befed5e29c1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247134</link>
            <description><![CDATA[<p class="para" id="N65539">Infectious Bursal Disease Virus (IBDV), the etiological agent of Gumboro disease, causes mortality and immunosuppression in chickens and major losses to poultry industry worldwide. The IBDV major capsid protein VP2 is considered the best candidate for the production of novel subunit vaccines. This structural protein contains the major conformational epitopes responsible for the induction of IBDV neutralizing antibodies in chickens and has been demonstrated able to form supramolecular structures in yeast and insect cells. The aim of this study was to express an engineered version of the VP2 protein (His-pVP2) to verify its ability to self-assemble into virus-like particles in plants. The recombinant VP2 was transiently expressed by agroinfiltration in <i>Nicotiana benthamiana</i> and transmission electron microscopy of sucrose density gradient fractions revealed the presence of a mixed population of differently shaped particles ranging from spherical capsids, with a diameter between ~25 and ~70 nm, to tubular structures, with variable length (from 100 to 400 nm). The recombinant VP2-based particles when used for the intramuscular immunization of specific-pathogen-free chicks resulted able to induce the production of anti-IBDV specific antibodies at titers comparable to those induced by a commercial vaccine. Moreover, all the immunized birds survived to the challenge with a Moroccan very virulent IBDV strain with no major histomorphological alterations of the Bursa of Fabricius, similarly to what obtained with the commercial inactivated vaccine.</p>]]></description>
            <pubDate><![CDATA[2021-02-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Prevalence of low high-density lipoprotein among young adults receiving antiretroviral therapy in Zambia: An opportunity to consider non-communicable diseases in resource-limited settings]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765900172702-43977d5e-4f20-4fc7-9fce-8c128a4101d8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0247004</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">With the introduction of effective antiretroviral therapy (ART), people living with HIV (PLWH) are surviving longer and are at risk for developing metabolic abnormalities that contribute to cardiovascular disease (CVD). In Sub-Saharan Africa (SSA), there is a paucity of epidemiological data on lipid profiles among young adults receiving ART. This study aimed to estimate the prevalence of low high-density lipoprotein cholesterol (HDL-c), a cardioprotective lipid class, and whether it differed by age among adults on ART in Livingstone, Zambia.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">From April to December 2019, we conducted a cross-sectional study of 597 PLWH [n = 58 aged 18–24 years (young adults); n = 539 aged ≥25 years (adults)] on ART for ≥6 months. Data collected included demographic and lifestyle information, anthropometrics, viral load (VL), CD4 count, blood pressure, lipid profiles and fasting/random blood glucose. Clinical measures were defined as: low HDL-c [&lt;1.0 mmol/L for men, &lt;1.3 for women], increased waist circumference (WC) [≥94 cm for men, ≥80 cm for women], high triglycerides (TG) [≥1.7 mmol/l], and virological failure (VF) [VL ≥1000 copies/μl]. We used logistic regression to examine the association between age and low HDL-c after adjusting for multiple variables.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Among the young adults, 60% (35/58) were women, median (25<sup>th</sup>, 75<sup>th</sup> percentile) age 21 years (18, 23), and median time on ART 116 months (60, 144). Among adults, 63% (342/539) were women, median age 46 years (40, 53) and median time on ART 108 months (60, 144). Young adults had a lower CD4 count compared to adults (median, 492 vs. 568 cells/μL, p = 0.010) and higher prevalence of VF (29% vs. 17%, p = 0.016). In young adults, prevalence of low HDL-c was significantly higher than in adults (63 vs. 38%, p&lt;0.001). A high proportion of young adults (75%) and adults (58%) with low HDL-c were on dolutegravir (DTG)-based ART regimens. After adjusting for sex, duration on ART, WC, body mass index, ART regimen, VF, CD4 count, low density lipoprotein cholesterol, blood pressure and smoking, young adults were significantly more likely than adults to have low HDL-c (odds ratio 2.93; 95% confidence interval 1.46–5.86).</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65567">Low HDL-c is highly prevalent among young adult with HIV in SSA independent of other risk factors for metabolic derangements. Lipid abnormalities among young PLWH may contribute to the early development of cardiovascular diseases in this population. This highlights the need to consider low HDL-c in the quest to reduce CVD risk among young adults on ART in SSA.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Mask usage, social distancing, racial, and gender correlates of COVID-19 vaccine intentions among adults in the US]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765899888959-b7ab87e7-8233-4d0b-aea0-8f8052f3ef1e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246970</link>
            <description><![CDATA[<p class="para" id="N65539">Vaccine hesitancy could become a significant impediment to addressing the COVID-19 pandemic. The current study examined the prevalence of COVID-19 vaccine hesitancy and factors associated with vaccine intentions. A national panel survey by the National Opinion Research Center (NORC) was designed to be representative of the US household population. Sampled respondents were invited to complete the survey between May 14 and 18, 2020 in English or Spanish. 1,056 respondents completed the survey—942 via the web and 114 via telephone. The dependent variable was assessed by the item “If a vaccine against the coronavirus becomes available, do you plan to get vaccinated, or not?” Approximately half (53.6%) reported intending to be vaccinated, 16.7% did not intend, and 29.7% were unsure. In the adjusted stepwise multinominal logistic regression, Black and Hispanic respondents were significantly less likely to report intending to be vaccinated as were respondents who were females, younger, and those who were more politically conservative. Compared to those who reported positive vaccine intentions, respondents with negative vaccine intentions were significantly less likely to report that they engaged in the COVID-19 prevention behaviors of wearing masks (aOR = 0.53, CI = 0.37–0.76) and social distancing (aOR = 0.22, CI = 0.12–0.42). In a sub-analysis of reasons not to be vaccinated, significant race/ethnic differences were observed. This national survey indicated a modest level of COVID-19 vaccine intention. These data suggest that public health campaigns for vaccine uptake should assess in greater detail the vaccine concerns of Blacks, Hispanics, and women to tailor programs.</p>]]></description>
            <pubDate><![CDATA[2021-02-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Evaluation of two automated low-cost RNA extraction protocols for SARS-CoV-2 detection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765899256442-b583dde1-0e28-4706-8a6f-0f1e03f11ab7/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246302</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Two automatable in-house protocols for high-troughput RNA extraction from nasopharyngeal swabs for SARS-CoV-2 detection have been evaluated.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">One hundred forty one SARS-CoV-2 positive samples were collected during a period of 10-days. In-house protocols were based on extraction with magnetic beads and designed to be used with either the Opentrons OT-2 (OT-2<sub>in-house</sub>) liquid handling robot or the MagMAX<sup>TM</sup> Express-96 system (MM<sub>in-house</sub>). Both protocols were tested in parallel with a commercial kit that uses the MagMAX<sup>TM</sup> system (MM<sub>kit</sub>). Nucleic acid extraction efficiencies were calculated from a SARS-CoV-2 DNA positive control.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65570">No significant differences were found between both in-house protocols and the commercial kit in their performance to detect positive samples. The MM<sub>kit</sub> was the most efficient although the MM<sub>in-house</sub> presented, in average, lower Cts than the other two. In-house protocols allowed to save between 350€ and 400€ for every 96 extracted samples compared to the commercial kit.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65582">The protocols described harness the use of easily available reagents and an open-source liquid handling system and are suitable for SARS-CoV-2 detection in high throughput facilities.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Impact of COVID-19 pandemic on the utilization of routine immunization services in Lebanon]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765899249958-e4289c37-6085-4653-9b70-ede0f887feb3/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246951</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction</h3><p class="para" id="N65543">The global abrupt progression of the COVID-19 pandemic may disrupt critical life-saving services such as routine immunization (RI), thus increasing the susceptibility of countries to outbreaks of vaccine-preventable diseases (VPDs). Being endemic to several infectious diseases, Lebanon might be at increased risk of outbreaks as the utilization of RI services might have deteriorated due to the pandemic and the country’s political unrest following the October 2019 uprising. The aim of this study was to assess the changes in the utilization of RI services in both the public and private sectors following the COVID-19 pandemic.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A self-administered cross-sectional survey was completed electronically, in April 2020, by 345 private pediatricians who are registered in professional associations of physicians in Lebanon and provide immunization services at their clinics. Means of the reported percentages of decrease in the utilization of vaccination services by pediatricians were calculated. As for the public sector, an examination of the monthly differences in the number of administered vaccine doses in addition to their respective percentages of change was performed. Adjustment for the distribution of RI services between the sectors was performed to calculate the national decrease rate.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">The utilization of vaccination services at the national level decreased by 31%. In the private sector, immunization services provision diminished by 46.9% mainly between February and April 2020. The highest decrease rates were observed for oral poliovirus vaccine (OPV) and hepatitis A, followed by measles and pneumococcal conjugate vaccines. The number of vaccine doses administered in the public sector decreased by 20%. The most prominent reductions were detected for the OPV and measles vaccines, and during October 2019 and March 2020.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">The substantial decrease in the utilization of RI as a result of the COVID-19 pandemic requires public health interventions to prevent future outbreaks of VPDs.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Epidemiological characterization of symptomatic and asymptomatic COVID-19 cases and positivity in subsequent RT-PCR tests in the United Arab Emirates]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765898934799-59442f19-5651-445c-bb8d-7e40de636b31/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246903</link>
            <description><![CDATA[<p class="para" id="N65539">The coronavirus disease 2019 (COVID-19) cases could be symptomatic or asymptomatic. We (1) characterized and analyzed data collected from the first cohort of reverse transcriptase polymerase chain reaction (RT-PCR)-confirmed COVID-19 cases reported in the Emirate of Abu Dhabi, United Arab Emirates, according to the symptomatic state, and (2) identified factors associated with the symptomatic state. The association between the symptomatic state and testing positive in three subsequent RT-PCR testing rounds was also quantified. Between February 28 and April 8, 2020, 1,249 cases were reported. Sociodemographic characteristics, working status, travel history, and chronic comorbidities of 791 cases were analyzed according to the symptomatic state (symptomatic or asymptomatic). After the first confirmatory test, the results of three subsequent tests were analyzed. The mean age of the 791 cases was 35.6 ± 12.7 years (range: 1–81). Nearly 57.0% of cases were symptomatic. The two most frequent symptoms were fever (58.0%) and cough (41.0%). Symptomatic cases (mean age 36.3 ± 12.6 years) were significantly older than asymptomatic cases (mean age 34.5 ± 12.7 years). Compared with nonworking populations, working in public places (adjusted odds ratio (aOR), 1.76, 95% confidence interval (95% CI): 1.11–2.80), healthcare settings (aOR, 2.09, 95% CI: 1.01–4.31), or in the aviation and tourism sectors (aOR, 2.24, 95% CI: 1.14–4.40) was independently associated with the symptomatic state. Reporting at least one chronic comorbidity was also associated with symptomatic cases (aOR, 1.76, 95% CI: 1.03–3.01). Compared with asymptomatic cases, symptomatic cases had a prolonged duration of viral shedding and consistent odds of ≥2 positive COVID-19 tests result out of the three subsequent testing rounds. A substantial proportion of the diagnosed COVID-19 cases in the Emirate of Abu Dhabi were asymptomatic. Quarantining asymptomatic cases, implementing prevention measures, and raising awareness among populations working in high-risk settings are warranted.</p>]]></description>
            <pubDate><![CDATA[2021-02-12T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Knowledge, attitudes, and practices of seasonal influenza vaccination among older adults in nursing homes and daycare centers, Honduras]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765881733338-4045cf42-e2a4-4a9c-a3b2-cbcd67f7298f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246382</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Older adults represent 70–90% of seasonal influenza-related deaths and 50–70% of influenza-related hospitalizations. Vaccination is the most efficient means of preventing influenza and reducing influenza-related illnesses. We aimed to describe knowledge, attitudes, and practices (KAP) of seasonal influenza vaccination among older adults in Honduras.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">From August 29–October 26, 2018, we conducted a cross-sectional KAP survey regarding seasonal influenza vaccinations to samples of older adults 1) admitted to nursing homes and 2) attending daycare centers. We used the Minimental State Examination (MMSE) psychometric tool to assess the cognitive status of older adults and included participants with scores of ≥23 points in the survey. We reported frequency distributions for demographics, KAP of influenza virus and vaccination, and vaccination coverage. We used logistic regression to analyze associations between demographics and verified influenza vaccination.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Of 511 MMSE participants, 341 completed the survey (95 adults in 12 nursing homes and 246 older adults in ten daycare centers). Almost all participants knew that influenza causes severe illness and may be transmitted from person to person, vaccination is safe and protects against disease, and older adults have greater risk of complications. Of 284 participants with verified vaccinations, 81.3% were vaccinated for influenza: 87.9% attending daycare centers and 61.4% in nursing homes. Among all participants, verified current influenza vaccination was associated with self-reported influenza vaccination in previous year (aOR: 14.05; 95% CI: 5.36–36.81); no formal education (aOR: 4.83; 95% CI: 1.63–14.37) or primary school education (aOR: 4.51; 95% CI: 1.79–11.37) having ≥secondary as reference; and indigenous (aOR: 4.55; 95% CI: 1.18–17.49) having Mestizo as reference. Reasons for vaccination were perceived self-benefits, protection against influenza complications, favorable vaccination hours, and healthcare provider recommendations.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">Four-fifths of older adults were vaccinated for seasonal influenza. Educational efforts provided in conjunction with vaccination campaigns resulted in high knowledge of influenza virus, transmission, and vaccination. Further outreach regarding disease risks and vaccine safety needs to be directed towards older adults in nursing homes who had lower knowledge and coverage than older adults in daycare centers.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Shedding and transmission of a live attenuated influenza A virus vaccine in pre-weaned pigs under field conditions]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765881628087-c20b1cd9-3292-497f-9194-0f35b4f68a31/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246690</link>
            <description><![CDATA[<p class="para" id="N65539">Influenza A virus (IAV) is one of the most important respiratory viruses affecting pig health and vaccination is the most common strategy to control influenza infections. In this field study we assessed the onset and duration of shedding of a live attenuated influenza virus (LAIV) vaccine, its ability to transmit to non-vaccinated pigs and whether the LAIV could be aerosolized and detected in the environment. Thirty-three litters (n = 33) of a farm using the LAIV vaccine were selected for the study, a subset of them (n = 12) were left unvaccinated and a subset of piglets (n = 3) in vaccinated litters were also left unvaccinated to serve as sentinels. Selected piglets from the litters were sampled multiple days post vaccination (DPV) by collecting nasal swabs and blood, and were tested using a LAIV vaccine specific RT-PCR assay and hemagglutination inhibition assay against the LAIV strains respectively. Environmental specimens consisting of air and surface wipes were also collected. One hundred percent (21/21) of the vaccinated litters tested LAIV positive 1 DPV and until 6 DPV. In contrast, only five (5/33) of the thirty-three non-vaccinated pigs tested positive during the course of the study. Viable LAIV was confirmed in vaccinated pigs by cell culture and whole genome sequencing. In addition, low levels of LAIV RNA (RT-PCR Ct values ranging between 33 and 38) were detected in all air specimens collected on the day of vaccination and until 6 DPV (3/10). Pigs had maternally derived antibodies reactive against the LAIV strains which may have influenced the degree of shedding observed. Under the conditions of this study, shedding of the LAIV from vaccinated pigs was limited in time, resulted in minimal transmission to non-vaccinated pigs and was detected in low levels in aerosols collected in the vaccinated rooms likely influenced by the presence of maternally derived antibodies against the LAIV strains.</p>]]></description>
            <pubDate><![CDATA[2021-02-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[ASC-dependent inflammasomes contribute to immunopathology and mortality in herpes simplex encephalitis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765879965539-8ff22ff7-fcbd-4508-9c58-fe28e4891799/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009285</link>
            <description><![CDATA[<p class="para" id="N65539">Herpes simplex virus encephalitis (HSE) is the most common cause of sporadic viral encephalitis, and despite targeted antiviral therapy, outcomes remain poor. Although the innate immune system is critical for restricting herpes simplex virus type I (HSV-1) in the brain, there is evidence that prolonged neuroinflammation contributes to HSE pathogenesis. In this study, we investigated the contribution of inflammasomes to disease pathogenesis in a murine model of HSE. Inflammasomes are signaling platforms that activate the pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18. We found that mice deficient in the inflammasome adaptor protein, apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC), had significantly improved survival and lower levels of IL-1β and IL-18 in the brain. Importantly, this difference in survival was independent of viral replication in the central nervous system (CNS). We found that microglia, the resident macrophages of the CNS, are the primary mediators of the ASC-dependent inflammasome response during infection. Using in vitro glial infections and a murine HSE model, we demonstrate that inflammasome activation contributes to the expression of chemokine (C-C motif) ligand 6 (CCL6), a leukocyte chemoattractant. The lower concentration of CCL6 in the brains of ASC<sup>-/-</sup> mice correlated with lower numbers of infiltrating macrophages during infection. Together, these data suggest that inflammasomes contribute to pathogenic inflammation in HSE and provide a mechanistic link between glial inflammasome activation and leukocyte infiltration. The contribution of inflammasomes to survival was independent of viral replication in our study, suggesting a promising new target in combating harmful inflammation in HSE.</p><p class="para" id="N65542">Although the immune system is critical for controlling herpes simplex virus (HSV) infection in the central nervous system (CNS), a prolonged or excessive immune response may be harmful. We studied the contribution of inflammasomes, innate immune proteins that initiate a pro-inflammatory response, to detrimental neuroinflammation in a murine model of herpes simplex encephalitis (HSE). We found that inflammasomes that rely on the adaptor protein ASC contribute to mortality and neuroinflammation independent of controlling viral replication. Additionally, we demonstrate that the inflammasome response to HSV is primarily mediated by microglia and leads to an influx of macrophages in the CNS. These results provide insights into the mechanisms that drive pathogenic inflammation in HSE and suggest a promising therapeutic target in treating HSE.</p>]]></description>
            <pubDate><![CDATA[2021-02-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Barriers and facilitators to prudent antibiotic prescribing for acute respiratory tract infections: A qualitative study with general practitioners in Malta]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765879340432-88fc346c-689d-44b8-a3d3-353b0dfaff1a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246782</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Antibiotic resistance is a leading global public health concern and antibiotic use is a key driver. Effective interventions are needed to target key stakeholders, including general practitioners (GPs). In Malta, little is known about factors that influence GPs’ antibiotic prescribing, making it challenging to implement targeted interventions. We therefore aimed to explore GPs’ understanding of antibiotic use and resistance, and describe their perceived barriers and facilitators to prudent antibiotic prescribing for acute respiratory tract infections in Malta.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">Face-to-face individual semi-structured interviews were held with a quota sample of 20 GPs in 2014. Interviews were audio recorded and transcribed verbatim, and later analysed iteratively using manifest and latent content analysis. Findings were collated in a socioecological model to depict how GPs as individuals are embedded within larger social systems and contexts, and how each component within this system impacts their prescribing behaviour.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Findings</h3><p class="para" id="N65555">We found that GPs’ antibiotic prescribing decisions are complex and impacted by numerous barriers and facilitators at the individual, interpersonal, organisational, community, and public policy level. Predominant factors found to impact GPs’ antibiotic prescribing included not only intrinsic GP factors such as knowledge, awareness, experience, and misconceptions, but also several external factors. At the interpersonal level, GPs’ perceived patient demand and behaviour to be a persistent issue that impacts their prescribing decisions. Similarly, some GPs found pressure from drug reps to be concerning despite being considered an important source of information. Organisational and public policy-level issues such as lack of access to relevant antibiotic prescribing guidelines and current antibiotic resistance data from the community, were also considered major barriers to appropriate antibiotic prescribing. Utilisation of diagnostic testing was found to be low and GPs’ perceptions on the introduction of rapid point-of-care tests to support antibiotic prescription decisions, were mixed.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">This study revealed the complexity of the antibiotic prescribing decision and the numerous barriers and facilitators that impact it, visualised through a socioecological model. Addressing GPs’ antibiotic prescribing practices will require targeted and coordinated implementation activities at all levels to change behaviour and address misconceptions, whilst also improving the physical and social environment.</p></div><div class="section" id="sec005"><h3 class="BHead" id="nov000-5">Trial registration number</h3><p class="para" id="N65567">NCT03218930; https://clinicaltrials.gov/ct2/show/NCT03218930.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Viral growth factor- and STAT3 signaling-dependent elevation of the TCA cycle intermediate levels during vaccinia virus infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765879249241-badeb049-b4c0-4cbd-b03f-3c56782e04db/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009303</link>
            <description><![CDATA[<p class="para" id="N65539">Metabolism is a crucial frontier of host-virus interaction as viruses rely on their host cells to provide nutrients and energy for propagation. Vaccinia virus (VACV) is the prototype poxvirus. It makes intensive demands for energy and macromolecules in order to build hundreds and thousands of viral particles in a single cell within hours of infection. Our comprehensive metabolic profiling reveals profound reprogramming of cellular metabolism by VACV infection, including increased levels of the intermediates of the tri-carboxylic acid (TCA) cycle independent of glutaminolysis. By investigating the level of citrate, the first metabolite of the TCA cycle, we demonstrate that the elevation of citrate depends on VACV-encoded viral growth factor (VGF), a viral homolog of cellular epidermal growth factor. Further, the upregulation of citrate is dependent on STAT3 signaling, which is activated non-canonically at the serine727 upon VACV infection. The STAT3 activation is dependent on VGF, and VGF-dependent EGFR and MAPK signaling. Together, our study reveals a novel mechanism by which VACV manipulates cellular metabolism through a specific viral factor and by selectively activating a series of cellular signaling pathways.</p><p class="para" id="N65542">Vaccinia virus (VACV) is a large DNA virus with an acute and increasing demand for energy and macromolecules to build hundreds and thousands of viral particles in a single cell within hours of infection. The demand postulates reprogramming of the TCA cycle, as it is the central metabolic hub of a cell that generates metabolites for energy production and macromolecule synthesis. We show that VACV infection reprograms cellular metabolism globally, elevating the TCA cycle intermediate levels and modulating related cell metabolism. The elevation of the TCA cycle intermediates depends on the virus-encoded growth factor that stimulates non-canonical STAT3 signaling during VACV infection. Our results provide the metabolic foundation of viral growth factor to boost VACV infection.</p>]]></description>
            <pubDate><![CDATA[2021-02-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Directed attenuation to enhance vaccine immunity]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765878823355-d471d3fd-3828-4e36-8965-6030e453b65f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pcbi.1008602</link>
            <description><![CDATA[<p class="para" id="N65539">Many viral infections can be prevented by immunizing with live, attenuated vaccines. Early methods of attenuation were hit-and-miss, now much improved by genetic engineering. However, even current methods operate on the principle of genetic harm, reducing the virus’s ability to grow. Reduced viral growth has the undesired side-effect of reducing the host immune response below that of infection with wild-type. Might some methods of attenuation instead lead to an increased immune response? We use mathematical models of the dynamics of virus with innate and adaptive immunity to explore the tradeoff between attenuation of virus pathology and immunity. We find that modification of some virus immune-evasion pathways can indeed reduce pathology yet enhance immunity. Thus, attenuated vaccines can, in principle, be directed to be safe yet create better immunity than is elicited by the wild-type virus.</p><p class="para" id="N65542">Live attenuated virus vaccines are among the most effective interventions to combat viral infections. Historically, the mechanism of attenuation has involved genetically reducing the viral growth rate, often achieved by adapting the virus to grow in a novel condition. More recent attenuation methods use genetic engineering but also are thought to impair viral growth rate. These classical attenuations typically result in a tradeoff whereby attenuation depresses the within-host viral load and pathology (which is beneficial to vaccine design), but reduces immunity (which is not beneficial). We use models to explore ways of directing the attenuation of a virus to avoid this tradeoff. We show that <i>directed attenuation</i> by interfering with (some) viral immune-evasion pathways can yield a mild infection but elicit higher levels of immunity than of the wild-type virus.</p>]]></description>
            <pubDate><![CDATA[2021-02-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765878732721-f50974b7-d28a-4415-b929-167fd7a5efa2/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009281</link>
            <description><![CDATA[<p class="para" id="N65539">Intrinsic resistance is a crucial line of defense against virus infections, and members of the Tripartite Ring Interaction Motif (TRIM) family of proteins are major players in this system, such as cytoplasmic TRIM5α or nuclear promyelocytic leukemia (PML/TRIM19) protein. Previous reports on the antiviral function of another TRIM protein, TRIM22, emphasized its innate immune role as a Type I and Type II interferon-stimulated gene against RNA viruses. This study shows that TRIM22 has an additional intrinsic role against DNA viruses. Here, we report that TRIM22 is a novel restriction factor of HSV-1 and limits ICP0-null virus replication by increasing histone occupancy and heterochromatin, thereby reducing immediate-early viral gene expression. The corresponding wild-type equivalent of the virus evades the TRIM22-specific restriction by a mechanism independent of ICP0-mediated degradation. We also demonstrate that TRIM22 inhibits other DNA viruses, including representative members of the β- and γ- herpesviruses. Allelic variants in <i>TRIM22</i> showed different degrees of anti-herpesviral activity; thus, <i>TRIM22</i> genetic variability may contribute to the varying susceptibility to HSV-1 infection in humans. Collectively, these results argue that TRIM22 is a novel restriction factor and expand the list of restriction factors functioning in the infected cell nucleus to counter DNA virus infection.</p><p class="para" id="N65542">The host immune response to herpesviruses includes intrinsic immunity, which is a constitutively active line of defense. Members of the Tripartite Motif (TRIM) superfamily of proteins, such as cytoplasmic TRIM5α and nuclear TRIM19, are examples of such restriction factors against the prototypical α-herpesvirus, herpes simplex virus-1 (HSV-1). Previous reports on the antiviral function of the protein encoded by <i>TRIM22</i>, a gene closely related to the <i>TRIM5</i> gene, emphasized its antiretroviral role. We show that <i>TRIM22</i> has an additional role as a restriction factor against herpesviruses. We found that TRIM22 inhibits a mutant form of HSV-1, by promoting chromatin compaction of the viral DNA encoding immediate-early viral genes–this consequently inhibits viral replication and reduces virus yields. Unlike other restriction factors that are degraded by the viral infected cell polypeptide 0 (ICP0), TRIM22 is not degraded by ICP0. We also show that TRIM22 inhibits representative members of the β-herpesvirus (cytomegalovirus) and γ- herpesviruses (Epstein-Barr virus). In addition, different <i>TRIM22</i> genetic variants show differing levels of HSV-1 inhibition. Together, these results argue for the importance of the <i>TRIM22</i> gene as a restriction factor against herpesviruses, and offer a novel avenue for further investigation on the role of <i>TRIM</i> genes in host genetic variation in herpesviral susceptibility.</p>]]></description>
            <pubDate><![CDATA[2021-02-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[High genetic variability of Schmallenberg virus M-segment leads to efficient immune escape from neutralizing antibodies]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765878644263-d9b33611-3dd6-4796-aba4-131df7bf9a48/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009247</link>
            <description><![CDATA[<p class="para" id="N65539">Schmallenberg virus (SBV) is the cause of severe fetal malformations when immunologically naïve pregnant ruminants are infected. In those malformed fetuses, a “hot-spot”-region of high genetic variability within the N-terminal region of the viral envelope protein Gc has been observed previously, and this region co-localizes with a known key immunogenic domain. We studied a series of M-segments of those SBV variants from malformed fetuses with point mutations, insertions or large in-frame deletions of up to 612 nucleotides. Furthermore, a unique cell-culture isolate from a malformed fetus with large in-frame deletions within the M-segment was analyzed.</p><p class="para" id="N65541">Each Gc-protein with amino acid deletions within the “hot spot” of mutations failed to react with any neutralizing anti-SBV monoclonal antibodies or a domain specific antiserum. In addition, <i>in vitro</i> virus replication of the natural deletion variant could not be markedly reduced by neutralizing monoclonal antibodies or antisera from the field. The large-deletion variant of SBV that could be isolated in cell culture was highly attenuated with an impaired <i>in vivo</i> replication following the inoculation of sheep.</p><p class="para" id="N65549">In conclusion, the observed amino acid sequence mutations within the N-terminal main immunogenic domain of glycoprotein Gc result in an efficient immune evasion from neutralizing antibodies in the special environment of a developing fetus. These SBV-variants were never detected as circulating viruses, and therefore should be considered to be dead-end virus variants, which are not able to spread further. The observations described here may be transferred to other orthobunyaviruses, particularly those of the Simbu serogroup that have been shown to infect fetuses. Importantly, such mutant strains should not be included in attempts to trace the spatial-temporal evolution of orthobunyaviruses in molecular-epidemiolocal approaches during outbreak investigations.</p><p class="para" id="N65542">Schmallenberg virus (SBV) is a pathogen of veterinary importance and is used as a model virus for studying peribunyaviruses, a complex and highly divergent family of RNA viruses. An SBV-infection of naïve dams during pregnancy may lead to the induction of severe malformation in the fetus. In the medium (M) genomic segment of SBV and related viruses, a region of high sequence variability was detected, affecting the N-terminal major immunogenic domain of envelope protein Gc in malformed fetuses. Variation of this mutation hot spot in fetuses was demonstrated to result in immune-evasion from neutralizing activity in the infected fetus. Accordingly, the neutralization capacity of SBV-specific antisera collected from SBV-infected animals on the <i>in vitro</i> growth of such a variant virus isolate was severely impaired. Furthermore, the deletion mutant was attenuated for adult sheep. This study provides important new insights into the mechanisms of virus persistence within chronically infected malformed fetuses and explains the mystery of the “hot-spot” of sequence variations not only observed in SBV, but also in related viruses. The model proposed can represent an example of virus mutations resulting in antibody induced immune escape.</p>]]></description>
            <pubDate><![CDATA[2021-01-26T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765878516552-f2e6c35c-84f0-4cbe-8bb6-c39e7911cdd1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245767</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction and aim</h3><p class="para" id="N65543">Comorbidities and comedication are common in patients with hepatitis C, which could result in a risk of drug-drug interaction. The objective of this study was to evaluate the prevalence of comorbidities, comedication and drug-drug interactions involving direct-acting antivirals in this population.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">Comorbidities and comedications were evaluated in a retrospective cohort of hepatitis C patients. Drug-drug interactions were estimated in real life and with simulated data on comedications following drug regimens: telaprevir; elbasvir/grazoprevir, ombitasvir/paritaprevir/r/ritonavir (2D regimen), and sofosbuvir/simeprevir, sofosbuvir/daclatasvir, sofosbuvir/ledipasvir; 2D/dasabuvir (3D regimen); glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. The interactions were evaluated according to the University of Liverpool database. Statistical analysis was performed by SPSS<sup>®</sup> 18.0.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65558">Data from 1433 patients with hepatitis C were evaluated. The mean patient age was 51.7 years (SD ± 10.7), and 50.6% were female. Direct-acting antivirals were prescribed for 345 (24.1%) patients, and a sustained virological response occurred in 264 (76.5%). The main comorbidities were systemic arterial hypertension [436 (30.4%)], diabetes mellitus [352 (24.6%)] and depression [130 (9.1%)]. The mean number of comorbidities was 1.52 (median [IQR] of 1.00 [1.00–2.00]). The mean number of comedications was 3.16 (median [IQR] of 3.00 [1.00–5.00]). A total of 12916 drug-drug interactions were found, of which 1.859 (14.4%) were high risk, with a mean of 1.29 ± 3.13 per patient. The 3D regimen, as well as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir, presented the highest drug-drug interaction indexes.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65564">Comorbidities and comedications are common in patients with hepatitis C, as are drug-drug interactions. Even when second generation drugs are used, the occurrence of drug-drug interactions still presents a significant risk.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-12T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Estimation of time of HIV seroconversion using a modified CD4 depletion model]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765878306023-8a3bf693-c71f-410f-8efb-fb1b177b8a16/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246135</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction</h3><p class="para" id="N65543">Several methods have been proposed to estimate the time of HIV seroconversion, including those based on CD4 cell depletion models. However, previous models have failed to consider the heterogeneity that exists in CD4 trajectories among different sub-populations. Our objective was to estimate the time from HIV seroconversion relative to the HIV diagnosis date in a population-based cohort of people living with HIV (PLWH) in the province of British Columbia, Canada.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">We used linked administrative and clinical data from the British Columbia Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) cohort, which contains longitudinal individual-level data on all PLWH ever diagnosed in the province. Eligible participants were aged ≥18 years and diagnosed with HIV between 1989 and 2013. The outcome was pre-antiretroviral treatment CD4 cell count measurements assessed every six months. Models were stratified by age and stage of HIV infection at diagnosis. Several explanatory variables were considered including longitudinal viral load measurements. Longitudinal CD4, square root transformed, was modeled via a non-linear mixed effects model; time was modeled using an exponential decay function. We assumed a Gaussian distribution (identity link), an AR(1) correlation structure, and a random intercept and slope for the longitudinal viral load measurements. Due to the population variation in CD4 count among uninfected individuals, we assumed 500 to 1500 cells/mm<sup>3</sup> as the normal range when estimating the time of HIV seroconversion.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65558">Longitudinal data on 1,253 individuals were analysed: 80% male, 33% White, and the median age at diagnosis was 38 years (25<sup>th</sup>-75<sup>th</sup> percentile [Q<sub>1</sub>-Q<sub>3</sub>], 31 to 45). CD4 decay differed by stage of infection at diagnosis and age, with those ≥50 years in Stages 1 and 2 experiencing a faster decline in CD4 over time. The median duration of infection from seroconversion until HIV diagnosis was 6.9 (Q<sub>1</sub>-Q<sub>3</sub>, 3.9 to 10.1) years.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65582">Considering the heterogeneity that exists in individual CD4 cell trajectories in a population, we presented a methodology that only relies on routinely collected HIV-related data, which can be further extended to estimate other epidemic measures.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-12T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The PB1 protein of influenza A virus inhibits the innate immune response by targeting MAVS for NBR1-mediated selective autophagic degradation]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765877792897-19bd596a-4816-49f1-9379-53ad87a050fc/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009300</link>
            <description><![CDATA[<p class="para" id="N65539">Influenza A virus (IAV) has evolved various strategies to counteract the innate immune response using different viral proteins. However, the mechanism is not fully elucidated. In this study, we identified the PB1 protein of H7N9 virus as a new negative regulator of virus- or poly(I:C)-stimulated IFN induction and specifically interacted with and destabilized MAVS. A subsequent study revealed that PB1 promoted E3 ligase RNF5 to catalyze K27-linked polyubiquitination of MAVS at Lys362 and Lys461. Moreover, we found that PB1 preferentially associated with a selective autophagic receptor neighbor of <i>BRCA1</i> (NBR1) that recognizes ubiquitinated MAVS and delivers it to autophagosomes for degradation. The degradation cascade mediated by PB1 facilitates H7N9 virus infection by blocking the RIG-I-MAVS-mediated innate signaling pathway. Taken together, these data uncover a negative regulatory mechanism involving the PB1-RNF5-MAVS-NBR1 axis and provide insights into an evasion strategy employed by influenza virus that involves selective autophagy and innate signaling pathways.</p><p class="para" id="N65542">In 2013, H7N9 influenza viruses appeared in China and other countries resulting in 1, 567 human infections and 615 deaths. Understanding the cross-talk between virus and host is vital for the development of effective vaccines and therapeutics. Here, we identified the PB1 protein of H7N9 virus as a novel negative regulator that enhances the degradation of MAVS, an essential adaptor protein in the innate signaling pathway. Mechanistically, PB1 promoted the E3 ligase RNF5-mediated ubiquitination of MAVS and recruited the selective autophagic receptor NBR1 to associate with and deliver the ubiquitinated MAVS to the autophagosomes for degradation. Thus, the PB1-RNF5-MAVS-NBR1 axis inhibited innate immune antiviral response and facilitated virus replication by mediating MAVS degradation in an autophagosome-dependent manner. Our findings reveal a novel mechanism by which influenza virus negatively regulates the innate immune response.</p>]]></description>
            <pubDate><![CDATA[2021-02-12T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765877171201-49b1243e-0451-4c7b-982b-cfd14357d990/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009292</link>
            <description><![CDATA[<p class="para" id="N65539">The human airway epithelium is the initial site of SARS-CoV-2 infection. We used flow cytometry and single cell RNA-sequencing to understand how the heterogeneity of this diverse cell population contributes to elements of viral tropism and pathogenesis, antiviral immunity, and treatment response to remdesivir. We found that, while a variety of epithelial cell types are susceptible to infection, ciliated cells are the predominant cell target of SARS-CoV-2. The host protease TMPRSS2 was required for infection of these cells. Importantly, remdesivir treatment effectively inhibited viral replication across cell types, and blunted hyperinflammatory responses. Induction of interferon responses within infected cells was rare and there was significant heterogeneity in the antiviral gene signatures, varying with the burden of infection in each cell. We also found that heavily infected secretory cells expressed abundant IL-6, a potential mediator of COVID-19 pathogenesis.</p><p class="para" id="N65542">SARS-CoV-2 infects the respiratory tract, targeting cells of the diverse airway epithelium. Infection outcomes depend on several factors that may vary in this heterogenous population including viral tropism, antiviral immunity, and response to antiviral therapies like remdesivir. We found that SARS-CoV-2 infects an array of airway epithelial cells, relying on the host protease TMPRSS2 for entry. Ciliated epithelial cells were the dominant target, and remdesivir blocked viral replication across multiple cell types. We uncovered cellular heterogeneity in early antiviral immunity to SARS-CoV-2 and identified cell type-specific ISGs associated with either high levels of viral replication or protection from infection.</p>]]></description>
            <pubDate><![CDATA[2021-01-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Assessing the potential impact of transmission during prolonged viral shedding on the effect of lockdown relaxation on COVID-19]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765876869881-ec87fe68-7da5-4bb0-b6cf-5d13eea1be1d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pcbi.1008609</link>
            <description><![CDATA[<p class="para" id="N65539">A key parameter in epidemiological modeling which characterizes the spread of an infectious disease is the generation time, or more generally the distribution of infectiousness as a function of time since infection. There is increasing evidence supporting a prolonged viral shedding window for COVID-19, but the transmissibility in this phase is unclear. Based on this, we develop a generalized Susceptible-Exposed-Infected-Resistant (SEIR) model including an additional compartment of chronically infected individuals who can stay infectious for a longer duration than the reported generation time, but with infectivity reduced to varying degrees. Using the incidence and fatality data from different countries, we first show that such an assumption also yields a plausible model in explaining the data observed prior to the easing of the lockdown measures (relaxation). We then test the predictive power of this model for different durations and levels of prolonged infectiousness using the incidence data after the introduction of relaxation in Switzerland, and compare it with a model without the chronically infected population to represent the models conventionally used. We show that in case of a gradual easing on the lockdown measures, the predictions of the model including the chronically infected population vary considerably from those obtained under a model in which prolonged infectiousness is not taken into account. Although the existence of a chronically infected population still remains largely hypothetical, we believe that our results provide tentative evidence to consider a chronically infected population as an alternative modeling approach to better interpret the transmission dynamics of COVID-19.</p><p class="para" id="N65542">A key epidemiological variable characterizing the spread of an infectious disease is the generation time, defining the time between successive cases in a chain of transmission. Although there is increasing evidence supporting a prolonged viral shedding window for COVID-19, it is currently unclear to what extent prolonged transmission also occurs. Here we investigate the plausibility of a population of chronically infected individuals who can stay infectious for a longer duration than the reported generation time, but with infectivity reduced to varying degrees. By using the daily case and fatality data from various countries, we show that the existence of a chronically infected population is not a possibility that can be easily rejected from an epidemiological perspective. Moreover, in case of a gradual easing on the lockdown measures, the predictions of the model including the chronically infected population vary considerably from the predictions of the conventional epidemiological models. Although it is not possible to either prove or disprove the existence of a hypothetical population purely by modeling, our results provide tentative evidence to consider a chronically infected population as an alternative modeling approach in assessing the transmission dynamics of COVID-19.</p>]]></description>
            <pubDate><![CDATA[2021-01-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Prioritizing investments in rapid response vaccine technologies for emerging infections: A portfolio decision analysis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765873881480-b1157886-bfd6-45d1-836e-fb2d4cb561b1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246235</link>
            <description><![CDATA[<p class="para" id="N65539">This study reports on the application of a Portfolio Decision Analysis (PDA) to support investment decisions of a non-profit funder of vaccine technology platform development for rapid response to emerging infections. A value framework was constructed via document reviews and stakeholder consultations. Probability of Success (PoS) data was obtained for 16 platform projects through expert assessments and stakeholder portfolio preferences via a Discrete Choice Experiment (DCE). The structure of preferences and the uncertainties in project PoS suggested a non-linear, stochastic value maximization problem. A simulation-optimization algorithm was employed, identifying optimal portfolios under different budget constraints. Stochastic dominance of the optimization solution was tested via mean-variance and mean-Gini statistics, and its robustness via rank probability analysis in a Monte Carlo simulation. Project PoS estimates were low and substantially overlapping. The DCE identified decreasing rates of return to investing in single platform types. Optimal portfolio solutions reflected this non-linearity of platform preferences along an efficiency frontier and diverged from a model simply ranking projects by PoS-to-Cost, despite significant revisions to project PoS estimates during the review process in relation to the conduct of the DCE. Large confidence intervals associated with optimization solutions suggested significant uncertainty in portfolio valuations. Mean-variance and Mean-Gini tests suggested optimal portfolios with higher expected values were also accompanied by higher risks of not achieving those values despite stochastic dominance of the optimal portfolio solution under the decision maker’s budget constraint. This portfolio was also the highest ranked portfolio in the simulation; though having only a 54% probability of being preferred to the second-ranked portfolio. The analysis illustrates how optimization modelling can help health R&amp;D decision makers identify optimal portfolios in the face of significant decision uncertainty involving portfolio trade-offs. However, in light of such extreme uncertainty, further due diligence and ongoing updating of performance is needed on highly risky projects as well as data on decision makers’ portfolio risk attitude before PDA can conclude about optimal and robust solutions.</p>]]></description>
            <pubDate><![CDATA[2021-02-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Hematopoietic cell-mediated dissemination of murine cytomegalovirus is regulated by NK cells and immune evasion]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765873655492-5e7e76bf-a95a-4d92-9384-092c3d8f4500/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009255</link>
            <description><![CDATA[<p class="para" id="N65539">Cytomegalovirus (CMV) causes clinically important diseases in immune compromised and immune immature individuals. Based largely on work in the mouse model of murine (M)CMV, there is a consensus that myeloid cells are important for disseminating CMV from the site of infection. In theory, such dissemination should expose CMV to cell-mediated immunity and thus necessitate evasion of T cells and NK cells. However, this hypothesis remains untested. We constructed a recombinant MCMV encoding target sites for the hematopoietic specific miRNA miR-142-3p in the essential viral gene IE3. This virus disseminated poorly to the salivary gland following intranasal or footpad infections but not following intraperitoneal infection in C57BL/6 mice, demonstrating that dissemination by hematopoietic cells is essential for specific routes of infection. Remarkably, depletion of NK cells or T cells restored dissemination of this virus in C57BL/6 mice after intranasal infection, while dissemination occurred normally in BALB/c mice, which lack strong NK cell control of MCMV. These data show that cell-mediated immunity is responsible for restricting MCMV to hematopoietic cell-mediated dissemination. Infected hematopoietic cells avoided cell-mediated immunity via three immune evasion genes that modulate class I MHC and NKG2D ligands (m04, m06 and m152). MCMV lacking these 3 genes spread poorly to the salivary gland unless NK cells were depleted, but also failed to replicate persistently in either the nasal mucosa or salivary gland unless CD8<sup>+</sup> T cells were depleted. Surprisingly, CD8<sup>+</sup> T cells primed after intranasal infection required CD4<sup>+</sup> T cell help to expand and become functional. Together, our data suggest that MCMV can use both hematopoietic cell-dependent and -independent means of dissemination after intranasal infection and that cell mediated immune responses restrict dissemination to infected hematopoietic cells, which are protected from NK cells during dissemination by viral immune evasion. In contrast, viral replication within mucosal tissues depends on evasion of T cells.</p><p class="para" id="N65542">Cytomegalovirus (CMV) is a common cause of disease in immune compromised individuals as well as a common cause of congenital infections leading to disease in newborns. The virus is thought to enter primarily via mucosal barrier tissues, such as the oral and nasal mucosa. However, it is not clear how the virus escapes these barrier tissues to reach distant sites. In this study, we used a mouse model of CMV infection. Our data illustrate a complex balance between the immune system and viral infection of “myeloid cells”, which are most commonly thought to carry the virus around the body after infection. In particular, our data suggest that robust immune responses at the site of infection force the virus to rely on myeloid cells to escape the site of infection. Moreover, viral genes designed to evade these immune responses were needed to protect the virus during and after its spread to distant sites. Together, this work sheds light on the mechanisms of immune control and viral survival during CMV infection of mucosal tissues and spread to distant sites of the body.</p>]]></description>
            <pubDate><![CDATA[2021-01-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Kaposi’s sarcoma-associated herpesvirus processivity factor (PF-8) recruits cellular E3 ubiquitin ligase CHFR to promote PARP1 degradation and lytic replication]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765873392487-79981951-ce34-428e-ba3b-4e9820ca4863/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009261</link>
            <description><![CDATA[<p class="para" id="N65539">Kaposi’s sarcoma–associated herpesvirus (KSHV), which belongs to the gammaherpesvirus subfamily, is associated with the pathogenesis of various tumors. Nuclear enzyme poly(ADP-ribose) polymerase 1 (PARP1) catalyzes the polymerization of ADP-ribose units on target proteins. In KSHV-infected cells, PARP1 inhibits <span style="text-decoration: underline"><i>r</i></span>eplication and <span style="text-decoration: underline"><i>t</i></span>ranscription <span style="text-decoration: underline"><i>a</i></span>ctivator (RTA), a molecular switch that initiates lytic replication, through direct interaction. Thus, for efficient replication, KSHV has to overcome the molecular barrier in the form of PARP1. Previously, we have demonstrated that KSHV downregulates the expression of PARP1 through PF-8, a viral processivity factor. PF-8 induces ubiquitin–proteasome system–mediated degradation of PARP1 via direct physical association and enhances RTA transactivation activity. Here, we showed that dimerization domains of PF-8 are crucial not only for PARP1 interaction and degradation but also for enhancement of the RTA transactivation activity. PF-8 recruited CHFR for the PARP1 degradation. A knockdown of CHFR attenuated the PF-8–induced PARP1 degradation and enhancement of the RTA transactivation activity, leading to reduced KSHV lytic replication. These findings reveal a mechanism by which KSHV PF-8 recruits a cellular E3 ligase to curtail the inhibitory effect of PARP1 on KSHV lytic replication.</p><p class="para" id="N65542">Kaposi’s sarcoma–associated herpesvirus (KSHV), a member of the gammaherpesvirus subfamily, is associated with the pathogenesis of various tumors. Poly(ADP-ribose) polymerase 1 (PARP1), which is involved in various cellular functions, restricts lytic replication of oncogenic gammaherpesviruses by inhibiting <span style="text-decoration: underline"><i>r</i></span>eplication and <span style="text-decoration: underline"><i>t</i></span>ranscription <span style="text-decoration: underline"><i>a</i></span>ctivator (RTA), a molecular switch that activates the viral lytic replication. To abrogate the inhibitory effect of PARP1, reactivated KSHV promotes PARP1 degradation via direct interaction between PARP1 and PF-8, a viral processivity factor. Dimerization domains of PF-8 were found to be critical for PARP1 interaction and degradation and for enhancing the RTA transactivation activity. Furthermore, we found that CHFR, an E3 ubiquitin ligase, is required for PF-8–induced PARP1 degradation and efficient lytic replication of KSHV. This is the first study to show the role of CHFR in viral replication or pathogenicity. This study revealed a molecular mechanism via which gammaherpesviruses overcome the PARP1-mediated inhibitory effect on viral replication: by means of PF-8, which recruits a cellular E3 ubiquitin ligase.</p>]]></description>
            <pubDate><![CDATA[2021-01-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765872915782-b6ef01b6-2e04-49c9-8f80-b54d7cc756e5/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009287</link>
            <description><![CDATA[<p class="para" id="N65539">The COVID-19 pandemic has revealed that infection with SARS-CoV-2 can result in a wide range of clinical outcomes in humans. An incomplete understanding of immune correlates of protection represents a major barrier to the design of vaccines and therapeutic approaches to prevent infection or limit disease. This deficit is largely due to the lack of prospectively collected, pre-infection samples from individuals that go on to become infected with SARS-CoV-2. Here, we utilized data from genetically diverse Collaborative Cross (CC) mice infected with SARS-CoV to determine whether baseline T cell signatures are associated with a lack of viral control and severe disease upon infection. SARS-CoV infection of CC mice results in a variety of viral load trajectories and disease outcomes. Overall, a dysregulated, pro-inflammatory signature of circulating T cells at baseline was associated with severe disease upon infection. Our study serves as proof of concept that circulating T cell signatures at baseline can predict clinical and virologic outcomes upon SARS-CoV infection. Identification of basal immune predictors in humans could allow for identification of individuals at highest risk of severe clinical and virologic outcomes upon infection, who may thus most benefit from available clinical interventions to restrict infection and disease.</p><p class="para" id="N65542">We used a screen of genetically diverse mice from the Collaborative Cross infected with mouse-adapted SARS-CoV in combination with comprehensive pre-infection immunophenotyping to identify baseline circulating immune correlates of severe virologic and clinical outcomes upon SARS-CoV infection.</p>]]></description>
            <pubDate><![CDATA[2021-01-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Genome-wide identification of <i>Aedes albopictus</i> long noncoding RNAs and their association with dengue and Zika virus infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765872462710-85e82b78-3531-4234-a65e-5c9cf30130c1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0008351</link>
            <description><![CDATA[<p class="para" id="N65539">The Asian tiger mosquito, <i>Aedes albopictus</i> (<i>Ae</i>. <i>albopictus</i>), is an important vector that transmits arboviruses such as dengue (DENV), Zika (ZIKV) and Chikungunya virus (CHIKV). Long noncoding RNAs (lncRNAs) are known to regulate various biological processes. Knowledge on <i>Ae</i>. <i>albopictus</i> lncRNAs and their functional role in virus-host interactions are still limited. Here, we identified and characterized the lncRNAs in the genome of an arbovirus vector, <i>Ae</i>. <i>albopictus</i>, and evaluated their potential involvement in DENV and ZIKV infection. We used 148 public datasets, and identified a total of 10, 867 novel lncRNA transcripts, of which 5,809, 4,139, and 919 were intergenic, intronic and antisense respectively. The <i>Ae</i>. <i>albopictus</i> lncRNAs shared many characteristics with other species such as short length, low GC content, and low sequence conservation. RNA-sequencing of <i>Ae</i>. <i>albopictus</i> cells infected with DENV and ZIKV showed that the expression of lncRNAs was altered upon virus infection. Target prediction analysis revealed that <i>Ae</i>. <i>albopictus</i> lncRNAs may regulate the expression of genes involved in immunity and other metabolic and cellular processes. To verify the role of lncRNAs in virus infection, we generated mutations in lncRNA loci using CRISPR-Cas9, and discovered that two lncRNA loci mutations, namely XLOC_029733 (novel lncRNA transcript id: lncRNA_27639.2) and LOC115270134 (known lncRNA transcript id: XR_003899061.1) resulted in enhancement of DENV and ZIKV replication. The results presented here provide an important foundation for future studies of lncRNAs and their relationship with virus infection in <i>Ae</i>. <i>albopictus</i>.</p><p class="para" id="N65542"><i>Ae</i>. <i>albopictus</i> is an important vector of arboviruses such as dengue and Zika viruses. Studies on virus-host interaction at gene expression and molecular level are crucial especially in devising methods to inhibit virus replication in <i>Aedes</i> mosquitoes. Previous reports have shown that, besides protein-coding genes, noncoding RNAs such as lncRNAs are also involved in virus-host interaction. In this study, we report a comprehensive catalog of novel lncRNA transcripts in the genome of <i>Ae</i>. <i>albopictus</i>. We also show that the expression of lncRNAs was altered upon infection with dengue and Zika. Additionally, depletion of certain lncRNAs resulted in increased replication of dengue and Zika; hence, suggesting potential association of lncRNAs in virus infection. Results of this study provide a new avenue to the investigation of mosquito-virus interactions, especially in the aspect of noncoding genes.</p>]]></description>
            <pubDate><![CDATA[2021-01-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Persistence of Ebola virus in semen among Ebola virus disease survivors in Sierra Leone: A cohort study of frequency, duration, and risk factors]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765872319472-950e2f3d-5a4d-4a27-9aa3-48124d8ab902/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pmed.1003273</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Sexual transmission chains of Ebola virus (EBOV) have been verified and linked to EBOV RNA persistence in semen, post-recovery. The rate of semen persistence over time, including the average duration of persistence among Ebola virus disease (EVD) survivors, is not well known. This cohort study aimed to analyze population estimates of EBOV RNA persistence rates in semen over time, and associated risk factors in a population of survivors from Sierra Leone.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods and findings</h3><p class="para" id="N65549">In this cohort study from May 2015 to April 2017 in Sierra Leone, recruitment was conducted in 2 phases; the first enrolled 100 male participants from the Western Area District in the capital of Freetown, and the second enrolled 120 men from the Western Area District and from Lungi, Port Loko District. Mean age of participants was 31 years. The men provided semen for testing, analyzed by quantitative reverse transcription PCR (qRT-PCR) for the presence of EBOV RNA. Follow-up occurred every 2 weeks until the endpoint, defined as 2 consecutive negative qRT-PCR results of semen specimen testing for EBOV RNA. Participants were matched with the Sierra Leone EVD case database to retrieve cycle threshold (Ct) values from the qRT-PCR analysis done in blood during acute disease. A purposive sampling strategy was used, and the included sample composition was compared to the national EVD survivor database to understand deviations from the general male survivor population. At 180 days (6 months) after Ebola treatment unit (ETU) discharge, the EBOV RNA semen positive rate was 75.4% (95% CI 66.9%–82.0%). The median persistence duration was 204 days, with 50% of men having cleared their semen of EBOV RNA after this time. At 270 days, persistence was 26.8% (95% CI 20.0%–34.2%), and at 360 days, 6.0% (95% CI 3.1%–10.2%). Longer persistence was significantly associated with severe acute disease, with probability of persistence in this population at 1 year at 10.1% (95% CI 4.6%–19.8%) compared to the probability approaching 0% for those with mild acute disease. Age showed a dose–response pattern, where the youngest men (≤25 years) were 3.17 (95% CI 1.60, 6.29) times more likely to be EBOV RNA negative in semen, and men aged 26–35 years were 1.85 (95% CI 1.04, 3.28) times more likely to be negative, than men aged &gt;35 years. Among participants with both severe acute EVD and a higher age (&gt;35 years), persistence remained above 20% (95% CI 6.0%–50.6%) at 1 year. Uptake of safe sex recommendations 3 months after ETU discharge was low among a third of survivors. The sample was largely representative of male survivors in Sierra Leone. A limitation of this study is the lack of knowledge about infectiousness.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusions</h3><p class="para" id="N65555">In this study we observed that EBOV RNA persistence in semen was a frequent phenomenon, with high population rates over time. This finding will inform forthcoming updated recommendations on risk reduction strategies relating to sexual transmission of EBOV. Our findings support implementation of a semen testing program as part of epidemic preparedness and response. Further, the results will enable planning of the magnitude of testing and targeted counseling needs over time.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-1">Why was this study done?</h3><p class="para" id="N65549">Evidence of traces of Ebola virus in semen had been reported among survivors for a very long time after their disease.</p><p class="para" id="N65552">This study originated out of a need to expand understanding beyond single reported cases, to gain knowledge on how many male survivors have Ebola virus persistence in semen over time, and for how long on average.</p><p class="para" id="N65555">We also aimed to analyze factors associated with longer persistence that could provide information on hypotheses on why some men carry virus in their semen for a very long time after the acute disease.</p></div><div class="section" id="sec005"><h3 class="BHead" id="nov000-2">What did the researchers do and find?</h3><p class="para" id="N65564">In this study, 220 men who had survived Ebola disease in Sierra Leone during 2015–2016 provided semen specimens, and all of those who had traces of Ebola virus detected were followed every other week until their specimen turned negative.</p><p class="para" id="N65567">Seventy-five percent of these men still had traces of Ebola virus in their semen specimen at 6 months after being discharged following acute EVD, and 50% at 204 days.</p><p class="para" id="N65570">We also found that longer persistence of virus was significantly associated with severe acute EVD and older age.</p></div><div class="section" id="sec006"><h3 class="BHead" id="nov000-3">What do these findings mean?</h3><p class="para" id="N65579">We show there is an urgent need to organize a national semen testing program as part of Ebola epidemic preparedness and response.</p><p class="para" id="N65582">The findings also show that in addition to testing, targeted safe sex counseling and free access to condoms should be a priority from the start of an outbreak.</p><p class="para" id="N65585">While we show that most of the survivors had traces of virus in semen at 6 months, more research is needed to understand the impact of viral RNA in semen on transmission of Ebola virus.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-10T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Uncovering potential host proteins and pathways that may interact with eukaryotic short linear motifs in viral proteins of MERS, SARS and SARS2 coronaviruses that infect humans]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765853784894-5ee611ae-0d48-46f2-bce8-44972b499514/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246150</link>
            <description><![CDATA[<p class="para" id="N65539">A coronavirus pandemic caused by a novel coronavirus (SARS-CoV-2) has spread rapidly worldwide since December 2019. Improved understanding and new strategies to cope with novel coronaviruses are urgently needed. Viruses (especially RNA viruses) encode a limited number and size (length of polypeptide chain) of viral proteins and must interact with the host cell components to control (hijack) the host cell machinery. To achieve this goal, the extensive mimicry of SLiMs in host proteins provides an effective strategy. However, little is known regarding SLiMs in coronavirus proteins and their potential targets in host cells. The objective of this study is to uncover SLiMs in coronavirus proteins that are present within host cells. These SLiMs have a high possibility of interacting with host intracellular proteins and hijacking the host cell machinery for virus replication and dissemination. In total, 1,479 SLiM hits were identified in the 16 proteins of 590 coronaviruses infecting humans. Overall, 106 host proteins were identified that may interact with SLiMs in 16 coronavirus proteins. These SLiM-interacting proteins are composed of many intracellular key regulators, such as receptors, transcription factors and kinases, and may have important contributions to virus replication, immune evasion and viral pathogenesis. A total of 209 pathways containing proteins that may interact with SLiMs in coronavirus proteins were identified. This study uncovers potential mechanisms by which coronaviruses hijack the host cell machinery. These results provide potential therapeutic targets for viral infections.</p>]]></description>
            <pubDate><![CDATA[2021-02-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[<i>Bartonella</i> type IV secretion effector BepC induces stress fiber formation through activation of GEF-H1]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765852960999-1099fdef-e797-4d2f-8705-333fca225b36/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009065</link>
            <description><![CDATA[<p class="para" id="N65539"><i>Bartonella</i> T4SS effector BepC was reported to mediate internalization of big <i>Bartonella</i> aggregates into host cells by modulating F-actin polymerization. After that, BepC was indicated to induce host cell fragmentation, an interesting cell phenotype that is characterized by failure of rear-end retraction during cell migration, and subsequent dragging and fragmentation of cells. Here, we found that expression of BepC resulted in significant stress fiber formation and contractile cell morphology, which depended on combination of the N-terminus FIC (<span style="text-decoration: underline">f</span>ilamentation <span style="text-decoration: underline">i</span>nduced by <span style="text-decoration: underline">c</span>-AMP) domain and C-terminus BID (<span style="text-decoration: underline"><i>B</i></span><i>artonella</i>
<span style="text-decoration: underline">i</span>ntracellular <span style="text-decoration: underline">d</span>elivery) domain of BepC. The FIC domain played a key role in BepC-induced stress fiber formation and cell fragmentation because deletion of FIC signature motif or mutation of two conserved amino acid residues abolished BepC-induced cell fragmentation. Immunoprecipitation confirmed the interaction of BepC with GEF-H1 (a microtubule-associated RhoA guanosine exchange factor), and siRNA-mediated depletion of GEF-H1 prevented BepC-induced stress fiber formation. Interaction with BepC caused the dissociation of GEF-H1 from microtubules and activation of RhoA to induce formation of stress fibers. The ROCK (Rho-associated protein kinase) inhibitor Y27632 completely blocked BepC effects on stress fiber formation and cell contractility. Moreover, stress fiber formation by BepC increased the stability of focal adhesions, which consequently impeded rear-edge detachment. Overall, our study revealed that BepC-induced stress fiber formation was achieved through the GEF-H1/RhoA/ROCK pathway.</p><p class="para" id="N65542">Intracellular pathogens modulate host cell actin cytoskeleton by secreting an array of effector molecules to ensure their cell invasion and intracellular survival. The zoonotic pathogen <i>Bartonella spp</i> trigger massive F-actin polymerization of host cells resulting the internalization of large bacterial aggregates (called “invasome” structure), which is dependent on a functional VirB/VirD4 type IV secretion system (T4SS) and its translocated Bep effector proteins. Here, we have used cell infection and ectopic expression assay to identify that <i>Bartonella</i> T4SS effector BepC induces stress fiber formation in infected host cells. However, BepC also disrupts the balance of stress fiber formation and focal adhesion maturation, and eventually causes cell fragmentation. Using immunoprecipitation and RNAi approaches, we identify GEF-H1 is the host factor targeted by BepC. Interaction with BepC induces the release of GEF-H1 from microtubules to plasma membrane and subsequently activates RhoA-ROCK to induce stress fiber formation. These findings shed light on our understanding of how <i>Bartonella</i> invade host cell and establish infection.</p>]]></description>
            <pubDate><![CDATA[2021-01-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated <i>in vitro</i> during propagation in TMPRSS2-deficient cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765852474355-c7952cb1-f835-43cd-adb3-f247181a458b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009233</link>
            <description><![CDATA[<p class="para" id="N65539">The spike (S) protein of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) binds to a host cell receptor which facilitates viral entry. A polybasic motif detected at the cleavage site of the S protein has been shown to broaden the cell tropism and transmissibility of the virus. Here we examine the properties of SARS-CoV-2 variants with mutations at the S protein cleavage site that undergo inefficient proteolytic cleavage. Virus variants with S gene mutations generated smaller plaques and exhibited a more limited range of cell tropism compared to the wild-type strain. These alterations were shown to result from their inability to utilize the entry pathway involving direct fusion mediated by the host type II transmembrane serine protease, TMPRSS2. Notably, viruses with S gene mutations emerged rapidly and became the dominant SARS-CoV-2 variants in TMPRSS2-deficient cells including Vero cells. Our study demonstrated that the S protein polybasic cleavage motif is a critical factor underlying SARS-CoV-2 entry and cell tropism. As such, researchers should be alert to the possibility of <i>de novo</i> S gene mutations emerging in tissue-culture propagated virus strains.</p><p class="para" id="N65542">SARS-CoV-2 uses its spike (S) protein to enter target cells. Unlike other similar coronaviruses, the nascent S protein has a polybasic cleavage motif and is cleaved by the host protease. We have identified SARS-CoV-2 variants with mutations at the cleavage motif of S protein (S gene mutants) which undergo inefficient proteolytic cleavage, generate smaller plaques, and infect fewer cell lines. Notably, S gene mutants emerged rapidly through SARS-CoV-2 propagation in Vero cells. Since Vero cells are commonly used for SARS-CoV-2 propagation, it is a very real possibility that researchers have performed experiments, screened antivirals, and developed vaccines using SARS-CoV-2 S gene mutants without realizing.</p>]]></description>
            <pubDate><![CDATA[2021-01-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Signatures of host–pathogen evolutionary conflict reveal MISTR—A conserved <span style="text-decoration: underline">MI</span>tochondrial <span style="text-decoration: underline">ST</span>ress <span style="text-decoration: underline">R</span>esponse network]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765849145807-dc67c206-f18d-46f7-bcc4-dd175dfbf0c0/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pbio.3001045</link>
            <description><![CDATA[<p class="para" id="N65539">Host–pathogen conflicts leave genetic signatures in genes that are critical for host defense functions. Using these “molecular scars” as a guide to discover gene functions, we discovered a vertebrate-specific <span style="text-decoration: underline">MI</span>tochondrial <span style="text-decoration: underline">ST</span>ress <span style="text-decoration: underline">R</span>esponse (MISTR) circuit. MISTR proteins are associated with electron transport chain (ETC) factors and activated by stress signals such as interferon gamma (IFNγ) and hypoxia. Upon stress, ultraconserved microRNAs (miRNAs) down-regulate MISTR1(NDUFA4) followed by replacement with paralogs MItochondrial STress Response <span style="text-decoration: underline">A</span>nti<span style="text-decoration: underline">V</span>iral (MISTRAV) and/or MItochondrial STress Response <span style="text-decoration: underline">H</span>ypoxia (MISTRH). While cells lacking MISTR1(NDUFA4) are more sensitive to chemical and viral apoptotic triggers, cells lacking MISTRAV or expressing the squirrelpox virus-encoded vMISTRAV exhibit resistance to the same insults. Rapid evolution signatures across primate genomes for <i>MISTR1(NDUFA4)</i> and <i>MISTRAV</i> indicate recent and ongoing conflicts with pathogens. MISTR homologs are also found in plants, yeasts, a fish virus, and an algal virus indicating ancient origins and suggesting diverse means of altering mitochondrial function under stress. The discovery of MISTR circuitry highlights the use of evolution-guided studies to reveal fundamental biological processes.</p><p class="para" id="N65540">Host-pathogen conflicts leave genetic signatures in genes that are critical for host defense functions. This study uses these “molecular scars” as a guide to identify a vertebrate-specific mitochondrial stress response circuit that interacts with the electron transport chain and is activated by stress signals such as interferon-gamma and hypoxia.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Role and effects of zinc supplementation in HIV-infected patients with immunovirological discordance: A randomized, double blind, case control study]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765848525256-6e2e0843-6ad7-4aa2-a1b4-c8f0ab0065d3/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244823</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction</h3><p class="para" id="N65543">It has been estimated that between 15% and 18% of patients who start antiretroviral therapy (ART) do not achieve a successful immune recovery despite complete virological suppression. In the literature this phenomenom is known as poor immune recovery or immunovirological discordance (IVD). Zinc has an immunomodulatory role associated with T lymphocytes and its supplementation could enhance immune recovery.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Objective</h3><p class="para" id="N65549">To determine if zinc supplementation on IVD patients prevents immune failure after 12 months of supplementation. Secondary objectives were to determine serum zinc levels in HIV patients with and without IVD and the frequency of hypozincemia in discordant patients.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Method</h3><p class="para" id="N65555">We reviewed the historical record of patients under care at Arriarán Foundation. Following inclusion criteria were defined: 1) age ≥ 18 years, 2) standard ART (three effective drugs) for at least 18 months, 3) virologically suppressed for 12 months, 3) persistence of CD4 count ≤200 cells/mm<sup>3</sup> and/or increase ≤ 80 cells/mm<sup>3</sup> after one year of viral undetectability. A control group was assigned paired 1:1 by sex, age (± 2 years) that did achieved an increase of CD4&gt; 350 cells/ mm<sup>3</sup>. In both groups plasma zinc levels were determined. In a later phase, patients with IVD were randomized to receive zinc (15 mg daily) versus placebo. Patients were followed for 12 months with CD4 count, viral load and zinc levels determinations every 4–6 months.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Results</h3><p class="para" id="N65570">A total of 80 patients, 40 patients with IVD criteria and 40 controls were included. 92.5% were men, and age average was 47.5 years. The median baseline CD4 was 189 cells/mm<sup>3</sup> (71–258) in the cases vs. 552.5 cells/ mm<sup>3</sup> (317–400) in the control group with a median increase at the end of the study of 39 cell/mm<sup>3</sup> and 19 cell/mm<sup>3</sup> respectively. There was no difference in baseline plasma zinc levels between both groups (81.7 + 18.1 in cases versus 86.2 + 11.0 in controls). In the 40 patients with IVD, the median absolute increase in CD4 after annual zinc supplementation was 31.5 cells/mm<sup>3</sup> in the treated group versus 50 cells/mm<sup>3</sup> in the placebo group, this difference being statistically not significant (p = 0.382).</p></div><div class="section" id="sec005"><h3 class="BHead" id="nov000-5">Conclusions</h3><p class="para" id="N65594">Patients with IVD have plasma zinc levels similar to those who achieve adequate immune recovery. Zinc supplementation in IVD patients showed a statistically non-significant difference in in CD4 levels between cases and controls. The results warrant a comparative study with a larger number of patients.</p></div>]]></description>
            <pubDate><![CDATA[2021-01-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Pyrimidone inhibitors targeting Chikungunya Virus nsP3 macrodomain by fragment-based drug design]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765848274398-f200da2f-f1f0-49c0-ada0-bb4d70d6ef25/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245013</link>
            <description><![CDATA[<p class="para" id="N65539">The macrodomain of nsP3 (nsP3MD) is highly conserved among the alphaviruses and ADP-ribosylhydrolase activity of Chikungunya Virus (CHIKV) nsP3MD is critical for CHIKV viral replication and virulence. No small molecule drugs targeting CHIKV nsP3 have been identified to date. Here we report small fragments that bind to nsP3MD which were discovered by virtually screening a fragment library and X-ray crystallography. These identified fragments share a similar scaffold, 2-pyrimidone-4-carboxylic acid, and are specifically bound to the ADP-ribose binding site of nsP3MD. Among the fragments, 2-oxo-5,6-benzopyrimidine-4-carboxylic acid showed anti-CHIKV activity with an IC<sub>50</sub> of 23 μM. Our fragment-based drug discovery approach provides valuable information to further develop a specific and potent nsP3 inhibitor of CHIKV viral replication based on the 2-pyrimidone-4-carboxylic acid scaffold. <i>In silico</i> studies suggest this pyrimidone scaffold could also bind to the macrodomains of other alphaviruses and coronaviruses and thus, have potential pan-antiviral activity.</p>]]></description>
            <pubDate><![CDATA[2021-01-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Urinary leukotrienes and histamine in patients with varying severity of acute dengue]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765848135589-2032d7ce-20d4-4ebd-8a83-38a4308b5ec2/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245926</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Vascular leak is a hallmark of severe dengue, and high leukotriene levels have been observed in dengue mouse models, suggesting a role in disease pathogenesis. We sought to explore their role in acute dengue, by assessing levels of urinary LTE4 and urinary histamine in patients with varying severity of acute dengue.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">Urinary LTE4<sub>,</sub> histamine and creatinine were measured by a quantitative ELISA, in healthy individuals (n = 19), patients with dengue fever (DF = 72) and dengue haemorrhagic fever DHF (n = 48). The kinetics of LTE4 and histamine and diurnal variations were assessed in a subset of patients.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65558">Urinary LTE4 levels were significantly higher (p = 0.004) in patients who proceed to develop DHF when compared to patients with DF during early illness (≤ 4 days) and during the critical phase (p = 0.02), which continued to rise in patients who developed DHF during the course of illness. However, LTE4 is unlikely to be a good biomarker as ROCs gave an AUC value of 0.67 (95% CI 0.57 and 0.76), which was nevertheless significant (p = 0.002). Urinary LTE4 levels did not associate with the degree of viraemia, infecting virus serotype and was not different in those with primary vs secondary dengue. Urinary histamine levels were significantly high in patients with acute dengue although no difference was observed between patients with DF and DHF and again did not associate with the viraemia. Interestingly, LTE4, histamine and the viral loads showed a marked diurnal variation in both patients with DF and DHF.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65564">Our data suggest that LTE4 could play a role in disease pathogenesis and since there are safe and effective cysteinyl leukotriene receptor blockers, it would be important to assess their efficacy in reducing dengue disease severity.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Molecular detection of Indian Ocean Lineage Chikungunya virus RNA in field collected <i>Culex quinquefasciatus</i> Say from Bangkok, Thailand but no evidence of virus replication]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765847984572-83ef7983-a79c-47b9-bd0a-9350cde26bea/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246026</link>
            <description><![CDATA[<p class="para" id="N65539">Following an outbreak of chikungunya virus (CHIKV) infections in Thailand in 2019, numerous cases of CHIKV infection have been diagnosed in Bangkok, the capital of the country. In our previous investigation of the vectors for disease transmission, we found natural infection of CHIKV in both male and female <i>Aedes aegypti</i> mosquitoes collected from the outbreak areas in Bangkok. Some reports mentioned the detection of CHIKV in <i>Culex</i> mosquitoes. In Thailand, the <i>Culex quinquefasciatus</i> Say mosquito is a common species found in urban and rural settings that coexists with <i>Ae</i>. <i>aegypti</i>. However, the role of <i>Cx</i>. <i>quinquefasciatus</i> mosquitoes in the spread of the Indian Ocean Lineage (IOL) of CHIKV in Thailand has never been investigated. In this study, <i>Cx</i>. <i>quinquefasciatus</i> were collected (16 males and 27 females) from an outbreak area in Bangkok. Eight of the 27 in field-caught female <i>Cx</i>. <i>quinquefasciatus</i> were positive for IOL CHIKV RNA, and 99–100% identity and full 100% coverage of sequences similar to CHIKV isolated from female <i>Ae</i>. <i>aegypti</i> in Bangkok, Thailand, whereas viral RNA was not detected in male samples using nested-RT-PCR. To determine whether CHIKV is able to replicate in <i>Cx</i>. <i>quinquefasciatus</i>, the laboratory strain of <i>Cx</i>. <i>quinquefasciatus</i> was allowed to feed on blood containing IOL CHIKV isolated from patient serum. The nested-RT-PCR, virus isolation, and immunofluorescence assay (IFA) were performed for CHIKV detection and replication. The results showed that CHIKV RNA was detected in <i>Cx</i>. <i>quinquefasciatus</i> until day 4 post infection. CHIKV did not produce any remarkable signs of infection, dissemination, or transmission in <i>Cx</i>. <i>quinquefasciatus</i>, and cytopathic effect (CPE) was not observed in C6/36 cells when infected with supernatant obtained from <i>Cx</i>. <i>quinquefasciatus</i> at days 7, 10, 14, and 21 post infection when compared to <i>Ae</i>. <i>aegypti</i>. The data from this study infer that CHIKV may be detected in <i>Cx</i>. <i>quinquefasciatus</i> but that the mosquito is not able to transmit CHIKV in Thailand.</p>]]></description>
            <pubDate><![CDATA[2021-01-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Infection of porcine small intestinal enteroids with human and pig rotavirus A strains reveals contrasting roles for histo-blood group antigens and terminal sialic acids]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765846871147-b11de5da-b57b-41ee-9224-33e357ddfb12/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009237</link>
            <description><![CDATA[<p class="para" id="N65539">Rotaviruses (RVs) are a leading cause of acute viral gastroenteritis in young children and livestock worldwide. Growing evidence suggests that host cellular glycans, such as histo-blood group antigens (HBGAs) and sialic acids (SA), are recognized by the RV surface protein VP4. However, a mechanistic understanding of these interactions and their effects on RV infection and pathogenesis is lacking. Here, we established a <span style="text-decoration: underline"><i>p</i></span><i>orcine</i> crypt-derived <i>3D</i>
<span style="text-decoration: underline"><i>i</i></span><i>ntestinal</i>
<span style="text-decoration: underline"><i>e</i></span><i>nteroids (PIEs) culture</i> system which contains all intestinal epithelial cells identified in vivo and represents a unique physiologically functional model to study RV-glycan interactions in vitro. PIEs expressing different HBGAs (A+, H+, and A+/H+) were established and isolation, propagation, differentiation and RV infection conditions were optimized. Differentiated PIEs were infected with human RV (HRV) G1P[8] Wa, porcine RV (PRV) G9P[13], PRV Gottfried G4P[6] or PRV OSU G5P[7] virulent and attenuated strains and virus replication was measured by qRT-PCR. Our results indicated that virulent HRV G1P[8] Wa replicated to the highest titers in A<sup>+</sup> PIEs, while a distinct trend was observed for PRV G9P[13] or G5P[7] with highest titers in H<sup>+</sup> PIEs. Attenuated Wa and Gottfried strains replicated poorly in PIEs while the replication of attenuated G9P[13] and OSU strains in PIEs was relatively efficient. However, the replication of all 4 attenuate strains was less affected by the PIE HBGA phenotypes. HBGA synthesis inhibitor 2-F-Peracetyl-Fucose (2F) treatment demonstrated that HBGAs are essential for G1P[8] Wa replication; however, they may only serve as a cofactor for PRVs G9P[13] and OSU G5P[7]. Interestingly, contrasting outcomes were observed following sialidase treatment which significantly enhanced G9P[13] replication, but inhibited the growth of G5P[7]. These observations suggest that some additional receptors recognized by G9P[13] become unmasked after removal of terminal SA. Overall, our results confirm that differential HBGAs-RV and SA-RV interactions determine replication efficacy of virulent group A RVs in PIEs. Consequently, targeting individual glycans for development of therapeutics may not yield uniform results for various RV strains.</p><p class="para" id="N65542">Cell surface glycans, including histo-blood group antigens (HBGA) and sialic acids (SAs), have been shown to serve as receptors/attachment factors for many pathogens including RVs. However, how those glycans affect RV replication remains largely unknown due the lack of reliable in vitro models. To solve this problem, we established a 3D porcine intestinal enteroid (PIE) model that recapitulates the complex intestinal morphology better than conventional cell lines. By utilizing PIEs expressing different types of HBGAs, we found that several RV strains including Wa G1P[8], OSU G5P[7] and G9P[13] show preference for certain HBGA types. Interestingly, only Wa replication was reduced when HBGAs synthesis was inhibited, while that of OSU and G9P[13] was only marginally affected, which indicates that they may utilize alternative attachment factors for infection. Sialidase treatment strongly inhibited the growth of OSU, while G9P[13] replication was significantly enhanced. These findings suggest that SAs play contrasting roles in the infection of PRV OSU and G9P[13] strains. Overall, our studies demonstrate that PIEs can serve as a model to study pathogen-glycan interactions and suggest that genetically distinct RVs have evolved diverse mechanisms of cell attachment and/or entry.</p>]]></description>
            <pubDate><![CDATA[2021-01-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Bacterial nucleomodulins: A coevolutionary adaptation to the eukaryotic command center]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765846645140-398446c9-5a7c-4558-841d-8f71c80a9b8e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009184</link>
            <description><![CDATA[<p class="para" id="N65539">Through long-term interactions with their hosts, bacterial pathogens have evolved unique arsenals of effector proteins that interact with specific host targets and reprogram the host cell into a permissive niche for pathogen proliferation. The targeting of effector proteins into the host cell nucleus for modulation of nuclear processes is an emerging theme among bacterial pathogens. These unique pathogen effector proteins have been termed in recent years as “nucleomodulins.” The first nucleomodulins were discovered in the phytopathogens <i>Agrobacterium</i> and <i>Xanthomonas</i>, where their nucleomodulins functioned as eukaryotic transcription factors or integrated themselves into host cell DNA to promote tumor induction, respectively. Numerous nucleomodulins were recently identified in mammalian pathogens. Bacterial nucleomodulins are an emerging family of pathogen effector proteins that evolved to target specific components of the host cell command center through various mechanisms. These mechanisms include: chromatin dynamics, histone modification, DNA methylation, RNA splicing, DNA replication, cell cycle, and cell signaling pathways. Nucleomodulins may induce short- or long-term epigenetic modifications of the host cell. In this extensive review, we discuss the current knowledge of nucleomodulins from plant and mammalian pathogens. While many nucleomodulins are already identified, continued research is instrumental in understanding their mechanisms of action and the role they play during the progression of pathogenesis. The continued study of nucleomodulins will enhance our knowledge of their effects on nuclear chromatin dynamics, protein homeostasis, transcriptional landscapes, and the overall host cell epigenome.</p><p class="para" id="N65542">Bacterial pathogens have evolved a repertoire of diverse effector proteins that are secreted or injected into the host cell cytosol, reprogramming the host cell into a more favorable environment. Many of these pathogens possess nuclear-targeted effector proteins (nucleomodulins) that modulate host cell gene expression without altering the cellular genomic sequence. By utilizing nucleomodulins obtained through evolution, pathogens can manipulate host cell gene regulation and alter host immune response to infection. Here, we provide a comprehensive review discussing a diverse array of nucleomodulins that target and modulate the host genome through interference with chromatin dynamics, histone modifications, regulation of transcription, interference of the cell cycle, and regulation of cell signaling pathways for immune response. This unique targeting of host cell gene regulation through bacterial nucleomodulins is an emerging theme and likely the tip of an iceberg regarding host–pathogen interactions at the level of the host command center.</p>]]></description>
            <pubDate><![CDATA[2021-01-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Multiple roles of PP2A binding motif in hepatitis B virus core linker and PP2A in regulating core phosphorylation state and viral replication]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765842132878-deb5682b-de18-4d16-9ce0-ae8ac8404d05/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009230</link>
            <description><![CDATA[<p class="para" id="N65539">Hepatitis B virus (HBV) capsid or core protein (HBc) contains an N-terminal domain (NTD) and a C-terminal domain (CTD) connected by a short linker peptide. HBc plays a critical role in virtually every step of viral replication, which is further modulated by dynamic phosphorylation and dephosphorylation of its CTD. While several cellular kinases have been identified that mediate HBc CTD phosphorylation, there is little information on the cellular phosphatases that mediate CTD dephosphorylation. Herein, a consensus binding motif for the protein phosphatase 2A (PP2A) regulatory subunit B56 was recognized within the HBc linker peptide. Mutations within this motif designed to block or enhance B56 binding showed pleiotropic effects on CTD phosphorylation state as well as on viral RNA packaging, reverse transcription, and virion secretion. Furthermore, linker mutations affected the HBV nuclear episome (the covalently closed circular or CCC DNA) differentially during intracellular amplification vs. infection. The effects of linker mutations on CTD phosphorylation state varied with different phosphorylation sites and were only partially consistent with the linker motif serving to recruit PP2A-B56, specifically, to dephosphorylate CTD, suggesting that multiple phosphatases and/or kinases may be recruited to modulate CTD (de)phosphorylation. Furthermore, pharmacological inhibition of PP2A could decrease HBc CTD dephosphorylation and increase the nuclear HBV episome. These results thus strongly implicate the HBc linker in recruiting PP2A and other host factors to regulate multiple stages of HBV replication.</p><p class="para" id="N65542">Hepatitis B virus (HBV) causes acute and chronic viral hepatitis, liver fibrosis, cirrhosis and cancer. The dynamic phosphorylation and dephosphorylation of the viral capsid protein (HBc), which are controlled by host cell protein kinases and phosphatases, play a critical role in regulating multiple stages of HBV replication. While a number of cellular kinases have been identified that mediate HBc phosphorylation, there is little information on cellular phosphatases that mediate its dephosphorylation. Herein we have identified a consensus binding motif in HBc for one of the major cellular phosphatases, the protein phosphatase 2A (PP2A). Genetic analysis of this motif revealed that it played multiple roles in regulating CTD phosphorylation state, as well as viral RNA packaging, reverse transcription, virion secretion, and formation of the nuclear HBV episome responsible for viral persistence. Furthermore, pharmacological inhibition of PP2A decreased HBc dephosphorylation and increased the nuclear episome, further supporting a role of PP2A in HBc dephosphorylation and HBV persistence. These results thus suggest that HBc recruits PP2A, among other host factors, to regulate HBc phosphorylation and dephosphorylation dynamics and HBV replication and persistence.</p>]]></description>
            <pubDate><![CDATA[2021-01-25T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Economic evaluation of Health Extension Program packages in Ethiopia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765841779245-6603b2a9-e1e6-4b38-af71-313b43674438/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246207</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Ethiopia launched the Health Extension Program (HEP) in 2004, aimed at ensuring equitable community-level healthcare services through Health Extension Workers. Despite the program’s being a flagship initiative, there is limited evidence on whether investment in the program represents good value for money. This study assessed the cost and cost-effectiveness of HEP interventions to inform policy decisions for resource allocation and priority setting in Ethiopia.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">Twenty-one health care interventions were selected under the hygiene and sanitation, family health services, and disease prevention and control sub-domains. The ingredient bottom-up and top-down costing method was employed. Cost and cost-effectiveness were assessed from the provider perspective. Health outcomes were measured using life years gained (LYG). Incremental cost per LYG in relation to the gross domestic product (GDP) per capita of Ethiopia (US$852.80) was used to ascertain the cost-effectiveness. All costs were collected in Ethiopian birr and converted to United States dollars (US$) using the average exchange rate for 2018 (US$1 = 27.67 birr). Both costs and health outcomes were discounted by 3%.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Result</h3><p class="para" id="N65555">The average unit cost of providing selected hygiene and sanitation, family health, and disease prevention and control services with the HEP was US$0.70, US$4.90, and US$7.40, respectively. The major cost driver was drugs and supplies, accounting for 53% and 68%, respectively, of the total cost. The average annual cost of delivering all the selected interventions was US$9,897. All interventions fall within 1 times GDP per capita per LYG, indicating that they are very cost-effective (ranges: US$22–$295 per LYG). Overall, the HEP is cost-effective by investing US$77.40 for every LYG.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">The unit cost estimates of HEP interventions are crucial for priority-setting, resource mobilization, and program planning. This study found that the program is very cost-effective in delivering community health services.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765841480554-31f33db6-24b7-4813-a434-8291c2a6f5cc/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009185</link>
            <description><![CDATA[<p class="para" id="N65539">HIV-1 envelope (Env) is a trimer of gp120-gp41 heterodimers, synthesized from a precursor gp160 that contains an ER-targeting signal peptide (SP) at its amino-terminus. Each trimer is swathed by ~90 N-linked glycans, comprising complex-type and oligomannose-type glycans, which play an important role in determining virus sensitivity to neutralizing antibodies. We previously examined the effects of single point SP mutations on Env properties and functions. Here, we aimed to understand the impact of the SP diversity on glycosylation of virus-derived Env and virus neutralization by swapping SPs. Analyses of site-specific glycans revealed that SP swapping altered Env glycan content and occupancy on multiple N-linked glycosites, including conserved N156 and N160 glycans in the V1V2 region at the Env trimer apex and N88 at the trimer base. Virus neutralization was also affected, especially by antibodies against V1V2, V3, and gp41. Likewise, SP swaps affected the recognition of soluble and cell-associated Env by antibodies targeting distinct V1V2 configurations, V3 crown, and gp41 epitopes. These data highlight the contribution of SP sequence diversity in shaping the Env glycan content and its impact on the configuration and accessibility of V1V2 and other Env epitopes.</p><p class="para" id="N65542">HIV-1 Env glycoprotein is produced by a precursor gp160 that has a signal peptide at its N-terminus. The SP is highly diverse among the HIV-1 isolates. This study presents site-specific analyses of N-linked glycosylation on HIV-1 envelope glycoproteins from infectious viruses produced with different envelope signal peptides. We show that signal peptide swapping alters the envelope glycan shield, including the conserved N156 and N160 glycans located in the V1V2 region on the trimer apex, to impact Env recognition and virus neutralization by antibodies. The data offer crucial insights into the role of signal peptide in the interplay between HIV-1 and antibodies and its potential utility to control Env glycosylation in the development of Env-based HIV-1 vaccine.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765841279634-d02db2be-e360-4666-8faa-fd1ed1bc3168/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245479</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background/Aims</h3><p class="para" id="N65543">Undetectable HCV RNA 12 weeks after the end of treatment (SVR12) has been the valid efficacy endpoint in the era of direct-acting antivirals (DAAs). Its concordance with SVR4 and SVR24 and long-term durability is unknown in Taiwanese chronic hepatitis C (CHC) patients.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A total of 1080 CHC patients who received all-oral DAAs and an achieved end-of-treatment virological response (EOTVR), defined as undetectable HCV RNA at the end of therapy, were consecutively enrolled. HCV RNA was monitored 4, 12, and 24 weeks after EOT. Patients who achieved SVR24, defined as undetectable HCV RNA 24 weeks after EOT, were followed annually for assessing SVR durability.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Eleven (1.02%) patients experienced HCV RNA reappearance after EOT. The most frequent timing of RNA reappearance was observed at SVR4 (n = 7), followed by SVR12 (n = 3) and SVR 24 (n = 1). The positive predictive value (PPV) and negative predictive value (NPV) of SVR4 in predicting SVR12 were 99.7% and 100%, respectively, whereas the PPV and NPV of SVR12 in predicting SVR24 were 99.9% and 100%, respectively. Pyrosequencing confirmed delayed relapse rather than reinfection for the patient who had detectable HCV RNA at SVR24. Among 978 patients who achieved SVR24, after a median follow-up period of 17.3±8.2 months, the SVR durability is 100% up to a 4-year follow-up.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">Achievement of SVR12 provides excellent durability of HCV seroclearance after DAA therapy. On-demand HCV RNA beyond SVR12 should be recommended for patients with unexplainable abnormal liver function or high-risk behaviors.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765841128890-77a8c895-6fa5-4390-9bfa-a0fa1d02751e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0243150</link>
            <description><![CDATA[<p class="para" id="N65539">Patients with autoimmune disorders (AD) have altered cancer risks compared to the general population. Systemic lupus erythematosus and multiple sclerosis lead to a heightened risk for hematological malignancies and decreased risk for breast, ovarian, and prostate malignancies. Often patients with autoimmune disease have dysregulated antiviral immune responses, including against oncogenic viruses. To uncover the relationship between viral incidence and cancer risk in the context of autoimmune disease, we extracted electronic health records (EHR) from Vanderbilt University. ICD-9/10 codes and laboratory values were collected for hematological, lung, anal-vaginal, thyroid, hepatobiliary, bladder, prostate, and breast cancers; and viruses including Epstein Barr virus (EBV), Human papilloma virus (HPV), and Hepatitis A/B/C (Hep). Only viral infections that led to a physician visit or laboratory test were entered into the EMR; therefore, only clinically relevant cases were noted and considered positive in this study. The relationship between virus infection and cancer in an SLE cohort (SLE-cases n = 2,313, and SLE-controls n = 5,702) and an MS cohort (MS-case n = 7,277, MS-control n = 7,277) was examined by multilinear logistic regression. Viral infection was strongly associated with increased risk for cancer overall. SLE and MS patients were more susceptible to all viral infections. MS patients trended toward increased risk for cancers overall, while decreased risk for hormone-based cancers in SLE patients non-significantly reduced their risk for overall cancer. Both SLE and MS patients had increased clinically relevant EBV infection, which was associated with risk for hematological cancers. Preventing viral infections by vaccination may be especially helpful in controlling risk for cancer in SLE and MS patients.</p>]]></description>
            <pubDate><![CDATA[2021-01-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765841097710-22d9f90d-5386-4e3c-be97-5351cd2f4003/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246140</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">While the proportion of HIV-positive children (under 15 years) enrolled on antiretroviral therapy (ART) has increased in recent years, up to 60% of children started on ART do not achieve virological suppression. We set out to determine the factors associated with virological non-suppression among children living with HIV receiving ART at a peri-urban HIV care clinic in Kampala, Uganda.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Method</h3><p class="para" id="N65549">This was a retrospective cohort study conducted at the pediatric HIV/AIDS clinic at the Joint Clinical Research Centre (JCRC) in Kampala, Uganda. Three hundred (300) HIV-positive children (0–14 years) were randomly selected from existing medical records and data on children’s socio-demographic and clinical characteristics (age at ART initiation, WHO clinical staging, and ART-induced side effects) were abstracted using a data abstraction form. Virological non-suppression was defined as a viral load ≥1000 copies/Ml of blood after six months of ART initiation. Incident rate ratios (IRRs) were determined as a measure of association between virological non-suppression and child/patient characteristics. The IRRs were obtained via a modified Poisson regression with corresponding 95% confidence intervals (95%CI). All analyses were done using statistical package, Stata version 15.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">The overall non-suppression rate among HIV-positive children on ART was 23%. Being at WHO clinical stage 4 at ART initiation [adj. IRR 2.74; 95%CI: 1.63, 4.61] and ART-induced side effects [adj. IRR 1.77; 95%CI: 1.06, 2.97] were significantly associated with non-suppression. Older age at ART initiation (age 5–9 years: [adj. IRR 0.42; 95%CI: 0.28, 0.65]; age 10–14 years: [adj. IRR 0.34; 95%CI: 0.18, 0.64] was less likely to be associated with virological non-suppression.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">Nearly a quarter of HIV-positive children on ART had a non-suppressed viral load after six months of treatment. Being at WHO clinical stage 4 at ART initiation and ART-induced side effects were significantly associated with virological non-suppression while older age at ART initiation was protective. Our findings suggest a need for age-specific interventions, particularly those targeting children below five years of age, to improve virological suppression among HIV-positive children receiving ART in this setting.</p></div>]]></description>
            <pubDate><![CDATA[2021-01-27T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765841082027-170cd714-2548-416a-9cec-c971775dd47c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009215</link>
            <description><![CDATA[<p class="para" id="N65539">Poxvirus systems have been extensively used as vaccine vectors. Herein a RNA-Seq analysis of intramuscular injection sites provided detailed insights into host innate immune responses, as well as expression of vector and recombinant immunogen genes, after vaccination with a new multiplication defective, vaccinia-based vector, Sementis Copenhagen Vector. Chikungunya and Zika virus immunogen mRNA and protein expression was associated with necrosing skeletal muscle cells surrounded by mixed cellular infiltrates. The multiple adjuvant signatures at 12 hours post-vaccination were dominated by TLR3, 4 and 9, STING, MAVS, PKR and the inflammasome. Th1 cytokine signatures were dominated by IFNγ, TNF and IL1β, and chemokine signatures by CCL5 and CXCL12. Multiple signatures associated with dendritic cell stimulation were evident. By day seven, vaccine transcripts were absent, and cell death, neutrophil, macrophage and inflammation annotations had abated. No compelling arthritis signatures were identified. Such injection site vaccinology approaches should inform refinements in poxvirus-based vector design.</p><p class="para" id="N65542">Poxvirus vector systems have been widely developed for vaccine applications. Despite considerable progress, so far only one recombinant poxvirus vectored vaccine has to date been licensed for human use, with ongoing efforts seeking to enhance immunogenicity whilst minimizing reactogenicity. The latter two characteristics are often determined by early post-vaccination events at the injection site. We therefore undertook an injection site vaccinology approach to analyzing gene expression at the vaccination site after intramuscular inoculation with a recombinant, multiplication defective, vaccinia-based vaccine. This provided detailed insights into <i>inter alia</i> expression of vector-encoded immunoregulatory genes, as well as host innate and adaptive immune responses. We propose that such injection site vaccinology can inform rational vaccine vector design, and we discuss how the information and approach elucidated herein might be used to improve immunogenicity and limit reactogenicity of poxvirus-based vaccine vector systems.</p>]]></description>
            <pubDate><![CDATA[2021-01-13T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Three-dimensional chromatin in infectious disease—A role for gene regulation and pathogenicity?]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765840960569-6618dd97-d057-488a-af5a-ac6cf5253e32/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009207</link>
            <description><![CDATA[<p class="para" id="N65539">The recent Coronavirus Disease 2019 pandemic has once again reminded us the importance of understanding infectious diseases. One important but understudied area in infectious disease research is the role of nuclear architecture or the physical arrangement of the genome in the nucleus in controlling gene regulation and pathogenicity. Recent advances in research methods, such as Genome-wide chromosome conformation capture using high-throughput sequencing (Hi-C), have allowed for easier analysis of nuclear architecture and chromosomal reorganization in both the infectious disease agents themselves as well as in their host cells. This review will discuss broadly on what is known about nuclear architecture in infectious disease, with an emphasis on chromosomal reorganization, and briefly discuss what steps are required next in the field.</p><p class="para" id="N65542">In this review, we examine the current state of nuclear architecture in infectious diseases with an emphasis on chromosomal reorganization. Nuclear architecture plays an important role in regulation of transcription for several pathogens, as well as inflammatory responses in their host. Recent advances in technologies such as Hi-C have allowed in-depth studies of chromosomal reorganization during infectious disease development and provided insights into transcription mechanisms and pathogenicity. In addition, it has been demonstrated that pathogens can also affect/utilize the hosts nuclear architecture. These areas are heavily understudied in pathogens, and we hope this review will provide a comprehensive review on the current state of nuclear architecture in infectious diseases and provide an additional avenue for eradication efforts.</p>]]></description>
            <pubDate><![CDATA[2021-02-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Dissecting genetic and sex-specific sources of host heterogeneity in pathogen shedding and spread]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765840660692-f2c5e73b-54ff-4b6a-b3c2-b386722cee56/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009196</link>
            <description><![CDATA[<p class="para" id="N65539">Host heterogeneity in disease transmission is widespread but precisely how different host traits drive this heterogeneity remains poorly understood. Part of the difficulty in linking individual variation to population-scale outcomes is that individual hosts can differ on multiple behavioral, physiological and immunological axes, which will together impact their transmission potential. Moreover, we lack well-characterized, empirical systems that enable the quantification of individual variation in key host traits, while also characterizing genetic or sex-based sources of such variation. Here we used <i>Drosophila melanogaster</i> and Drosophila C Virus as a host-pathogen model system to dissect the genetic and sex-specific sources of variation in multiple host traits that are central to pathogen transmission. Our findings show complex interactions between genetic background, sex, and female mating status accounting for a substantial proportion of variance in lifespan following infection, viral load, virus shedding, and viral load at death. Two notable findings include the interaction between genetic background and sex accounting for nearly 20% of the variance in viral load, and genetic background alone accounting for ~10% of the variance in viral shedding and in lifespan following infection. To understand how variation in these traits could generate heterogeneity in individual pathogen transmission potential, we combined measures of lifespan following infection, virus shedding, and previously published data on fly social aggregation. We found that the interaction between genetic background and sex explained ~12% of the variance in individual transmission potential. Our results highlight the importance of characterising the sources of variation in multiple host traits to understand the drivers of heterogeneity in disease transmission.</p><p class="para" id="N65542">Host heterogeneity in pathogen transmission presents a major hurdle to predicting and minimizing the spread of infectious agents. Part of the difficulty in linking individual variation to epidemic outcomes is that individual hosts can vary on multiple behavioral, physiological, immunological axes that may affect their transmission potential. Moreover, we lack well-characterized empirical systems that allow to measure multiple facets of individual variation in pathogen transmission. In this work, we capitalize on the strengths of the fruit fly Drosophila as an established and powerful model system for genetics, behavior, and immunity. We provide individual-level data on several axes of infection and test how each of these components experiences variation arising from host genetic background, sex, and mating status. We are therefore able to identify the sources of host heterogeneity (i.e., genetic background, sex) and the specific host traits (social aggregation, pathogen shedding, infection duration) that are most important in determining disease dynamics. We find that a substantial proportion of between-individual heterogeneity in disease transmission is explained by genotype-by-sex interactions affecting the likelihood that individuals will shed virus, but also how much they are likely to shed.</p>]]></description>
            <pubDate><![CDATA[2021-01-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Synergistic effect and ultrastructural changes in <i>Trypanosoma cruzi</i> caused by isoobtusilactone A in short exposure of time]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765839915281-eda84c13-b098-4bdf-bf26-9438c1408bc8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245882</link>
            <description><![CDATA[<p class="para" id="N65539">Butanolides have shown a variety of biological effects including anti-inflammatory, antibacterial, and antiprotozoal effects against certain strains of <i>Trypanosoma cruzi</i>. Considering the lack of an effective drug to treat <i>T</i>. <i>cruzi</i> infections and the prominent results obtained in literature with this class of lactones, we investigated the anti-<i>T</i>. <i>cruzi</i> activity of five butanolides isolated from two species of Lauraceae, <i>Aiouea trinervis</i> and <i>Mezilaurus crassiramea</i>. Initially, the activity of these compounds was evaluated on epimastigote forms of the parasite, after a treatment period of 4 h, followed by testing on amastigotes, trypomastigotes, and mammalian cells. Next, the synergistic effect of active butanolides against amastigotes was evaluated. Further, metacyclogenesis inhibition and infectivity assays were performed for the most active compound, followed by ultrastructural analysis of the treated amastigotes and trypomastigotes. Among the five butanolides studied, majoranolide and isoobtusilactone A were active against all forms of the parasite, with good selectivity indexes in Vero cells. Both butanolides were more active than the control drug against trypomastigote and epimastigote forms and also had a synergic effect on amastigotes. The most active compound, isoobtusilactone A, which showed activity against all tested strains inhibited metacyclogenesis and infection of new host cells. In addition, ultrastructural analysis revealed that this butanolide caused extensive damage to the mitochondria of both amastigotes and trypomastigotes, resulting in severe morphological changes in the infective forms of the parasite. Altogether, our results highlight the potential of butanolides against the etiologic agent of Chagas disease and the relevance of isoobtusilactone A as a strong anti-<i>T</i>. <i>cruzi</i> drug, affecting different events of the life cycle and all evolutionary forms of parasite after a short period of exposure.</p>]]></description>
            <pubDate><![CDATA[2021-01-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Converting the maybes: Crucial for a successful COVID-19 vaccination strategy]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765839747472-a86af230-df98-49b5-9ef5-ecd136e704dc/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245907</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Broad community acceptance of a COVID-19 vaccination will be critical for effectively halting the spread of the virus. In this study, we focus on factors that differentiate those who are undecided from those who are either willing or unwilling to accept a prospective COVID-19 vaccine.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">An online survey in May 2020 assessed Australian adults’ willingness to receive a COVID-19 vaccine (yes, maybe, no). A multinomial logistical regression of responses (N = 1,313) was used to identify correlates of vaccine willingness between the three groups.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">65% were willing to vaccinate, with 27% being in the ‘maybe’ category. Respondents were more likely to be in the ‘maybe’ than the ‘yes’ group when they perceived COVID-19 to be less severe, had less trust in science, were less willing to vaccinate for influenza, and were female. They were more likely to be in the ‘maybe’ than ‘no’ group when they perceived COVID-19 as severe, and less likely to be a hoax, had more trust in science, and greater willingness to vaccinate for influenza. A repeat of the survey in November 2020 with a subset of participants found fewer of them saying yes to the vaccine (56%) and more saying maybe (31%).</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65561">The effectiveness of any COVID-19 vaccine rollout will be reliant on maximizing uptake. The significant number of people who remain undecided about whether or not to get a COVID-19 vaccine, despite the ongoing devastating consequences of the virus for individuals, communities, and economies, is concerning. Our findings aid current research seeking to inform policy regarding how to convince the undecided to vaccinate.</p></div>]]></description>
            <pubDate><![CDATA[2021-01-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[<i>Toxoplasma gondii</i> PPM3C, a secreted protein phosphatase, affects parasitophorous vacuole effector export]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765838972416-c2781f81-061c-44ce-a23c-d6a6a5a2f20c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1008771</link>
            <description><![CDATA[<p class="para" id="N65539">The intracellular parasite <i>Toxoplasma gondii</i> infects a large proportion of humans worldwide and can cause adverse complications in the settings of immune-compromise and pregnancy. <i>T</i>. <i>gondii</i> thrives within many different cell types due in part to its residence within a specialized and heavily modified compartment in which the parasite divides, termed the parasitophorous vacuole. Within this vacuole, numerous proteins optimize intracellular survival following their secretion by the parasite. We investigated the contribution of one of these proteins, TgPPM3C, predicted to contain a PP2C-class serine/threonine phosphatase domain and previously shown to interact with the protein MYR1, an essential component of a putative vacuolar translocon that mediates effector export into the host cell. Parasites lacking the TgPPM3C gene exhibit a minor growth defect <i>in vitro</i>, are avirulent during acute infection in mice, and form fewer cysts in mouse brain during chronic infection. Phosphoproteomic assessment of TgPPM3C deleted parasite cultures demonstrated alterations in the phosphorylation status of many secreted vacuolar proteins including two exported effector proteins, GRA16 and GRA28, as well as MYR1. Parasites lacking TgPPM3C are defective in GRA16 and GRA28 export, but not in the export of other MYR1-dependant effectors. Phosphomimetic mutation of two GRA16 serine residues results in export defects, suggesting that de-phosphorylation is a critical step in the process of GRA16 export. These findings provide another example of the emerging role of phosphatases in regulating the complex environment of the <i>T</i>. <i>gondii</i> parasitophorous vacuole and influencing the export of specific effector proteins from the vacuolar lumen into the host cell.</p><p class="para" id="N65542">The flexible life cycle of the intracellular parasite <i>Toxoplasma gondii</i> allows it to infect many different types of warm-blooded hosts, as well as diverse cell types once inside the host organism. This formidable achievement is partly mediated by the establishment of a unique compartment following host cell invasion, termed the parasitophorous vacuole. While advancements have been made in cataloguing <i>Toxoplasma</i> secreted proteins that reside within this vacuole, the specific functions and contributions of many of these secreted parasite “tools” remain elusive. Here, we assessed the contribution of a parasite vacuolar protein called TgPPM3C, predicted to function as an enzyme that dephosphorylates other proteins. We found that deleting the TgPPM3C gene in the parasite results in a profound virulence defect during infection in mice, likely due to the dysregulated phosphorylation status of many vacuolar proteins detected by phosphoproteomic analysis of TgPPM3C-deleted parasites. We found that the phosphorylation status of one such protein, GRA16, influences its ability to cross the parasitophorous vacuole membrane and enter the host cell, where it is known to induce host transcriptional changes that benefit parasite growth. These findings illustrate the emerging role of <i>Toxoplasma</i> vacuolar phosphatases in regulating host-parasite interactions during infection.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Relevance of oxidative stress in inhibition of eIF2 alpha phosphorylation and stress granules formation during Usutu virus infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765838793904-bacda01c-8933-48a4-935e-8e40cc7e7cef/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0009072</link>
            <description><![CDATA[<p class="para" id="N65539">Usutu virus (USUV) is an African mosquito-borne flavivirus closely related to West Nile, Japanese encephalitis, Zika, and dengue viruses. USUV emerged in 1996 in Europe, where quickly spread across the continent causing a considerable number of bird deaths and varied neurological disorders in humans, including encephalitis, meningoencephalitis, or facial paralysis, thus warning about USUV as a potential health threat. USUV replication takes place on the endoplasmic reticulum (ER) of infected cells, inducing ER stress and resulting in the activation of stress-related cellular pathways collectively known as the integrated stress response (ISR). The alpha subunit of the eukaryotic initiation factor eIF2 (eIF2α), the core factor in this pathway, is phosphorylated by stress activated kinases: protein kinase R (PKR), PKR-like endoplasmic reticulum kinase (PERK), heme-regulated inhibitor kinase (HRI), and general control non-repressed 2 kinase (GCN2). Its phosphorylation results, among others, in the downstream inhibition of translation with accumulation of discrete foci in the cytoplasm termed stress granules (SGs). Our results indicated that USUV infection evades cellular stress response impairing eIF2α phosphorylation and SGs assembly induced by treatment with the HRI activator ArsNa. This protective effect was related with oxidative stress responses in USUV-infected cells. Overall, these results provide new insights into the complex connections between the stress response and flavivirus infection in order to maintain an adequate cellular environment for viral replication.</p><p class="para" id="N65542">Usutu virus (USUV) infection impairs eIF2α phosphorylation and SGs assembly, in an oxidative stress related manner, as a mechanism to evade cellular stress response. Our results provide new insights into the complex connections between the stress response and USUV infection to maintain a better cellular environment for viral replication.</p>]]></description>
            <pubDate><![CDATA[2021-01-25T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A comparison of medication adherence and viral suppression in antiretroviral treatment-naïve patients with HIV/AIDS depending on the drug formulary]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765838611684-169e1c72-ae0e-4745-b037-d63a518f4d17/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245185</link>
            <description><![CDATA[<p class="para" id="N65539">Antiretroviral treatment (ART) adherence is highlighted in management of patients living with human immunodeficiency virus. In South Korea, ART medication research has rarely been conducted due to the low economic burden associated with government-funded treatment. This cross-sectional study aimed to compare the pill burden impact between ART regimen compliance and HIV-RNA viral load suppression. Data were collected from 2008 to 2016 at a general hospital in South Korea. A total of 210 HIV/AIDS treatment-naïve patients were grouped as follows: single-tablet regimen (STR, one tablet/day), mild pill burden (two-four tablets/day), and heavy pill burden (≥ five tablets/day). Patients were analyzed according to gender, age at index date, medical insurance type, comorbidities, depression, HIV/AIDS disease burden as indicated by HIV-RNA viral load and CD4, and laboratory variables. In a multivariate logistic regression model, the STR group demonstrated adherence 5.10 times more often than the heavy pill burden group. Females and patients with an initial viral load of 500,000 or more were 0.090- and 0.040-fold less adherent to the ART regimen. Among these patients, 95% or more of the MPR group were 7.38 times more likely to have a lower limit of detection (LLOD) of viral load suppression. The highest initial viral load group was 0.090-fold less likely to have an LLOD than the reference group. These results suggest that a single-tablet regimen could improve medication adherence and the clinical virologic outcome. Therefore, general population research on ART adherence and polypharmacy is needed.</p>]]></description>
            <pubDate><![CDATA[2021-01-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765838484487-9d6c55d2-dfb0-457e-83b5-3926bf407e6d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245962</link>
            <description><![CDATA[<p class="para" id="N65539">Effective SARS-CoV-2 antiviral drugs are desperately needed. The SARS-CoV-2 main protease (Mpro) appears as an attractive target for drug development. We show that the existing pharmacopeia contains many drugs with potential for therapeutic repurposing as selective and potent inhibitors of SARS-CoV-2 Mpro. We screened a collection of ~6,070 drugs with a previous history of use in humans for compounds that inhibit the activity of Mpro <i>in vitro</i> and found ~50 compounds with activity against Mpro. Subsequent dose validation studies demonstrated 8 dose responsive hits with an IC50 ≤ 50 μM. Hits from our screen are enriched with hepatitis C NS3/4A protease targeting drugs including boceprevir, ciluprevir. narlaprevir, and telaprevir. This work suggests previous large-scale commercial drug development initiatives targeting hepatitis C NS3/4A viral protease should be revisited because some previous lead compounds may be more potent against SARS-CoV-2 Mpro than boceprevir and suitable for rapid repurposing.</p>]]></description>
            <pubDate><![CDATA[2021-02-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765838104191-39716b2f-9d4f-4d52-a8c8-06dcf7ef3550/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246113</link>
            <description><![CDATA[<p class="para" id="N65539">A 12-dose weekly regimen of rifapentine plus isoniazid (3HP) is recommended for the prevention of active tuberculosis (TB); however, it is unclear whether 3HP should be provided by directly observed therapy (DOT) or self-administered therapy (SAT). In addition, the introduction of patient informed choice between delivery modalities may have a positive impact on factors leading to treatment completion. The authors randomized 252 participants with HIV to a hypothetical scenario of providing preventive therapy by either DOT or an informed choice between DOT and SAT. Out of 104 participants who were randomized to a choice between DOT and SAT, 103 chose therapy by SAT. Participants rated their level of confidence and intention to complete therapy. Compared to those assigned to the DOT scenario, patients assigned to the choice scenario expressed greater confidence and intention to complete preventive therapy. Convenience and travel required to complete 3HP therapy were important factors in deciding between delivery modalities. Those assigned to DOT identified more barriers to completing therapy than those given a choice. Empowering patients to make informed decisions about how they receive TB preventive therapy may improve completion rates.</p>]]></description>
            <pubDate><![CDATA[2021-02-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Assembly of infectious enteroviruses depends on multiple, conserved genomic RNA-coat protein contacts]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765837924910-19a6c6d5-1e42-4139-8541-e79d0fc4154c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009146</link>
            <description><![CDATA[<p class="para" id="N65539">Picornaviruses are important viral pathogens, but despite extensive study, the assembly process of their infectious virions is still incompletely understood, preventing the development of anti-viral strategies targeting this essential part of the life cycle. We report the identification, via RNA SELEX and bioinformatics, of multiple RNA sites across the genome of a typical enterovirus, enterovirus-E (EV-E), that each have affinity for the cognate viral capsid protein (CP) capsomer. Many of these sites are evolutionarily conserved across known EV-E variants, suggesting they play essential functional roles. Cryo-electron microscopy was used to reconstruct the EV-E particle at ~2.2 Å resolution, revealing extensive density for the genomic RNA. Relaxing the imposed symmetry within the reconstructed particles reveals multiple RNA-CP contacts, a first for any picornavirus. Conservative mutagenesis of the individual RNA-contacting amino acid side chains in EV-E, many of which are conserved across the enterovirus family including poliovirus, is lethal but does not interfere with replication or translation. Anti-EV-E and anti-poliovirus aptamers share sequence similarities with sites distributed across the poliovirus genome. These data are consistent with the hypothesis that these RNA-CP contacts are RNA Packaging Signals (PSs) that play vital roles in assembly and suggest that the RNA PSs are evolutionarily conserved between pathogens within the family, augmenting the current protein-only assembly paradigm for this family of viruses.</p><p class="para" id="N65542">Picornaviruses are important pathogens but their assembly is incompletely understood, preventing development of anti-viral drugs and vaccines. We report identification of multiple RNA stem–loops, with purine trinucleotide sequence motifs in each loop, distributed across the genomes of two enteroviruses, enterovirus-E and poliovirus. Each motif appears to have affinity for its cognate capsid protein. Cryo-EM reconstruction of enterovirus-E without imposed symmetry identifies many repeated CP-RNA contacts. These include stem-loops adjacent to the particle two-fold axes, which appear conserved between viruses, as are the amino acid side-chains that contact all the genomic RNA segments. Mutagenesis shows that these amino acids are essential for virion formation, consistent with an RNA-dependent assembly mechanism. These results suggest that all enteroviruses utilise a common assembly mechanism that requires defined CP-RNA contacts.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Rapid adaptation to human protein kinase R by a unique genomic rearrangement in rhesus cytomegalovirus]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765837618158-afeefed6-3852-4aa5-b585-69aa6f6af9d1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009088</link>
            <description><![CDATA[<p class="para" id="N65539">Cytomegaloviruses (CMVs) are generally unable to cross species barriers, in part because prolonged coevolution with one host species limits their ability to evade restriction factors in other species. However, the limitation in host range is incomplete. For example, rhesus CMV (RhCMV) can replicate in human cells, albeit much less efficiently than in rhesus cells. Previously we reported that the protein kinase R (PKR) antagonist encoded by RhCMV, rTRS1, has limited activity against human PKR but is nonetheless necessary and sufficient to enable RhCMV replication in human fibroblasts (HF). We now show that knockout of PKR in human cells or treatment with the eIF2B agonist ISRIB, which overcomes the translational inhibition resulting from PKR activation, augments RhCMV replication in HF, indicating that human PKR contributes to the inefficiency of RhCMV replication in HF. Serial passage of RhCMV in HF reproducibly selected for viruses with improved ability to replicate in human cells. The evolved viruses contain an inverted duplication of the terminal 6.8 kb of the genome, including rTRS1. The duplication replaces ~11.8 kb just downstream of an internal sequence element, <i>pac</i>1-like, which is very similar to the <i>pac</i>1 cleavage and packaging signal found near the terminus of the genome. Plaque-purified evolved viruses produced at least twice as much rTRS1 as the parental RhCMV and blocked the PKR pathway more effectively in HF. Southern blots revealed that unlike the parental RhCMV, viruses with the inverted duplication isomerize in a manner similar to HCMV and other herpesviruses that have internal repeat sequences. The apparent ease with which this duplication event occurs raises the possibility that the <i>pac</i>1-like site, which is conserved in Old World monkey CMV genomes, may serve a function in facilitating rapid adaptation to evolutionary obstacles.</p><p class="para" id="N65542">Rhesus macaque CMV (RhCMV) is an important model for human CMV (HCMV) pathogenesis and vaccine development. Therefore, it is important to understand the similarities and differences in infectivity and interaction of these viruses with their host species. In contrast to the strict species-specificity of HCMV, RhCMV is able to cross species barriers to replicate in human cells. We know from past work that a component of this broader host range is RhCMV’s ability to counteract both the rhesus and human versions of a key antiviral factor. Here we delve further into the mechanisms by which RhCMV can adapt to counteract human cellular defenses. We find that RhCMV appears to be poised to undergo a specific genomic rearrangement that facilitates increased replication efficiency in human cells. Besides providing insights into CMV species-specificity and host barriers to cross-species transmission, this work also provides more generalized clues about viral adaptative mechanisms.</p>]]></description>
            <pubDate><![CDATA[2021-01-26T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A novel aqueous extract from rice fermented with <i>Aspergillus oryzae</i> and <i>Saccharomyces cerevisiae</i> possesses an anti-influenza A virus activity]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765837038200-82998e38-2429-4e25-9786-9713134d4522/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244885</link>
            <description><![CDATA[<p class="para" id="N65539">Human influenza virus infections occur annually worldwide and are associated with high morbidity and mortality. Hence, development of novel anti-influenza drugs is urgently required. Rice Power<sup>®</sup> extract developed by the Yushin Brewer Co. Ltd. is a novel aqueous extract of rice obtained via saccharization and fermentation with various microorganisms, such as <i>Aspergillus oryzae</i>, yeast [such as <i>Saccharomyces cerevisiae</i>], and lactic acid bacteria, possessing various biological and pharmacological properties. In our previous experimental screening with thirty types of Rice Power<sup>®</sup> extracts, we observed that the 30<sup>th</sup> Rice Power<sup>®</sup> (Y30) extract promoted the survival of influenza A virus-infected Madin-Darby canine kidney (MDCK) cells. Therefore, to identify compounds for the development of novel anti-influenza drugs, we aimed to investigate whether the Y30 extract exhibits anti-influenza A virus activity. In the present study, we demonstrated that the Y30 extract strongly promoted the survival of influenza A H1N1 Puerto Rico 8/34 (A/PR/8/34), California 7/09, or H3N2 Aichi 2/68 (A/Aichi/2/68) viruses-infected MDCK cells and inhibited A/PR/8/34 or A/Aichi/2/68 viruses infection and growth in the co-treatment and pre-infection experiments. The pre-treatment of Y30 extract on MDCK cells did not induce anti-influenza activity in the cell. The Y30 extract did not significantly affect influenza A virus hemagglutination, and neuraminidase and RNA-dependent RNA polymerase activities. Interestingly, the electron microscopy experiment revealed that the Y30 extract disrupts the integrity of influenza A virus particles by permeabilizing the viral membrane envelope, suggesting that Y30 extract has a direct virucidal effect against influenza A virus. Furthermore, we observed that compared to the ethyl acetate (EtOAc) extract, the water extract of Y30 extract considerably promoted the survival of cells infected with A/PR/8/34 virus. These results indicated that more anti-influenza components were present in the water extract of Y30 extract than in the EtOAc extract. Our results highlight the potential of a rice extract fermented with <i>A</i>. <i>oryzae</i> and <i>S</i>. <i>cerevisiae</i> as an anti-influenza medicine and a drug source for the development of anti-influenza compounds.</p>]]></description>
            <pubDate><![CDATA[2021-01-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[An indirect method to monitor the fraction of people ever infected with COVID-19: An application to the United States]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765836815794-e35cd45d-92eb-40db-9c54-25f92e076e2c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245845</link>
            <description><![CDATA[<p class="para" id="N65539">The number of COVID-19 infections is key for accurately monitoring the pandemics. However, due to differential testing policies, asymptomatic individuals and limited large-scale testing availability, it is challenging to detect all cases. Seroprevalence studies aim to address this gap by retrospectively assessing the number of infections, but they can be expensive and time-intensive, limiting their use to specific population subgroups. In this paper, we propose a complementary approach that combines estimated (1) infection fatality rates (IFR) using a Bayesian melding SEIR model with (2) reported case-fatality rates (CFR) in order to indirectly estimate the fraction of people ever infected (from the total population) and detected (from the ever infected). We apply the technique to the U.S. due to their remarkable regional diversity and because they count with almost a quarter of all global confirmed cases and deaths. We obtain that the IFR varies from 1.25% (0.39–2.16%, 90% CI) in Florida, the most aged population, to 0.69% in Utah (0.21–1.30%, 90% CI), the youngest population. By September 8, 2020, we estimate that at least five states have already a fraction of people ever infected between 10% and 20% (New Jersey, New York, Massachussets, Connecticut, and District of Columbia). The state with the highest estimated fraction of people ever infected is New Jersey with 17.3% (10.0, 55.8, 90% CI). Moreover, our results indicate that with a probability of 90 percent the fraction of detected people among the ever infected since the beginning of the epidemic has been less than 50% in 15 out of the 20 states analyzed in this paper. Our approach can be a valuable tool that complements seroprevalence studies and indicates how efficient have testing policies been since the beginning of the outbreak.</p>]]></description>
            <pubDate><![CDATA[2021-01-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Measuring research mistrust in adolescents and adults: Validity and reliability of an adapted version of the Group-Based Medical Mistrust Scale]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765836665945-70baad79-a8b7-4a54-ba86-81fe9bca53c4/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245783</link>
            <description><![CDATA[<p class="para" id="N65539">Mistrust of health care providers among persons of color is a significant barrier to engaging them in research studies. Underrepresentation of persons of color is particularly problematic when the health problem under study disproportionately affects minoritized communities. The purpose of this study was to test the validity and reliability of an abbreviated and adapted version of the Group Based Medical Mistrust Scale. The GBMMS is a 12-item scale with three subscales that assess suspicion, experiences of discrimination, and lack of support in the health care setting. To adapt for use in the research setting, we shortened the scale to six items, and replaced “health care workers” and “health care” with “medical researchers” and “medical research,” respectively. Using panelists from a market research firm, we recruited and enrolled a racially and ethnically diverse sample of American adults (N = 365) and adolescents aged 14–17 (N = 250). We administered the adapted scale in a web-based survey. We used Cronbach’s alpha to evaluate measure internal reliability of the scale and external factor analysis to evaluate the relationships between the revised scale items. Five of the six items loaded onto a single factor, with (α = 0.917) for adolescents and (α = 0.912) for adults. Mean scores for each item ranged from 2.5–2.9, and the mean summary score (range 6–25) was 13.3 for adults and 13.1 for adolescents. Among adults, Black respondents had significantly higher mean summary scores compared to whites and those in other racia/ethnic groups (p&lt;0.001). There was a trend toward significance for Black adolescents as compared to white respondents and those in other racial/ethnic groups (p = 0.09). This five-item modified version of the GBMMS is reliable and valid for measuring research mistrust with American adults and adolescents of diverse racial and ethnic identities.</p>]]></description>
            <pubDate><![CDATA[2021-01-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Inositol phosphates promote HIV-1 assembly and maturation to facilitate viral spread in human CD4<sup>+</sup> T cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765836079017-3bd51afa-9019-4267-ba08-687926d026df/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009190</link>
            <description><![CDATA[<p class="para" id="N65539">Gag polymerization with viral RNA at the plasma membrane initiates HIV-1 assembly. Assembly processes are inefficient <i>in vitro</i> but are stimulated by inositol (1,3,4,5,6) pentakisphosphate (IP5) and inositol hexakisphosphate (IP6) metabolites. Previous studies have shown that depletion of these inositol phosphate species from HEK293T cells reduced HIV-1 particle production but did not alter the infectivity of the resulting progeny virions. Moreover, HIV-1 substitutions bearing Gag/CA mutations ablating IP6 binding are noninfectious with destabilized viral cores. In this study, we analyzed the effects of cellular depletion of IP5 and IP6 on HIV-1 replication in T cells in which we disrupted the genes encoding the kinases required for IP6 generation, IP5 2-kinase (IPPK) and Inositol Polyphosphate Multikinase (IPMK). Knockout (KO) of IPPK from CEM and MT-4 cells depleted cellular IP6 in both T cell lines, and <i>IPMK</i> disruption reduced the levels of both IP5 and IP6. In the KO lines, HIV-1 spread was delayed relative to parental wild-type (WT) cells and was rescued by complementation. Virus release was decreased in all IPPK or IPMK KO lines relative to WT cells. Infected IPMK KO cells exhibited elevated levels of intracellular Gag protein, indicative of impaired particle assembly. IPMK KO compromised virus production to a greater extent than IPPK KO suggesting that IP5 promotes HIV-1 particle assembly in IPPK KO cells. HIV-1 particles released from infected IPPK or IPMK KO cells were less infectious than those from WT cells. These viruses exhibited partially cleaved Gag proteins, decreased virion-associated p24, and higher frequencies of aberrant particles, indicative of a maturation defect. Our data demonstrate that IP6 enhances the quantity and quality of virions produced from T cells, thereby preventing defects in HIV-1 replication.</p><p class="para" id="N65542">The discovery that the host cell metabolite inositol hexakisphosphate (IP6) stimulates both immature and mature HIV-1 particle assembly began to uncover the mechanism by which HIV-1 particles become infectious. Inhibitors that block HIV-1 capsid assembly effectively lower HIV-1 production <i>in cellulo</i>, however the mechanistic underpinning of how the immature and mature HIV-1 capsids assemble remains enigmatic. We sought to expand upon previous studies and illuminate how IP6, and the related metabolite inositol (1,3,4,5,6) pentakisphosphate (IP5), affect HIV-1 infection. With this goal in mind, we disrupted genes essential for IP5 and/or IP6 production in HIV-1-permissive T cell lines. HIV-1 was less able to propagate in the cells due to defects in intracellular HIV-1 assembly and defects in progeny virion maturation. Our data demonstrate that inositol phosphates are exploited by HIV-1 to orchestrate both virion assembly and maturation. We propose that pharmacological targeting of the HIV-1 inositol phosphate binding pockets in Gag and CA with small molecules will inhibit distinct aspects of HIV-1 replication.</p>]]></description>
            <pubDate><![CDATA[2021-01-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The coronavirus proofreading exoribonuclease mediates extensive viral recombination]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765836023498-9c0fe79d-38b3-4ad4-863d-e5a6c536c55d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009226</link>
            <description><![CDATA[<p class="para" id="N65539">Recombination is proposed to be critical for coronavirus (CoV) diversity and emergence of SARS-CoV-2 and other zoonotic CoVs. While RNA recombination is required during normal CoV replication, the mechanisms and determinants of CoV recombination are not known. CoVs encode an RNA proofreading exoribonuclease (nsp14-ExoN) that is distinct from the CoV polymerase and is responsible for high-fidelity RNA synthesis, resistance to nucleoside analogues, immune evasion, and virulence. Here, we demonstrate that CoVs, including SARS-CoV-2, MERS-CoV, and the model CoV murine hepatitis virus (MHV), generate extensive and diverse recombination products during replication in culture. We show that the MHV nsp14-ExoN is required for native recombination, and that inactivation of ExoN results in decreased recombination frequency and altered recombination products. These results add yet another critical function to nsp14-ExoN, highlight the uniqueness of the evolved coronavirus replicase, and further emphasize nsp14-ExoN as a central, completely conserved, and vulnerable target for inhibitors and attenuation of SARS-CoV-2 and future emerging zoonotic CoVs.</p><p class="para" id="N65542">Recombination is an essential part of normal coronavirus replication, required for the generation of the sub-genomic mRNAs as well as defective viral genome (DVGs) and is also implicated in novel strain emergence. However, the molecular mechanisms and determinants of RNA recombination in CoVs are unknown. Here, we compare recombination in 3 divergent beta-coronaviruses; murine hepatitis virus (MHV), MERS-CoV, and SARS-CoV-2. We show that they have striking similarities in the populations of RNA produced and in the sequences surrounding recombination junctions. Further, we demonstrate that the coronavirus proofreading exoribonuclease (nsp14-ExoN) is required to maintain the rates and loci of recombination generated during infection. These data suggest that recombination and the coronavirus exoribonuclease are conserved and important determinants of replication that may be targeted for inhibition and attenuation to control the ongoing pandemic of SARS-CoV-2 and prevent future outbreaks of novel coronaviruses.</p>]]></description>
            <pubDate><![CDATA[2021-01-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Defective viral genomes from chikungunya virus are broad-spectrum antivirals and prevent virus dissemination in mosquitoes]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765835324374-da6bd2c1-a55b-4adf-a569-69f586b1ac74/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009110</link>
            <description><![CDATA[<p class="para" id="N65539">Defective viral genomes (DVGs) are truncated and/or rearranged viral genomes produced during virus replication. Described in many RNA virus families, some of them have interfering activity on their parental virus and/or strong immunostimulatory potential, and are being considered in antiviral approaches. Chikungunya virus (CHIKV) is an alphavirus transmitted by <i>Aedes spp</i>. that infected millions of humans in the last 15 years. Here, we describe the DVGs arising during CHIKV infection <i>in vitro</i> in mammalian and mosquito cells, and <i>in vivo</i> in experimentally infected <i>Aedes aegypti</i> mosquitoes. We combined experimental and computational approaches to select DVG candidates most likely to have inhibitory activity and showed that, indeed, they strongly interfere with CHIKV replication both in mammalian and mosquito cells. We further demonstrated that some DVGs present broad-spectrum activity, inhibiting several CHIKV strains and other alphaviruses. Finally, we showed that pre-treating <i>Aedes aegypti</i> with DVGs prevented viral dissemination <i>in vivo</i>.</p><p class="para" id="N65542">Defective viral genomes (DVGs) are produced during virus replication. On their own they cannot replicate, but some of them can compete with wild-type virus for viral and/or cellular resources. For chikungunya virus, interference by DVGs has not been described. Here, we use a new approach based on experimental evolution and computational analysis to characterize all DVGs generated in a virus population and identify those with the highest antiviral potential. We confirm their antiviral activity in both mammalian and mosquito host environments and show that some can broadly interfere with other strains or related alphaviruses. Finally, we show that DVGs can inhibit virus dissemination in mosquitoes.</p>]]></description>
            <pubDate><![CDATA[2021-02-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765834348347-478d3265-b8bc-4d3a-bf65-6fa47a2b48fa/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pcbi.1008535</link>
            <description><![CDATA[<p class="para" id="N65539">Lassa fever is an haemorrhagic fever caused by Lassa virus (LASV). There is no vaccine approved against LASV and the only recommended antiviral treatment relies on ribavirin, despite limited evidence of efficacy. Recently, the nucleotide analogue favipiravir showed a high antiviral efficacy, with 100% survival obtained in an otherwise fully lethal non-human primate (NHP) model of Lassa fever. However the mechanism of action of the drug is not known and the absence of pharmacokinetic data limits the translation of these results to the human setting. Here we aimed to better understand the antiviral effect of favipiravir by developping the first mathematical model recapitulating Lassa viral dynamics and treatment. We analyzed the viral dynamics in 24 NHPs left untreated or treated with ribavirin or favipiravir, and we put the results in perspective with those obtained with the same drugs in the context of Ebola infection. Our model estimates favipiravir EC<sub>50</sub>
<i>in vivo</i> to 2.89 <i>μ</i>g.mL<sup>-1</sup>, which is much lower than what was found against Ebola virus. The main mechanism of action of favipiravir was to decrease virus infectivity, with an efficacy of 91% at the highest dose. Based on our knowledge acquired on the drug pharmacokinetics in humans, our model predicts that favipiravir doses larger than 1200 mg twice a day should have the capability to strongly reduce the production infectious virus and provide a milestone towards a future use in humans.</p><p class="para" id="N65542">Lassa virus is the etiological agent of Lassa fever, an haemorrhagic fever endemic that cause nearly 5000 deaths every year in West Africa. Here, we provide the first within-host mathematical model of the infection by Lassa virus in a macaque model and we analyze the antiviral effect of two candidate drugs, favipiravir or ribavirin. We show that both drugs act primarily by increasing mutagenesis in vivo. Both drugs had a strong antiviral efficacy in reducing the proportion of non infectious virus produced by infected cells, up to 91 and 40% for favipiravir and ribavirin, respectively. We bridge these predictions with our knowledge of the drugs pharmacokinetics to identify target concentrations having the capability to rapidly clear infectious virus from infected individuals.</p>]]></description>
            <pubDate><![CDATA[2021-01-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Rotavirus breakthrough infections responsible for gastroenteritis in vaccinated infants who presented with acute diarrhoea at University Teaching Hospitals, Children’s Hospital in 2016, in Lusaka Zambia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765834305569-a3a3952a-18f3-4f92-a4dd-a88781dfd820/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246025</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">In Zambia, before rotavirus vaccine introduction, the virus accounted for about 10 million episodes of diarrhoea, 63 000 hospitalisations and 15 000 deaths in 2015, making diarrhoea the third leading cause of death after pneumonia and malaria. In Zambia, despite the introduction of the vaccine acute diarrhoea due to rotaviruses has continued to affect children aged five years and below. This study aimed to characterise the rotavirus genotypes which were responsible for diarrhoeal infections in vaccinated infants aged 2 to 12 months and to determine the relationship between rotavirus strains and the severity of diarrhoea in 2016.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">Stool samples from infants aged 2 to 12 months who presented to the hospital with acute diarrhoea of three or more episodes in 24 hours were tested for group A rotavirus. All positive specimens that had enough sample were genotyped using reverse transcriptase Polymerase Chain Reaction (RT-PCR). A 20-point Vesikari clinical score between 1–5 was considered as mild, 6–10 as moderate and greater or equal to 11 as severe.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">A total of 424 stool specimens were tested of which 153 (36%, 95% CI 31.5% to 40.9%) were positive for VP6 rotavirus antigen. The age-specific rotavirus infections decreased significantly (p = 0.041) from 2–4 months, 32.0% (49/118) followed by a 38.8% (70/181) infection rate in the 5–8 months’ category and subsequently dropped in the infants aged 9–12 months with a positivity rate of 27.2%. 38.5% of infants who received a single dose, 34.5% of those who received a complete dose and 45.2% (19/42) of the unvaccinated tested positive for rotavirus. The predominant rotavirus genotypes included G2P[6] 36%, G1P[8] 32%, mixed infections 19%, G2P[4] 6%, G1P[6] 4% and G9P[6] 3%.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Discussion and conclusion</h3><p class="para" id="N65561">Results suggest breakthrough infection of heterotypic strains (G2P[6] (36%), homotypic, G1P[8] (32%) and mixed infections (19%) raises concerns about the effects of the vaccination on the rotavirus diversity, considering the selective pressure that rotavirus vaccines could exert on viral populations. This data indicates that the rotavirus vaccine has generally reduced the severity of diarrhoea despite the detection of the virus strains.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Defining an intermediate category of tuberculin skin test: A mixture model analysis of two high-risk populations from Kampala, Uganda]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765833930088-9f90ad90-a28f-4318-b2f5-63f221fd7b36/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245328</link>
            <description><![CDATA[<p class="para" id="N65539">One principle of tuberculosis control is to prevent the development of tuberculosis disease by treating individuals with latent tuberculosis infection. The diagnosis of latent infection using the tuberculin skin test is not straightforward because of concerns about immunologic cross reactivity with the Bacille Calmette-Guerin (BCG) vaccine and environmental mycobacteria. To parse the effects of BCG vaccine and environmental mycobacteria on the tuberculin skin test, we estimated the frequency distribution of skin test results in two divisions of Kampala, Uganda, ten years apart. We then used mixture models to estimate parameters for underlying distributions and defined clinically meaningful criteria for latent infection, including an indeterminate category. Using percentiles of two underlying normal distributions, we defined two skin test readings to demarcate three ranges. Values of 10 mm or greater contained 90% of individuals with latent infection; values less than 7.2 mm contained 80% of individuals without infection. Contacts with values between 7.2 and 10 mm fell into an indeterminate zone where it was not possible to assign infection. We conclude that systematic tuberculin skin test surveys within populations at risk, combined with mixture model analysis, may be a reproducible, evidence-based approach to define meaningful criteria for latent tuberculosis infection.</p>]]></description>
            <pubDate><![CDATA[2021-01-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765833703958-ffaa57f4-2871-4d01-851a-45715559c0ab/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245024</link>
            <description><![CDATA[<p class="para" id="N65539">Ebola virus (EBOV), a member of the mononegaviral family <i>Filoviridae</i>, causes severe disease associated with high lethality in humans. Despite enormous progress in development of EBOV medical countermeasures, no anti-EBOV treatment has been approved. We designed an immunotoxin in which a single-chain variable region fragment of the EBOV glycoprotein-specific monoclonal antibody 6D8 was fused to the effector domains of <i>Pseudomonas aeruginosa</i> exotoxin A (PE38). This immunotoxin, 6D8-PE38, bound specifically to cells expressing EBOV glycoproteins. Importantly, 6D8-PE38 targeted EBOV-infected cells, as evidenced by inhibition of infectious EBOV production from infected cells, including primary human macrophages. The data presented here provide a proof of concept for immunotoxin-based targeted killing of infected cells as a potential antiviral intervention for Ebola virus disease.</p>]]></description>
            <pubDate><![CDATA[2021-01-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765833611377-fc556349-8328-45ba-b3b7-81ba6c682a40/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245955</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction</h3><p class="para" id="N65543">Combination antiretroviral therapy (cART) improves outcomes for people living with HIV (PLWH) but requires adherence to daily dosing. Suboptimal adherence results in reduced treatment effectiveness, increased costs, and greater risk of resistance and onwards transmission. Treatment with long-acting (LA), injection-based ART administered by healthcare professionals (directly observed therapy (DOT)) eliminates the need for adherence to daily dosing and may improve clinical outcomes. This study reports the cost-effectiveness of the cabotegravir plus rilpivirine LA regimen (CAB+RPV LA) and models the potential impact of LA DOT therapies.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">Parameterisation was performed using pooled data from recent CAB+RPV LA Phase III trials. The analysis was conducted using a cohort-level hybrid decision-tree and state-transition model, with states defined by viral load and CD4 cell count. The efficacy of oral cART was adjusted to reflect adherence to daily regimens from published data. A Canadian health service perspective was adopted.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">CAB+RPV LA is predicted to be the dominant intervention when compared to oral cART, generating, per 1,000 patients treated, lifetime cost-savings of $1.5 million, QALY and life-year gains of 107 and 138 respectively with three new HIV cases averted.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65561">Economic evaluations of LA DOTs need to account for the impact of adherence and HIV transmission. This study adds to the existing literature by incorporating transmission and using clinical data from the first LA DOT regimen. Providing PLWH and healthcare providers with novel modes of ART administration, enhancing individualisation of treatment, may facilitate the achievement of UNAIDS 95-95-95 objectives.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Knowledge, attitudes, and practices of seasonal influenza vaccination in healthcare workers, Honduras]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765833342030-dbfcc086-f72d-4d6e-9add-1560c905c140/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246379</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Seasonal influenza is a highly contagious vaccine-preventable disease that may cause high morbidity and mortality in susceptible populations. Healthcare workers are a priority group for seasonal influenza vaccination to protect them from contracting influenza and prevent nosocomial transmission to patients. This study aimed to evaluate knowledge, attitudes, and practices (KAP) of seasonal influenza vaccination among healthcare workers in Honduras.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Method</h3><p class="para" id="N65549">From August 24 to October 21, 2018, we conducted a cross-sectional KAP survey regarding seasonal influenza vaccination to a random sample of healthcare workers who attended patients in hospitals of the Ministry of Health of Honduras (SESAL) and Honduran Social Security Institute (IHSS). We reported frequency distributions of demographics, vaccination KAP, sources of information, and reasons for non-vaccination. We used principal components factor analysis to create knowledge and attitude scores. We used linear regression to analyze associations between demographics and sources of information about the influenza vaccine, and knowledge and attitude scores. We used logistic regression to analyze associations between demographics, sources of information, knowledge scores, and attitude scores, and influenza vaccination.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Result</h3><p class="para" id="N65555">We surveyed 947 healthcare workers who attended patients in 13 SESAL hospitals and two IHSS hospitals. Only 4.6% of participants knew the seasonal influenza vaccine was composed of inactivated viruses, 94.7% believed vaccination causes flu-like symptoms, and 52.0% were vaccinated for influenza in 2018. Knowledge scores were lower for nursing assistants and other healthcare professionals compared to doctors, and higher for healthcare workers who attended a healthcare facility training (<i>P</i>-values≤0.030). Attitude scores were higher for healthcare workers who attended ≥11 patients per day having ≤10 patients per day as reference, self-reported influenza vaccination in previous year, and cited trainings and informal information at the healthcare facility as sources of information for influenza vaccination (<i>P</i>-values≤0.030). Factors associated with self-reported vaccination were self-reported influenza vaccination in previous year (aOR: 7.61; 95% CI: 5.24–11.04), attitude score (aOR: 1.14; 95% CI: 1.07–1.21), and worked in a SESAL hospital (aOR: 1.73; 95% CI: 1.12–2.68) having IHSS as reference.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65567">Although influenza vaccination is required by law in Honduras and available for free in public health centers, coverage of healthcare workers in 2018 was half that reported in 2017. Lower coverage may be attributed to misconceptions of vaccination side effects.</p></div>]]></description>
            <pubDate><![CDATA[2021-02-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Within-farm transmission characteristics of bluetongue virus serotype 8 in cattle and sheep in the Netherlands, 2007-2008]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765824763502-0ae1015f-729f-4f0c-8711-5878edb96633/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0246565</link>
            <description><![CDATA[<p class="para" id="N65539">In 2006 and 2007, sheep and cattle farms in the Netherlands were affected by an epidemic of bluetongue virus serotype 8 (BTV-8). In order to obtain insight into the within-farm spread of the virus, five affected cattle and five affected sheep farms were longitudinally monitored between early 2007 and mid or late 2008. The farms were visited between four and seven times to collect blood samples. During each visit, all animals present in the flock or herd were sampled. The samples were analysed for the presence of BTV-8 antibodies (ELISA) and BTV-8 antigen (rRT-PCR). The observed patterns of RT-PCR positives indicate a rapid within-farm virus spread during the vector season. During vector-free periods we observed a complete rRT-PCR positivity decline within a few months. During the vector season a lower bound estimate of the basic reproduction number (R<sub>0</sub>) ranges from 2.9–6.9 in the cattle herds (one herd not analysed), and from 1.3–3.2 in the sheep flocks in this study.</p>]]></description>
            <pubDate><![CDATA[2021-02-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Extensive proteomic and transcriptomic changes quench the TCR/CD3 activation signal of latently HIV-1 infected T cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765824494970-3c994600-4241-4b85-8f6a-76cd98f0511d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1008748</link>
            <description><![CDATA[<p class="para" id="N65539">The biomolecular mechanisms controlling latent HIV-1 infection, despite their importance for the development of a cure for HIV-1 infection, are only partially understood. For example, <i>ex vivo</i> studies have recently shown that T cell activation only triggered HIV-1 reactivation in a fraction of the latently infected CD4+ T cell reservoir, but the molecular biology of this phenomenon is unclear. We demonstrate that HIV-1 infection of primary T cells and T cell lines indeed generates a substantial amount of T cell receptor (TCR)/CD3 activation-inert latently infected T cells. RNA-level analysis identified extensive transcriptomic differences between uninfected, TCR/CD3 activation-responsive and -inert T cells, but did not reveal a gene expression signature that could functionally explain TCR/CD3 signaling inertness. Network analysis suggested a largely stochastic nature of these gene expression changes (transcriptomic noise), raising the possibility that widespread gene dysregulation could provide a reactivation threshold by impairing overall signal transduction efficacy. Indeed, compounds that are known to induce genetic noise, such as HDAC inhibitors impeded the ability of TCR/CD3 activation to trigger HIV-1 reactivation. Unlike for transcriptomic data, pathway enrichment analysis based on phospho-proteomic data directly identified an altered TCR signaling motif. Network analysis of this data set identified drug targets that would promote TCR/CD3-mediated HIV-1 reactivation in the fraction of otherwise TCR/CD3-reactivation inert latently HIV-1 infected T cells, regardless of whether the latency models were based on T cell lines or primary T cells. The data emphasize that latent HIV-1 infection is largely the result of extensive, stable biomolecular changes to the signaling network of the host T cells harboring latent HIV-1 infection events. In extension, the data imply that therapeutic restoration of host cell responsiveness prior to the use of any activating stimulus will likely have to be an element of future HIV-1 cure therapies.</p><p class="para" id="N65542">A curative therapy for HIV-1 infection will at least require the eradication of a small pool of CD4+ helper T cells in which the virus can persist in an inactive, latent state, even after years of successful antiretroviral therapy. It has been assumed that activation of these viral reservoir T cells will also reactivate the latent virus, which is a prerequisite for the destruction of these cells. Remarkably, this is not always the case and following application of even the most potent stimuli that activate normal T cells through their T cell receptor, a large portion of the latent virus pool remains in a dormant state. Herein we demonstrate that a large part of latent HIV-1 infection events reside in T cells that have been rendered activation inert. We provide a systemwide, biomolecular description of the changes that render latently HIV-1 infected T cells activation inert and using this description, devise pharmacologic interference strategies that render initially activation inert T cells responsive to stimulation. This in turn allows for efficient triggering of HIV-1 reactivation in a large part of the otherwise unresponsive latently HIV-1 infected T cell reservoir.</p>]]></description>
            <pubDate><![CDATA[2021-01-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A lysine ring in HIV capsid pores coordinates IP6 to drive mature capsid assembly]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765824257146-6369f418-49a2-49a0-9f75-9382255d739c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009164</link>
            <description><![CDATA[<p class="para" id="N65539">The HIV capsid self-assembles a protective conical shell that simultaneously prevents host sensing whilst permitting the import of nucleotides to drive DNA synthesis. This is accomplished through the construction of dynamic, highly charged pores at the centre of each capsid multimer. The clustering of charges required for dNTP import is strongly destabilising and it is proposed that HIV uses the metabolite IP6 to coordinate the pore during assembly. Here we have investigated the role of inositol phosphates in coordinating a ring of positively charged lysine residues (K25) that forms at the base of the capsid pore. We show that whilst IP5, which can functionally replace IP6, engages an arginine ring (R18) at the top of the pore, the lysine ring simultaneously binds a second IP5 molecule. Dose dependent removal of K25 from the pore severely inhibits HIV infection and concomitantly prevents DNA synthesis. Cryo-tomography reveals that K25A virions have a severe assembly defect that inhibits the formation of mature capsid cones. Monitoring both the kinetics and morphology of capsids assembled in vitro reveals that while mutation K25A can still form tubes, the ability of IP6 to drive assembly of capsid cones has been lost. Finally, in single molecule TIRF microscopy experiments, capsid lattices in permeabilised K25 mutant virions are rapidly lost and cannot be stabilised by IP6. These results suggest that the coordination of IP6 by a second charged ring in mature hexamers drives the assembly of conical capsids capable of reverse transcription and infection.</p><p class="para" id="N65542">HIV protects its RNA genome while copying it into DNA by carrying out reverse transcription inside its capsid. This is accomplished by importing nucleotides through highly charged pores at the centre of each capsid multimer. These pores contain two rings of positively charged residues–R18 and K25 –but assembling capsids with these features is challenging because they are intrinsically destabilising. Here we show that the metabolite IP6 coordinates both residues within the pore to drive the assembly of stable capsids capable of nucleotide import. R18 or K25 mutants lose infectivity and the ability to synthesise DNA but have differing assembly phenotypes. Mutant K25A is unable to undergo efficient capsid assembly, while replacing K25 with a neutral polar residue partially restores assembly but not infectivity. We propose that IP6-driven assembly is conserved by HIV not because it is the only way to build a capsid, but because it allows the construction of a capsid with a charged pore that can import nucleotides.</p>]]></description>
            <pubDate><![CDATA[2021-02-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A type VII secretion system of <i>Streptococcus gallolyticus</i> subsp. <i>gallolyticus</i> contributes to gut colonization and the development of colon tumors]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765823978507-a2fd03c1-53dd-4275-9ff4-17601593cbef/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009182</link>
            <description><![CDATA[<p class="para" id="N65539"><i>Streptococcus gallolyticus</i> subspecies <i>gallolyticus</i> (<i>Sgg</i>) has a strong clinical association with colorectal cancer (CRC) and actively promotes the development of colon tumors. However, the molecular determinants involved in <i>Sgg</i> pathogenicity in the gut are unknown. Bacterial type VII secretion systems (T7SS) mediate pathogen interactions with their host and are important for virulence in pathogenic mycobacteria and <i>Staphylococcus aureus</i>. Through genome analysis, we identified a locus in <i>Sgg</i> strain TX20005 that encodes a putative type VII secretion system (designated as <i>Sgg</i>T7SS<sup>T05</sup>). We showed that core genes within the <i>Sgg</i>T7SS<sup>T05</sup> locus are expressed <i>in vitro</i> and in the colon of mice. Western blot analysis showed that <i>Sgg</i>EsxA, a protein predicted to be a T7SS secretion substrate, is detected in the bacterial culture supernatant, indicating that this <i>Sgg</i>T7SS<sup>T05</sup> is functional. Deletion of <i>Sgg</i>T7SS<sup>T05</sup> (TX20005Δ<i>esx</i>) resulted in impaired bacterial adherence to HT29 cells and abolished the ability of <i>Sgg</i> to stimulate HT29 cell proliferation. Analysis of bacterial culture supernatants suggest that <i>Sgg</i>T7SS<sup>T05</sup>-secreted factors are responsible for the pro-proliferative activity of <i>Sgg</i>, whereas <i>Sgg</i> adherence to host cells requires both <i>Sgg</i>T7SS<sup>T05</sup>-secreted and bacterial surface-associated factors. In a murine gut colonization model, TX20005Δ<i>esx</i> showed significantly reduced colonization compared to the parent strain. Furthermore, in a mouse model of CRC, mice exposed to TX20005 had a significantly higher tumor burden compared to saline-treated mice, whereas those exposed to TX20005Δ<i>esx</i> did not. Examination of the <i>Sgg</i> load in the colon in the CRC model suggests that <i>Sgg</i>T7SS<sup>T05</sup>-mediated activities are directly involved in the promotion of colon tumors. Taken together, these results reveal <i>Sgg</i>T7SS<sup>T05</sup> as a previously unrecognized pathogenicity determinant for <i>Sgg</i> colonization of the colon and promotion of colon tumors.</p><p class="para" id="N65542">Colorectal cancer (CRC) is a leading cause of cancer-related death. The development of CRC can be strongly influenced by specific gut microbes. Understanding how gut microbes modulate CRC is critical to developing novel strategies to improve clinical diagnosis and treatment of this disease. <i>S</i>. <i>gallolyticus</i> subsp. <i>gallolyticus</i> (<i>Sgg</i>) has a strong clinical association with CRC and actively promotes the development of colon tumors. However, the specific <i>Sgg</i> molecules that mediate its pro-tumor activity are unknown. Here we report the first characterization of a type VII secretion system (T7SS) in <i>Sgg</i>, designated as <i>Sgg</i>T7SS<sup>T05</sup>. We further demonstrate that <i>Sgg</i>T7SS<sup>T05</sup>-mediated activities are important for <i>Sgg</i> to colonize the colon and to promote the development of colon tumors. These findings reveal <i>Sgg</i>T7SS<sup>T05</sup> as a novel pathogenicity determinant of <i>Sgg</i> and provide a critical breakthrough in our efforts to understand how <i>Sgg</i> influences the development of CRC. Future investigations of the biological activities of specific effectors of <i>Sgg</i>T7SS<sup>T05</sup> will likely lead to the discovery of <i>Sgg</i> molecules that can be used as diagnostic markers and intervention targets aimed at mitigating the harmful effect of <i>Sgg</i>.</p>]]></description>
            <pubDate><![CDATA[2021-01-06T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Survey of five major grapevine viruses infecting Blatina and Žilavka cultivars in Bosnia and Herzegovina]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765823856765-bf2e4c63-f5d6-4ac1-a33c-91a82145451b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245959</link>
            <description><![CDATA[<p class="para" id="N65539">The sanitary status of grapevines has not yet been considered sufficiently in vineyards throughout Bosnia and Herzegovina (BiH). An extensive survey of five major grapevine viruses in the country was carried out in 2019. A total of 630 samples from the two dominant autochthonous cultivars, named Žilavka and Blatina, were tested by DAS-ELISA for the presence of grapevine leafroll-associated viruses (GLRaV-1 and 3), grapevine fleck virus (GFkV), grapevine fanleaf virus (GFLV) and Arabis mosaic virus (ArMV). Eighty-eight % of the samples were positive for at least one virus, and all five viruses were detected, thought with different incidence, i.e. GLRaV-3 (84%), GFLV (43%), GLRaV-1 (14%), GFkV (10%) and ArMV (0.2%). The majority of infected plants (about 75%) were asymptomatic. Specific virus symptoms were observed in the remaining infected plants, together with the reported GLRaV vectors, <i>Planococcus ficus</i> and <i>Parthenolecanium corni</i>, while nematodes of the <i>Xiphinema</i> genus were not found in the GFLV- or ArMV-infected vineyards. The GLRaV-3 <i>CP</i> phylogenetic analyses showed 75–100% nucleotide identity between the BiH and reference isolates, and the BiH isolates clustered into the major group. The dNS/dS ratio indicated a negative selection of the virus population, and the lack of geographical structuring within the population was observed. In addition, putative GLRaV-3 recombinants with breakpoints in the 5’ of the <i>CP</i> gene were detected, while no recombinant strains were identified for the other four viruses. The obtained results indicate a deteriorated sanitary status of the cultivated grapevines, the prevalence and intraspecies genetic diversity of GLRaV-3 throughout the country. The establishment of certified grapevine material and adequate virus vector control is therefore of primary importance to prevent further spread of these viruses. This study presents the results of the first molecular characterisation of grapevine viruses in Bosnia and Herzegovina.</p>]]></description>
            <pubDate><![CDATA[2021-01-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Zika virus dynamics: Effects of inoculum dose, the innate immune response and viral interference]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765823839466-1fb1f189-b19b-4a51-b559-2247be06524d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pcbi.1008564</link>
            <description><![CDATA[<p class="para" id="N65539">Experimental Zika virus infection in non-human primates results in acute viral load dynamics that can be well-described by mathematical models. The inoculum dose that would be received in a natural infection setting is likely lower than the experimental infections and how this difference affects the viral dynamics and immune response is unclear. Here we study a dataset of experimental infection of non-human primates with a range of doses of Zika virus. We develop new models of infection incorporating both an innate immune response and viral interference with that response. We find that such a model explains the data better than models with no interaction between virus and the immune response. We also find that larger inoculum doses lead to faster dynamics of infection, but approximately the same total amount of viral production.</p><p class="para" id="N65542">The relationship between the infecting dose of a pathogen and the subsequent viral dynamics is unclear in many disease settings, and this relationship has implications for both the timing and the required efficacy of antiviral therapy. Since experimental challenge studies often employ higher doses of virus than would generally be present in natural infection assessment of this relationship is particularly important for translation of findings. In this study we used mathematical modelling of viral load data from a multi-dose study of Zika virus infection in a macaque model to describe the impact of varying the dose of Zika virus on model parameters, and developed a novel mathematical model incorporating viral interference with the innate immune response.</p>]]></description>
            <pubDate><![CDATA[2021-01-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Intrinsic apoptosis and cytokine induction regulated in human tonsillar epithelial cells infected with enterovirus A71]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765823464230-a9913394-9fd8-4e0b-9ea3-a3528e858425/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245529</link>
            <description><![CDATA[<p class="para" id="N65539">Enterovirus A71 (EV-A71) has emerged as a clinically important neurotropic virus following poliovirus eradication. Recent studies have shown that human tonsillar epithelial cell lines (UT-SCC-60A and UT-SCC-60B) were susceptible to EV-A71, suggesting that human tonsillar crypt epithelium could be important in EV-A71 pathogenesis. However, the mechanism about how EV-A71 infects the upper oro-digestive tract remains largely unclear. In this study, we demonstrated that the human tonsillar epithelial cells infected with EV-A71 underwent apoptotic, in which cytochrome <i>c</i> was released from the mitochondria to the cytosol and caspase-9 was activated, while caspase-2 and -8 were not cleaved or activated during the infection. A selective inhibitor of caspase-9, Z-LEHD-FMK, inhibited the cleavage of the executioner caspase-3 and -7, indicating that only mitochondria-mediated intrinsic apoptotic pathway was activated in EV-A71-infected tonsillar epithelial cells. No evidence of pyroptosis or necroptosis was involved in the cell death. EV-A71 infection induced interferon, pro-inflammatory cytokines and chemokines, including IFN-β, IL-6, CCL5, and TNF-α in tonsillar epithelial cells, which may play a critical role in EV-A71-caused herpangina. Our data indicated that the induction of the cytokines was partially regulated by the mitogen-activated protein kinases (MAPKs) signaling pathway. The findings unveiled the host response to EV-A71 and its regulation mechanism, and will further our understanding the significance about the tonsillar crypt epithelium as the initial and primary portal in viral pathogenesis for EV-A71 infection.</p>]]></description>
            <pubDate><![CDATA[2021-01-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765822479197-a35f559e-746c-432b-a0be-fb54361ddbb9/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009212</link>
            <description><![CDATA[<p class="para" id="N65539">Hydroxychloroquine, used to treat malaria and some autoimmune disorders, potently inhibits viral infection of SARS coronavirus (SARS-CoV-1) and SARS-CoV-2 in cell-culture studies. However, human clinical trials of hydroxychloroquine failed to establish its usefulness as treatment for COVID-19. This compound is known to interfere with endosomal acidification necessary to the proteolytic activity of cathepsins. Following receptor binding and endocytosis, cathepsin L can cleave the SARS-CoV-1 and SARS-CoV-2 spike (S) proteins, thereby activating membrane fusion for cell entry. The plasma membrane-associated protease TMPRSS2 can similarly cleave these S proteins and activate viral entry at the cell surface. Here we show that the SARS-CoV-2 entry process is more dependent than that of SARS-CoV-1 on TMPRSS2 expression. This difference can be reversed when the furin-cleavage site of the SARS-CoV-2 S protein is ablated or when it is introduced into the SARS-CoV-1 S protein. We also show that hydroxychloroquine efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, and that a combination of hydroxychloroquine and a clinically-tested TMPRSS2 inhibitor prevents SARS-CoV-2 infection more potently than either drug alone. These studies identify functional differences between SARS-CoV-1 and -2 entry processes, and provide a mechanistic explanation for the limited <i>in vivo</i> utility of hydroxychloroquine as a treatment for COVID-19.</p><p class="para" id="N65542">The novel pathogenic coronavirus SARS-CoV-2 causes COVID-19 and remains a threat to global public health. Chloroquine and hydroxychloroquine have been shown to prevent viral infection in cell-culture systems, but human clinical trials did not observe a significant improvement in COVID-19 patients treated with these compounds. Here we show that hydroxychloroquine interferes with only one of two somewhat redundant pathways by which the SARS-CoV-2 spike (S) protein is activated to mediate infection. The first pathway is dependent on the endosomal protease cathepsin L and sensitive to hydroxychloroquine, whereas the second pathway is dependent on TMPRSS2, which is unaffected by this compound. We further show that SARS-CoV-2 is more reliant than SARS coronavirus (SARS-CoV-1) on the TMPRSS2 pathway, and that this difference is due to a furin cleavage site present in the SARS-CoV-2 S protein. Finally, we show that combinations of hydroxychloroquine and a clinically tested TMPRSS2 inhibitor work together to effectively inhibit SARS-CoV-2 entry. Thus TMPRSS2 expression on physiologically relevant SARS-CoV-2 target cells may bypass the antiviral activities of hydroxychloroquine, and explain its lack of <i>in vivo</i> efficacy.</p>]]></description>
            <pubDate><![CDATA[2021-01-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765821801810-fb819ba4-cb9c-4ee2-81a3-242d001df290/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245085</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction</h3><p class="para" id="N65543">Maintaining virologic suppression of children and adolescents on ART in rural communities in sub-Saharan Africa is challenging. We explored switching drug regimens to protease inhibitor (PI) based treatment and reducing nevirapine and zidovudine use in a differentiated community service delivery model in rural Zimbabwe.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">From 2016 through 2018, we followed 306 children and adolescents on ART in Hurungwe, Zimbabwe at Chidamoyo Christian Hospital, which provides compact ART regimens at 8 dispersed rural community outreach sites. Viral load testing was performed (2016) by Roche and at follow-up (2018) by a point of care viral load assay. Virologic failure was defined as viral load ≥1,000 copies/ml. A logistic regression model which included demographics, treatment regimens and caregiver’s characteristics was used to assess risks for virologic failure and loss to follow-up (LTFU).</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">At baseline in 2016, 296 of 306 children and adolescents (97%) were on first-line ART, and only 10 were receiving a PI-based regimen. The median age was 12 years (IQR 8–15) and 55% were female. Two hundred and nine (68%) had viral load suppression (&lt;1,000 copies/ml) and 97(32%) were unsuppressed (viral load ≥1000). At follow-up in 2018, 42/306 (14%) were either transferred 23 (7%) or LTFU 17 (6%) and 2 had died. In 2018, of the 264 retained in care, 107/264 (41%), had been switched to second-line, ritonavir-boosted PI with abacavir as a new nucleotide analog reverse transcriptase inhibitor (NRTI). Overall viral load suppression increased from 68% in 2016 to 81% in 2018 (P&lt;0.001).</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">Viral load testing, and switching to second-line, ritonavir-boosted PI with abacavir significantly increased virologic suppression among HIV-infected children and adolescents in rural Zimbabwe.</p></div>]]></description>
            <pubDate><![CDATA[2021-01-14T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Orthopoxvirus K3 orthologs show virus- and host-specific inhibition of the antiviral protein kinase PKR]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765821609760-ce1ea346-3308-4a0a-bb57-42c1d0e18eba/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009183</link>
            <description><![CDATA[<p class="para" id="N65539">The antiviral protein kinase R (PKR) is an important host restriction factor, which poxviruses must overcome to productively infect host cells. To inhibit PKR, many poxviruses encode a pseudosubstrate mimic of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2), designated K3 in vaccinia virus. Although the interaction between PKR and eIF2α is highly conserved, some K3 orthologs from host-restricted poxviruses were previously shown to inhibit PKR in a species-specific manner. To better define this host range function, we compared the sensitivity of PKR from 17 mammals to inhibition by K3 orthologs from closely related orthopoxviruses, a genus with a generally broader host range. The K3 orthologs showed species-specific inhibition of PKR and exhibited three distinct inhibition profiles. In some cases, PKR from closely related species showed dramatic differences in their sensitivity to K3 orthologs. Vaccinia virus expressing the camelpox virus K3 ortholog replicated more than three orders of magnitude better in human and sheep cells than a virus expressing vaccinia virus K3, but both viruses replicated comparably well in cow cells. Strikingly, in site-directed mutagenesis experiments between the variola virus and camelpox virus K3 orthologs, we found that different amino acid combinations were necessary to mediate improved or diminished inhibition of PKR derived from different host species. Because there is likely a limited number of possible variations in PKR that affect K3-interactions but still maintain PKR/eIF2α interactions, it is possible that by chance PKR from some potential new hosts may be susceptible to K3-mediated inhibition from a virus it has never previously encountered. We conclude that neither the sensitivity of host proteins to virus inhibition nor the effectiveness of viral immune antagonists can be inferred from their phylogenetic relatedness but must be experimentally determined.</p><p class="para" id="N65542">Most virus families are composed of large numbers of virus species. However, in general, only a few prototypic viruses are experimentally studied in-depth, and it is often assumed that the obtained results are representative of other viruses in the same family. In order to test this assumption, we compared the sensitivity of the antiviral protein kinase PKR from various mammals to inhibition by multiple orthologs of K3, a PKR inhibitor expressed by several closely related orthopoxviruses. We found strong differences in PKR inhibition by the K3 orthologs, demonstrating that sensitivity to a specific inhibitor was not indicative of broad sensitivity to orthologs of these inhibitors from closely related viruses. We also show that PKR from even closely related species displayed markedly different sensitivities to these poxvirus inhibitors. Furthermore, we identified amino acid residues in these K3 orthologs that are critical for enhanced or decreased PKR inhibition and found that distinct amino acid combinations affected PKRs from various species differently. Our study shows that even closely related inhibitors of an antiviral protein can vary dramatically in their inhibitory potential, and cautions that results from host-virus interaction studies of a prototypic virus genus member cannot necessarily be extrapolated to other viruses in the same genus without experimental verification.</p>]]></description>
            <pubDate><![CDATA[2021-01-14T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Naturally occurring substitution in one amino acid in VHSV phosphoprotein enhances viral virulence in flounder]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765821538092-16988af0-c5b1-4275-b4a3-2134da6ced31/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009213</link>
            <description><![CDATA[<p class="para" id="N65539">Viral hemorrhagic septicemia virus (VHSV) is a rhabdovirus that causes high mortality in cultured flounder. Naturally occurring VHSV strains vary greatly in virulence. Until now, little has been known about genetic alterations that affect the virulence of VHSV in flounder. We recently reported the full-genome sequences of 18 VHSV strains. In this study, we determined the virulence of these 18 VHSV strains in flounder and then the assessed relationships between differences in the amino acid sequences of the 18 VHSV strains and their virulence to flounder. We identified one amino acid substitution in the phosphoprotein (P) (Pro55-to-Leu substitution in the P protein; P<sup>P55L</sup>) that is specific to highly virulent strains. This P<sup>P55L</sup> substitution was maintained stably after 30 cell passages. To investigate the effects of the P<sup>P55L</sup> substitution on VHSV virulence in flounder, we generated a recombinant VHSV carrying P<sup>P55L</sup> (rVHSV-P) from rVHSV carrying P55 in the P protein (rVHSV-wild). The rVHSV-P produced high level of viral RNA in cells and showed increased growth in cultured cells and virulence in flounder compared to the rVHSV-wild. In addition, rVHSV-P significantly inhibited the induction of the IFN1 gene in both cells and fish at 6 h post-infection. An RNA-seq analysis confirmed that rVHSV-P infection blocked the induction of several IFN-related genes in virus-infected cells at 6 h post-infection compared to rVHSV-wild. Ectopic expression of P<sup>P55L</sup> protein resulted in a decrease in IFN induction and an increase in viral RNA synthesis in rVHSV-wild-infected cells. Taken together, our results are the first to identify that the P55L substitution in the P protein enhances VHSV virulence in flounder. The data from this study add to the knowledge of VHSV virulence in flounder and could benefit VHSV surveillance efforts and the generation of a VHSV vaccine.</p><p class="para" id="N65542">Viral hemorrhagic septicemia virus (VHSV) is a rhabdovirus that causes huge economic losses to the fish culture industry throughout the world. Virulence among naturally occurring VHSV strains varies widely. However, little is known about the viral factors that determine VHSV virulence. Here, we identify a naturally-occurring, single-amino-acid substitution in the VHSV P protein that enhances VHSV virulence in flounder. This amino acid substitution in the P protein was detected only in highly virulent VHSV strains, and it enhances viral RNA synthesis and inhibits the interferon response of host cells early after virus infection. Recombinant VHSV containing this amino acid substitution caused increased mortality in flounder compared with the wild type. This is the first study to identify a naturally occurring amino acid substitution in VHSV that determines its virulence in flounder. We expect that our result can be applied to other fish species, and this finding will provide new opportunities to generate an effective VHSV vaccine.</p>]]></description>
            <pubDate><![CDATA[2021-01-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Carbomer-based adjuvant elicits CD8 T-cell immunity by inducing a distinct metabolic state in cross-presenting dendritic cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765820934678-ec99941f-6459-4af0-9fbc-6c7f4ae182a9/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009168</link>
            <description><![CDATA[<p class="para" id="N65539">There is a critical need for adjuvants that can safely elicit potent and durable T cell-based immunity to intracellular pathogens. Here, we report that parenteral vaccination with a carbomer-based adjuvant, Adjuplex (ADJ), stimulated robust CD8 T-cell responses to subunit antigens and afforded effective immunity against respiratory challenge with a virus and a systemic intracellular bacterial infection. Studies to understand the metabolic and molecular basis for ADJ’s effect on antigen cross-presentation by dendritic cells (DCs) revealed several unique and distinctive mechanisms. ADJ-stimulated DCs produced IL-1β and IL-18, suggestive of inflammasome activation, but <i>in vivo</i> activation of CD8 T cells was unaffected in caspase 1-deficient mice. Cross-presentation induced by TLR agonists requires a critical switch to anabolic metabolism, but ADJ enhanced cross presentation without this metabolic switch in DCs. Instead, ADJ induced in DCs, an unique metabolic state, typified by dampened oxidative phosphorylation and basal levels of glycolysis. In the absence of increased glycolytic flux, ADJ modulated multiple steps in the cytosolic pathway of cross-presentation by enabling accumulation of degraded antigen, reducing endosomal acidity and promoting antigen localization to early endosomes. Further, by increasing ROS production and lipid peroxidation, ADJ promoted antigen escape from endosomes to the cytosol for degradation by proteasomes into peptides for MHC I loading by TAP-dependent pathways. Furthermore, we found that induction of lipid bodies (LBs) and alterations in LB composition mediated by ADJ were also critical for DC cross-presentation. Collectively, our model challenges the prevailing metabolic paradigm by suggesting that DCs can perform effective DC cross-presentation, independent of glycolysis to induce robust T cell-dependent protective immunity to intracellular pathogens. These findings have strong implications in the rational development of safe and effective immune adjuvants to potentiate robust T-cell based immunity.</p><p class="para" id="N65542">An adjuvant is the pharmacological agent that is added to vaccines to boost immune responses. Currently, there are only seven FDA-approved adjuvants for human use, and vaccines based on these adjuvants have mainly been evaluated for elicitation of antibody-based immunity. However, vaccines need to also stimulate T cell-mediated immunity to protect against diseases such as AIDS, TB and Malaria. Hence, there is a critical need to develop adjuvants that stimulate protective T cell immunity. Here, we identified an adjuvant (Adjuplex; ADJ) that safely induces strong T cell immunity and protects against virus and intracellular bacteria. We also found that ADJ stimulated T cell immunity by unique mechanisms that did not include metabolic activation of antigen-presenting dendritic cells. Instead, ADJ induced a low metabolic state and engaged mechanisms including lipid pathways and induction of reactive oxygen species to promote activation of T cells by dendritic cells, following vaccination. These data not only provide new mechanistic insights into the mechanisms driving activation of T cells by ADJ, it provides a blue print for what adjuvants need to do to induce protection against infections that require T cell immunity.</p>]]></description>
            <pubDate><![CDATA[2021-01-14T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765820807722-7d673226-80f0-4bef-95a6-1f7fd7f6a795/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009246</link>
            <description><![CDATA[<p class="para" id="N65539">Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infects cells by binding to the host cell receptor ACE2 and undergoing virus-host membrane fusion. Fusion is triggered by the protease TMPRSS2, which processes the viral Spike (S) protein to reveal the fusion peptide. SARS-CoV-2 has evolved a multibasic site at the S1-S2 boundary, which is thought to be cleaved by furin in order to prime S protein for TMPRSS2 processing. Here we show that CRISPR-Cas9 knockout of furin reduces, but does not prevent, the production of infectious SARS-CoV-2 virus. Comparing S processing in furin knockout cells to multibasic site mutants reveals that while loss of furin substantially reduces S1-S2 cleavage it does not prevent it. SARS-CoV-2 S protein also mediates cell-cell fusion, potentially allowing virus to spread virion-independently. We show that loss of furin in either donor or acceptor cells reduces, but does not prevent, TMPRSS2-dependent cell-cell fusion, unlike mutation of the multibasic site that completely prevents syncytia formation. Our results show that while furin promotes both SARS-CoV-2 infectivity and cell-cell spread it is not essential, suggesting furin inhibitors may reduce but not abolish viral spread.</p><p class="para" id="N65542">The main focus of research into the COVID-19 pandemic is the SARS-CoV-2 Spike (S) protein, which is the viral protein responsible for binding the ACE2 receptor on the host cell. Prior to and after attachment, the S needs to be activated by cellular proteases (e.g. furin, TMPRSS2), triggering the virus entry into the target cell. The unique feature of SARS-CoV-2 S is the presence of a multibasic site, an amino acid motif recognised by furin protease, and whose cleavage activates the S protein. Intensive antiviral research has been focused on developing furin inhibitors against SARS-CoV-2 infection. Here we show that furin is not absolutely required for SARS-CoV-2 virus production, suggesting that current SARS-CoV-2 antiviral therapies based on furin-targeting drugs may not completely prevent viral infection. Apart from the virus entry process, the S protein plays a key role in triggering cell-cell fusion, potentially allowing the quick spread of the virus among neighbouring cells. We show that furin-mediated pre-activation of S protein in virus infected cells is not necessary for triggering cell-cell fusion, while the multibasic site and the concomitant presence of TMPRSS2 protease on host cell membrane plays an important role in orchestrating the formation of multinucleated cells. Our results also suggest a key role of TMPRSS2 protease in promoting S-mediated cell-cell fusion paving the way for utilising a cocktail of inhibitors to efficiently treat SARS-CoV-2 infections.</p>]]></description>
            <pubDate><![CDATA[2021-01-25T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Asymptomatic <i>Leishmania</i> infection in HIV-positive outpatients on antiretroviral therapy in Pernambuco, Brazil]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765820488137-744c401e-80a6-4203-97f2-265e8704144a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0009067</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Visceral leishmaniasis (VL) in HIV-positive individuals is a global health problem. HIV-<i>Leishmania</i> coinfection worsens prognosis and mortality risk, and HIV-<i>Leishmania</i> coinfected individuals are more susceptible to VL relapses. Early initiation of antiretroviral therapy can protect against <i>Leishmania</i> infection in individuals living in VL-endemic areas, and regular use of antiretrovirals might prevent VL relapses in these individuals. We conducted a cross-sectional study in Petrolina, Brazil, an VL-endemic area, to estimate the prevalence of asymptomatic <i>Leishmania</i> cases among HIV-positive outpatients.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65561">We invited any HIV-positive patients, aged ≥ 18-years-old, under antiretroviral therapy, and who were asymptomatic for VL. Patients were tested for <i>Leishmania</i> with enzyme-linked immunosorbent assays (ELISA)-rK39, immunochromatographic test (ICT)-rK39, direct agglutination test (DAT), latex agglutination test (KAtex), and conventional polymerase chain reaction (PCR). HIV-<i>Leishmania</i> coinfection was diagnosed when at least one VL test was positive.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65573">A total of 483 patients were included. The sample was predominantly composed of single, &lt; 48-years-old, black/<i>pardo</i>, heterosexual males, with fewer than 8 years of schooling. The prevalence of asymptomatic HIV-<i>Leishmania</i> coinfection was 9.11% (44/483). HIV mono-infected and HIV-<i>Leishmania</i> coinfected groups differed statistically significantly in terms of race (p = 0.045), marital status (p = 0.030), and HIV viral load (p = 0.046). Black/<i>pardo</i> patients, married patients, and those with an HIV viral load up to 100,000 copies/ml presented higher odds for HIV-<i>Leishmania</i> coinfection.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65594">A considerable number of asymptomatic <i>Leishmania</i> cases were observed among HIV-positive individuals in a VL-endemic area. Given the potential impact on transmission and health costs, as well as the impact on these coinfected individuals, studies of asymptomatic <i>Leishmania</i> carriers can be useful for guiding public health policies in VL-endemic areas aiming to control and eliminate the disease.</p></div><p class="para" id="N65542">Every year up to 90,000 new cases of visceral leishmaniasis (VL) occurs globally. One of the most neglected diseases, VL is endemic in 60 countries in four continents. Brazil is one of seven countries in which 90% of all cases in the world occur. When co-occurring with HIV, VL tends to be more severe than in HIV-negative persons, leading to worse prognosis and frequent relapses. In this study HIV-positive outpatients, aged 18 years or older, under antiretroviral therapy, who were asymptomatic for VL, were tested for <i>Leishmania</i>. We observed a prevalence of 9.11% (44/483) of HIV-<i>Leishmania</i> coinfection. For those HIV-positive/<i>Leishmania</i>-negative individuals who live in VL-endemic areas, early initiation of antiretroviral therapy can be a protective factor against <i>Leishmania</i> infection. On the other hand, for HIV-<i>Leishmania</i> coinfected individuals who regularly use antiretrovirals might prevent VL relapses. Studies centering on asymptomatic <i>Leishmania</i> carriers can be useful for guiding public health measures in VL-endemic areas seeking to control and eliminate the disease.</p>]]></description>
            <pubDate><![CDATA[2021-01-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Evaluating the competence of the primary vector, <i>Culex tritaeniorhynchus</i>, and the invasive mosquito species, <i>Aedes japonicus japonicus</i>, in transmitting three Japanese encephalitis virus genotypes]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765820437689-96ae2f81-8e5d-44a6-9c8b-5bb380948419/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0008986</link>
            <description><![CDATA[<p class="para" id="N65539">Japanese encephalitis virus (JEV) is maintained in an enzootic cycle between swine, water birds, and mosquitoes. JEV has circulated indigenously in Asia, with <i>Culex tritaeniorhynchus</i> as the primary vector. In some areas where the primary vector is scarce or absent, sporadic cases of Japanese encephalitis have been reported, with <i>Aedes japonicus japonicus</i> presumed to have the potential as a secondary vector. As one of the world’s most invasive culicid species, <i>Ae</i>. <i>j</i>. <i>japonicus</i> carries a considerable health risk for spreading diseases to wider areas, including Europe and North America. Thus, evaluation of its competency as a JEV vector, particularly in a native population, will be essential in preventing potential disease spread. In this study, the two mosquito species’ vector competence in transmitting three JEV genotypes (I, III, and V) was assessed, with <i>Cx</i>. <i>tritaeniorhynchus</i> serving as a point of reference. The mosquitoes were virus-fed and the infection rate (IR), dissemination rate (DR), and transmission rate (TR) evaluated individually by either RT-qPCR or focus forming assay. Results showed striking differences between the two species, with IR of 95% (261/274) and 9% (16/177) in <i>Cx</i>. <i>tritaeniorhynchus</i> and <i>Ae</i>. <i>j</i>. <i>japonicus</i>, respectively. Both mosquitoes were susceptible to all three JEV genotypes with significant differences in IR and mean viral titer. Results confirm the primary vector’s competence, but the fact that JEV was able to establish in <i>Ae</i>. <i>j</i>. <i>japonicus</i> is of public health significance, and with 2%–16% transmission rate it has the potential to successfully transmit JEV to the next host. This may explain the human cases and infrequent detection in primary vector-free areas. Importantly, <i>Ae</i>. <i>j</i>. <i>japonicus</i> could be a relevant vector spreading the disease into new areas, indicating the need for security measures in areas where the mosquito is distributed or where it may be introduced.</p><p class="para" id="N65542">It is widely known that not all mosquito species serve as medically-important virus’ vectors. Even among the vectors, there are variations in their ability to transmit one virus or the other. Nonetheless, while the known primary vectors’ transmission efficiency is evident, the importance of confirming the ability of other potential vectors is indispensable when it comes to the threat of disease introduction to new areas. Japanese encephalitis is a mosquito-borne disease mainly circulating in Asia. However, pockets of infection have been detected outside this endemic area, where the primary mosquito vector (a Culex species) is almost nonexistent. One possibility is that the causal virus is carried by the invasive mosquito species (an Aedes species), originating from Asia, confirmed to adapt well in Europe and North America. Thus, a thorough evaluation will be needed to determine the competence of both the Culex and Aedes species to transmit Japanese encephalitis virus (JEV). Here, the authors found that although the difference in the transmission efficiency between the Culex and Aedes was significant, their competence as vector is evident. This research provides evidence of the possible relevance of the Aedes species in the distribution and spread of JE into new areas.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Measles epidemic in pediatric population in Greece during 2017–2018: Epidemiological, clinical characteristics and outcomes]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765820303310-daf883fd-0d39-4920-8248-24dc751033a9/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245512</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background and aim</h3><p class="para" id="N65543">A measles outbreak occurred in Greece during 2017–2018 affecting mainly pediatric population. The aim of the study was to describe the epidemiological and clinical characteristics of the cases diagnosed in the major pediatric tertiary hospital of Athens, where 26.5% of national pediatric measles cases were diagnosed and treated.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">This is a retrospective study of children 0–16 years old, who presented at the emergency department and/or were hospitalized with clinical presentation compatible with measles and diagnosis was confirmed with molecular detection of the measles RNA in pharyngeal swabs. Epidemiological, clinical and laboratory characteristics were retrieved from medical records and analyzed.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">A total of 578 children with measles were identified during the study period. 322 (55.7%) were male with median age 36 months (range:1–193), while the largest number of documented cases (251; 43.4%) were children aged 1–5 years. Most children (429/578; 74.2%) belonged to the Roma minority and only 64 (11.1%) had Greek origin. 497 (91.5%) children were unvaccinated and 37 (6.8%) were partially vaccinated with measles vaccine. Hospitalization was required for 342 (59.2%) children, whereas one or more complications were reported in 230 (67.2%) of them. Most frequent complications were elevated transaminases (139; 40.6%), acute otitis media (72; 21%), dehydration (67; 19.6%) and pneumonia (58; 16.9%). 11 children (3.2%) required intensive care admission for altered mental status/status epilepticus (3), sepsis (2) and ARDS (6). 119/342 (34.8%) children were treated with antibiotics because of possible or confirmed bacterial coinfection. One death was reported, concerning an 11-month-old unvaccinated infant, with underlying dystrophy, who died of sepsis.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">Measles is not an innocent viral infection, as it is still characterized by high morbidity and complications rates. Unvaccinated or partially vaccinated populations could trigger new outbreaks, resulting in significant cost in public health. To avoid future measles outbreaks, high vaccination coverage should be achieved, as well as closing immunity gaps in the population and ensuring high-quality measles surveillance.</p></div>]]></description>
            <pubDate><![CDATA[2021-01-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765820211777-8b0384a2-5de8-479c-8bdd-31a2f1fcfc7c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0241708</link>
            <description><![CDATA[<p class="para" id="N65539">Benign ethnic neutropenia (BEN) is defined as a neutrophil count of &lt;1.5×10<sup>9</sup> cells/L in healthy individuals and is more common in populations of certain ethnicities, e.g. African or Middle Eastern ethnicity. Neutrophil values are commonly included in eligibility criteria for research participation, but little is known about the relationship between BEN, HIV acquisition, and the occurrence of adverse events during clinical trials. We investigated these relationships using data from an HIV vaccine efficacy trial of healthy adults from 5 South African sites. We analysed data from the double-blind, placebo-controlled, randomized trial HVTN 503, and its follow-on study HVTN 503-S to assess the prevalence of BEN, its association with HIV infection, and adverse event reporting. These data were then compared with a time- and age-matched, non-pregnant cohort from the National Health and Nutrition Examination Survey (NHANES) conducted between 2007–2008 in the United States (US). The 739 South African participants had a median age of 22.0 years (interquartile range = 20–26) and 56% (n = 412) were male. Amongst the US cohort of 845 participants, the median age was 26 (IQR: 21–30) and the majority (54%, 457/745) were also male. BEN was present at enrolment in 7.0% (n = 52) of South African participants (6% in the placebo group versus 8% in the vaccine group); 81% (n = 42) of those with BEN were male. Pretoria North had the highest prevalence of BEN (11.6%, 5/43), while Cape Town had the lowest (0.7%, 1/152). Participants with BEN had a lower median neutrophil count (1.3 vs. 3.2x10<sup>9</sup> cells/L; p&lt;0.001) and BMI (20.8 vs. 22.3 kg/m<sup>2</sup>; p&lt;0.001) when compared to those without BEN. A greater proportion of Black South Africans had neutrophil counts &lt;1.5×10<sup>9</sup> cells/L compared to US non-Hispanic Whites from the NHANES cohort (7% [52/739] vs. 0.6% [3/540]; p&lt;0.001). BEN did not increase the odds for HIV infection (adjusted odds ratio [aOR]: 1.364, 95% confidence interval [95% CI]: 0.625–2.976; p = 0.4351). However, female gender (aOR: 1.947, 95% CI: 1.265–2.996; p = 0.0025) and cannabis use (aOR: 2.192, 95% CI: 1.126–4.266; p = 0.0209) increased the odds of HIV acquisition. The incidence rates of adverse events were similar between participants in the placebo group with BEN, and those without: 12.1 (95% CI: 7.3–20.1) vs. 16.5 (95% CI: 14.6–18.7; p = 0.06) events per 100 person-years (py) were noted in the infections and infestations system organ class, respectively. The vaccine group had an event incidence rate of 19.7 (95% CI: 13.3–29.2) vs. 14.8 (95% CI: 13.0–16.8; p = 0.07) events per 100py in the group with, and without BEN, respectively. BEN is more prevalent in Black South Africans compared to US Non-Hispanic Whites. Our data do not support excluding populations from HIV vaccine trials because of BEN. BEN was not associated with increased risk for HIV infection or Adverse events on a vaccine trial. Predictors of HIV infection risk were females and cannabis use, underlying the continued importance of prevention programmes in focusing on these populations.</p>]]></description>
            <pubDate><![CDATA[2021-01-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765819655926-2a93990f-c5fb-42c1-a63d-ad085873454d/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009220</link>
            <description><![CDATA[<p class="para" id="N65539">The eponymous member of the interferon regulatory factor (IRF) family, IRF1, was originally identified as a nuclear factor that binds and activates the promoters of type I interferon genes. However, subsequent studies using genetic knockouts or RNAi-mediated depletion of IRF1 provide a much broader view, linking IRF1 to a wide range of functions in protection against invading pathogens. Conserved throughout vertebrate evolution, IRF1 has been shown in recent years to mediate constitutive as well as inducible host defenses against a variety of viruses. Fine-tuning of these ancient IRF1-mediated host defenses, and countering strategies by pathogens to disarm IRF1, play crucial roles in pathogenesis and determining the outcome of infection.</p>]]></description>
            <pubDate><![CDATA[2021-01-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765819625902-2a4c0e51-8582-4c88-8077-f7ccf527c083/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0245072</link>
            <description><![CDATA[<p class="para" id="N65539">Middle East respiratory syndrome (MERS-COV), first identified in Saudi Arabia, was caused by a novel strain of coronavirus. Outbreaks were recorded from different regions of the world, especially South Korea and the Middle East, and were correlated with a 35% mortality rate. MERS-COV is a single-stranded, positive RNA virus that reaches the host by binding to the receptor of dipeptidyl-peptides. Because of the unavailability of the vaccine available for the protection from MERS-COV infection, the rapid case detection, isolation, infection prevention has been recommended to combat MERS-COV infection. So, vaccines for the treatment of MERS-COV infection need to be developed urgently. A possible antiviral mechanism for preventing MERS-CoV infection has been considered to be MERS-CoV vaccines that elicit unique T-cell responses. In the present study, we incorporated both molecular docking and immunoinformatic approach to introduce a multiepitope vaccine (MEP) against MERS-CoV by selecting 15 conserved epitopes from seven viral proteins such as three structural proteins (envelope, membrane, and nucleoprotein) and four non-structural proteins (ORF1a, ORF8, ORF3, ORF4a). The epitopes, which were examined for non-homologous to host and antigenicity, were selected on the basis of conservation between T-cell, B-cell, and IFN-γ epitopes. The selected epitopes were then connected to the adjuvant (β-defensin) at the N-terminal through an AAY linker to increase the immunogenic potential. Structural modelling and physiochemical characteristic were applied to the vaccine construct developed. Afterwards the structure has been successfully docked with antigenic receptor, Toll-like receptor 3 (TLR-3) and <i>in-silico</i> cloning ensures that its expression efficiency is legitimate. Nonetheless the MEP presented needs tests to verify its safety and immunogenic profile.</p>]]></description>
            <pubDate><![CDATA[2021-02-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Long-term experimental evolution of HIV-1 reveals effects of environment and mutational history]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765819561420-9911c974-3800-4517-961f-4c11b993601f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pbio.3001010</link>
            <description><![CDATA[<p class="para" id="N65539">An often-returning question for not only HIV-1, but also other organisms, is how predictable evolutionary paths are. The environment, mutational history, and random processes can all impact the exact evolutionary paths, but to which extent these factors contribute to the evolutionary dynamics of a particular system is an open question. Especially in a virus like HIV-1, with a large mutation rate and large population sizes, evolution is expected to be highly predictable if the impact of environment and history is low, and evolution is not neutral. We investigated the effect of environment and mutational history by analyzing sequences from a long-term evolution experiment, in which HIV-1 was passaged on 2 different cell types in 8 independent evolutionary lines and 8 derived lines, 4 of which involved a switch of the environment. The experiments lasted for 240–300 passages, corresponding to approximately 400–600 generations or almost 3 years. The sequences show signs of extensive parallel evolution—the majority of mutations that are shared between independent lines appear in both cell types, but we also find that both environment and mutational history significantly impact the evolutionary paths. We conclude that HIV-1 evolution is robust to small changes in the environment, similar to a transmission event in the absence of an immune response or drug pressure. We also find that the fitness landscape of HIV-1 is largely smooth, although we find some evidence for both positive and negative epistatic interactions between mutations.</p><p class="para" id="N65540">Analysis of the longest evolutionary experiment with HIV-1 to-date reveals continuous viral adaptation over several years. The authors quantify the environment-specific mutations that arise and determine the fraction of mutations that co-occur with significantly different frequencies than expected by chance.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Effect of early oxygen therapy and antiviral treatment on disease progression in patients with COVID-19: A retrospective study of medical charts in China]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765818952975-b6d6561d-1afa-49dd-a044-89b737bb8c94/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0009051</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Until now, no antiviral treatment has been proven to be effective for the coronavirus disease 2019 (COVID-19). The timing of oxygen therapy was considered to have a great influence on the symptomatic relief of hypoxemia and seeking medical intervention, especially in situations with insufficient medical resources, but the evidence on the timing of oxygen therapy is limited.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods and findings</h3><p class="para" id="N65549">Medical charts review was carried out to collect the data of hospitalized patients with COVID-19 infection confirmed in Tongji hospital, Wuhan from 30<sup>th</sup> December 2019 to 8<sup>th</sup> March 2020. In this study, the appropriate timing of oxygen therapy and risk factors associated with severe and fatal illness were identified and the effectiveness of antivirus on disease progression was assessed. Among 1362 patients, the prevalence of hypoxia symptoms was significantly higher in those patients with severe and fatal illness than in those with less severe disease. The onset of hypoxia symptoms was most common in the second to third week after symptom onset, and patients with critical and fatal illness experienced these symptoms earlier than those with mild and severe illness. In multivariable analyses, the risk of death increased significantly when oxygen therapy was started more than 2 days after hypoxia symptoms onset among critical patients (OR, 1.92; 95%CI, 1.20 to 3.10). Compared to the critically ill patients without IFN-a, the patients who were treated with IFN-a had a lower mortality (OR, 0.60; 95%CI, 0.39 to 0.91).</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusions</h3><p class="para" id="N65561">Early initiation of oxygen therapy was associated with lower mortality among critical patients. This study highlighted the importance of early oxygen therapy after the onset of hypoxia symptoms. Our results also lend support to potentially beneficial effects of IFNα on critical illness.</p></div><p class="para" id="N65542">Until now, no antiviral treatment has been proven to be effective for the coronavirus disease 2019 (COVID-19). The timing of oxygen therapy, which has rarely been mentioned in the current literature, has a great influence on the symptomatic relief of hypoxemia and seeking medical intervention, especially in situations with limited medical resources. It is worthwhile to find clues from the exploratory use of oxygen and antiviral drugs in Wuhan at the beginning of the COVID-29 pandemic. Therefore, in this study, a retrospective review was carried out to identify the risk factors associated with a severe and fatal illness, including the use of antivirus and timing of oxygen therapy. The main differences in the clinical features of patients with different severities of COVID-19 were described and the risk factors were explored to expand the current recommendations for high-risk groups. Initiation of oxygen treatment less than 2 days after onset after onset of hypoxia symptoms and the use of IFN-a among critically ill patients were significantly associated with lower risk of COVID-19 mortality. Our study highlighted the importance of early oxygen therapy and lend support to the potentially beneficial effects of IFNα on critical illness.</p>]]></description>
            <pubDate><![CDATA[2021-01-06T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Generalized linear models provide a measure of virulence for specific mutations in SARS-CoV-2 strains]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765818822884-80ad8c8d-2b79-4e93-a47f-71a47bc1ce1f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0238665</link>
            <description><![CDATA[<p class="para" id="N65539">This study aims to highlight SARS-COV-2 mutations which are associated with increased or decreased viral virulence. We utilize genetic data from all strains available from GISAID and countries’ regional information, such as deaths and cases per million, as well as COVID-19-related public health austerity measure response times. Initial indications of selective advantage of specific mutations can be obtained from calculating their frequencies across viral strains. By applying modelling approaches, we provide additional information that is not evident from standard statistics or mutation frequencies alone. We therefore, propose a more precise way of selecting informative mutations. We highlight two interesting mutations found in genes <i>N</i> (P13L) and <i>ORF3a</i> (Q57H). The former appears to be significantly associated with decreased deaths and cases per million according to our models, while the latter shows an opposing association with decreased deaths and increased cases per million. Moreover, protein structure prediction tools show that the mutations infer conformational changes to the protein that significantly alter its structure when compared to the reference protein.</p>]]></description>
            <pubDate><![CDATA[2021-01-26T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[T-cell responses to sequentially emerging viral escape mutants shape long-term HIV-1 population dynamics]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765799203433-79f12857-84d7-47d8-b442-b2780d35afb5/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009177</link>
            <description><![CDATA[<p class="para" id="N65539">HIV-1 strains harboring immune escape mutations can persist in circulation, but the impact of selection by multiple HLA alleles on population HIV-1 dynamics remains unclear. In Japan, HIV-1 Reverse Transcriptase codon 135 (RT135) is under strong immune pressure by HLA-B*51:01-restricted and HLA-B*52:01-restricted T cells that target a key epitope in this region (TI8; spanning RT codons 128–135). Major population-level shifts have occurred at HIV-1 RT135 during the Japanese epidemic, which first affected hemophiliacs (via imported contaminated blood products) and subsequently non-hemophiliacs (via domestic transmission). Specifically, threonine accumulated at RT135 (RT135T) in hemophiliac and non-hemophiliac HLA-B*51:01<sup>+</sup> individuals diagnosed before 1997, but since then RT135T has markedly declined while RT135L has increased among non-hemophiliac individuals. We demonstrated that RT135V selection by HLA-B*52:01-restricted TI8-specific T-cells led to the creation of a new HLA-C*12:02-restricted epitope TN9-8V. We further showed that TN9-8V-specific HLA-C*12:02-restricted T cells selected RT135L while TN9-8T-specific HLA-C*12:02-restricted T cells suppressed replication of the RT135T variant. Thus, population-level accumulation of the RT135L mutation over time in Japan can be explained by initial targeting of the TI8 epitope by HLA-B*52:01-restricted T-cells, followed by targeting of the resulting escape mutant by HLA-C*12:02-restricted T-cells. We further demonstrate that this phenomenon is particular to Japan, where the HLA-B*52:01-C*12:02 haplotype is common: RT135L did not accumulate over a 15-year longitudinal analysis of HIV sequences in British Columbia, Canada, where this haplotype is rare. Together, our observations reveal that T-cell responses to sequentially emerging viral escape mutants can shape long-term HIV-1 population dynamics in a host population-specific manner.</p><p class="para" id="N65542">HIV-1 strains harboring immune escape mutations can accumulate in circulation, but it remains unclear to what extent these 'escaped' HIV-1 strains continue to evolve under ongoing population-level immune pressures. We investigated population-level changes at HIV-1 Reverse Transcriptase codon 135 (RT135), which is under pressure by T cells restricted by HLA-B*51:01 and B*52:01, highly frequent alleles in Japan. While threonine initially accumulated at RT135, RT135L has subsequently increased markedly. Our findings revealed that RT135V selection by HLA-B*52:01-restricted T-cells led to the creation of a new epitope restricted by HLA-C*12:02, an allele in strong linkage disequilibrium with HLA-B*52:01. HLA-C*12:02-restricted T cells in turn suppressed replication of RT135T virus and selected RT135L. Notably, population-level shifts at this codon are particular to Japan, where HLA-B*52:01-C*12:02 represents the most prevalent HLA haplotype. Our findings highlight multiple virus-specific T cells as dynamic drivers of population-level − and host population-specific − HIV-1 evolution over the long term.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Key interplay between the co-opted sorting nexin-BAR proteins and PI3P phosphoinositide in the formation of the tombusvirus replicase]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765798944910-457108fe-dd6c-4043-b764-380cb61b4b0b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009120</link>
            <description><![CDATA[<p class="para" id="N65539">Positive-strand RNA viruses replicate in host cells by forming large viral replication organelles, which harbor numerous membrane-bound viral replicase complexes (VRCs). In spite of its essential role in viral replication, the biogenesis of the VRCs is not fully understood. The authors identified critical roles of cellular membrane-shaping proteins and PI(3)P (phosphatidylinositol 3-phosphate) phosphoinositide, a minor lipid with key functions in endosomal vesicle trafficking and autophagosome biogenesis, in VRC formation for <i>tomato bushy stunt virus</i> (TBSV). The authors show that TBSV co-opts the endosomal SNX-BAR (sorting nexin with Bin/Amphiphysin/Rvs- BAR domain) proteins, which bind to PI(3)P and have membrane-reshaping function during retromer tubular vesicle formation, directly into the VRCs to boost progeny viral RNA synthesis. We find that the viral replication protein-guided recruitment and pro-viral function of the SNX-BAR proteins depends on enrichment of PI(3)P at the site of viral replication. Depletion of SNX-BAR proteins or PI(3)P renders the viral double-stranded (ds)RNA replication intermediate RNAi-sensitive within the VRCs in the surrogate host yeast and <i>in planta</i> and ribonuclease-sensitive in cell-free replicase reconstitution assays in yeast cell extracts or giant unilamellar vesicles (GUVs). Based on our results, we propose that PI(3)P and the co-opted SNX-BAR proteins are coordinately exploited by tombusviruses to promote VRC formation and to play structural roles and stabilize the VRCs during viral replication. Altogether, the interplay between the co-opted SNX-BAR membrane-shaping proteins, PI(3)P and the viral replication proteins leads to stable VRCs, which provide the essential protection of the viral RNAs against the host antiviral responses.</p><p class="para" id="N65542">Positive-stranded RNA viruses are major pathogens of plants, humans and animals. These viruses hijack and deform intracellular membranes to build viral replication compartments, which support virus replication. In this paper, the authors have identified the critical roles of cellular membrane-shaping proteins and a unique lipid in the formation of the replicase complex for tomato bushy stunt virus (TBSV). TBSV co-opts and retargets the endosomal sorting nexin-BAR proteins into the large TBSV-induced replication compartment. TBSV also promotes the enrichment of PI(3)P phosphoinositide within the subverted membranes. The interplay between the membrane-shaping proteins, PI(3)P and the viral replication proteins leads to stable membranous structures around the viral replicase, which provide the essential protection of the viral RNAs against the host antiviral responses.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765793759126-69880530-9aac-4d51-acc4-8d779b68794c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009103</link>
            <description><![CDATA[<p class="para" id="N65539">The antibody molecule comprises a variable domain conferring antigen specificity and affinity distinct from the heavy chain constant (CH) domains dictating effector functions. We here interrogate this paradigm by evaluating the unique influence of the CH1<b>α</b> domain on epitope specificity and functions using two mucosal gp41-specific Fab-IgAs (FabA) derived from HIV-1 highly-exposed but persistently seronegative individuals (HESN). These HESN develop selectively affinity-matured HIV-1-specific mucosal IgA that target the gp41 viral envelope and might provide protection although by unclear mechanisms. Isotype-switching FabAs into Fab-IgGs (FabGs) results in a &gt;10-fold loss in affinity for HIV-1 clade A, B, and C gp41, together with reduced neutralization of HIV-1 cross-clade. The FabA conformational epitopes map selectively on gp41 in 6-Helix bundle and pre-fusion conformations cross-clade, unlike FabGs. Finally, we designed <i>in silico</i>, a 12 amino-acid peptide recapitulating one FabA conformational epitope that inhibits the FabA binding to gp41 cross-clade and its neutralizing activity. Altogether, our results reveal that the CH1<b>α</b> domain shapes the antibody paratope through an allosteric effect, thereby strengthening the antibody specificity and functional activities. Further, they clarify the mechanisms by which these HESN IgAs might confer protection against HIV-1-sexual acquisition. The IgA-specific epitope we characterized by reverse vaccinology could help designing a mucosal HIV-1 vaccine.</p><p class="para" id="N65542">In HIV-1 highly exposed persistently seronegative individuals (HESN), protection is a multifactorial phenomenon whereby mucosal IgA, but not IgG, play a determinant anti-viral role. The HESN IgA response focuses on conserved regions of the HIV-1 envelope gp41 subunit, in contrast with the broader IgG and IgA response observed in HIV-1-infected individuals. How protective only IgA, but not IgG, develop in HESN remains unclear. We addressed the role of the CH1 domain of each isotype in antigen recognition and functions by comparing mucosal gp41 specific Fab-IgA1 (FabA) derived from HESN with paired Fab-IgG1 (FabG). We show that structural differences in the CH1α and γ domains impact affinity constants, FabA having higher affinity for gp41 derived from clade A, B and C. FabA neutralization of clade A, B and C HIV-1 infection and transfer from Langerhans to CD4+T cells were cross clade and higher than that observed with corresponding IgG. Accordingly, FabA and G recognize different gp41 epitopes on gp41 clade A, B and C gp41 crystal structures. Using molecular modeling, we defined a peptide corresponding to one 3-D epitope common to gp41 clade A, B and C gp41 specific for one of the FabA that reverses the FabA neutralizing activities. Altogether, we show here that the CH1 domain influences the antibody paratope and in turn its specificity and functional activities. The FabA cross-clade epitopes retrieved on gp41 could be useful in mucosal vaccine design against HIV-1.</p>]]></description>
            <pubDate><![CDATA[2020-12-14T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The SUMOylation pathway suppresses arbovirus replication in <i>Aedes aegypti</i> cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765793603152-1b5bc302-66ee-4ba9-b637-ef09da972720/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009134</link>
            <description><![CDATA[<p class="para" id="N65539">Mosquitoes are responsible for the transmission of many clinically important arboviruses that cause significant levels of annual mortality and socioeconomic health burden worldwide. Deciphering the mechanisms by which mosquitoes modulate arbovirus infection is crucial to understand how viral-host interactions promote vector transmission and human disease. SUMOylation is a post-translational modification that leads to the covalent attachment of the Small Ubiquitin-like MOdifier (SUMO) protein to host factors, which in turn can modulate their stability, interaction networks, sub-cellular localisation, and biochemical function. While the SUMOylation pathway is known to play a key role in the regulation of host immune defences to virus infection in humans, the importance of this pathway during arbovirus infection in mosquito vectors, such as <i>Aedes aegypti</i> (<i>Ae</i>. <i>aegypti</i>), remains unknown. Here we characterise the sequence, structure, biochemical properties, and tissue-specific expression profiles of component proteins of the <i>Ae</i>. <i>aegypti</i> SUMOylation pathway. We demonstrate significant biochemical differences between <i>Ae</i>. <i>aegypti</i> and <i>Homo sapiens</i> SUMOylation pathways and identify cell-type specific patterns of SUMO expression in <i>Ae</i>. <i>aegypti</i> tissues known to support arbovirus replication. Importantly, depletion of core SUMOylation effector proteins (SUMO, Ubc9 and PIAS) in <i>Ae</i>. <i>aegypti</i> cells led to enhanced levels of arbovirus replication from three different families; Zika (<i>Flaviviridae</i>), Semliki Forest (<i>Togaviridae</i>), and Bunyamwera (<i>Bunyaviridae</i>) viruses. Our findings identify an important role for mosquito SUMOylation in the cellular restriction of arboviruses that may directly influence vector competence and transmission of clinically important arboviruses.</p><p class="para" id="N65542">Half the world’s population is at risk of infection from arboviruses transmitted by mosquitoes. Deciphering the viral-host interactions that influence the outcome of arbovirus infection in mosquitoes is beneficial to the development of future vector control strategies to limit arbovirus transmission and viral emergence within the human population. Similar to humans, mosquitoes possess different immune pathways to limit the replication of arboviruses. While the Small Ubiquitin-like MOdifier (SUMO) pathway is known to play an important role in the regulation of immune defences to viral infection in humans, the influence of this pathway during arbovirus infection in mosquito cells is currently unknown. Here we define the conservation, biochemical activity, and tissue distribution of the core effector proteins of the <i>Aedes aegypti</i> SUMOylation pathway. We show that the mosquito SUMOylation pathway plays a broadly antiviral role against a wide range of clinically important arboviruses, including Zika, Semliki Forest, and Bunyamwera viruses. Our findings identify SUMOylation as an important component of the antiviral response to arbovirus infection in mosquito cells.</p>]]></description>
            <pubDate><![CDATA[2020-12-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765789811161-a4c04dc9-5d7f-41f1-afb0-537a91638995/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0243712</link>
            <description><![CDATA[<p class="para" id="N65539">To respond to the urgent need for COVID-19 testing, countries perform nucleic acid amplification tests (NAAT) for the detection of SARS-CoV-2 in centralized laboratories. Real-time RT—PCR (Reverse transcription—Polymerase Chain Reaction), used to amplify and detect the viral RNA., is considered, as the current gold standard for diagnostics. It is an efficient process, but the complex engineering required for automated RNA extraction and temperature cycling makes it incompatible for use in point of care settings [<a href="#pone.0243712.ref001">1</a>]. In the present work, by harnessing progress made in the past two decades in isothermal amplification and paper microfluidics, we created a portable test, in which SARS-CoV-2 RNA is extracted, amplified isothermally by RT—LAMP (Loop-mediated Isothermal Amplification), and detected using intercalating dyes or fluorescent probes. Depending on the viral load in the tested samples, the detection takes between twenty minutes and one hour. Using a set of 16 pools of naso-pharyngal swab eluates, we estimated a limit of detection comparable to real-time RT-PCR (i.e. 1 genome copies per microliter of clinical sample) and no cross‐reaction with eight major respiratory viruses currently circulating in Europe. We designed and fabricated an easy-to-use portable device called “COVIDISC” to carry out the test at the point of care. The low cost of the materials along with the absence of complex equipment will expedite the widespread dissemination of this device. What is proposed here is a new efficient tool to help managing the pandemics.</p>]]></description>
            <pubDate><![CDATA[2021-01-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Full length genomic sanger sequencing and phylogenetic analysis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Nigeria]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765789302231-8e6fbadb-46cd-4a42-8c65-571f18d8b9ce/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0243271</link>
            <description><![CDATA[<p class="para" id="N65539">In an outbreak, effective detection of the aetiological agent(s) involved using molecular techniques is key to efficient diagnosis, early prevention and management of the spread. However, sequencing is necessary for mutation monitoring and tracking of clusters of transmission, development of diagnostics and for vaccines and drug development. Many sequencing methods are fast evolving to reduce test turn-around-time and to increase through-put compared to Sanger sequencing method; however, Sanger sequencing remains the gold standard for clinical research sequencing with its 99.99% accuracy This study sought to generate sequence data of SARS-CoV-2 using Sanger sequencing method and to characterize them for possible site(s) of mutations. About 30 pairs of primers were designed, synthesized, and optimized using endpoint PCR to generate amplicons for the full length of the virus. Cycle sequencing using BigDye Terminator v.3.1 and capillary gel electrophoresis on ABI 3130xl genetic analyser were performed according to the manufacturers’ instructions. The sequence data generated were assembled and analysed for variations using DNASTAR Lasergene 17 SeqMan Ultra. Total length of 29,760bp of SARS-CoV-2 was assembled from the sample analysed and deposited in GenBank with accession number: MT576584. Blast result of the sequence assembly shows a 99.97% identity with the reference sequence. Variations were noticed at positions: nt201, nt2997, nt14368, nt16535, nt20334, and nt28841-28843, which caused amino acid alterations at the S (aa614) and N (aa203-204) regions. The mutations observed at S and N-gene in this study may be indicative of a gradual changes in the genetic coding of the virus hence, the need for active surveillance of the viral genome.</p>]]></description>
            <pubDate><![CDATA[2021-01-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A novel circulating tamiami mammarenavirus shows potential for zoonotic spillover]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765782999089-f811831c-033e-49d7-b6f1-e3f4cf32cb46/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0009004</link>
            <description><![CDATA[<p class="para" id="N65539">A detailed understanding of the mechanisms underlying the capacity of a virus to break the species barrier is crucial for pathogen surveillance and control. New World (NW) mammarenaviruses constitute a diverse group of rodent-borne pathogens that includes several causative agents of severe viral hemorrhagic fever in humans. The ability of the NW mammarenaviral attachment glycoprotein (GP) to utilize human transferrin receptor 1 (hTfR1) as a primary entry receptor plays a key role in dictating zoonotic potential. The recent isolation of Tacaribe and lymphocytic choriominingitis mammarenaviruses from host-seeking ticks provided evidence for the presence of mammarenaviruses in arthropods, which are established vectors for numerous other viral pathogens. Here, using next generation sequencing to search for other mammarenaviruses in ticks, we identified a novel replication-competent strain of the NW mammarenavirus Tamiami (TAMV-FL), which we found capable of utilizing hTfR1 to enter mammalian cells. During isolation through serial passaging in mammalian immunocompetent cells, the quasispecies of TAMV-FL acquired and enriched mutations leading to the amino acid changes N151K and D156N, within GP. Cell entry studies revealed that both substitutions, N151K and D156N, increased dependence of the virus on hTfR1 and binding to heparan sulfate proteoglycans. Moreover, we show that the substituted residues likely map to the sterically constrained trimeric axis of GP, and facilitate viral fusion at a lower pH, resulting in viral egress from later endosomal compartments. In summary, we identify and characterize a naturally occurring TAMV strain (TAMV-FL) within ticks that is able to utilize hTfR1. The TAMV-FL significantly diverged from previous TAMV isolates, demonstrating that TAMV quasispecies exhibit striking genetic plasticity that may facilitate zoonotic spillover and rapid adaptation to new hosts.</p><p class="para" id="N65542">Mammarenaviruses include emergent pathogens responsible of severe disease in humans in zoonotic events. The ability to use the human Transferrin receptor 1 (hTfR1) strongly correlates with their pathogenicity in humans. We isolated a new infectious Tamiami virus strain (TAMV-FL) from host-seeking ticks, which, contrary to the previous rodent-derived reference strain, can use hTfR1 to enter human cells. Moreover, serial passaging of TAMV-FL in human immunocompetent cells selected for two substitutions in the viral envelope glycoprotein: N151K and D156N. These substitutions increase the ability to highjack hTfR1 and the binding capacity to heparan sulfate proteoglycans and cause delayed endosomal escape. Our findings provide insight into the acquisition of novel traits by currently circulating TAMV that increase its potential to trespass the inter-species barrier.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The axonal sorting activity of pseudorabies virus Us9 protein depends on the state of neuronal maturation]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765782590222-c3abd36f-524a-4895-94c2-a818c0fc4759/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1008861</link>
            <description><![CDATA[<p class="para" id="N65539">Alpha-herpesviruses establish a life-long infection in the nervous system of the affected host; while this infection is restricted to peripheral neurons in a healthy host, the reactivated virus can spread within the neuronal circuitry, such as to the brain, in compromised individuals and lead to adverse health outcomes. Pseudorabies virus (PRV), an alpha-herpesvirus, requires the viral protein Us9 to sort virus particles into axons and facilitate neuronal spread. Us9 sorts virus particles by mediating the interaction of virus particles with neuronal transport machinery. Here, we report that Us9-mediated regulation of axonal sorting also depends on the state of neuronal maturation. Specifically, the development of dendrites and axons is accompanied with proteomic changes that influence neuronal processes. Immature superior cervical ganglionic neurons (SCGs) have rudimentary neurites that lack markers of mature axons. Immature SCGs can be infected by PRV, but they show markedly reduced Us9-dependent regulation of sorting, and increased Us9-independent transport of particles into neurites. Mature SCGs have relatively higher abundances of proteins characteristic of vesicle-transport machinery. We also identify Us9-associated neuronal proteins that can contribute to axonal sorting and subsequent anterograde spread of virus particles in axons. We show that SMPD4/nsMase3, a sphingomyelinase abundant in lipid-rafts, associates with Us9 and is a negative regulator of PRV sorting into axons and neuronal spread, a potential antiviral function.</p><p class="para" id="N65542">Viral pathogenesis often is age-dependent, with more severe outcomes for infected fetuses and neonates compared to adults. As neurons age and mature, dendrites and axons polarize with distinct functions that affect neurotropic virus replication and neuronal spread of infection. This study investigates how neuronal maturation of peripheral nervous system neurons, the site of alpha-herpesvirus life-long latency and reactivation, affects replication and neuronal spread of pseudorabies virus. Characterization of infected immature and mature primary cultures of superior cervical ganglionic neurons revealed significant differences in protein composition and cellular processes that affected the activity of Us9, a viral protein required for sorting virus particles into axons. We identified neuronal and viral proteins that interact with Us9 in immature and mature neurons. Among these, we demonstrate that SMPD4/nsMase3, a sphingomyelinase critical for membrane organization and neuronal function, regulates PRV neuronal spread by preventing capsid association with Us9-containing membranes, presenting a possible antiviral function.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The latency-associated transcript locus of herpes simplex virus 1 is a virulence determinant in human skin]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765782472756-999b9d2a-a48c-4e18-98c3-e7a0824b9178/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009166</link>
            <description><![CDATA[<p class="para" id="N65539">Herpes simplex virus 1 (HSV-1) infects skin and mucosal epithelial cells and then travels along axons to establish latency in the neurones of sensory ganglia. Although viral gene expression is restricted during latency, the latency-associated transcript (LAT) locus encodes many RNAs, including a 2 kb intron known as the hallmark of HSV-1 latency. Here, we studied HSV-1 infection and the role of the LAT locus in human skin xenografts <i>in vivo</i> and in cultured explants. We sequenced the genomes of our stock of HSV-1 strain 17s<i>yn</i><sup>+</sup> and seven derived viruses and found nonsynonymous mutations in many viral proteins that had no impact on skin infection. In contrast, deletions in the LAT locus severely impaired HSV-1 replication and lesion formation in skin. However, skin replication was not affected by impaired intron splicing. Moreover, although the LAT locus has been implicated in regulating gene expression in neurones, we observed only small changes in transcript levels that were unrelated to the growth defect in skin, suggesting that its functions in skin may be different from those in neurones. Thus, although the LAT locus was previously thought to be dispensable for lytic infection, we show that it is a determinant of HSV-1 virulence during lytic infection of human skin.</p><p class="para" id="N65542">Herpes simplex virus type 1 (HSV-1) infects and destroys the outer layer of skin cells, producing lesions known as cold sores. Although these lesions heal, the virus persists in the host for the lifetime and can reactivate to cause new lesions. This is possible because the virus enters the axons of neurones in the skin and moves to their cell bodies located in spinal or cranial nerve bundles called ganglia, where the virus becomes dormant (latent). The most abundant viral RNAs expressed during this state are the latency associated transcripts (LATs), which have been considered a hallmark of HSV-1 latency. Here, we studied HSV-1 infection and spread in human skin. Unexpectedly, we found that the LAT locus is necessary for lesion formation in skin. HSV-1 viruses that were genetically mutated to delete the start of the locus could not spread in skin, whereas viruses with many other genetic mutations had this capacity. Our results suggest that an antiviral drug that inhibits transcripts from this region of the viral genome could block viral spread in skin, or a vaccine could possibly be produced by genetically modifying the virus at the LAT locus and by doing so, limit the virus’ ability become latent in neurones.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765782398424-aaec30a0-fe27-44b1-a549-3fcba00ccef5/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pmed.1003501</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Numerous clinical trials and observational studies have investigated various pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19), but the results are heterogeneous and sometimes even contradictory to one another, making it difficult for clinicians to determine which treatments are truly effective.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods and findings</h3><p class="para" id="N65549">We carried out a systematic review and network meta-analysis (NMA) to systematically evaluate the comparative efficacy and safety of pharmacological interventions and the level of evidence behind each treatment regimen in different clinical settings. Both published and unpublished randomized controlled trials (RCTs) and confounding-adjusted observational studies which met our predefined eligibility criteria were collected. We included studies investigating the effect of pharmacological management of patients hospitalized for COVID-19 management. Mild patients who do not require hospitalization or have self-limiting disease courses were not eligible for our NMA. A total of 110 studies (40 RCTs and 70 observational studies) were included. PubMed, Google Scholar, MEDLINE, the Cochrane Library, medRxiv, SSRN, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov were searched from the beginning of 2020 to August 24, 2020. Studies from Asia (41 countries, 37.2%), Europe (28 countries, 25.4%), North America (24 countries, 21.8%), South America (5 countries, 4.5%), and Middle East (6 countries, 5.4%), and additional 6 multinational studies (5.4%) were included in our analyses. The outcomes of interest were mortality, progression to severe disease (severe pneumonia, admission to intensive care unit (ICU), and/or mechanical ventilation), viral clearance rate, QT prolongation, fatal cardiac complications, and noncardiac serious adverse events. Based on RCTs, the risk of progression to severe course and mortality was significantly reduced with corticosteroids (odds ratio (OR) 0.23, 95% confidence interval (CI) 0.06 to 0.86, <i>p</i> = 0.032, and OR 0.78, 95% CI 0.66 to 0.91, <i>p</i> = 0.002, respectively) and remdesivir (OR 0.29, 95% CI 0.17 to 0.50, <i>p</i> &lt; 0.001, and OR 0.62, 95% CI 0.39 to 0.98, <i>p</i> = 0.041, respectively) compared to standard care for moderate to severe COVID-19 patients in non-ICU; corticosteroids were also shown to reduce mortality rate (OR 0.54, 95% CI 0.40 to 0.73, <i>p</i> &lt; 0.001) for critically ill patients in ICU. In analyses including observational studies, interferon-alpha (OR 0.05, 95% CI 0.01 to 0.39, <i>p</i> = 0.004), itolizumab (OR 0.10, 95% CI 0.01 to 0.92, <i>p</i> = 0.042), sofosbuvir plus daclatasvir (OR 0.26, 95% CI 0.07 to 0.88, <i>p</i> = 0.030), anakinra (OR 0.30, 95% CI 0.11 to 0.82, <i>p</i> = 0.019), tocilizumab (OR 0.43, 95% CI 0.30 to 0.60, <i>p</i> &lt; 0.001), and convalescent plasma (OR 0.48, 95% CI 0.24 to 0.96, <i>p</i> = 0.038) were associated with reduced mortality rate in non-ICU setting, while high-dose intravenous immunoglobulin (IVIG) (OR 0.13, 95% CI 0.03 to 0.49, <i>p</i> = 0.003), ivermectin (OR 0.15, 95% CI 0.04 to 0.57, <i>p</i> = 0.005), and tocilizumab (OR 0.62, 95% CI 0.42 to 0.90, <i>p</i> = 0.012) were associated with reduced mortality rate in critically ill patients. Convalescent plasma was the only treatment option that was associated with improved viral clearance rate at 2 weeks compared to standard care (OR 11.39, 95% CI 3.91 to 33.18, <i>p</i> &lt; 0.001). The combination of hydroxychloroquine and azithromycin was shown to be associated with increased QT prolongation incidence (OR 2.01, 95% CI 1.26 to 3.20, <i>p</i> = 0.003) and fatal cardiac complications in cardiac-impaired populations (OR 2.23, 95% CI 1.24 to 4.00, <i>p</i> = 0.007). No drug was significantly associated with increased noncardiac serious adverse events compared to standard care. The quality of evidence of collective outcomes were estimated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. The major limitation of the present study is the overall low level of evidence that reduces the certainty of recommendations. Besides, the risk of bias (RoB) measured by RoB2 and ROBINS-I framework for individual studies was generally low to moderate. The outcomes deducted from observational studies could not infer causality and can only imply associations. The study protocol is publicly available on PROSPERO (CRD42020186527).</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusions</h3><p class="para" id="N65611">In this NMA, we found that anti-inflammatory agents (corticosteroids, tocilizumab, anakinra, and IVIG), convalescent plasma, and remdesivir were associated with improved outcomes of hospitalized COVID-19 patients. Hydroxychloroquine did not provide clinical benefits while posing cardiac safety risks when combined with azithromycin, especially in the vulnerable population. Only 29% of current evidence on pharmacological management of COVID-19 is supported by moderate or high certainty and can be translated to practice and policy; the remaining 71% are of low or very low certainty and warrant further studies to establish firm conclusions.</p></div><p class="para" id="N65540">In this meta-analysis, Min Seo Kim and colleagues synthesise results from randomized trials and observational studies on COVID-19 treatments.</p><div class="section" id="sec004"><h3 class="BHead" id="nov000-1">Why was the study done?</h3><p class="para" id="N65549">Numerous clinical trials and observational studies have investigated various pharmacological agents as potential treatments for Coronavirus Disease 2019 (COVID-19), but systematic synthesis of this large body of information is not readily available.</p><p class="para" id="N65552">Results from these studies are heterogeneous and sometimes even contradictory to one another, making it difficult for clinicians to determine which treatments are truly effective.</p><p class="para" id="N65555">Level of evidence behind these drugs are diverse and must be classified into categories to effectively inform policy and practice.</p></div><div class="section" id="sec005"><h3 class="BHead" id="nov000-2">What did the researchers do and find?</h3><p class="para" id="N65564">In randomized controlled trials (RCTs), remdesivir and corticosteroid were shown to reduce COVID-19 aggravation and mortality rates.</p><p class="para" id="N65567">In the whole dataset, including data from RCTs and observational studies, anti-inflammatory agents (corticosteroid, tocilizumab, anakinra, and IVIG), convalescent plasma, and remdesivir were associated with improved clinical outcomes of COVID-19.</p><p class="para" id="N65570">Hydroxychloroquine provides no benefit in mitigating COVID-19 disease course while posing safety risks, especially to vulnerable populations.</p></div><div class="section" id="sec006"><h3 class="BHead" id="nov000-3">What do these findings mean?</h3><p class="para" id="N65579">These findings could help prioritize further research on drugs of possible benefit.</p><p class="para" id="N65582">Only 29% of current evidence on pharmacological management of COVID-19 is based on moderate/high evidence certainty and can be reflected in practice and policy; remaining 71% are of low or very low evidence certainty and warrant further studies to establish firm conclusions.</p></div>]]></description>
            <pubDate><![CDATA[2020-12-30T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765768315479-c0031bef-606c-422d-a0a7-690afdb5550f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244947</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Occult hepatitis B virus (HBV) infection (OBI) is a phase of HBV infection characterised by the presence of HBV DNA in the absence of detectable hepatitis B surface antigen (HBsAg). OBI is of concern in the HIV-infected due to high prevalence and risk of HBV reactivation. The prevalence and clinico-demographic characteristics of OBI in anti-retroviral therapy (ART) naïve HIV infected adults in Kenya is unknown.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A cross sectional study carried was out at three sites in Kenya. HIV infected ART naïve adults were enrolled and demographic data collected. Blood samples were assayed for HBsAg, HBV DNA, alanine aminotransferase, aspartate aminotransferase, antibodies to hepatitis B surface antigen (anti-HBs) and hepatitis B core antigen (anti-HBc). Data on CD4 count, HIV viral load and platelet count were obtained from medical records.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Of 208 patients, 199 (95.7%) did not report HBV vaccination, 196 (94.2%) were HBsAg negative, 119 (57.2%) had no HBV markers, 58 (27.9%) had previous HBV infection (anti-HBc positive) and 11 (5.3%) had OBI. All 11 (100%) OBI patients were anti-HBc positive. OBI patients comprised 19.0% of HBsAg negative, anti-HBc positive patients. There was no difference in clinico-demographic characteristics between the overt HBV, OBI and HBV negative patients.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">This was the first study on OBI in ART naïve HIV infected adults in Kenya. The lower OBI prevalence compared to other sub-Saharan African countries could be attributed to lower HBV exposure. Most patients were HBV unexposed and unimmunized, outlining the need to implement guideline recommended immunization strategies.</p></div>]]></description>
            <pubDate><![CDATA[2021-01-06T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Depression and associated factors among HIV-positive youths attending antiretroviral therapy clinics in Jimma town, southwest Ethiopia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765767803609-979b97b9-8a95-4af3-88f2-f08f3f9dbdda/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244879</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Depression is recognized as a prominent health problem and a growing public health concern in HIV-positive youths. Despite this fact, in Ethiopia, there is a dearth of evidence on the prevalence of depression and its associated factors among HIV-positive youths.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A facility-based cross-sectional study was conducted from March 16 to June 01, 2020, among 331 HIV-positive youths attending antiretroviral therapy clinics in Jimma town. A systematic random sampling technique was used to enroll study participants. Bivariable and multivariable logistic regression was done to identify factors associated with depression. Variables with a p-value ≤0.25 on the bivariable analysis were candidates for multivariable analysis. Adjusted odds ratios with the respective 95% CI were calculated and p-value &lt;0.05 were used to set statistically significant variables in the multivariable analysis.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Out of a total of 331 sampled HIV positive youth, 325 have participated in this study with a response rate of 98.2%. The prevalence of depression was 30.2% (95%CI:25.2%-35.1%). Female sex (AOR = 4.12, 95%CI:2.28–7.47), history of hospital admission (AOR = 2.45, 95%CI:1.28–4.70), discontinued education due to HIV/AIDS illness (AOR = 2.09, 95%CI:1.12–3.90), poor treatment adherence (AOR = 2.23, 95%CI:1.04–4.78), opportunistic infections (AOR = 2.16, 95%CI:1.17–3.97), high baseline viral load (AOR = 3.35, 95%CI:1.82–6.16) and ≤6 months duration of HIV diagnosis (AOR = 3.14, 95%CI: 1.47–5.72) were factors significantly associated with depression.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">This study demonstrated a high prevalence of depression among HIV-positive youths. Factors such as female sex, treatment non-adherence, opportunistic infections, &lt;six months since diagnosed with HIV, hospitalization history, high baseline viral load, and school discontinuation due to HIV/AIDS were significantly associated with depression. Therefore, we recommend regular screening for depression co-morbidity among HIV-positive youths and linkage with mental health service providers.</p></div>]]></description>
            <pubDate><![CDATA[2021-01-06T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Novel modulators of p53-signaling encoded by unknown genes of emerging viruses]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765767706905-e2c28fbf-26e0-4df1-a8cb-c9dc150b4712/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009033</link>
            <description><![CDATA[<p class="para" id="N65539">The p53 transcription factor plays a key role both in cancer and in the cell-intrinsic response to infections. The ORFEOME project hypothesized that novel p53-virus interactions reside in hitherto uncharacterized, unknown, or hypothetical open reading frames (orfs) of human viruses. Hence, 172 orfs of unknown function from the emerging viruses SARS-Coronavirus, MERS-Coronavirus, influenza, Ebola, Zika (ZIKV), Chikungunya and Kaposi Sarcoma-associated herpesvirus (KSHV) were <i>de novo</i> synthesized, validated and tested in a functional screen of p53 signaling. This screen revealed novel mechanisms of p53 virus interactions and two viral proteins KSHV orf10 and ZIKV NS2A binding to p53. Originally identified as the target of small DNA tumor viruses, these experiments reinforce the notion that all viruses, including RNA viruses, interfere with p53 functions. These results validate this resource for analogous systems biology approaches to identify functional properties of uncharacterized viral proteins, long non-coding RNAs and micro RNAs.</p><p class="para" id="N65542">New viruses are constantly emerging. The ORFEOME project was based on the hypothesis that every virus, regardless of its molecular makeup and biology should encode functions that intersect the p53 signaling network, since p53 guards the cell from genomic insults, of which depositing a foreign, viral nucleic acid is one. The result of the ORFEOME screen of proteins without any known function, of predicted open reading frames and of suspected non-coding RNAs is the identification of two viral proteins that interact with p53. The first one, orf10, is encoded by Kaposi Sarcoma-associated herpesvirus and the second one, NS2A, is encoded by the Zika virus.</p>]]></description>
            <pubDate><![CDATA[2021-01-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765767597495-83f07831-9fa3-4f53-9e77-ef8d173d3622/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pcbi.1008470</link>
            <description><![CDATA[<p class="para" id="N65539">Finding medications or vaccines that may decrease the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could potentially reduce transmission in the broader population. We developed a computational model of the U.S. simulating the spread of SARS-CoV-2 and the potential clinical and economic impact of reducing the infectious period duration. Simulation experiments found that reducing the average infectious period duration could avert a median of 442,852 [treating 25% of symptomatic cases, reducing by 0.5 days, reproductive number (R<sub>0</sub>) 3.5, and starting treatment when 15% of the population has been exposed] to 44.4 million SARS-CoV-2 cases (treating 75% of all infected cases, reducing by 3.5 days, R<sub>0</sub> 2.0). With R<sub>0</sub> 2.5, reducing the average infectious period duration by 0.5 days for 25% of symptomatic cases averted 1.4 million cases and 99,398 hospitalizations; increasing to 75% of symptomatic cases averted 2.8 million cases. At $500/person, treating 25% of symptomatic cases saved $209.5 billion (societal perspective). Further reducing the average infectious period duration by 3.5 days averted 7.4 million cases (treating 25% of symptomatic cases). Expanding treatment to 75% of all infected cases, including asymptomatic infections (R<sub>0</sub> 2.5), averted 35.9 million cases and 4 million hospitalizations, saving $48.8 billion (societal perspective and starting treatment after 5% of the population has been exposed). Our study quantifies the potential effects of reducing the SARS-CoV-2 infectious period duration.</p><p class="para" id="N65542">Finding medications or vaccines that may decrease the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could potentially reduce transmission in the broader population. We developed a computational model of the U.S. simulating the spread of SARS-CoV-2 and the potential clinical and economic impact of reducing the infectious period duration. Our simulation experiments found that reducing the average infectious period duration could avert a median of 442,852 to 44.4 million SARS-CoV-2 cases, varying the proportion of cases treated, average duration of the infectious period, and the reproductive rate. At $500/person, treating 25% of symptomatic cases saved $209.5 billion (societal perspective, R<sub>0</sub> 2.5). Further reducing the average infectious period duration by 3.5 days averted 7.4 million cases (treating 25% of symptomatic cases). Expanding treatment to 75% of all infected cases, including asymptomatic infections (R<sub>0</sub> 2.5), averted 35.9 million cases and 4 million hospitalizations, saving $48.8 billion (societal perspective and starting treatment after 5% of the population has been exposed). Our study suggests that finding ways to reduce the infectious period of SARS-CoV-2 could help decrease its spread and impact.</p>]]></description>
            <pubDate><![CDATA[2021-01-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Circulation of hepatitis delta virus and occult hepatitis B virus infection amongst HIV/HBV co-infected patients in Korle-Bu, Ghana]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765767455344-190c7a0a-bf20-426c-a21e-b5f07d603cd3/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244507</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Within HIV/HBV infected patients, an increase in HDV infection has been observed; there is inadequate information on HDV prevalence as well as virologic profile in Ghana. This study sought to determine the presence of HDV in HIV/HBV co-infected patients in Ghana.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">This was a longitudinal purposive study which enrolled 113 HIV/HBV co-infected patients attending clinic at Korle-Bu Teaching Hospital (KBTH) in Accra, Ghana. After consenting, 5 mL whole blood was collected at two-time points (baseline and 4–6 months afterwards). The sera obtained were tested to confirm the presence of HIV, HBV antibodies and/or antigens, and HBV DNA. Antibodies and viral RNA were also determined for HDV. Amplified HBV DNA and HDV RNA were sequenced and phylogenetic analysis carried out with reference sequences from the GenBank to establish the genotypes.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Of the 113 samples tested 63 (55.7%) were females and 50 (44.25%) were males with a median age of 45 years. A total of 100 (88.5%) samples had detectable HBV surface antigen (HBsAg), and 32 out of the 113 had detectable HBV DNA. Nucleotide sequences were obtained for 15 and 2 samples of HBV and HDV, respectively. Phylogenetic analysis was predominantly genotype E for the HBVs and genotype 1 for the HDVs. Of the 13 samples that were HBsAg unreactive, 4 (30.8%) had detectable HBV DNA suggesting the incidence of occult HBV infections. The percentage occurrence of HDV in this study was observed to be 3.54.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">Our data suggest the presence and circulation of HDV and incidence of occult HBV infection in HIV/HBV co-infected patients in Ghana. This informs health staff and makes it imperative to look out for the presence of HDV and occult HBV in HIV/HBV co-infected patients presenting with potential risk of liver cancers and HBV transmission through haemodialysis and blood transfusions.</p></div>]]></description>
            <pubDate><![CDATA[2021-01-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[TRK-Fused Gene (TFG), a protein involved in protein secretion pathways, is an essential component of the antiviral innate immune response]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765767271902-e927b32f-617d-4b81-a657-fd78e9cdfe15/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009111</link>
            <description><![CDATA[<p class="para" id="N65539">Antiviral innate immune response to RNA virus infection is supported by Pattern-Recognition Receptors (PRR) including RIG-I-Like Receptors (RLR), which lead to type I interferons (IFNs) and IFN-stimulated genes (ISG) production. Upon sensing of viral RNA, the E3 ubiquitin ligase TNF Receptor-Associated Factor-3 (TRAF3) is recruited along with its substrate TANK-Binding Kinase (TBK1), to MAVS-containing subcellular compartments, including mitochondria, peroxisomes, and the mitochondria-associated endoplasmic reticulum membrane (MAM). However, the regulation of such events remains largely unresolved. Here, we identify TRK-Fused Gene (TFG), a protein involved in the transport of newly synthesized proteins to the endomembrane system via the Coat Protein complex II (COPII) transport vesicles, as a new TRAF3-interacting protein allowing the efficient recruitment of TRAF3 to MAVS and TBK1 following Sendai virus (SeV) infection. Using siRNA and shRNA approaches, we show that TFG is required for virus-induced TBK1 activation resulting in C-terminal IRF3 phosphorylation and dimerization. We further show that the ability of the TRAF3-TFG complex to engage mTOR following SeV infection allows TBK1 to phosphorylate mTOR on serine 2159, a post-translational modification shown to promote mTORC1 signaling. We demonstrate that the activation of mTORC1 signaling during SeV infection plays a positive role in the expression of Viperin, IRF7 and IFN-induced proteins with tetratricopeptide repeats (IFITs) proteins, and that depleting TFG resulted in a compromised antiviral state. Our study, therefore, identifies TFG as an essential component of the RLR-dependent type I IFN antiviral response.</p><p class="para" id="N65542">Antiviral innate immune response is the first line of defence against the invading viruses through type I interferon (IFN) signaling. However, viruses have devised ways to target signaling molecules for aberrant IFN response and worsen the disease outcome. As such, deciphering the roles of new regulators of innate immunity could transform the antiviral treatment paradigm by introducing novel panviral therapeutics designed to reinforce antiviral host responses. This could be of great use in fighting recent outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome MERS-CoV, and the more recent SARS-CoV-2 causing the COVID-19 pandemic. However, aberrant activation of such pathways can lead to detrimental consequences, including autoimmune diseases. Regulation of type I IFN responses is thus of paramount importance. To prevent an uncontrolled response, signaling events happen in discrete subcellular compartments, therefore, distinguishing sites involved in recognition of pathogens and those permitting downstream signaling. Here, we show TFG as a new regulator of type I IFN response allowing the efficient organization of signaling molecules. TFG, thus, further substantiates the importance of the protein trafficking machinery in the regulation of optimal antiviral responses. Our findings have implications for both antiviral immunity and autoimmune diseases.</p>]]></description>
            <pubDate><![CDATA[2021-01-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Quorum sensing across bacterial and viral domains]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765766459937-8c4fb12c-0e48-4adb-9f7d-92af285b087f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009074</link>
            <description><![CDATA[]]></description>
            <pubDate><![CDATA[2021-01-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765762048216-53044bc6-fdd6-48d1-864e-80d59b1562db/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pcbi.1008451</link>
            <description><![CDATA[<p class="para" id="N65539">Simulations of tissue-specific effects of primary acute viral infections like COVID-19 are essential for understanding disease outcomes and optimizing therapies. Such simulations need to support continuous updating in response to rapid advances in understanding of infection mechanisms, and parallel development of components by multiple groups. We present an open-source platform for multiscale spatiotemporal simulation of an epithelial tissue, viral infection, cellular immune response and tissue damage, specifically designed to be modular and extensible to support continuous updating and parallel development. The base simulation of a simplified patch of epithelial tissue and immune response exhibits distinct patterns of infection dynamics from widespread infection, to recurrence, to clearance. Slower viral internalization and faster immune-cell recruitment slow infection and promote containment. Because antiviral drugs can have side effects and show reduced clinical effectiveness when given later during infection, we studied the effects on progression of treatment potency and time-of-first treatment after infection. In simulations, even a low potency therapy with a drug which reduces the replication rate of viral RNA greatly decreases the total tissue damage and virus burden when given near the beginning of infection. Many combinations of dosage and treatment time lead to stochastic outcomes, with some simulation replicas showing clearance or control (treatment success), while others show rapid infection of all epithelial cells (treatment failure). Thus, while a high potency therapy usually is less effective when given later, treatments at late times are occasionally effective. We illustrate how to extend the platform to model specific virus types (<i>e</i>.<i>g</i>., hepatitis C) and add additional cellular mechanisms (tissue recovery and variable cell susceptibility to infection), using our software modules and publicly-available software repository.</p><p class="para" id="N65542">This study presents an open-source, extensible, multiscale platform for simulating viral immune interactions in epithelial tissues, which enables the rapid development and deployment of sophisticated models of viruses, infection mechanisms and tissue types. The model is used to investigate how potential treatments influence disease progression. Simulation results suggest that drugs which interfere with virus replication (e.g., remdesivir) yield substantially better infection outcomes when administered prophylactically even at very low doses than when used at high doses as treatment for an infection that has already begun.</p>]]></description>
            <pubDate><![CDATA[2020-12-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[<i>i</i>BRAB: <i>In silico</i> based-designed broad-spectrum Fab against H1N1 influenza A virus]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765758907755-216277e9-001d-4bd0-9133-3da026c86707/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0239112</link>
            <description><![CDATA[<p class="para" id="N65539">Influenza virus A is a significant agent involved in the outbreak of worldwide epidemics, causing millions of fatalities around the world by respiratory diseases and seasonal illness. Many projects had been conducting to investigate recovered infected patients for therapeutic vaccines that have broad-spectrum activity. With the aid of the computational approach in biology, the designation for a vaccine model is more accessible. We developed an <i>in silico</i> protocol called <i>i</i>BRAB to design a broad-reactive Fab on a wide range of influenza A virus. The Fab model was constructed based on sequences and structures of available broad-spectrum Abs or Fabs against a wide range of H1N1 influenza A virus. As a result, the proposed Fab model followed <i>i</i>BRAB has good binding affinity over 27 selected HA of different strains of H1 influenza A virus, including wild-type and mutated ones. The examination also took by computational tools to fasten the procedure. This protocol could be applied for a fast-designed therapeutic vaccine against different types of threats.</p>]]></description>
            <pubDate><![CDATA[2020-12-31T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[“I would really want to know that they had my back”: Transgender women’s perceptions of HIV cure-related research in the United States]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765758844354-6804526c-25a9-46a1-917c-b077fd3b4951/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244490</link>
            <description><![CDATA[<p class="para" id="N65539">Forty-four percent of Black transgender women are living with HIV, and many face challenges with HIV care engagement. An HIV cure has much to offer this population, however little HIV cure-related research has included them. We conducted 19 face-to-face in-depth interviews with 10 Black transgender women living with HIV. Interviews were audio recorded, transcribed verbatim, coded, and analyzed using content analysis. Our interview guide contained three categories: 1) perceptions of HIV cure-related research and participation, 2) perceptions of HIV treatment and treatment interruptions, and 3) considerations for transgender women and HIV cure-related research. Salient themes included skepticism about HIV cure strategies and limited benefits compared with an undetectable viral load. Willingness to interrupt HIV treatment for research was low and linked to being able to go back on the same HIV treatment without consequence when the study ended. Concerns about being a test subject and perceptions of risks versus benefits of various strategies also affected willingness to take part in HIV cure-related research. Centering the dignity and autonomy of research participants as well as building upon and supporting existing social networks were identified as important facilitators for engaging Black transgender women in HIV cure-related research. Specific to Black transgender women, other concerns included the desire for gender-affirming research staff, community-building among transgender women, and safety issues associated with risk of transphobic violence when traveling to study visits. Participants stressed the importance of HIV cure-related researchers providing accessible and complete information and expressing genuine care and concern for transgender communities.</p>]]></description>
            <pubDate><![CDATA[2020-12-31T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[SARS-CoV-2 PCR cycle threshold at hospital admission associated with patient mortality]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765758124487-5798bdad-4a86-40e9-903b-8e90193fe253/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244777</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cycle threshold (Ct) has been suggested as an approximate measure of initial viral burden. The utility of cycle threshold, at admission, as a predictor of disease severity has not been thoroughly investigated.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods and findings</h3><p class="para" id="N65549">We conducted a retrospective study of SARS-CoV-2 positive, hospitalized patients from 3/26/2020 to 8/5/2020 who had SARS-CoV-2 Ct data within 48 hours of admission (n = 1044). Only patients with complete survival data, discharged (n = 774) or died in hospital (n = 270), were included in our analysis. Laboratory, demographic, and clinical data were extracted from electronic medical records. Multivariable logistic regression was applied to examine the relationship of patient mortality with Ct values while adjusting for established risk factors. Ct was analyzed as continuous variable and subdivided into quartiles to better illustrate its relationship with outcome. Cumulative incidence curves were created to assess whether there was a survival difference in the setting of the competing risks of death versus patient discharge. Mean Ct at admission was higher for survivors (28.6, SD = 5.8) compared to non-survivors (24.8, SD = 6.0, P&lt;0.001). In-hospital mortality significantly differed (p&lt;0.05) by Ct quartile. After adjusting for age, gender, BMI, hypertension and diabetes, increased cycle threshold was associated with decreased odds of in-hospital mortality (0.91, CI 0.89–0.94, p&lt;0.001). Compared to the 4<sup>th</sup> Quartile, patients with Ct values in the 1st Quartile (Ct &lt;22.9) and 2nd Quartile (Ct 23.0–27.3) had an adjusted odds ratio of in-hospital mortality of 3.8 and 2.6 respectively (p&lt;0.001). The discriminative ability of Ct to predict inpatient mortality was found to be limited, possessing an area under the curve (AUC) of 0.68 (CI 0.63–0.71).</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65558">SARS-CoV-2 Ct was found to be an independent predictor of patient mortality. However, further study is needed on how to best clinically utilize such information given the result variation due to specimen quality, phase of disease, and the limited discriminative ability of the test.</p></div>]]></description>
            <pubDate><![CDATA[2020-12-31T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A direct RT-qPCR approach to test large numbers of individuals for SARS-CoV-2]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765757485218-21a160f5-6ac6-49ab-905d-8cbd53bde902/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244824</link>
            <description><![CDATA[<p class="para" id="N65539">SARS-CoV-2 causes substantial morbidity and mortality in elderly and immunocompromised individuals, particularly in retirement homes, where transmission from asymptomatic staff and visitors may introduce the infection. Here we present a cheap and fast screening method based on direct RT-qPCR to detect SARS-CoV-2 in single or pooled gargle lavages (“mouthwashes”). This method detects individuals with large viral loads (Ct≤29) and we use it to test all staff at a nursing home daily over a period of three weeks in order to reduce the risk that the infection penetrates the facility. This or similar approaches can be implemented to protect hospitals, nursing homes and other institutions in this and future viral epidemics.</p>]]></description>
            <pubDate><![CDATA[2020-12-31T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Optimizing direct RT-LAMP to detect transmissible SARS-CoV-2 from primary nasopharyngeal swab samples]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765757191491-82acac82-b019-42ac-83c3-cba05583b48c/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244882</link>
            <description><![CDATA[<p class="para" id="N65539">SARS-CoV-2 testing is crucial to controlling the spread of this virus, yet shortages of nucleic acid extraction supplies and other key reagents have hindered the response to COVID-19 in the US. Several groups have described loop-mediated isothermal amplification (LAMP) assays for SARS-CoV-2, including testing directly from nasopharyngeal swabs and eliminating the need for reagents in short supply. Frequent surveillance of individuals attending work or school is currently unavailable to most people but will likely be necessary to reduce the ~50% of transmission that occurs when individuals are nonsymptomatic. Here we describe a fluorescence-based RT-LAMP test using direct nasopharyngeal swab samples and show consistent detection in clinically confirmed primary samples with a limit of detection (LOD) of ~625 copies/μl, approximately 100-fold lower sensitivity than qRT-PCR. While less sensitive than extraction-based molecular methods, RT-LAMP without RNA extraction is fast and inexpensive. Here we also demonstrate that adding a lysis buffer directly into the RT-LAMP reaction improves the sensitivity of some samples by approximately 10-fold. Furthermore, purified RNA in this assay achieves a similar LOD to qRT-PCR. These results indicate that high-throughput RT-LAMP testing could augment qRT-PCR in SARS-CoV-2 surveillance programs, especially while the availability of qRT-PCR testing and RNA extraction reagents is constrained.</p>]]></description>
            <pubDate><![CDATA[2020-12-31T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[HIV treatment cascade among people who inject drugs in Ukraine]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765756641256-801b02f6-1626-465d-8125-9b87b03b39b8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244572</link>
            <description><![CDATA[<p class="para" id="N65539">The HIV treatment cascade is an effective tool to track progress and gaps in the HIV response among key populations. People who inject drugs (PWID) remain the most affected key population in Ukraine with HIV prevalence of 22% in 2015. We performed secondary analysis of the 2017 Integrated Bio-Behavioral Surveillance (IBBS) survey data to construct the HIV treatment cascade for PWID and identify correlates of each indicator achievement. The biggest gap in the cascade was found in the first “90”, HIV status awareness: only 58% [95% CI: 56%-61%] of HIV-positive PWID reported being aware of their HIV-positive status. Almost 70% [67%-72%] of all HIV-infected PWID who were aware of their status reported that they currently received antiretroviral therapy (ART). Almost three quarters (74% [71%-77%]) of all HIV-infected PWID on ART were virally suppressed. Access to harm reduction services in the past 12 months and lifetime receipt of opioid agonist treatment (OAT) had the strongest association with HIV status awareness. Additionally, OAT patients who were aware of HIV-positive status had 1.7 [1.2–2.3] times the odds of receiving ART. Being on ART for the last 6 months or longer increased odds to be virally suppressed; in contrast, missed recent doses of ART significantly decreased the odds of suppression. The HIV treatment cascade analysis for PWID in Ukraine revealed substantial gaps at each step and identified factors contributing to achievement of the outcomes. More intensive harm reduction outreach along with targeted case finding could help to fill the HIV awareness gap among PWID in Ukraine. Scale up of OAT and community-level linkage to care and ART adherence interventions are viable strategies to improve ART coverage and viral suppression among PWID.</p>]]></description>
            <pubDate><![CDATA[2020-12-31T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Socio-economic condition and lack of virological suppression among adults and adolescents receiving antiretroviral therapy in Ethiopia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765746518021-fd3bfe6d-14e2-4d85-9423-91665b3490e2/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244066</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Introduction</h3><p class="para" id="N65543">The potential impact of socio-economic condition on virological suppression during antiretroviral treatment (ART) in sub-Saharan Africa is largely unknown. In this case-control study, we compared socio-economic factors among Ethiopian ART recipients with lack of virological suppression to those with undetectable viral load (VL).</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">Cases (VL&gt;1000 copies/ml) and controls (VL&lt;150 copies/ml) aged ≥15years, with ART for &gt;6 months and with available VL results within the last 3 months, were identified from registries at public ART clinics in Central Ethiopia. Questionnaire-based interviews on socio-economic characteristics, health condition and transmission risk behavior were conducted. Univariate variables associated with VL&gt;1000 copies/ml (p&lt;0.25) were added to a multivariable logistic regression model.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Among 307 participants (155 cases, 152 controls), 61.2% were female, and the median age was 38 years (IQR 32–46). Median HIV-RNA load among cases was 6,904 copies/ml (IQR 2,843–26,789). Compared to controls, cases were younger (median 36 vs. 39 years; p = 0.004), more likely to be male (46.5% vs. 30.9%; p = 0.005) and had lower pre-ART CD4 cell counts (170 vs. 220 cells/μl; p = 0.009). In multivariable analysis of urban residents (94.8%), VL&gt;1000 copies/ml was associated with lower relative wealth (adjusted odds ratio [aOR] 2.98; 95% CI 1.49–5.94; p = 0.016), geographic work mobility (aOR 6.27, 95% CI 1.82–21.6; p = 0.016), younger age (aOR 0.94 [year], 95% CI 0.91–0.98; p = 0.011), longer duration of ART (aOR 1.19 [year], 95% CI 1.07–1.33; p = 0.020), and suboptimal (aOR 3.83, 95% CI 1.33–10.2; p = 0.048) or poor self-perceived wellbeing (aOR 9.75, 95% CI 2.85–33.4; p = 0.012), after correction for multiple comparisons. High-risk sexual behavior and substance use was not associated with lack of virological suppression.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusion</h3><p class="para" id="N65561">Geographic work mobility and lower relative wealth were associated with lack of virological suppression among Ethiopian ART recipients in this predominantly urban population. These characteristics indicate increased risk of treatment failure and the need for targeted interventions for persons with these risk factors.</p></div>]]></description>
            <pubDate><![CDATA[2020-12-15T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Metagenomic sequencing generates the whole genomes of porcine rotavirus A, C, and H from the United States]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765746079682-f27f37ca-da1b-4bd9-bd96-d3bf40b13729/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244498</link>
            <description><![CDATA[<p class="para" id="N65539">The genus <i>Rotavirus</i> comprises eight species, designated <i>A</i> to <i>H</i>, and two recently identified tentative species <i>I</i> in dogs and <i>J</i> in bats. Species <i>Rotavirus A</i>, <i>B</i>, <i>C and H</i> (RVA, RVB, RVC and RVH) have been detected in humans and animals. While human and animal RVA are well characterized and defined, complete porcine genome sequences in the GenBank are limited compared to human strains. Here, we used a metagenomic approach to sequence the 11 segments of RVA, RVC and RVH strains from piglets in the United States (US) and explore the evolutionary relations of these RV species. Metagenomics identified <i>Astroviridae</i>, <i>Picornaviridae</i>, <i>Caliciviridae</i>, <i>Coronoviridae</i> in samples MN9.65 and OK5.68 while <i>Picobirnaviridae</i> and <i>Arteriviridae</i> were only identified in sample OK5.68. Whole genome sequencing and phylogenetic analyses identified multiple genotypes with the RVA of strain MN9.65 and OK5.68, with the genome constellation of G5/G9-P[<a href="#pone.0244498.ref007">7</a>]/P[<a href="#pone.0244498.ref013">13</a>]-I5/I5- R1/R1-C1-M1-A8-N1-T7-E1/E1-H1 and G5/G9-P[<a href="#pone.0244498.ref006">6</a>]/P[<a href="#pone.0244498.ref007">7</a>]-I5-R1/R1-C1-M1-A8-N1-T1/T7-E1/E1-H1, respectively. The RVA strains had a complex evolutionary relationship with other mammalian strains. The RVC strain OK5.68 had a genome constellation of G9-P[<a href="#pone.0244498.ref006">6</a>]-I1-R1-C5-M6-A5-N1-T1-E1-H1, and shared an evolutionary relationship with porcine strains from the US. The RVH strains MN9.65 and OK5.68 had the genome constellation of G5-P1-I1-R1-C1-M1-A5-N1-T1-E4-H1 and G5-P1-I1-R1-C1-M1-A5-N1-T1-E1-H1, indicating multiple RVH genome constellations are circulating in the US. These findings allow us to understand the complexity of the enteric virome, develop improved screening methods for RVC and RVH strains, facilitate expanded rotavirus surveillance in pigs, and increase our understanding of the origin and evolution of rotavirus species.</p>]]></description>
            <pubDate><![CDATA[2020-12-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Tracing the active genetic diversity of <i>Microcystis</i> and <i>Microcystis</i> phage through a temporal survey of <i>Taihu</i>]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765746073006-1a2b54d6-4d97-4466-98b2-f131aa812221/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244482</link>
            <description><![CDATA[<p class="para" id="N65539">Harmful algal blooms are commonly thought to be dominated by a single genus, but they are not homogenous communities. Current approaches, both molecular and culture-based, often overlook fine-scale variations in community composition that can influence bloom dynamics. We combined homology-based searches (BLASTX) and phylogenetics to distinguish and quantify <i>Microcystis</i> host and phage members across a summer season during a 2014 <i>Microcystis-</i> dominated bloom that occurred in Lake Tai (<i>Taihu</i>), China. We found 47 different genotypes of the <i>Microcystis-</i>specific DNA-dependent RNA polymerase (<i>rpo</i>B), which included several morphospecies. <i>Microcystis flos-aquae</i> and <i>Microcystis wesenbergii</i> accounted for ~86% of total <i>Microcystis</i> transcripts, while the more commonly studied <i>Microcystis aeruginosa</i> only accounted for ~7%. <i>Microcystis</i> genotypes were classified into three temporal groups according to their expression patterns across the course of the bloom: early, constant and late. All <i>Microcystis</i> morphospecies were present in each group, indicating that expression patterns were likely dictated by competition driven by environmental factors, not phylogeny. We identified three primary <i>Microcystis</i>-infecting phages based on the viral terminase, including a novel <i>Siphoviridae</i> phage that may be capable of lysogeny. Within our dataset, <i>Myoviridae</i> phages consistent with those infecting <i>Microcystis</i> in a lytic manner were positively correlated to the early host genotypes, while the <i>Siphoviridae</i> phages were positively correlated to the late host genotypes, when the <i>Myoviridae</i> phages express putative genetic markers for lysogeny. The expression of genes in the microcystin-encoding <i>mcy</i> cassette was estimated using <i>mcyA</i>, which revealed 24 <i>Microcystis-</i>specific genotypes that were negatively correlated to the early host genotypes. Of all environmental factors measured, pH best described the temporal shift in the <i>Microcystis</i> community genotypic composition, promoting hypotheses regarding carbon concentration mechanisms and oxidative stress. Our work expounds on the complexity of HAB events, using a well-studied dataset to highlight the need for increased resolution of community dynamics.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Which COVID policies are most effective? A Bayesian analysis of COVID-19 by jurisdiction]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765745610900-af88921f-a9b9-43ff-96cd-6d527adfbdec/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244177</link>
            <description><![CDATA[<p class="para" id="N65539">This paper reports the results of a Bayesian analysis on large-scale empirical data to assess the effectiveness of eleven types of COVID-control policies that have been implemented at various levels of intensity in 40 countries and U.S. states since the onset of the pandemic. The analysis estimates the marginal impact of each type and level of policy as implemented in concert with other policies. The purpose is to provide policymakers and the general public with an estimate of the relative effectiveness of various COVID-control strategies. We find that a set of widely implemented core policies reduces the spread of virus but not by enough to contain the pandemic except in a few highly compliant jurisdictions. The core policies include the cancellation of public events, restriction of gatherings to fewer than 100 people, recommendation to stay at home, recommended restrictions on internal movement, implementation of a partial international travel ban, and coordination of information campaigns. For the median jurisdiction, these policies reduce growth rate in new infections from an estimated 270% per week to approximately 49% per week, but this impact is insufficient to prevent eventual transmission throughout the population because containment occurs only when a jurisdiction reduces growth in COVID infection to below zero. Most jurisdictions must also implement additional policies, each of which has the potential to reduce weekly COVID growth rate by 10 percentage points or more. The slate of these additional high-impact policies includes targeted or full workplace closings for all but essential workers, stay-at-home requirements, and targeted school closures.</p>]]></description>
            <pubDate><![CDATA[2020-12-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765745394963-eed2b6fa-d26b-4972-b5c4-70a41a65d2a0/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244269</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Various factors may determine the duration of viral shedding (the time from infection to viral RNA-negative conversion or recovery) in COVID-19 patients. Understanding the average duration of recovery and its predictors is crucial in formulating preventive measures and optimizing treatment options. Therefore, evidence showing the duration of recovery from COVID-19 in different contexts and settings is necessary for tailoring appropriate treatment and prevention measures. This study aimed to investigate the average duration and the predictors of recovery from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection among COVID-19 patients.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Method</h3><p class="para" id="N65549">A hospital-based prospective cohort study was conducted at Eka Kotebe General Hospital, COVID-19 Isolation and Treatment Center from March 18 to June 27, 2020. The Center was the first hospital designated to manage COVID-19 cases in Ethiopia. The study participants were all COVID-19 adult patients who were admitted to the center during the study period. Follow up was done for the participants from the first date of diagnosis to the date of recovery (negative Real-time Reverse Transcriptase Polymerase Chain Reaction (rRT-PCT) test of throat swab).</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Result</h3><p class="para" id="N65555">A total of 306 COVID-19 cases were followed up to observe the duration of viral clearance by rRT-PCR. Participants’ mean age was 34 years (18–84 years) and 69% were male. The median duration of viral clearance from each participant’s body was 19 days, but the range was wide: 2 to 71 days. Cough followed by headache was the leading sign of illness among the 67 symptomatic COVID-19 patients; and nearly half of those with comorbidities were known cancer and HIV/AIDS patients on clinical follow up. The median duration of recovery from COVID-19 was different for those with and without previous medical conditions or comorbidities. The rate of recovery from SARS-CoV-2 infection was 36% higher in males than in females (p = 0.043, CI: 1.01, 1.85). The rate of recovery was 93% higher in those with at least one comorbidity than in those without any comorbidity. The risk of delayed recovery was not influenced by blood type, BMI and presence of signs or symptoms. The findings showed that study participants without comorbidities recovered more quickly than those with at least one comorbidity. Therefore, isolation and treatment centers should be prepared to manage the delayed stay of patients having comorbidity.</p></div>]]></description>
            <pubDate><![CDATA[2020-12-30T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Annual and durable HIV retention in care and viral suppression among patients of Peter Ho Clinic, 2013-2017]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765745214105-23d12e13-2c4d-4d64-89d8-7226e9f1a988/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244376</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Objectives</h3><p class="para" id="N65543">To determine rates of annual and durable retention in medical care and viral suppression among patients enrolled in the Peter Ho Clinic, from 2013–2017.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">This is a retrospective review of medical record data in an urban clinic, located in Newark, New Jersey, a high prevalence area of persons living with HIV. Viral load data were electronically downloaded, in rolling 1-year intervals, in two-month increments, from January 1, 2013 to December 31, 2019. Three teams were established, and every two months, they were provided with an updated list of patients with virologic failure. Retention and viral suppression rates were first calculated for each calendar-year. After patients were determined to be retained/suppressed annually, the proportion of patients with durable retention and viral suppression were calculated in two, three, four, five and six-year periods. Descriptive statistics were used to summarize sample characteristics by retention in care, virologic failure and viral suppression with Pearson Chi-square; p-value &lt;0.05 was statistically significant. Multiple logistic regression models identified patient characteristics associated with retention in medical care, virologic failure and suppression.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">As of December 31, 2017, 1000 (57%) patients were retained in medical care of whom 870 (87%) were suppressed. Between 2013 and 2016, decreases in annual (85% to 77%) and durable retention in care were noted: two-year (72% to 70%) and three-year (63% to 59%) periods. However, increases were noted for 2017, in annual (89%) and durable retention in the two-year period (79%). In the adjusted model, when compared to current patients, retention in care was less likely among patients reengaging in medical care (adjusted Odds Ratio (aOR): 0.77, 95% CI: 0.61–0.98) but more likely among those newly diagnosed from 2014–2017 (aOR: 1.57, 95% CI: 1.08–2.29), compared to those in care since 2013. A higher proportion of patients re-engaging in medical care had virologic failure than current patients (56% vs. 47%, p &lt; 0.0001). As age decreased, virologic failure was more likely (p&lt;0.0001). Between 2013 and 2017, increases in annual (74% to 87%) and durable viral suppression were noted: two-year (59% to 73%) and three-year (49% to 58%) periods. Viral suppression was more likely among patients retained in medical care up to 2017 versus those who were not (aOR: 5.52, 95% CI: 4.08–7.46). Those less likely to be suppressed were 20–29 vs. 60 years or older (aOR: 0.52, 95% CI: 0.28–0.97), had public vs. private insurance (aOR: 0.29, 95% CI: 0.15–0.55) and public vs. private housing (aOR: 0.59, 95% CI: 0.40–0.87).</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65561">Restructuring clinical services at this urban clinic was associated with improved viral suppression. However, concurrent interventions to ensure retention in medical care were not implemented. Both retention in care and viral suppression interventions should be implemented in tandem to achieve an end to the epidemic. Retention in care and viral suppression should be measured longitudinally, instead of cross-sectional yearly evaluations, to capture dynamic changes in these indicators.</p></div>]]></description>
            <pubDate><![CDATA[2020-12-29T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Parents’ and guardians’ views and experiences of accessing routine childhood vaccinations during the coronavirus (COVID-19) pandemic: A mixed methods study in England]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765744771488-a869b1b3-354d-41d2-834a-9333800b59dd/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244049</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Objective</h3><p class="para" id="N65543">To explore parents’ and guardians’ views and experiences of accessing National Health Service (NHS) general practices for routine childhood vaccinations during the coronavirus (COVID-19) pandemic in England.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Design</h3><p class="para" id="N65549">Mixed methods approach involving an online cross-sectional survey (conducted between 19<sup>th</sup> April and 11<sup>th</sup> May 2020) and semi-structured telephone interviews (conducted between 27<sup>th</sup> April and 27<sup>th</sup> May 2020).</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Participants</h3><p class="para" id="N65567">1252 parents and guardians (aged 16+ years) who reported living in England with a child aged 18 months or under completed the survey. Nineteen survey respondents took part in follow-up interviews.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Results</h3><p class="para" id="N65573">The majority of survey respondents (85.7%) considered it important for their children to receive routine vaccinations on schedule during the COVID-19 pandemic; however, several barriers to vaccination were identified. These included a lack of clarity around whether vaccination services were operating as usual, particularly amongst respondents from lower income households and those self-reporting as Black, Asian, Chinese, Mixed or Other ethnicity; difficulties in organising vaccination appointments; and fears around contracting COVID-19 while attending general practice.</p><p class="para" id="N65575">Concerns about catching COVID-19 while accessing general practice were weighed against concerns about children acquiring a vaccine-preventable disease if they did not receive scheduled routine childhood vaccinations. Many parents and guardians felt their child’s risk of acquiring a vaccine-preventable disease was low as the implementation of stringent physical distancing measures (from March 23<sup>rd</sup> 2020) meant they were not mixing with others.</p></div><div class="section" id="sec005"><h3 class="BHead" id="nov000-5">Conclusion</h3><p class="para" id="N65584">To promote routine childhood vaccination uptake during the current COVID-19 outbreak, further waves of COVID-19 infection, and future pandemics, prompt and sustained national and general practice level communication is needed to raise awareness of vaccination service continuation and the importance of timely vaccination, and invitation-reminder systems for vaccination need to be maintained. To allay concerns about the safety of accessing general practice, practices should communicate the measures being implemented to prevent COVID-19 transmission.</p></div>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Profiles of expression pattern and tissue distribution of host defense peptides genes in different chicken (<i>Gallus gallus</i>) breeds related to body weight]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765744438632-eaf96440-83e0-4e4d-a296-0705802e5c1e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0238675</link>
            <description><![CDATA[<p class="para" id="N65539">Host defense peptides (HDPs) are an important first line of defense with antimicrobial and immunomodulatory properties. Selection for increased body weight is hypothesized to be related to reduced immune response. We studied the relationships among body weight, age, and the HDP expression patterns in intestine and immune organs. We used chickens with marked differences of body sizes. The non-selected Daweishan mini chickens showed the highest indexes of immune organs and the lowest concentrations of the plasma immune parameters C3, C4, IgA, and IgY, while the commercial Avian broiler showed the opposite results. The Daweishan mini chickens showed the highest mRNA expressions of HDP genes in small intestine followed by the semi-selected Wuding chickens. Compared with local breeds, broiler chickens showed higher mRNA expression of HDP genes in spleen, thymus, and bursa. Body weight and HDP expression levels were negatively correlated in the intestine and positively in the immune organs. Our results indicated that the HDP immune regulatory roles in small intestine acted as first line of defense in innate immunity in local breeds, and as an adaptive immunity in broiler chickens. Selection was associated with different expression expressions of HDP genes in breed-, age-, and organ-specific manners.</p>]]></description>
            <pubDate><![CDATA[2020-12-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[T cells in the brain enhance neonatal mortality during peripheral LCMV infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765740905459-d9bd020b-4f9d-4cc3-ab5e-6c6bdc598807/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009066</link>
            <description><![CDATA[<p class="para" id="N65539">In adult mice the severity of disease from viral infections is determined by the balance between the efficiency of the immune response and the magnitude of viral load. Here, the impact of this dynamic is examined in neonates. Newborns are highly susceptible to infections due to poor innate responses, lower numbers of T cells and Th2-prone immune responses. Eighty-percent of 7-day old mice, immunologically equivalent to human neonates, succumbed to extremely low doses (5 PFU) of the essentially non-lethal lymphocytic choriomeningitis virus (LCMV-Armstrong) given intraperitoneally. This increased lethality was determined to be dependent upon poor early viral control, as well as, T cells and perforin as assessed in knockout mice. By day 3, these neonatal mice had 400-fold higher viral loads as compared to adults receiving a 10,000-fold (5X10<sup>4</sup> PFU) higher dose of LCMV. The high viral load in combination with the subsequent immunological defect of partial CD8 T cell clonal exhaustion in the periphery led to viral entry and replication in the brain. Within the brain, CD8 T cells were protected from exhaustion, and thus were able to mediate lethal immunopathology. To further delineate the role of early viral control, neonatal mice were infected with Pichinde virus, a less virulent arenavirus, or LCMV was given to pups of LCMV-immune mothers. In both cases, peak viral load was at least 29-fold lower, leading to functional CD8 T cell responses and 100% survival.</p><p class="para" id="N65542">As in adults the general principle that the balance between viral load and immune responses determines disease outcome applies in neonates, although the immune environments and exact mechanisms differ. A better understanding of these differences will improve strategies to optimize protection of the highly susceptible neonatal population. These results also suggest that the environment of the brain may protect T cells from exhaustion.</p>]]></description>
            <pubDate><![CDATA[2021-01-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765740281345-e691ecf7-4fd7-48ba-bac7-96f592284c12/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009127</link>
            <description><![CDATA[<p class="para" id="N65539">Viruses are obligate intracellular parasites that make use of the host metabolic machineries to meet their biosynthetic needs. Thus, identifying the host pathways essential for the virus replication may lead to potential targets for therapeutic intervention. The mechanisms and pathways explored by SARS-CoV-2 to support its replication within host cells are not fully known. Lipid droplets (LD) are organelles with major functions in lipid metabolism, energy homeostasis and intracellular transport, and have multiple roles in infections and inflammation. Here we described that monocytes from COVID-19 patients have an increased LD accumulation compared to SARS-CoV-2 negative donors. <i>In vitro</i>, SARS-CoV-2 infection were seen to modulate pathways of lipid synthesis and uptake as monitored by testing for CD36, SREBP-1, PPARγ, and DGAT-1 expression in monocytes and triggered LD formation in different human cell lines. LDs were found in close apposition with SARS-CoV-2 proteins and double-stranded (ds)-RNA in infected Vero cells. Electron microscopy (EM) analysis of SARS-CoV-2 infected Vero cells show viral particles colocalizing with LDs, suggestive that LDs might serve as an assembly platform. Pharmacological modulation of LD formation by inhibition of DGAT-1 with A922500 significantly inhibited SARS-CoV-2 replication as well as reduced production of mediators pro-inflammatory response. Taken together, we demonstrate the essential role of lipid metabolic reprograming and LD formation in SARS-CoV-2 replication and pathogenesis, opening new opportunities for therapeutic strategies to COVID-19.</p><p class="para" id="N65542">In spite of the enormous scientific efforts to understand mechanisms of SARS-CoV2-induced disease and to develop strategies to control COVID-19 pandemic, many aspects of SARS-CoV2 biology and pathogenesis remain elusive. Several RNA viruses are able to modulate the host lipid metabolism and to recruit LDs to enhance their replication/particle assembling capacity through mechanisms that vary according to the virus and the host cell infected. The mechanisms and pathways explored by SARS-CoV-2 to support its replication within host cells are still largely unknown. Here we demonstrated that lipid droplets (LDs) participate in SARS-CoV2 infection favoring virus replication and heightening inflammatory mediator production. SARS-CoV2 infection increased the expression of key proteins in the regulation of lipid metabolism and the amounts of LDs per cell. In addition, we have found SARS-CoV2 and/or its components associated with LDs in infected cells, suggestive that LDs are recruited as part of replication compartment. Moreover, pharmacological inhibition of DGAT-1, a key enzyme for LD formation, reduces SARS-CoV2 replication, inflammatory mediator production and cell death. Our findings contribute to unveil the complex mechanism by which SARS-CoV-2 make use of cellular metabolism and organelles to coordinate different steps of the viral replication cycle and host immunity, opening new perspectives for SARS-CoV2 antiviral development.</p>]]></description>
            <pubDate><![CDATA[2020-12-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A simplified SARS-CoV-2 detection protocol for research laboratories]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765740113277-d9a363cd-9c7e-428c-9324-356d3d038b52/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244271</link>
            <description><![CDATA[<p class="para" id="N65539">Widespread testing is required to limit the current public health crisis caused by the COVID-19 pandemic. Multiple tests protocols have been authorized by the food and drugs administration (FDA) under an emergency use authorization (EUA). The majority of these protocols are based on the gold-standard RT-qPCR test pioneered by the U.S. Centers for Disease Control and Prevention (CDC). However, there is still a widespread lack of testing in the US and many of the clinical diagnostics protocols require extensive human labor and materials that could face supply shortages and present biosafety concerns. Given the need to develop alternative reagents and approaches to provide nucleic-acid testing in the face of heightened demand and potential shortages, we have developed a simplified SARS-CoV-2 testing protocol adapted for its use in research laboratories with minimal molecular biology equipment and expertise. The protocol utilizes TRIzol to purify the viral RNA from different types of clinical specimens, requires minimal BSL-1 precautions and, given its high sensitivity, can be easily adapted to pooling samples strategies.</p>]]></description>
            <pubDate><![CDATA[2020-12-18T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Permeability of the HIV-1 capsid to metabolites modulates viral DNA synthesis]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765739753425-59a81fe3-eff2-48ec-b279-7d6dda45c2e7/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pbio.3001015</link>
            <description><![CDATA[<p class="para" id="N65539">Reverse transcription, an essential event in the HIV-1 life cycle, requires deoxynucleotide triphosphates (dNTPs) to fuel DNA synthesis, thus requiring penetration of dNTPs into the viral capsid. The central cavity of the capsid protein (CA) hexamer reveals itself as a plausible channel that allows the passage of dNTPs into assembled capsids. Nevertheless, the molecular mechanism of nucleotide import into the capsid remains unknown. Employing all-atom molecular dynamics (MD) simulations, we established that cooperative binding between nucleotides inside a CA hexamer cavity results in energetically favorable conditions for passive translocation of dNTPs into the HIV-1 capsid. Furthermore, binding of the host cell metabolite inositol hexakisphosphate (IP<sub>6</sub>) enhances dNTP import, while binding of synthesized molecules like benzenehexacarboxylic acid (BHC) inhibits it. The enhancing effect on reverse transcription by IP<sub>6</sub> and the consequences of interactions between CA and nucleotides were corroborated using atomic force microscopy, transmission electron microscopy, and virological assays. Collectively, our results provide an atomistic description of the permeability of the HIV-1 capsid to small molecules and reveal a novel mechanism for the involvement of metabolites in HIV-1 capsid stabilization, nucleotide import, and reverse transcription.</p><p class="para" id="N65540">This study shows that the HIV-1 capsid protein, in addition to its structural role, regulates reverse transcription, an essential metabolic process of the virus, by mediating the import of nucleotides. In addition, host cell metabolites such as inositol phosphates are recruited by the capsid to regulate viral DNA synthesis.</p>]]></description>
            <pubDate><![CDATA[2020-12-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765739692081-1584d546-d17d-45ca-baf4-e95f5c164116/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0008931</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Despite direct-acting antivirals (DAA), aims to “eradicate” viral hepatitis by 2030 remain unlikely. In Nepal, an expert consortium was established to treat HCV through Nepal earthquakes aftermath offering a model for HCV treatment expansion in a resource-poor setting.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methodology/Principal findings</h3><p class="para" id="N65549">In 2015, we established a network of hepatologists, laboratory experts, and community-based leaders at 6 Opioid Substitution Treatment (OST) sites from 4 cities in Nepal screening 838 patients for a treatment cohort of 600 individuals with HCV infection and past or current drug use. During phase 1, patients were treated with interferon-based regimens (n = 46). During phase 2, 135 patients with optimal predictors (HIV controlled, without cirrhosis, low baseline HCV viral load) were treated with DAA-based regimens. During phase 3, IFN-free DAA treatment was expanded, regardless of HCV disease severity, HIV viremia or drug use. Sustained virologic response (SVR) was assessed at 12 weeks.</p><p class="para" id="N65551">Median age was 37 years and 95.5% were males. HCV genotype was 3 (53.2%) or 1a (40.7%) and 32% had cirrhosis; 42.5% were HIV-HCV coinfected. The intention-to-treat (ITT) SVR rates in phase 2 and 3 were 97% and 81%, respectively. The overall per-protocol and ITT SVR rates were 97% and 85%, respectively. By multivariable analysis, treatment at the Kathmandu site was protective and substance use, treatment during phase 3 were associated with failure to achieve SVR.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Conclusions/Significance</h3><p class="para" id="N65557">Very high SVR rates may be achieved in a difficult-to-treat, low-income population whatever the patient’s profile and disease severity. The excellent treatment outcomes observed in this real-life community study should prompt further HCV treatment initiatives in Nepal.</p></div><p class="para" id="N65542">Despite very effective antiviral therapies, Hepatitis C virus (HCV) eradication remains a major challenge, especially in resource-limited countries. In Nepal, which ranks among the poorest countries in the world an expert consortium was established to treat HCV patients in six centers throughout the country.</p><p class="para" id="N65544">A cohort of 600 individuals with HCV infection and past or current drug use were treated using different treatment strategies over time. Very high treatment response rates were achieved in a difficult-to-treat, low-income population whatever the patient’s profile and disease severity and despite the severe 2015 earthquakes in Nepal. The excellent treatment outcomes observed in this real-life community study should prompt further HCV treatment initiatives in Nepal.</p>]]></description>
            <pubDate><![CDATA[2020-12-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[IP-10 and CXCR3 signaling inhibit Zika virus replication in human prostate cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765739660580-5090e18e-1e5b-48ce-b636-07ecf8c92fc2/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244587</link>
            <description><![CDATA[<p class="para" id="N65539">Our previous studies have shown that Zika virus (ZIKV) replicates in human prostate cells, suggesting that the prostate may serve as a long-term reservoir for virus transmission. Here, we demonstrated that the innate immune responses generated to three distinct ZIKV strains (all isolated from human serum) were significantly different and dependent on their passage history (in mosquito, monkey, or human cells). In addition, some of these phenotypic differences were reduced by a single additional cell culture passage, suggesting that viruses that have been passaged more than 3 times from the patient sample will no longer reflect natural phenotypes. Two of the ZIKV strains analyzed induced high levels of the IP-10 chemokine and IFNγ in human prostate epithelial and stromal mesenchymal stem cells. To further understand the importance of these innate responses on ZIKV replication, we measured the effects of IP-10 and its downstream receptor, CXCR3, on RNA and virus production in prostate cells. Treatment with IP-10, CXCR3 agonist, or CXCR3 antagonist significantly altered ZIKV viral gene expression, depending on their passage in cells of relevant hosts (mosquito or human). We detected differences in gene expression of two primary CXCR3 isoforms (CXCR3-A and CXCR3-B) on the two cell types, possibly explaining differences in viral output. Lastly, we examined the effects of IP-10, agonist, or antagonist on cell death and proliferation under physiologically relevant infection rates, and detected no significant differences. Although we did not measure protein expression directly, our results indicate that CXCR3 signaling may be a target for therapeutics, to ultimately stop sexual transmission of this virus.</p>]]></description>
            <pubDate><![CDATA[2020-12-30T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765739386128-bc77d64c-fc13-4794-923a-62fb8ad7cc4b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pntd.0008961</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">This study attempts to understand coronavirus disease 2019 (COVID-19) vaccine demand and hesitancy by assessing the public’s vaccination intention and willingness-to-pay (WTP). Confidence in COVID-19 vaccines produced in China and preference for domestically-made or foreign-made vaccines was also investigated.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">A nationwide cross-sectional, self-administered online survey was conducted on 1–19 May 2020. The health belief model (HBM) was used as a theoretical framework for understanding COVID-19 vaccination intent and WTP.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">A total of 3,541 complete responses were received. The majority reported a <i>probably yes</i> intent (54.6%), followed by a <i>definite yes</i> intent (28.7%). The perception that vaccination decreases the chances of getting COVID-19 under the perceived benefit construct (OR = 3.14, 95% CI 2.05–4.83) and not being concerned about the efficacy of new COVID-19 vaccines under the perceived barriers construct (OR = 1.65, 95% CI 1.31–2.09) were found to have the highest significant odds of a definite intention to take the COVID-19 vaccine. The median (interquartile range [IQR]) of WTP for COVID-19 vaccine was CNY¥200/US$28 (IQR CNY¥100–500/USD$14–72). The highest marginal WTP for the vaccine was influenced by socio-economic factors. The majority were <i>confident</i> (48.7%) and <i>completely confident</i> (46.1%) in domestically-made COVID-19 vaccine. 64.2% reported a preference for a domestically-made over foreign-made COVID-19 vaccine.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65573">The findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intent and WTP. It is important to improve health promotion and reduce the barriers to COVID-19 vaccination.</p></div><p class="para" id="N65542">This study investigated vaccine demand and hesitancy by assessing the intention to vaccinate against COVID-19 and willingness-to-pay. We found that a considerable proportion of the public in China has a definite intention to receive the COVID-19 vaccine; a higher proportion expressed a probable intention. Perceived benefits and barriers to vaccination (namely vaccine efficacy and adverse event concerns) of the health belief model constructs were significant predictors of COVID-19 vaccination intent. A substantial proportion was concerned about fake or faulty COVID-19 vaccines; however, this was not a significant predictor of vaccination intention. The willingness-to-pay for the COVID-19 was determined and was found to be positively associated with income. Higher confidence in domestically-made COVID-19 vaccines was also found in this study. The preference for domestically-made over foreign-made COVID-19 vaccines indicates that a future COVID-19 vaccine developed by domestic companies will receive a favourable response from the public in China.The findings of this study provide useful guidance for tailored interventions to enhance the acceptance of a new COVID-19 vaccine once it is available. Promotional messages framing the benefit of vaccination and concerns about new vaccine safety to enhance vaccine uptake is warranted.</p>]]></description>
            <pubDate><![CDATA[2020-12-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Recombination events are concentrated in the spike protein region of <i>Betacoronaviruses</i>]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765739134652-6867af42-1600-4faf-aa70-ac21dbb663dc/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pgen.1009272</link>
            <description><![CDATA[<p class="para" id="N65539">The <i>Betacoronaviruses</i> comprise multiple subgenera whose members have been implicated in human disease. As with SARS, MERS and now SARS-CoV-2, the origin and emergence of new variants are often attributed to events of recombination that alter host tropism or disease severity. In most cases, recombination has been detected by searches for excessively similar genomic regions in divergent strains; however, such analyses are complicated by the high mutation rates of RNA viruses, which can produce sequence similarities in distant strains by convergent mutations. By applying a genome-wide approach that examines the source of individual polymorphisms and that can be tested against null models in which recombination is absent and homoplasies can arise only by convergent mutations, we examine the extent and limits of recombination in <i>Betacoronaviruses</i>. We find that recombination accounts for nearly 40% of the polymorphisms circulating in populations and that gene exchange occurs almost exclusively among strains belonging to the same subgenus. Although experimental studies have shown that recombinational exchanges occur at random along the coronaviral genome, in nature, they are vastly overrepresented in regions controlling viral interaction with host cells.</p><p class="para" id="N65542">The high mutation rate of RNA viruses makes it problematic to understand and resolve the role of recombination in generating genomic variation. Frequent mutations will (1) increase the likelihood of convergent mutations, particularly in regions subject to strong positive selection, causing sequence similarities that can be mistaken for recombination events, and (2) introduce new changes that accumulate and obscure recognition of past recombination events. We analyzed the patterns of recombination across <i>Betacoronaviruses</i> using a dedicated approach to distinguish true recombination from convergent mutations. The <i>Betacoronaviruses</i> comprise several populations that could be considered distinct biological species in that they do not engage in gene flow with one another. Moreover, recombination events within the <i>Sarbecovirus</i> subgenus, which includes SARS-CoV-2, are highly biased and predominate in the spike protein region, implicating recombination as having a substantial role in host tropism and viral ecology.</p>]]></description>
            <pubDate><![CDATA[2020-12-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Modeling intra-mosquito dynamics of Zika virus and its dose-dependence confirms the low epidemic potential of <i>Aedes albopictus</i>]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765738852936-6021e47f-603e-4be6-8869-a7aa5a43f143/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009068</link>
            <description><![CDATA[<p class="para" id="N65539">Originating from African forests, Zika virus (ZIKV) has now emerged worldwide in urbanized areas, mainly transmitted by <i>Aedes aegypti</i> mosquitoes. Although <i>Aedes albopictus</i> can transmit ZIKV experimentally and was suspected to be a ZIKV vector in Central Africa, the potential of this species to sustain virus transmission was yet to be uncovered until the end of 2019, when several autochthonous transmissions of the virus vectored by <i>Ae</i>. <i>albopictus</i> occurred in France. Aside from these few locally acquired ZIKV infections, most territories colonized by <i>Ae</i>. <i>albopictus</i> have been spared so far. The risk level of ZIKV emergence in these areas remains however an open question. To assess <i>Ae</i>. <i>albopictus</i>’ vector potential for ZIKV and identify key virus outbreak predictors, we built a complete framework using the complementary combination of (i) dose-dependent experimental <i>Ae</i>. <i>albopictus</i> exposure to ZIKV followed by time-dependent assessment of infection and systemic infection rates, (ii) modeling of intra-human ZIKV viremia dynamics, and (iii) <i>in silico</i> epidemiological simulations using an Agent-Based Model. The highest risk of transmission occurred during the pre-symptomatic stage of the disease, at the peak of viremia. At this dose, mosquito infection probability was estimated to be 20%, and 21 days were required to reach the median systemic infection rates. Mosquito population origin, either temperate or tropical, had no impact on infection rates or intra-host virus dynamic. Despite these unfavorable characteristics for transmission, <i>Ae</i>. <i>albopictus</i> was still able to trigger and yield large outbreaks in a simulated environment in the presence of sufficiently high mosquito biting rates. Our results reveal a low but existing epidemic potential of <i>Ae</i>. <i>albopictus</i> for ZIKV, that might explain the absence of large scale ZIKV epidemics so far in territories occupied only by <i>Ae</i>. <i>albopictus</i>. They nevertheless support active surveillance and eradication programs in these territories to maintain the risk of emergence to a low level.</p><p class="para" id="N65542">Zika virus (ZIKV) has emerged worldwide and triggered large outbreaks in human populations. While the yellow fever mosquito <i>Aedes aegypti</i> is considered the primary vector of ZIKV, the Asian tiger mosquito <i>Aedes albopictus</i> has been shown experimentally to transmit the virus and has been involved in a few autochthonous transmission in France in 2019. Here, we provide a comprehensive study on the ability of <i>Ae</i>. <i>albopictus</i> mosquitoes to transmit ZIKV by considering the within-host dynamics of ZIKV infection in humans and its impact on both mosquito infection probability and time to mosquito infectiousness. These empirical data were then leveraged by <i>in silico</i> simulations to embed them into their epidemiological context. Our study reveals a low but existing epidemic potential of <i>Ae</i>. <i>albopictus</i> for ZIKV, whatever their tropical or temperate origins. We identified mosquito density as a predictor for ZIKV outbreak occurrence when vectored by <i>Ae</i>. <i>albopictus</i>. Our findings help to explain the absence of large scale ZIKV epidemics in territories occupied by <i>Ae</i>. <i>albopictus</i> but call for active surveillance and eradication programs to maintain the risk of emergence to a low level.</p>]]></description>
            <pubDate><![CDATA[2020-12-31T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Distinct polymorphisms in a single herpesvirus gene are capable of enhancing virulence and mediating vaccinal resistance]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765738789567-4f663c0c-32ce-4c3c-9766-200f5844ad6e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009104</link>
            <description><![CDATA[<p class="para" id="N65539">Modified-live herpesvirus vaccines are widely used in humans and animals, but field strains can emerge that have a higher virulence and break vaccinal protection. Since the introduction of the first vaccine in the 1970s, Marek’s disease virus overcame the vaccine barrier by the acquisition of numerous genomic mutations. However, the evolutionary adaptations in the herpesvirus genome responsible for the vaccine breaks have remained elusive. Here, we demonstrate that point mutations in the multifunctional <i>meq</i> gene acquired during evolution can significantly alter virulence. Defined mutations found in highly virulent strains also allowed the virus to overcome innate cellular responses and vaccinal protection. Concomitantly, the adaptations in <i>meq</i> enhanced virus shedding into the environment, likely providing a selective advantage for the virus. Our study provides the first experimental evidence that few point mutations in a single herpesviral gene result in drastically increased virulence, enhanced shedding, and escape from vaccinal protection.</p><p class="para" id="N65542">Viruses can acquire mutations during evolution that alter their virulence. An example of a virus that has shown repeated shifts to higher virulence in response to more efficacious vaccines is the oncogenic Marek’s disease virus (MDV) that infects chickens. Until now, it remained unknown which mutations in the large virus genome are responsible for this increase in virulence. We could demonstrate that very few amino acid changes in the <i>meq</i> oncogene of MDV can significantly alter the virulence of the virus. In addition, these changes also allow the virus to overcome vaccinal protection and enhance the shedding into the environment. Taken together, our data provide fundamental insights into evolutionary changes that allow this deadly veterinary pathogen to evolve towards greater virulence.</p>]]></description>
            <pubDate><![CDATA[2020-12-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765610129914-8cfcb952-d224-42ae-8f8e-48771a929ea3/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pbio.3001024</link>
            <description><![CDATA[<p class="para" id="N65539">Zoonotic avian influenza viruses pose severe health threats to humans. Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate. Vaccination of poultry appears to reduce human infections. However, the emergence of highly pathogenic strains has increased concerns about H7N9 pandemics. To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of <i>N</i>-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes. Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity. Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs. In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines. In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy. These results suggest the strong potential of HA NLG modifications in designing avian influenza vaccines.</p><p class="para" id="N65540">This study shows that changing the pattern of N-glycosylation of the pathogenic avian influenza H7N9 virus hemagglutinin protein increases the amount of hemagglutinin incorporated into the viral membrane; the candidate vaccine virus induces neutralizing antibodies and protects animal models from lethal viral challenge.</p>]]></description>
            <pubDate><![CDATA[2020-12-23T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Patterns of smallpox mortality in London, England, over three centuries]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765609640726-b7d9fd89-3c8e-44be-9273-18a7117fe558/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pbio.3000506</link>
            <description><![CDATA[<p class="para" id="N65539">Smallpox is unique among infectious diseases in the degree to which it devastated human populations, its long history of control interventions, and the fact that it has been successfully eradicated. Mortality from smallpox in London, England was carefully documented, weekly, for nearly 300 years, providing a rare and valuable source for the study of ecology and evolution of infectious disease. We describe and analyze smallpox mortality in London from 1664 to 1930. We digitized the weekly records published in the London Bills of Mortality (LBoM) and the Registrar General’s Weekly Returns (RGWRs). We annotated the resulting time series with a sequence of historical events that might have influenced smallpox dynamics in London. We present a spectral analysis that reveals how periodicities in reported smallpox mortality changed over decades and centuries; many of these changes in epidemic patterns are correlated with changes in control interventions and public health policies. We also examine how the seasonality of reported smallpox mortality changed from the 17th to 20th centuries in London.</p><p class="para" id="N65540">This study presents the complete historical weekly record of smallpox mortality in London over more than 250 years (1664-1930), describes it using spectral analyses, and discusses it in the context of events and interventions that might have influenced infectious disease dynamics.</p>]]></description>
            <pubDate><![CDATA[2020-12-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Decreased diarrheal and respiratory disease in HIV exposed uninfected children following vaccination with rotavirus and pneumococcal conjugate vaccines]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765609591054-0ec51758-69fb-44e2-bb17-a7d2cb9a718f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244100</link>
            <description><![CDATA[<div class="section" id="sec001"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65543">Rotavirus vaccine (RV) and pneumococcal vaccine (PCV) decrease diarrheal and respiratory disease incidence and severity, but there are few data about the effects of these vaccines among HIV-exposed uninfected (HEU) children.</p></div><div class="section" id="sec002"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65549">We recorded RV and PCV vaccination history in a placebo-controlled trial that studied the need for cotrimoxazole among HEU infants in Botswana (the Mpepu Study). We categorized infants by enrollment before or after the simultaneous April 2012 introduction of RV and PCV, and compared diagnoses of diarrhea and pneumonia (grade 3/4), hospitalizations, and deaths from both disease conditions through the 12-month study visit by vaccine era/status across two sites (a city and a village) by Kaplan-Meier estimates.</p></div><div class="section" id="sec003"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65555">Two thousand six hundred and thirty-five HEU infants were included in this secondary analysis, of these 1689 (64%) were enrolled in Gaborone (344 pre-vaccine, 1345 vaccine) and 946 (36%) in Molepolole (209 pre-vaccine, 737 vaccine). We observed substantial reduction in hazard of hospitalization or death for reason of diarrhea and pneumonia in the vaccine era versus the pre-vaccine era in Molepolole (hazard ratio, HR = 0.44, 95% confidence interval, CI = 0.28, 0.71) with smaller reduction in Gaborone (HR = 0.91, 95% CI = 0.57, 1.45). Similar downward trends were observed for diagnoses of diarrhea and pneumonia separately during the vaccine versus pre-vaccine era.</p></div><div class="section" id="sec004"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65561">Although temporal confounding cannot be excluded, significant declines in the burden of diarrheal and respiratory illness were observed among HEU children in Botswana following the introduction of RV and PCV. RV and PCV may maximally benefit HEU children in rural areas with higher disease burden.</p></div>]]></description>
            <pubDate><![CDATA[2020-12-21T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A modified lysosomal organelle mediates nonlytic egress of reovirus]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765608772344-3957b973-3042-40f0-9b5d-3fd3499a9762/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1083/jcb.201910131</link>
            <description><![CDATA[<p class="para" id="N65540">Mammalian orthoreoviruses are nonenveloped viruses that exit cells by poorly understood nonlytic mechanisms. Fernández de Castro et al. show that modified lysosomes move toward viral replication factories and collect mature virions. Membranous carriers then emerge from these sorting organelles, transporting virions to the plasma membrane for egress.</p><p class="para" id="N65539">Mammalian orthoreoviruses (reoviruses) are nonenveloped viruses that replicate in cytoplasmic membranous organelles called viral inclusions (VIs) where progeny virions are assembled. To better understand cellular routes of nonlytic reovirus exit, we imaged sites of virus egress in infected, nonpolarized human brain microvascular endothelial cells (HBMECs) and observed one or two distinct egress zones per cell at the basal surface. Transmission electron microscopy and 3D electron tomography (ET) of the egress zones revealed clusters of virions within membrane-bound structures, which we term membranous carriers (MCs), approaching and fusing with the plasma membrane. These virion-containing MCs emerged from larger, LAMP-1–positive membranous organelles that are morphologically compatible with lysosomes. We call these structures sorting organelles (SOs). Reovirus infection induces an increase in the number and size of lysosomes and modifies the pH of these organelles from ∼4.5–5 to ∼6.1 after recruitment to VIs and before incorporation of virions. ET of VI–SO–MC interfaces demonstrated that these compartments are connected by membrane-fusion points, through which mature virions are transported. Collectively, our results show that reovirus uses a previously undescribed, membrane-engaged, nonlytic egress mechanism and highlights a potential new target for therapeutic intervention.</p>]]></description>
            <pubDate><![CDATA[2020-05-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The SARS-CoV-2 ORF10 is not essential <i>in vitro</i> or <i>in vivo</i> in humans]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765608337350-73ffebf2-acae-4b54-b844-8bcb87a93f13/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1008959</link>
            <description><![CDATA[<p class="para" id="N65539">SARS-CoV-2 genome annotation revealed the presence of 10 open reading frames (ORFs), of which the last one (ORF10) is positioned downstream of the N gene. It is a hypothetical gene, which was speculated to encode a 38 aa protein. This hypothetical protein does not share sequence similarity with any other known protein and cannot be associated with a function. While the role of this ORF10 was proposed, there is growing evidence showing that the ORF10 is not a coding region. Here, we identified SARS-CoV-2 variants in which the ORF10 gene was prematurely terminated. The disease was not attenuated, and the transmissibility between humans was maintained. Also, <i>in vitro</i>, the strains replicated similarly to the related viruses with the intact ORF10. Altogether, based on clinical observation and laboratory analyses, it appears that the ORF10 protein is not essential in humans. This observation further proves that the ORF10 should not be treated as the protein-coding gene, and the genome annotations should be amended.</p><p class="para" id="N65542">Coronaviral genomes code for several proteins, with the large 1a/1ab being expressed directly from genomic (g)RNA. For the expression of other viral proteins, a set of subgenomic mRNAs is produced during replication. It includes mRNAs for structural (S-E-M-N) and accessory proteins. While the function of structural proteins is well described, the function of the latter ones is under debate. Some of them are required for replication, while others are dispensable in vitro but essential in vivo. Initially, 10 open reading frames (ORFs) were annotated in the SARS-CoV-2 genome, amongst which ORF10 is the most peculiar, as it does not share sequence homology with any known protein. Shortly after the genomic sequences became available, speculations on this protein's role in pathogenesis and innate immunity breaching started. Here, we identified two patients infected with SARS-CoV-2 variants with the ORF10 gene prematurely terminated. The disease was not attenuated, and the transmissibility was maintained. The in vitro study showed that the ORF10 is also not essential for replication. Consequently, ORF10 should not be treated as the protein-coding gene, and the genome annotations should be amended.</p>]]></description>
            <pubDate><![CDATA[2020-12-10T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765608215690-a4d21e93-9196-415c-a085-05dc34451b21/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pone.0244418</link>
            <description><![CDATA[<p class="para" id="N65539">We compare and contrast the expected duration and number of infections and deaths averted among several designs for clinical trials of COVID-19 vaccine candidates, including traditional and adaptive randomized clinical trials and human challenge trials. Using epidemiological models calibrated to the current pandemic, we simulate the time course of each clinical trial design for 756 unique combinations of parameters, allowing us to determine which trial design is most effective for a given scenario. A human challenge trial provides maximal net benefits—averting an additional 1.1M infections and 8,000 deaths in the U.S. compared to the next best clinical trial design—if its set-up time is short or the pandemic spreads slowly. In most of the other cases, an adaptive trial provides greater net benefits.</p>]]></description>
            <pubDate><![CDATA[2020-12-23T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[RV144 HIV-1 vaccination impacts post-infection antibody responses]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765477397096-2ed80f3d-ad8d-4f66-8350-4e4193bbfb51/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.ppat.1009101</link>
            <description><![CDATA[<p class="para" id="N65539">The RV144 vaccine efficacy clinical trial showed a reduction in HIV-1 infections by 31%. Vaccine efficacy was associated with stronger binding antibody responses to the HIV Envelope (Env) V1V2 region, with decreased efficacy as responses wane. High levels of Ab-dependent cellular cytotoxicity (ADCC) together with low plasma levels of Env-specific IgA also correlated with decreased infection risk. We investigated whether B cell priming from RV144 vaccination impacted functional antibody responses to HIV-1 following infection. Antibody responses were assessed in 37 vaccine and 63 placebo recipients at 6, 12, and 36 months following HIV diagnosis. The magnitude, specificity, dynamics, subclass recognition and distribution of the binding antibody response following infection were different in RV144 vaccine recipients compared to placebo recipients. Vaccine recipients demonstrated increased IgG1 binding specifically to V1V2, as well as increased IgG2 and IgG4 but decreased IgG3 to HIV-1 Env. No difference in IgA binding to HIV-1 Env was detected between the vaccine and placebo recipients following infection. RV144 vaccination limited the development of broadly neutralizing antibodies post-infection, but enhanced Fc-mediated effector functions indicating B cell priming by RV144 vaccination impacted downstream antibody function. However, these functional responses were not associated with clinical markers of disease progression. These data reveal that RV144 vaccination primed B cells towards specific binding and functional antibody responses following HIV-1 infection.</p><p class="para" id="N65542">The RV144 vaccine efficacy trial showed a reduction in HIV-1 infections that associated with binding antibody responses to the Envelope (Env) V1V2 loops but precise mechanisms remain unclear. To evaluate the effect of vaccine priming, we performed a systems serology analysis in 37 vaccine and 63 placebo recipients 6, 12 and 36 months after HIV-1 breakthrough infections. Vaccinees were characterized by strong V1V2-specific antibody responses synergized with V1V2-specific ADCP responses, whereas placebo recipients had stronger IgG3 and gp120-specific responses. The strongest distinguishing feature for vaccinees was IgG4 responses. RV144 vaccination enhanced Fc-mediated effector functions but limited the development of broadly neutralizing antibodies post-infection, which were found in eight placebo recipients but no vaccinee. These data show that RV144 vaccination primed B cells towards specific binding and functional antibody responses, with differences between groups still manifest three years after infection, i.e. on average five years after vaccination. These long-term consequences highlight that imprinting certain functions (while deterring other responses) could offer benefits even for leaky vaccines.</p>]]></description>
            <pubDate><![CDATA[2020-12-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765477290714-b3b2b6b7-1577-4d79-9222-9f21bb38bc5a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1371/journal.pcbi.1008461</link>
            <description><![CDATA[<p class="para" id="N65539">The entry of SARS-CoV-2 into target cells requires the activation of its surface spike protein, S, by host proteases. The host serine protease TMPRSS2 and cysteine proteases Cathepsin B/L can activate S, making two independent entry pathways accessible to SARS-CoV-2. Blocking the proteases prevents SARS-CoV-2 entry <i>in vitro</i>. This blockade may be achieved <i>in vivo</i> through ‘repurposing’ drugs, a potential treatment option for COVID-19 that is now in clinical trials. Here, we found, surprisingly, that drugs targeting the two pathways, although independent, could display strong synergy in blocking virus entry. We predicted this synergy first using a mathematical model of SARS-CoV-2 entry and dynamics <i>in vitro</i>. The model considered the two pathways explicitly, let the entry efficiency through a pathway depend on the corresponding protease expression level, which varied across cells, and let inhibitors compromise the efficiency in a dose-dependent manner. The synergy predicted was novel and arose from effects of the drugs at both the single cell and the cell population levels. Validating our predictions, available <i>in vitro</i> data on SARS-CoV-2 and SARS-CoV entry displayed this synergy. Further, analysing the data using our model, we estimated the relative usage of the two pathways and found it to vary widely across cell lines, suggesting that targeting both pathways <i>in vivo</i> may be important and synergistic given the broad tissue tropism of SARS-CoV-2. Our findings provide insights into SARS-CoV-2 entry into target cells and may help improve the deployability of drug combinations targeting host proteases required for the entry.</p><p class="para" id="N65542">The COVID-19 pandemic has triggered urgent efforts to repurpose available drugs for the treatment of SARS-CoV-2 infection. Synergistic drug combinations are particularly desirable because they allow the achievement of desired efficacies with minimal toxicities. Here, we predict that drugs targeting the host proteases, TMPRSS2 and Cathepsin B/L, which facilitate SARS-CoV-2 entry into cells through independent pathways, would be synergistic. We identified the synergy using a mathematical model and found evidence for it in available <i>in vitro</i> data. We found the estimated usage of the two pathways to vary vastly across cell types, highlighting the need to target both pathways. Our findings would help maximize the impact of combination therapies targeting host proteases involved in SARS-CoV-2 entry, which are currently in clinical trials.</p>]]></description>
            <pubDate><![CDATA[2020-12-08T00:00]]></pubDate>
        </item>
    </channel>
</rss>